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Preface to ”AR Signaling in Human Malignancies:
Prostate Cancer and Beyond”
The notion that androgens and androgen receptor (AR) signaling are the hallmarks of prostate 
cancer oncogenesis and disease progression is generally well accepted. What is more poorly 
understood is the role of AR signaling in other human malignancies. This Special Issue of Cancers 
initially reviews the role of AR in advanced prostate cancer, and then explores the potential 
importance of AR signaling in other epithelial malignancies. The first few articles focus on the use of 
novel AR-targeting therapies in castration-resistant prostate cancer and the mechanisms of resistance 
to novel antiandro-gens, and they also outline the interaction between AR and other cellular 
pathways, including PI3 kinase signaling, transcriptional regulation, angiogenesis, stromal factors, 
Wnt signaling, and epige-netic regulation in prostate cancer. The next several articles review the 
possible role of androgens and AR signaling in breast cancer, bladder cancer, salivary gland cancer, 
and hepatocellular carcinoma, as well as the potential treatment implications of using antiandrogen 
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Abstract: The notion that androgens and androgen receptor (AR) signaling are the hallmarks of
prostate cancer oncogenesis and disease progression is generally well accepted. What is more
poorly understood is the role of AR signaling in other human malignancies. This special issue of
Cancers initially reviews the role of AR in advanced prostate cancer, and then explores the potential
importance of AR signaling in other epithelial malignancies. The first few articles focus on the
use of novel AR-targeting therapies in castration-resistant prostate cancer and the mechanisms of
resistance to novel antiandrogens, and they also outline the interaction between AR and other cellular
pathways, including PI3 kinase signaling, transcriptional regulation, angiogenesis, stromal factors,
Wnt signaling, and epigenetic regulation in prostate cancer. The next several articles review the
possible role of androgens and AR signaling in breast cancer, bladder cancer, salivary gland cancer,
and hepatocellular carcinoma, as well as the potential treatment implications of using antiandrogen
therapies in these non-prostatic malignancies.
Androgens and androgen receptor (AR) signaling are the hallmarks of prostate cancer oncogenesis
and disease progression. While the medical literature is saturated by studies examining the role of
androgens/AR in prostate cancer, less attention has been given to the potential importance of the AR
pathway in other human malignancies. The goal of this special issue of Cancers is to shed more light
on the clinical significance of androgen/AR signaling, not just in prostate cancer, but also in other
epithelial malignancies.
This theme issue begins with a thoughtful summary by Schweizer et al. [1] introducing the AR
signaling field in prostatic and other malignancies. After describing the biological and therapeutic
roles of AR in prostate cancer, the authors review the evidence supporting AR-directed therapies
in other tumor types including breast cancer, bladder cancer, kidney cancer, pancreatic cancer,
hepatocellular cancer, ovarian and endometrial cancers, mantle cell lymphoma, and salivary gland
cancers. This is followed by a review by Crumbaker et al. [2] that summarizes the interaction between
AR and PI3 kinase signaling in prostate cancer, outlines the role of the PI3K pathway in prostate
cancer, and reviews the potential clinical utility of dual targeting of AR and PI3K as a therapeutic
strategy in prostate cancer. The next review by Obinata et al. [3] delves deeper into the interplay
between AR and other collaborative transcription factors (such as FOXA1, GATA2, and OCT1),
and proposes new strategies to co-target AR together with some of these transcriptional collaborators,
with particular attention to pyrrole–imidazole polyamide as a candidate compound. This is followed
by a review article by Eisermann et al. [4] discussing the interactions between AR, angiogenesis, and the
vascular endothelial growth factor (VEGF) in prostate cancer, hormone-mediated mechanisms of VEGF
regulation, and potential therapeutic strategies that take into account both AR and hypoxia as potential
regulators of angiogenesis. The next article, by Leach et al. [5], reviews the important but understudied
subject of AR signaling in the stromal compartment (primarily in fibroblasts and myofibroblasts) in
the context of prostate cancer, suggesting that stromal AR activity strongly influences prognosis and
progression of this disease. The next article, by Cucchiara et al. [6], summarizes our knowledge of
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epigenomic regulation of AR in prostate cancer, discusses the various types of epigenetic control
(including DNA methylation, chromatin modification, and noncoding RNAs), and ends with some
therapeutic implications including the use of the demethylase inhibitor SD-70. Finally, the article by
Pakula et al. [7] reviews our current understanding of the interaction between AR and Wnt pathway
signaling in prostate cancer, the central role of beta-catenin in this context, and possible therapeutic
applications of drugs that target both AR and Wnt/beta-catenin pathways in prostate cancer.
The second series of articles begins to address the role of AR signaling in other human cancers,
with a focus on potential therapeutic implications. Rahim et al. [8] begin with a thoughtful overview
of the role of androgens and AR signaling in breast cancer (especially in triple-negative breast cancer),
they summarize the biology and prognostic/predictive role of AR in breast cancer, and they end with
some thoughts on potential therapeutic strategies. This is followed by a second review article on this
topic by Narayanan et al. [9] who delve deeper into the therapeutic strategies (nonsteroidal agonists
and antagonists) that target androgen/AR signaling in breast cancer. Asano et al. [10] then present
an original research article investigating protein expression (by immunohistochemistry) of the AR
molecule in 190 cases of triple-negative breast cancer, showing that positive AR protein expression
in triple-negative breast cancer tissues is associated with a better prognosis and should perhaps be
used to sub-classify cases of triple-negative disease for prognostic purposes. Next, Li et al. [11] review
the current knowledge of AR signaling in urothelial carcinoma of the bladder, summarize the data
linking androgens to urothelial carcinogenesis and tumor growth, and offer some chemopreventive
and therapeutic options for bladder cancer management. After this, the article by Dalin et al. [12]
reviews the data on AR signaling in salivary gland cancer (particularly salivary duct carcinoma),
and summarizes the prevalence, biology, and therapeutic implications of AR signaling in salivary
gland cancers. Finally, the last article in this special issue, by Kanda et al. [13], reviews the role of AR
in hepatocellular cancer, its centrality in the development of this malignancy, the potential role of AR
in regulating the innate immune response in this disease, and strategies combining sorafenib with AR
inhibitors for therapeutic purposes.
We hope that the readership enjoys this this special issue of Cancers, that they become informed
about the role of androgens and AR signaling in the context of multiple different cancer types, and that
this treatise will ignite further clinical research and therapeutic trials aiming to modulate the AR
pathway in various human malignancies.
Conflicts of Interest: E.S.A. is a paid consultant/advisor to Janssen, Astellas, Sanofi, Dendreon, Medivation,
ESSA, AstraZeneca, Clovis, and Merck and has received research funding to his institution from Janssen,
Johnson & Johnson, Sanofi, Dendreon, Genentech, Novartis, Tokai, Bristol Myers-Squibb, AstraZeneca, Clovis,
and Merck; he is also the co-inventor of a biomarker technology that has been licensed to Qiagen.
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Abstract: In the 1940s Charles Huggins reported remarkable palliative benefits following surgical
castration in men with advanced prostate cancer, and since then the androgen receptor (AR)
has remained the main therapeutic target in this disease. Over the past couple of decades, our
understanding of AR-signaling biology has dramatically improved, and it has become apparent
that the AR can modulate a number of other well-described oncogenic signaling pathways.
Not surprisingly, mounting preclinical and epidemiologic data now supports a role for AR-signaling
in promoting the growth and progression of several cancers other than prostate, and early phase
clinical trials have documented preliminary signs of efficacy when AR-signaling inhibitors are used in
several of these malignancies. In this article, we provide an overview of the evidence supporting the
use of AR-directed therapies in prostate as well as other cancers, with an emphasis on the rationale
for targeting AR-signaling across tumor types.
Keywords: prostate cancer; breast cancer; bladder cancer; renal cell carcinoma; pancreatic cancer;
ovarian cancer; hepatocellular cancer; ovarian cancer; endometrial cancer; androgen receptor
1. Androgen Receptor Biology
Androgens, or male sex hormones, have a wide range of functions, including promoting the
development of male secondary sexual characteristics, stimulating erythropoiesis, increasing metabolic
rate, increasing bone density and stimulating libido [1]. In men, androgens are produced predominately
by the testes, while the sole source of androgens in women are the adrenal glands. Consequently,
women have considerably lower androgen levels compared to men. The normal physiologic function
of androgens is a result of stimulating the androgen receptor (AR).
The AR is a member of the nuclear hormone receptor family of transcription factors, which
also includes the estrogen receptor (ER), glucocorticoid receptor (GR), progesterone receptor (PR)
and others [2,3]. Like the other nuclear hormone receptors, transcription of AR target genes is
induced by the receptor binding androgenic ligands. Canonical AR-signaling involves a well-described
series of events, including: (1) AR binding to androgens; (2) dissociating from heat-shock proteins;
(3) translocating to the nucleus and the formation of AR homodimers; (4) binding to androgen response
elements (AREs) within the promoter region of AR target genes; (5) recruitment of coactivators;
and (6) transcription of target genes [4].
In addition to its normal physiologic role, prostatic adenocarcinomas remain dependent on
AR-signaling even at later stages. Supporting the importance of AR to prostate cancer biology is
the observation that AR target genes (e.g., PSA) are usually expressed even in men progressing on
androgen deprivation therapy (ADT), with AR pathway alterations commonly observed in late stage
Cancers 2017, 9, 7 4 www.mdpi.com/journal/cancers
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disease [5]. This has served as the basis for ADT through medical and surgical castration, as well as
the development of next generation AR-directed therapies like abiraterone and enzalutamide.
As our understanding of AR biology has improved, it has become apparent that the AR-signaling
pathway can interact with a number of additional oncogenic signaling pathways, including those
involved in promoting growth and resistance across a variety of tumor types (e.g., AKT/mTOR/PI3K,
EGFR, HER2/Neu, Wnt) [5–12]. Interestingly, in spite of differences in consensus DNA binding motifs,
AR is able to bind estrogen response elements and activate a transcriptional program similar to the
ER—indicating that AR may be important mediator of breast cancer cell survival as well as other
ER-dependent tumors [13,14]. The pleiotropic effects of AR-signaling raise the specter that targeting
this pathway may have beneficial effects in a number of different cancers. In this review, we will outline
the current evidence for testing AR-directed therapies in prostate, breast and other “non-hormonally”
driven cancer like bladder, renal cell and pancreatic cancer, to name a few.
2. AR Targeting in Prostate Cancer
In 1941, Charles Huggins published his seminal paper describing the remarkable palliative effects
of surgical castration in men with advanced prostate cancer [15]. We now understand that the beneficial
effects of castrating therapy are a direct result of inhibiting AR-signaling, and as such targeting the AR
has remained the backbone of prostate cancer therapy since the 1940s. As it stands, ADT is most often
achieved through the use of luteinizing hormone releasing hormone (LHRH) agonists/antagonists as
opposed to surgical castration; however, both achieve the same effect of lowering testosterone levels to
the castrate range (i.e., <20–50 ng/dL) [16]. While ADT is initially highly effective, it does not represent
a cure, and the vast majority of men with advanced prostate cancer will progress on ADT, developing
castration-resistant prostate cancer (CRPC) [17,18].
Work over the last decade has shown that the AR remains a viable therapeutic target even in
the castration-resistant setting. This was born out of the observation that AR target genes (e.g., PSA)
are often expressed at high levels in patients with CRPC, and that expression of AR will go up in
response to ADT [19,20]. It has also come to light that alternative sources of androgens, including
those generated intratumorally, may also drive tumor growth in this setting [21,22]. As such, a number
of next-generation AR-directed therapies have been developed to further inhibit AR-signaling,
with abiraterone and enzalutamide both approved on the basis of Phase III data demonstrating
improved overall survival compared to controls [23–27]. Abiraterone is a CYP17 inhibitor that
targets extragonadal androgen biosynthesis in the tumor microenvironment and adrenal glands.
Enzalutamide is an AR antagonist that is more effective than the first generation non-steroidal
antiandrogens (e.g., bicalutamide, nilutamide). Because both of these agents target the ligand-AR
interaction—abiraterone through ligand depletion and enzalutamide through antagonizing the
AR-ligand binding domain—it is not surprising that numerous groups have documented evidence of
cross-resistance between these drugs [28–35].
More recently, a number of studies have described mechanisms whereby AR-signaling is
able to reemerge in spite of treatment with next generation AR-signaling inhibitors. Examples of
these mechanisms include: AR amplification/overexpression, intratumoral androgen production,
activation via feedback pathways (e.g., AKT/mTOR/Pi3K, HER2/Neu), activating AR ligand binding
domain mutation, emergence of constitutively active AR splice variants and activation through other
nuclear hormone transcription factors (e.g., GR) [6,7,19,21,36–48]. Several in depth reviews of these
mechanisms have been published, and a detailed overview of their role in promoting resistance to
AR-directed therapies is beyond the scope of this paper [3,20,49]. Suffice it to say, many ongoing drug
development efforts are focused on developing more effective AR-directed therapies (e.g., drugs not
targeting the ligand-AR interaction like EPI-506) or drugs to target key feedback pathways in selected
populations (e.g., Akt inhibitors in patients with PTEN loss) [50–52].
5
Cancers 2017, 9, 7
3. Breast Cancer
3.1. AR in Breast Cancer
Like prostate cancer, breast cancer is a hormonally regulated malignancy. Indeed, shortly
following the discovery that surgical castration was effective in men with advanced prostate cancer,
Charles Huggins began exploring oophorectomy and adrenalectomy (with hormone replacement)
as treatments for advanced breast cancer [53]. It is worth noting, however, that the German surgeon
Albert Schinzinger was first credited with proposing oophorectomy as a treatment for breast cancer in
the late 19th century [54]. While most hormonal-based therapies for breast cancer involve inhibiting
estrogen receptor (ER)-signaling in hormone receptor positive subtypes, it has recently come to light
that AR-signaling is likely an important modulator of breast cancer cell survival and may also be a
viable target [55,56].
Several lines of clinical data support the biologic importance of AR-signaling in breast cancer, although
AR positivity has been found to have variable prognostic impact across studies. Vera-Badillo, et al.
conducted a systemic review of 19 studies that assessed AR immunohistochemistry (IHC) in
7693 patients with early stage breast cancer and found AR staining present in 60.5% of patients;
interestingly, AR positivity was associated with improved overall survival (OS) [57]. The authors
also found that AR positivity was more common in ER positive compared to ER negative tumors
(74.8% vs. 31.8%, p < 0.001). However, it should be noted that AR antibodies used across studies was
not consistent, nor was the cutoff defining “positivity”, making it difficult to draw firm conclusion
regarding the overall prevalence of AR positivity across breast cancer subtypes.
Another study analyzing AR expression from tissue microarrays (TMAs) of 931 patients reported
that 58.1% stained positive for AR, and that the association of AR with improved OS was only true
for patients with ER positive tumors [58]. Apocrine tumors (ER negative, AR positive) with HER2
positivity associated with poorer survival, while AR did not appear to impact OS in triple negative
breast cancer (TNBC) cases. A study by Choi and colleagues focused specifically on TNBCs (n = 559),
found that AR was expressed in 17.7% of these cases, and that AR positivity was a negative prognostic
feature. Two subsequent meta-analyses found that AR expression associated with better outcomes
across tumor subtypes, however (i.e., ER positive, ER negative, and TNBC) [59,60].
3.2. Targeting AR in Breast Cancer
As mentioned, AR and ER are both nuclear hormone transcription factors and share a number of
similar biologic features [55]. Upon binding their respective ligands, they undergo conformational
changes, dissociate from heat shock proteins, dimerize and bind to DNA response elements where
they promote transcription of target genes [3,61]. A number of studies have documented mechanisms
whereby crosstalk between AR and ER exists, with most evidence supporting a model in which AR
inhibits ER signaling through a variety of mechanisms—providing a biological basis for why AR
positivity may associate with improved outcomes in ER positive breast cancers. AR is able to compete
with ER for bindings at ER response elements (EREs), and transfection of MDA-MB-231 breast cancer
cells with the AR DNA binding domain has been shown to inhibit ER activity [13]. Because the
transcriptional machinery of both ER and AR involves a number of shared coactivator proteins, AR
also likely inhibits ER activity through competing for binding of these cofactors [62,63]. Interestingly,
there is also evidence that AR and ER can directly interact, with the AR N-terminal domain binding to
the ERα ligand binding domain leading to decreased ERα transactivation [64].
The biologic action of AR in ER-negative breast cancers may differ significantly. AR is expressed in
12% to 36% of TNBCs, and in contrast to ER-positive breast cancers, data suggests that AR may be able
to drive progression in some ER-negative cell lines [65–71]. Supporting the biologic importance
of AR, and its viability as a therapeutic target, preclinical data has shown that AR antagonists
(e.g., bicalutamide, enzalutamide) exert an anti-tumor effect in a number of ER-negative breast cancer
models [65,67,72].
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AR positive TNBCs are generally referred to as molecular apocrine tumors; however, more
recent work has defined TNBCs on the basis of their molecular phenotype [73,74]. Work by Lehmann
and colleagues have defined six subtypes of TNBC on the basis of their gene expression profiles:
basal-like 1 and 2, immunomodulatory, mesenchymal, mesenchymal stem-like, and luminal androgen
receptor (LAR) [74]. Interestingly, in spite of being ER-negative, the LAR subtype shares a gene
expression signature similar to the luminal, ER-positive breast cancers. Chromatin immunoprecipitation
(ChIP)-sequencing studies demonstrate that AR-binding events are similar to those of ERα in ER-positive
breast cancer cell lines, indicating that AR may be able to substitute for ER in this context [14].
It should be noted that in addition to LAR tumors, other ER-negative, AR-positive breast cancer
subtypes are sensitive to the effects of androgens [65,67]. Ni and colleagues have shown that in
HER2-positive, ER-negative cell lines, AR mediates activation of Wnt and HER2 signaling in a
ligand-dependent manner [67]. Further speaking to the importance of AR across breast cancer subtypes,
Barton and colleagues reported that the next-generation AR antagonist enzalutamide is effective in
several non-LAR TNBC subtypes. Interestingly, it has been shown that constitutively active AR
splice variants (AR-Vs)—a well-described resistance mechanism in prostate cancer—are present in
a large subset of breast cancer tumors, and that treatment of MDA-MB-453 cells (ER/PR-negative,
HER2-negative, AR-positive) with enzalutamide can lead to the induction of AR-Vs [75]. The fact that
a well-known resistance mechanism to AR-directed therapy appears relevant to breast cancer provides
further support for the importance of AR-signaling in breast cancer.
3.3. Clinical Trials Targeting AR-Signaling in Breast Cancer
Early clinical data reported by Gucalp and colleagues supported AR as a therapeutic target in
AR-positive, ER-negative/PR-negative breast cancers [76]. They conducted a single-arm, Phase II
study testing bicalutamide 150 mg daily in patients with >10% nuclear AR staining. The primary
endpoint was clinical benefit rate (CBR) defined as complete response (CR), partial response (PR) or
stable disease >6 months. Overall, 51 of 424 (12%) screened patients were AR-positive as defined
by the study. Twenty-eight patients were treated per protocol, with only 26 being evaluable for the
primary endpoint. The study reported a clinical benefit in five patients (all with stable disease), which
exceeded the predefined threshold (CBR = 4/28 patients) needed to justify further study.
A single-arm Phase II study testing enzalutamide in AR-positive TNBCs was more recently
reported [77]. The primary endpoint was the CBR in “evaluable” patients which were defined as
those with ≥10% AR staining and a response assessment. After testing 404 patient samples, 55% were
found to have AR staining in ≥10% of cells. 118 patients were treated with enzalutamide, and 75 were
“evaluable”. Of the evaluable patients, the CBR at 16 and 24 weeks was 35% and 29% respectively.
The median progression free survival (PFS) in this group was 14 weeks. In patients with an AR gene
signature (n = 56), clinical outcomes were numerically improved compared to the overall “evaluable”
group and those lacking the gene signature (N = 62)—suggesting that further refinement of predictive
biomarkers beyond AR IHC is necessary.
7
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Abiraterone, an inhibitor of extragonadal androgen biosynthesis, has also been tested in breast
cancer [78]. In a randomized Phase II trial, abiraterone was compared to the aromatase inhibitor
exemestane or the combination. In contrast to the aforementioned studies, this study focused on
ER-positive patients and did not require positive AR staining in order to enroll. The authors cited
two reasons for not mandating AR-positivity: (1) upwards of 80% of ER-positive breast cancers
are also positive for AR; and (2) inhibition of CYP17 will also decrease estrogen levels. The primary
endpoint was PFS. A total of 297 patients were randomized between treatment arms, with 102 receiving
exemestane, 106 receiving exemestane plus abiraterone and 89 receiving abiraterone. Of note,
enrollment to the abiraterone monotherapy arm was discontinued early after a pre-specified analysis
determined that futility conditions had been met. After a median follow up of 11.4 months, there was no
difference in median PFS between when abiraterone was compared to exemestane (3.7 vs. 3.7 months,
p = 0.437), or when abiraterone plus exemestane was compared to exemestane (4.5 vs. 3.7 months,
p = 0.794). Of note, there was also no difference in PFS in the subset of patients with AR-positive disease.
Given that some studies have shown signs of activity for AR-signaling inhibitors, a number of
additional trials are either planned or underway testing AR-directed therapies in breast cancer patients
(Table 1). However, it seems likely that these agents will only be effective in a subset of patients, and as
such, the development of predictive biomarkers will be critical. Whether the AR will prove to be
a clinically important target in breast cancer remains to be seen, but evidence to date does support
further testing of drugs designed to inhibit this oncogenic pathway.
4. Other Tumor Types
In addition to prostate and breast cancer, there are a number of other malignancies in which
AR-signaling appears to play a role in driving tumor growth. As such, there are several ongoing
clinical trials testing AR-directed therapies across an array of cancer types (Table 2). A brief overview
of the rationale for targeting AR in these malignancies is provided below.
4.1. Bladder Cancer
In 2016, it is estimated that 58,950 American men will be diagnosed with bladder cancer compared
to only 18,010 women [79]. Even after controlling for environmental risk factors (e.g., tobacco
exposure) men still have a 3–4-fold increased risk of developing bladder cancer [80–82]. The observed
epidemiologic differences in bladder cancer risk between the sexes points to the potential for sex
steroid pathways to play a role in the pathogenesis of this disease [83]. Women have also been found
to have a worse prognosis compared to men after adjusting for stage at presentation, further bolstering
the case that underlying biologic differences between the sexes influencing outcomes [84].
Androgen receptor has been found to be variably expressed in urothelial carcinoma specimens,
with AR staining present in 12% to 77% of patients [85–89]. In general, AR expression appears
comparable in men and women [85,86]. There is no clear relationship between AR expression and
clinical outcomes, and gene expression profiling studies do not demonstrate a clear relationship
between AR expression levels and The Cancer Genome Atlas (TCGA) subtype [86,90,91].
Preclinical studies evaluating the effect of androgens and AR-signaling on urothelial carcinoma
tumorigenesis have found that AR-signaling may promote tumor formation. In vitro siRNA studies
have found that AR knockdown can lead to decreased tumor cell proliferation and increased apoptosis,
possibly mediated through AR’s effect on cyclin D1, Bcl-x(L) and MMP-9 gene expression [92].
In a separate set of experiments, mice engineered to not express AR in urothelial cells were
found to have a lower incidence of bladder cancer following exposure to the carcinogen BBN
[N-butyl-N-(4-hydroxybutyl)-nitrosamine] [93]. In vitro experiments found that this effect may be due
to modulation of p53 and DNA damage repair. Studies have also implicated AR in modulating various
other oncogenic signaling pathways (e.g., EGFR, ERBB2, β-catenin), offering more evidence for the
importance of AR-signaling as it pertains to bladder cancer biology [94,95].
9
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Kawahara and colleagues recently published a paper describing a series of in vitro and in vivo
experiments in AR-positive and AR-null bladder cancer models [96]. They found that DHT increased
AR-positive bladder cancer cell line viability and migration in culture, while AR antagonists
(i.e., hydroxyflutamide, bicalutamide and enzalutamide) inhibited viability and migration. Similarly,
apoptosis was decreased following exposure to DHT, and anti-androgens had the opposite effect.
Importantly, enzalutamide was found to inhibit AR-positive bladder cancer xenograft growth in vivo.
On the basis of these findings, two clinical trials have opened to test enzalutamide in patients
with bladder cancer. One is testing enzalutamide monotherapy as a chemoprevention strategy in
patients with non-muscle invasive bladder cancer [clinicaltrials.gov: NCT02605863], and the other is
testing it in patients with advanced bladder cancer in combination with gemcitabine plus cisplatin
[clinicaltrials.gov: NCT02300610].
4.2. Renal Cell Carcinoma
Androgen receptor is expressed in the distal and proximal tubules of normal kidneys and is
expressed in approximately 15% to 42% of renal cell carcinomas (RCC) [97–99]. IHC studies correlating
AR expression with clinical outcomes have not been consistent, with some reporting an association
with decreased survival, while others have found that AR expression was correlated with a favorable
pathologic stage and an overall favorable prognosis [97,100,101].
In a study evaluating AR transcript levels using real-time PCR, it was found that AR mRNA
expression levels correlated with pathologic T stage and cancer specific survival. Multivariate
regression analysis found AR transcript levels were independently associated with cancer specific
survival. Of note, AR mRNA levels did not differ between sexes.
A more recent analysis of the TCGA data revealed that high AR protein and transcript levels
was associated with improved overall survival in patients with clear cell RCC (the most common
pathologic subtype), but not other histologic subtypes of RCC (i.e., papillary or chromophobe) [102].
Interestingly, in clear cell RCC cases they found that AR mRNA expression did not differ between men
and women, but that AR protein expression was significantly higher in men. The authors concluded
that AR might function as a tumor suppressor in this context.
In vitro experiments have reported that exposure to DHT causes proliferation in AR-positive
RCC cells, while enzalutamide can reduce cell viability [103]. Other groups have found that AR may
mediate tumor growth through activating HIF-2α/VEGF-signaling [104]. Preclinical studies have
shown that enzalutamide can inhibit RCC cell migration and invasion by modulating HIF-2α/VEGF
expression at the mRNA and protein levels. A neoadjuvant Pilot study testing enzalutamide in RCC
patients is currently underway, with the primary goal to determine the effects of enzalutamide on RCC
apoptosis and cellular proliferation [clinicaltrials.gov: NCT02885649].
4.3. Pancreatic Cancer
Although the incidence of AR expression is not well defined in pancreatic cancer, AR does appear
to be expressed [105]. A number of in vitro/in vivo studies have tested the effects of antiandrogens
and/or androgen deprivation in pancreatic cancer models, and have, for the most part, shown that
inhibiting AR-signaling exerts anti-tumor effect [106–113]. Preclinical work has demonstrated that this
effect may be mediated through IL-6, with a model whereby IL-6 activates AR-signaling via STAT3
and MAPK. Importantly, IL-6 has been shown to enhance pancreatic cell migration, an effect that is
blocked through AR knockdown with an AR siRNA [114].
Greenway reported the results of a randomized trial comparing flutamide (a non-steroidal
antiandrogen) vs. placebo (n = 49) in patients with both localized and metastatic pancreatic cancer [115].
It should be noted that histologic confirmation of pancreatic cancer was not required, and 32 included
subjects were diagnosed on the basis of clinical presentation/imaging studies. This trial reported
a median survival of 226 vs. 120 days in the flutamide and placebo groups, respectively (p = 0.079,
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Wilcoxon; p = 0.01, log-rank). Several other studies in patients with pancreatic cancer have not shown
hormonal therapies to be beneficial, however [116–121].
Preliminary results from an ongoing Phase I study testing enzalutamide in combination with
gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer have recently been
reported [122]. They have treated 19 patients, and report that 37% had tumor tissue positive for AR.
Among 15 evaluable patients, two had a partial response and 13 had stable disease. Pharmacokinetic
(PK) analyses did not find any evidence that enzalutamide altered the PK of either chemotherapeutic
agent. Whether enzalutamide will prove to be an effective treatment for pancreatic cancer remains
to be seen.
4.4. Hepatocellular Carcinoma
Androgen receptor appears to be expressed in subset of hepatocellular carcinomas (HCC),
although, like pancreatic cancer, the incidence has not been well defined [123–126]. The majority
of studies show that AR-positivity is associated with worse outcomes, including decreased progression
free and overall survival as well as increased tumor size [126–129]. Studies have also linked AR-signaling
with increased risk of developing hepatitis B and C related HCC [130–133]. AR has been found
to promote HCC growth, migration and invasion in several preclinical studies, possibly through
increasing oxidative stress and DNA damage, as well as suppressing p53 [134–136]. In vitro and
in vivo studies targeting AR with either AR-siRNA or ASC-J9 (an AR protein degrader) resulted in
decreased tumor growth [134]. A randomized Phase II study testing enzalutamide vs. placebo in HCC
is currently underway [clinicaltrials.gov: NCT02528643].
4.5. Ovarian Cancer
In 1998, Risch hypothesized that epithelial ovarian cancers may develop as a result of androgens
stimulating epithelial cell proliferation, and as it stands, a number of lines of evidence support the
role for AR-signaling in the pathogenesis of the disease [137,138]. AR is highly expressed in ovarian
cancers, with approximately 44% to 82% of tumors staining positive for AR [139–141]. Polycystic
ovarian syndrome (PCOS), and its resultant hyperandrogenic state, are associated with hyperplastic
and metaplastic changes in the surface epithelium of the ovaries, and women with ovarian cancer
are more likely to have a history of PCOS compared to control cases [142,143]. The use of exogenous
androgens (i.e., danazol, testosterone) has been associated with a >3-fold increased risk of developing
ovarian cancer [144]. Preclinical models also support the hypothesis that androgens play a role in the
development of epithelial ovarian cancers, with a number of oncogenic signaling pathways implicated
in this process (e.g., TGF-β, IL-6/IL-8, EGFR) [138,145–147]. However, as it stand, the prognostic
impact of AR expression in epithelial ovarian cancers is not clear [138].
A handful of clinical trials testing AR-signaling inhibitors in women with ovarian cancer have
been completed, with no clear signs of activity. A single-arm Phase II study testing flutamide in
ovarian cancer patients progressing on platinum chemotherapy has previously been reported [148].
Out of 68 women enrolled, only two objective responses (one complete and one partial response)
were observed. In a second single-arm Phase II study, flutamide was given to 24 ovarian cancer
patients who failed chemotherapy and only one partial response was observed [149]. Finally, in a
single-arm Phase II study, Levine and colleagues treated 35 women with ovarian cancer who were in
second or greater complete remission with bicalutamide and goserelin (LHRH agonist) [150]. This trial
failed to meet the pre-specified metric to justify further studies testing this regimen, which was
arbitrarily set at median PFS >13.5 months. More recent preclinical work has shown that enzalutamide
is able to significantly inhibit the growth of ovarian cancer xenografts [151]. On this basis, a Phase II
study has been launched to test enzalutamide in women with AR-positive, advanced ovarian cancer
[clinicaltrials.gov: NCT01974765].
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4.6. Endometrial Cancer
Similar to prostate and breast cancer, endometrial cancers are hormonally dependent, and hormonal
agents targeting ER-/PR-signaling are options for select patients [152]. Given the similarities to breast
and prostate cancer, Tangen and colleagues sought to explore the potential for targeting AR-signaling
in advanced endometrial cancer [153]. They found that the majority of hyperplastic endometrial
specimens evaluated (93%) had evidence of AR expression. This number decreased in primary
tumors, and high-grade tumors (i.e., grade 3) were found to express less AR than low-grade tumors
(i.e., grade 1) (53% vs. 74%). Metastatic specimens from 142 patients revealed AR expression in 48% of
samples. On multivariate analyses, AR status did not provide additional prognostic value, however.
Short-term cell culture experiments demonstrated that cell proliferation was inhibited by enzalutamide,
and stimulated by the synthetic androgen R1881, providing justification for a Phase II study testing
enzalutamide in combination with carboplatin and paclitaxel [clinicaltrials.gov: NCT02684227].
4.7. Mantle Cell Lymphoma
Mantle cell lymphoma shows a male predominance, and interestingly, male sex appears to
associate with higher mortality based on a retrospective SEER analysis [154]. While it is not clear what
underlies the poor outcomes in men with mantle cell lymphoma, AR is expressed across an array of
hematopoietic cells, and may account for gender differences in the function of platelets and the immune
system [155–157]. Furthermore, in contrast to other lymphomas, AR appears to be hypomethylated in
mantle cell lymphoma—indicating that epigenetic silencing of AR gene expression may not be present
in mantle cell lymphoma [158,159]. To our knowledge, large studies examining AR protein expression
in mantle cell lymphoma samples have not been conducted. On the basis of these observations a pilot
study was recently launched to assess the clinical effects of enzalutamide in patients with mantle cell
lymphoma [clinicaltrials.gov: NCT02489123].
4.8. Salivary Gland Cancer
AR is expressed in the majority of lacrimal gland ductal carcinomas, and as a result AR staining is
often used as part of the workup to confirm the diagnosis [160–166]. To date, there have been a handful
of case reports/series documenting favorable outcomes in patients with salivary gland cancers treated
with AR-directed therapies. A small case series (n = 10) reported a clinical benefit when ADT—most
often single agent bicalutamide—was given to patients with salivary ductal carcinoma, with 50% of
patients experiencing clinical benefit (i.e., stable disease, n = 3; partial response, n = 2) [167]. A case
report has also reported favorable outcomes when ADT was combined with radiation therapy in a
patient with AR-positive salivary gland cancer [168]. A single arm Phase II study testing enzalutamide
in AR-positive salivary gland cancers is ongoing [clinicaltrials.gov: NCT02749903].
5. Conclusions
AR signaling is involved in a number of normal physiologic processes, and there is varying levels
of evidence for its role in promoting cancer growth and progression across an array of malignancies.
To date, prostate cancer remains the only malignancy with Level 1 evidence supporting the use of
AR-directed therapies as an integral part of its treatment paradigm. However, mounting preclinical,
epidemiologic and early phase clinical trial data support the further exploration of these drugs in
diseases as varied as breast and salivary gland cancers, and it is likely that in the ensuing decade next
generation AR-directed drugs will extend their reach beyond prostate cancer.
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Abstract: Prostate cancer is a leading cause of cancer-related death in men worldwide. Aberrant
signaling in the androgen pathway is critical in the development and progression of prostate cancer.
Despite ongoing reliance on androgen receptor (AR) signaling in castrate resistant disease, in addition
to the development of potent androgen targeting drugs, patients invariably develop treatment
resistance. Interactions between the AR and PI3K pathways may be a mechanism of treatment
resistance and inhibitors of this pathway have been developed with variable success. Herein we
outline the role of the PI3K pathway in prostate cancer and, in particular, its association with androgen
receptor signaling in the pathogenesis and evolution of prostate cancer, as well as a review of the
clinical utility of PI3K targeting.
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1. Introduction
Prostate cancer is the second most common non-cutaneous cancer in men and the fifth cause of
cancer death in men worldwide [1]. The understanding that androgen receptor signaling continues to
influence the evolution and development of metastatic castrate-resistant prostate cancer (mCRPC) has
prompted the development of novel androgen pathway targeting agents such as enzalutamide and
abiraterone acetate. These drugs have yielded practice-changing results with improvements in overall
survival as well as a number of meaningful surrogate endpoints. Both enzalutamide and abiraterone
are now licensed for the treatment of mCRPC pre- or post-chemotherapy [2–5].
However, resistance to these agents invariably develops via multi-factorial mechanisms [6,7].
It is generally believed that strategies to target inherent and or acquired resistance will lead to more
efficacious therapeutic combinations. Activation of the phosphatidylinositol 3-kinase (PI3K) pathway
is seen commonly in castrate-resistant disease, and this pathway may represent a therapeutic target
with which to overcome treatment resistance. Herein we outline the role of the PI3K pathway in
prostate cancer and, in particular, its association with androgen receptor signaling in the pathogenesis
and evolution of prostate cancer as well as a review of the clinical utility of PI3K targeting.
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2. The Androgen Receptor Pathway
The AR is a ligand-dependent nuclear transcription factor expressed in a variety of tissues which,
in the absence of ligand, remains in the cytosol bound to heat shock proteins (Hsps). Though numerous
ligands interact with the AR, its predominant native ligands are the androgens, 5α-dihydrotestosterone
(DHT) and testosterone. The binding of these ligands to the AR initiates male sexual development and
pubertal changes in addition to maintaining libido, spermatogenesis, muscle mass, erythropoiesis and
bone mineral density in adult males [8].
Once the AR is engaged its effects manifest via three mechanisms. Firstly, classical AR signaling
occurs when androgen binds to the ligand binding domain (LBD) to displace the Hsps triggering
AR dimerization, phosphorylation and conformational change leading to exposure of the nuclear
localization sequence (NLS). The AR then translocates to the nucleus and the DNA binding domain
(DBD) binds to androgen responsive elements (AREs) to induce transcription of specific AR-responsive
genes that recruit transcription co-activators and co-suppressors [9,10]. Alternatively, the androgen/AR
complex can also trigger second messenger pathways leading to activation of several signaling cascades
including MAPK/ERK and AKT [10,11]. This occurs in the cytosol through non-nuclear signaling
and is rapid in onset as compared to classical signaling [10,12]. Thirdly ligand-independent activation
of the AR is possible via growth factors (such as cytokines e.g., IL-6 [13,14]) and subsequent protein
kinase and MAPK pathway activation, phosphorylation of the AR or co-activator stimulation such as
insulin-like growth factor (IGF) activation of the AR [15,16]. Such alternative activation can stimulate
distinct genes compared to classical AR signaling and may be particularly important in mCRPC [6].
In the normal prostate gland, AR is expressed in the stromal and epithelial compartments [12,17];
postnatal development of the gland is dependent on reciprocal signaling between these two
compartments [18]. AR is expressed in both basal and luminal cells of the prostatic epithelium
where its primary role is to promote expression of genes involved in terminal differentiation, secretion
and suppression of proliferation to maintain homeostasis [12,19–24].
3. AR Signaling in Prostate Cancer
Aberrant AR signaling is critical to the evolution of prostatic carcinogenesis. The AR has
been shown to be necessary for cell proliferation, survival and invasion in early and late prostate
cancer [25–27]. Rates of cell proliferation and programmed cell death are balanced in the normal
prostatic epithelium but this balance is lost in prostate cancer cells [28]. The mechanism for the switch
from homeostatic to proliferative AR signaling in prostate cancer is unknown [12]. AR-regulated
cancer-specific gene fusions are relatively common and may play a role. Fusion of the ARE-containing
promoter from the AR target gene TMPRSS2 to the coding sequence of several members of the
Ets family has been well-described [29,30]. These fusions result in AR-driven production of Ets
transcription factors potentially leading to proliferation and promotion of cell survival. These fusions
however are not present in all tumors. Alternatively, studies mapping genomic binding sites of the AR
using ChIP technology have revealed that direct AR binding to aberrant targets may drive prostate
pathogenesis [31].
The reliance of prostate cancer on AR signaling has led to the development of potent androgen
pathway targeted treatments. Despite initial responses in many however, resistance to these
agents is inevitable and remains an intractable problem. Resistance to these therapies may occur
broadly through at least three mechanisms [6,10,12,15,24,32–35]: (1) AR-independent activation of
AR-dependent pathways via bypass mechanisms, such as through up-regulation of glucocorticoid
receptor expression [32]; (2) De-differentiation such as BRN2-mediated trans-differentiation to
neuroendocrine prostate carcinoma [36]; and (3) The most commonly targeted mechanism, direct
reactivation of the AR and its signaling despite castrate levels of androgens. The third mechanism
can occur via AR gene amplification or AR protein overexpression. It may be ligand-dependent,
such as intra-tumoral androgen synthesis activating classical signaling and AR LBD mutations
leading to increased sensitivity to agonists or alternate non-androgen ligands [37,38]. Conversely,
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AR reactivation may also be ligand-independent; examples include AR splice variants resulting in
constitutive activation [39–42] (reviewed by Sprenger and Plymate [43]) or AR activation through
other proliferation pathways. The PI3K pathway may be involved in more than one of the above
mechanisms through non-nuclear interactions between ligand-activated AR and PI3K [10,12] and
direct stimulatory feedback from the PI3K pathway [44].
4. The PI3K Signaling Pathway
PI3Ks are a family of lipid kinases that regulate anabolic and catabolic activities in the cell through
phosphorylation of the 3′-hydroxyl group of phosphoinositides and phosphatidylinositol. PI3Ks are
divided into three classes according to their preferred substrate and sequence homology with class IA
thought to be most relevant to human cancers [45].
Class IA PI3Ks are heterodimers made up of a regulatory subunit (p85α, p55α, p50α, p85β or
p85γ) and a catalytic subunit (p110α, β or δ) that can be activated by receptor tyrosine kinases,
G-protein coupled receptors or oncogenes [46,47]. Following stimulation, the catalytic subunit
of PI3K phosphorylates phosphatidylinositol-4,5-biphosphate (PIP2) to phosphatidylinositol-3,4,5-
triphosphate (PIP3), a reaction negatively regulated by the phosphatase and tensin homolog
chromosome 10 (PTEN) and INPP4B. PIP3 acts as a second messenger to propagate intracellular
signaling by binding pleckstrin homology domains. This signaling cascade eventually leads to
AKT activation through phosphorylation by PDK1 and the mTORC 1/2 complexes. AKT, in turn,
phosphorylates several cellular proteins which regulate cellular processes including cell growth,
survival, proliferation, metabolism and angiogenesis through effectors such as p27, BAD, glycogen
synthetase kinase 3 (GSK3) and forkhead box O (FOXO) transcription factors [46].
PIK3CA, PIK3CB and PIK3CD genes encode the p110α, β and δ isoforms respectively. The p110α
and 110β isoforms are both widely expressed but p110δ is generally only found in leucocytes. Both the
alpha and beta isoforms generate PIP3 but have differing roles: p110α is mainly found in the cytoplasm
and is crucial in insulin signaling, glucose metabolism and G1 cell cycle entry while p110β is found in
the nucleus and is important in DNA synthesis and replication and cell mitosis [48]. Both isoforms
have been implicated in human cancer. Oncogenicity of the p110α isoform is well established [49–52]
and mutations of PIK3CA play a causative role in the development of many cancer types (reviewed by
Samuels [53]). PIK3CB and PIK3CD genes are rarely mutated in cancers but are often amplified
or over-expressed [54]. Aberrant PI3K signaling in cancer can also occur via PTEN abnormalities
including mutations, promotor hypermethylation or loss of heterozygosity; AKT isoform mutations or
amplifications can occur as well (reviewed by Sadeghi and Gerber [55]).
5. PI3K Pathway Activation in Prostate Cancer
Aberrations in PI3K/AKT/mTOR signaling have been identified in approximately 40% of early
prostate cancer cases and 70–100% in advanced disease [56,57]. In particular, loss of PTEN leading
to constitutive activation of the PI3K pathway has been documented in 30% of primary and 60% of
castrate-resistant prostate cancers [58]. Activation of the PI3K pathway is associated with resistance
to androgen deprivation therapy, disease progression and poor outcomes in prostate cancer [59–62].
Over-activation via PTEN loss has been shown to initiate prostate cancer development. Varying rates
of prostatic hyperplasia and cancer are seen in mouse models with heterozygous loss of PTEN [63–66]
and combined deletion of a second tumor suppressor gene can induce prostate cancer with complete
penetrance in some models [67]; heterozygous models failed to develop metastatic disease however.
Conditional PTEN knockout mice though can mimic the course of human prostate cancer with
progression from hyperplasia to invasive cancer to metastatic disease [68]. Moreover, pre-clinical data
demonstrate that some PTEN-deficient neoplasms, including prostate cancer, particularly activate the
PI3K pathway through the p110β isoform of the PI3K catalytic subunit [69–71]. Ablation of p110β but
not p110α inhibits downstream AKT signaling resulting in reduced tumorogenesis in these models.
Importantly however, selective p110β inhibition only temporarily inhibits signaling in PTEN deficient
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models because it removes feedback inhibition on receptors which in turn up-regulate signaling
via p110α [72]. Combined inhibition of p110α and p110β results in more sustained suppression of
signaling with improved tumor shrinkage in PTEN null models of prostate cancer as compared to
p110β inhibition alone.
The association of PI3K pathway activation with castrate-refractory disease suggests that a critical
component of the poor prognostic value of PI3K aberrations may be its interaction with androgen
signaling. Additionally, responses to AR inhibitors in prostate cancers with PTEN loss may depend on
the level of PI3K pathway activation.
6. Interaction of PI3K and AR Signaling
Despite the association outlined above, the effect of PI3K activation on prostate cancer growth
pre-clinically is not dichotomous as some cell lines with PTEN loss (e.g., LNCaP) retain sensitivity to
castration, while the robust response to castration in de novo disease suggests that most PTEN null
tumors retain some sensitivity to androgen deprivation. The mechanism of the interaction between
these two pathways remained unclear until relatively recently.
Two landmark papers defined the interplay between PTEN loss/PI3K activation and AR signaling
in the development of prostate cancer [56,73]. Carver et al. first demonstrated in a series of studies
on PTEN deficient murine and human cell lines that pharmacological PI3K inhibition increased
AR protein thereby activating AR-related gene expression through a HER3 dependent mechanism
(HER2 and Her3 promote AR activity and stability); similar effects were seen with AKT inhibition.
They cross-validated this data in human samples indirectly demonstrating that a gene set enrichment
score (GESA) of AR activity was significantly repressed in PTEN null human samples, as well as
being associated with decreased HER2 expression [74,75]. Thereafter, they also demonstrated the
inverse relationship with AR inhibition being associated with upregulated AKT signaling as a result
of increased phosphorylation of AKT target genes such as GSK-alpha and PRAS40. The mechanism
was determined to be through AR inhibition causing downregulation of the androgen dependent
immunophilin FKBP5 that in turn is a chaperone for the AKT phosphatase PHLPP [8,76]. Finally, to
confirm their finding of cross-regulation between the AR and PI3K pathways, they tested the effect of
single pathway and combined pathway inhibition on PTEN deficient models. While single pathway
inhibition with either enzalutamide or BEZ235 (a PI3K inhibitor) only had modest cytostatic effects,
the combination of AR and PI3K pathway inhibition (in particular PI3K and/or mTORC 1/2) or PI3K
inhibition and HER2/3 inhibition led to significant tumor reductions.
Utilizing a PTEN conditional murine prostate cancer model, Mulholland et al. demonstrated
that PTEN loss suppresses AR transcriptional output and generally drives gene expression towards
a castrate-like phenotype. To determine how PTEN loss causes suppression of AR transcriptional
output, they used a doxycycline-dependent PTEN loss murine model. They found PTEN re-expression
did not affect AR expression but did lead to reduced expression of EGR1 and c-JUN transcription
factors, factors that are known to be up-regulated particularly in CRPC and to promote cancer growth
in an androgen-depleted environment through direct interaction with and downregulation of the
AR [77,78]. Through Network Component Analysis, they showed that PTEN re-expression was
associated with reduced transcription factor activities (TFAs) of EGR1 and c-JUN followed by increased
AR TFA. Reduced AR TFA seen in PTEN null models can be reversed by mTOR inhibition, suggesting
involvement of the PI3K/AKT/mTOR pathway as seen by Carver et al. Additionally, Mulholland et al.
found that downregulation of FKBP5/PHLPP by AR inhibition/loss may release the negative feedback
on the AKT pathway to promote AKT-dependent, AR-independent cell growth. They showed more
significant tumor regressions with dual pathway inhibition via Enzalutamide and rapamycin rather
than single pathway inhibition in both PTEN null/AR+ prostate cancer cell lines and PTEN null mice.
Given the complexity of the AR and PI3K pathways, they likely interact at numerous levels.
AR-induced PI3K stimulation may also occur through Src-mediated non-nuclear signaling, particularly
in the context of ADT [79,80]. Androgen-bound AR can form a complex with Src to induce cell
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proliferation pathways. Aberrant Src signaling is present in prostate cancer cells. In low passage,
androgen sensitive LNCaP prostate cancer cell lines, Src signaling is androgen-dependent. High
passage cell lines however demonstrate constitutively activated AR/Src-induced proliferation in the
absence of androgen [81]. AR and PI3K cross talk may occur through interactions of AR/Src and
the p85α subunit of PI3K may trigger downstream pathway activation to promote cell survival in
androgen-deplete conditions [10]. These interactions may be particularly important in patients treated
with enzalutamide which prevents translocation of the AR into the nucleus promoting more cytosolic
interactions which stimulate non-nuclear signaling.
Though Mulholland and Carver proposed somewhat different mechanisms, they independently
demonstrated with both pharmacologic and genetic approaches PI3K/AKT activation via PTEN loss
promotes prostate cancer growth in the absence of AR signaling; as a result, they hypothesize that
strong suppression of AR-signaling with potent anti-androgen therapy may select for tumors with
PI3K pathway activation and repressed AR activity leading to CRPC. They showed that dual pathway
inhibition with androgen deprivation and a PI3K, AKT or mTOR inhibitor could lead to significant
tumor regression as compared to single pathway inhibition.
Subsequent studies have supported the presence of AR-PI3K pathway interactions. Zhu et al.
showed that conditional expression of human AR transgene in transgenic mice prostates not only
induced malignancy but also resulted in decreased AKT activation in the tumor cells [82]. They further
investigated the interaction between the PI3K/AKT and AR pathways in a series of in vitro and in vivo
experiments [83] which confirmed a functional interaction between the pathways. They showed that
depletion of androgens by various means results in increased expression of phosphorylated AKT
and castration of conditional PTEN knockout mice increases AKT expression in prostate cancer cells.
Furthermore, they demonstrated decreased endogenous AR expression in PTEN-null prostatic cells.
7. Therapeutic Implications
Recognition of the role the PI3K pathway plays in the development and propagation of cancer has
led to the development of several PI3K inhibitors. Classes of drugs targeting the PI3K pathway and its
downstream targets include pan-class I PI3K inhibitors, isoform-selective PI3K inhibitors, rapamycin
analogues, active-site mTOR inhibitors, pan-PI3K/mTOR inhibitors and AKT inhibitors (Figure 1).
Though some studies have yet to be reported, early studies in both pan-PI3K class I inhibitors and
isoform-specific PI3K inhibitors have shown limited activity due to a combination of dose limiting
toxicities, inadequate target inhibition and likely up-regulation of compensatory pathways [84–86].
For example, Hotte et al. presented data at ASCO 2013 on the use of PX-866, an irreversible pan-isoform
inhibitor of class I PI3K, in men with mCRPC [87]. In this single-arm phase II study, 43 docetaxel-naïve
men with mCRPC were treated with PX-866 with a primary endpoint of lack of progression at 12 weeks.
Overall, PX-866 was well tolerated, but only 12 patients (28.4%) were progression-free at 12 weeks
with one confirmed prostate-specific antigen (PSA) response. This agent did not meet the a priori
benchmarks for further development as a single agent in unselected patients. Trials of monotherapy
with AKT or mTOR inhibitors have also failed to progress. Burris et al., reported at ASCO 2011
the safety, pharmacokinetics and pharmacodynamics of the pan-AKT inhibitor GSK2141795 in nine
prostate cancer patients of whom five were documented to have had PTEN loss [88]. In this cohort,
seven patients had measurable responses, and six had stable disease with two having treatment
durations in excess of 180 days; based on the phase I study results, development of this agent as
monotherapy was not pursued, however. A recent systematic review of mTOR inhibition for mCRPC
similarly found limited efficacy [89].
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Figure 1. PI3K pathway targeting agents in development for the treatment of prostate cancer.
There are a number of explanations for the lack of efficacy seen in these trials of single pathway
inhibition. Clinical correlation of the pre-clinical data on AR and PI3K pathway crosstalk was suggested
in a phase I/II trial of everolimus, an mTOR inhibitor, in combination with gefitinib in patients with
metastatic CRPC [90]. Rapid PSA rises occurred which often declined upon treatment discontinuation.
In light of Carver and Mulholland’s work, these transient PSA rises may represent a surrogate marker
of AR reactivation and AR-dependent transcription as a result of mTOR inhibition.
8. Combined Therapeutic Targeting of AR and PI3K Signaling
If the mutual inhibition of both pathways is required, and from the results above it seems that PI3K
activation is not the sole route of standard androgen resistance, then the combination of AR targeting
and PI3K targeting would appear to be intuitive. Studies currently underway in prostate cancer are
particularly focused on using PI3K inhibitors to overcome castrate-resistance. Thus, PI3K inhibitors
are largely being tested in combinations in patients who have progressed on either enzalutamide or
abiraterone to test the hypothesis of emerging resistance to these agents via the PI3K pathway.
Hotte et al. presented the second part of their phase 2 study of PX-866 at ASCO GU 2015;
25 patients with progressive CRPC on abiraterone/prednisone were treated with a combination
of PX-866 and continued abiraterone/prednisone [91]. Six patients (24%) were progression-free at
12 weeks, but no objective or PSA responses (PCWG2) were seen. Similarly, in another phase 2
study presented at the same meeting, PI3K inhibition with BKM120 with or without AR inhibition
with enzalutamide failed to improve progression-free survival (PFS) in men with progressive CRPC
on enzalutamide [92]. However, AKT inhibition with ipatasertib in combination with abiraterone
improved radiographic PFS and overall survival (OS) in men with CRPC previously treated with
docetaxel [93]. Unlike the two previous studies, only a small portion (23/253) of these patients
had received treatment with a novel anti-androgen prior to enrolment. Two other phase 2 studies
have been published exploring the combination of the mTOR inhibitor, everolimus and bicalutamide.
Nakabayashi et al. reported a study of bicalutamide in combination with everolimus in which only
two of 36 patients (6%) treated with bicalutamide in combination with everolimus achieved a PSA fall
≥50% [94]. Thirty-one (86%) of the men had been treated with bicalutamide previously. Chow et al.
however, reported on 24 bicalutamide naïve men with CRPC treated with this combination based on a
historic PSA response rate of 25% for bicalutamide alone in CRPC [95]. Though they achieved a PSA
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response (50% PSA fall) rate of 62.5%, this level of activity was abrogated by a high rate (54%) of grade
3 or 4 adverse events attributable to treatment.
These studies raise the question of whether earlier PI3K pathway inhibition, prior to development
of castrate resistance or significant pre-treatment with androgen-targeted treatments, would be more
efficacious. Some pre-clinical models have shown more durable responses to dual AR and PI3K
pathway inhibition in castrate sensitive-cell lines as compared to castrate-resistant [96–98]. Another
issue may be patient selection as most of the data are in unselected, heavily pre-treated patients.
9. Biomarkers for PI3K Inhibition
The prolonged responses seen in two of the patients presented by Burris et al. raise the question
of whether patient selection may be another contributing factor to the lack of overall efficacy seen
in many of these trials. Attempts to identify subpopulations that will yield maximum benefit from
PI3K inhibitors are underway with testing for PIK3CA or AKT alterations and PTEN loss. Pre-clinical
data indicate that tumors with PIK3CA mutations or PTEN loss are more sensitive to PIK3CA and
AKT inhibition but the value of these markers in clinical practice is uncertain due to the complexity
of the pathway and unknown effects of these agents on the tumor microenvironment [99]. Some
PIK3CA mutations result in minimal activation of AKT as compared to PTEN loss suggesting that
AKT inhibitors may be more efficacious in cancers with AKT alterations and PTEN loss [99,100]. One
patient with mCRPC harboring a PIK3CA mutation treated with PX-866 on the phase I study achieved
a prolonged clinical response to the PI3K inhibitor [84]. However, the predictive value of PIK3CA
mutations has not been confirmed in other studies [85,101].
Most recently, de Bono, et al. presented data supporting PTEN loss as a predictor of response to
treatment with ipatasertib in combination with abiraterone acetate in men with mCRPC [102]. PTEN
expression was assessed by immunohistochemistry (IHC) in archival or fresh tumor samples and
genomic loss was detected by fluorescence in situ hybridization (FISH) and next generation sequencing
(NGS). Of the 253 patients randomized, PTEN IHC was evaluable in 165 with PTEN loss detected in
71 (41%). There was good concordance between IHC, FISH and NGS results. Median radiographic
progression-free survival (rPFS) was 5.6 months vs. 7.5 months in the non-PTEN loss abiraterone
plus placebo arm and abiraterone plus ipatasertib arms respectively. PTEN loss was associated with a
shorter rPFS in the placebo plus abiraterone arm and a greater treatment effect in the 400 mg ipatasertib
plus abiraterone arm (4.6 months and 11.5 months). Based on these results, this combination is planned
to proceed to a phase III trial.
10. Current Clinical Trials of PI3K Pathway Inhibitors in Prostate Cancer
Table 1 details the different agents in development and the trials currently being conducted
with these agents. Three of the five trials actively recruiting involve PI3K/AKT/mTOR agents in
combination with anti-androgen therapy while another is examining combination with docetaxel.
GSK2636771 is a p110β isoform-specific inhibitor with preliminary signs of activity in PTEN-deficient
tumors [103]. AZD8186 inhibits both p110β and -δ isoforms and has demonstrated anti-tumor
effects in vitro as monotherapy and in combination with docetaxel in prostate cancer models [104].
Interestingly, AZD8186 showed activity in both PTEN null and PTEN wildtype models. LY3023414
is a dual class I PI3K and mTOR inhibitor with phase I monotherapy data in advanced solid
tumors [105]. AZD5363, on the other hand, is an inhibitor of AKT isoforms 1, 2 and 3 which
has synergy with enzalutamide in preclinical models of enzalutamide-resistant prostate cancer and
docetaxel in CRPC [106]. AZD5363 in combination with docetaxel is proceeding to a phase II study
following determination of the recommended dose in the recently published ProCaid study in men
with mCRPC [107]. In this study, 10 patients were treated, of whom seven (70%) had a >50% reduction
of PSA from baseline to 12 weeks. The most common toxicities were rash and diarrhea with self-limiting
hyperglycemia seen in all patients.
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11. Conclusions
The androgen receptor and PI3K pathways are the two most commonly deregulated pathways in
prostate cancer. There is evidence that PI3K signaling is involved in the evolution to castrate-resistant
disease, a form of prostate cancer that remains lethal despite recent advances. This understanding
has led to the development of several drugs targeting the PI3K pathway and its downstream targets
but, unfortunately, early results overall have been disappointing. Adding complexity to early trials is
the issue of interpreting a rising PSA, the most commonly measured marker of response in prostate
cancer, in the context of potential activation of AR transcription with resultant PSA rises following
PI3K pathway inhibition. Pre-clinical data supporting combined pathway inhibition coupled with
the lack of substantial single-agent activity have prompted studies of PI3K pathway inhibition in
combination with androgen pathway inhibition and/or additional downstream AKT/mTOR inhibition;
the results continue to be mixed with efficacy often compromised by toxicity. There is a suggestion
that earlier treatment with these agents, to prevent rather than overcome castrate-resistance, may be a
useful strategy.
Ongoing studies to address the optimal timing, sequence and combinations of these treatments in
addition to potential predictive biomarkers are underway. Given the reciprocal activation of p110α
upon p110β inhibition in PTEN null tumors, it will be interesting to see the outcomes with the
isoform-specific PI3K inhibitors in combination with enzalutamide. It is unclear whether the preferred
agent should target multiple nodes of the pathway, such as with LY3023414, or induce pan-isoform
inhibition of a single node, such as with AZD 5363. Despite their promise, it is yet to be seen whether
these strategies can successfully overcome endocrine resistance to yield a significant improvement in
outcomes for patients.
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Abstract: Prostate cancer is the second leading cause of death from cancer among males in Western
countries. It is also the most commonly diagnosed male cancer in Japan. The progression of prostate
cancer is mainly influenced by androgens and the androgen receptor (AR). Androgen deprivation
therapy is an established therapy for advanced prostate cancer; however, prostate cancers frequently
develop resistance to low testosterone levels and progress to the fatal stage called castration-resistant
prostate cancer (CRPC). Surprisingly, AR and the AR signaling pathway are still activated in most
CRPC cases. To overcome this problem, abiraterone acetate and enzalutamide were introduced for
the treatment of CRPC. Despite the impact of these drugs on prolonged survival, CRPC acquires
further resistance to keep the AR pathway activated. Functional molecular studies have shown
that some of the AR collaborative transcription factors (TFs), including octamer transcription
factor (OCT1), GATA binding protein 2 (GATA2) and forkhead box A1 (FOXA1), still stimulate
AR activity in the castration-resistant state. Therefore, elucidating the crosstalk between the AR and
collaborative TFs on the AR pathway is critical for developing new strategies for the treatment of
CRPC. Recently, many compounds targeting this pathway have been developed for treating CRPC.
In this review, we summarize the AR signaling pathway in terms of AR collaborators and focus on
pyrrole-imidazole (PI) polyamide as a candidate compound for the treatment of prostate cancer.
Keywords: androgen receptor; androgen receptor signaling pathway; coregulator; octamer
transcription factor 1; pyrrole-imidazole polyamide
1. Introduction
Prostate cancer is the major cause of death from cancer among males in Western countries.
For example, the American Cancer Society has estimated 180,890 new cases of prostate cancer and
26,120 deaths from the disease in the United States in 2016. The Australian Institute of Health and
Welfare estimated 18,138 new diagnoses and 3398 deaths from prostate cancer in 2016. This amounts
to 21.4% and 12.8% of all male deaths from cancer in each country in 2016. In Japan, although prostate
cancer is the seventh-leading cause of cancer death, recently both the number of cases and the mortality
rate due to prostate cancer have increased significantly. The increased population of older males is
presumed to be one of the contributors in Japan.
The androgen receptor (AR) signaling pathway plays an integral role in the progression of prostate
cancer. The AR is a member of the steroid hormone receptor superfamily. The AR is activated by
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ligands, such as dihydrotestosterone (DHT), and then functions as a transcription factor to modulate
the expression of its target genes. Approximately 80%–90% of prostate cancers are androgen-dependent
at the time of diagnosis [1–5]. Since the finding in the 1940s that castration inhibits the progression
of prostate cancer [6,7], androgen deprivation therapy (ADT), or castration, has become the most
effective and widely used treatment for unresectable prostate cancer, which includes metastasis and
recurrence after local therapies [8–11]. Through the combination of luteinizing hormone-releasing
hormone (LH-RH) analogs and anti-androgens, ADT decreases the production of androgens and
inhibits androgen binding to the AR. ADT can inhibit the progression of prostate cancer for up to
3 years, however, prostate cancer cells eventually adapt to low testosterone levels and progress to
castration-resistant prostate cancer (CRPC). Surprisingly, even in a low testosterone environment,
AR and its target genes, including prostate-specific antigen (PSA), are still highly expressed in the
majority of CRPC lesions [10–12]. Indeed, the rise in serum PSA levels in patients that no longer
respond to ADT shows that CRPC is not hormone-insensitive. In addition, anti-androgen drugs can
work as AR agonists in CRPC [13]. Some tumours acquire genomic amplifications of the AR gene,
which increases their sensitivity to androgens and maintains AR signaling under the low testosterone
environment of ADT [14,15]. About 30% of CRPC cases have amplifications of the AR locus [16].
Using AR-overexpressing cells, an in vitro study showed that first generation anti-androgen drugs
promote AR nuclear translocation, DNA binding and co-activator recruitment [17]. AR stability
also relates to AR hypersensitivity. Under physiological androgen levels, the AR is involved in a
negative feedback where it suppresses the expression of genes that promote its translation. In ADT,
the testosterone level is too low for the AR to inhibit these genes, but is still sufficient to stimulate
AR signaling in CRPC [18]. Furthermore, deregulation of the interplay of AR with AR collaborating
factors commonly occurs in CRPC cells [19].
The extragonadal androgens synthesized in adrenal or CRPC cells are one of the key mechanisms
for sustaining AR signaling in CRPC. They activate the cytochrome P450 (CYP) family, which facilitates
the unusual conversion of cholesterol to androgen under low testosterone conditions. Thus,
the expression of androgen-dependent genes is induced by a very small amount of androgens
under castration [20]. Abiraterone acetate and enzalutamide strongly target the AR pathway and
improve cancer specific survival in the case with CRPC [21–23]. Abiraterone is a dual inhibitor of
the 17α-hydroxylase and 17,20-lyase, which belong to the CYP17 family and play a key role in the
novel androgen synthesis pathway in CRPC cells [24]. Enzalutamide is a novel AR antagonist that
binds directly to AR with a higher affinity than bicalutamide or flutamide and targets multiple steps
including AR nuclear translocation, DNA binding, and co-activator recruitment [21]. Despite the
development of these notable drugs in the last decade, CRPC still evolves to acquire further resistance
to these drugs. Aberrant AR function and cross-talk with factors that activate the AR pathway are
assumed to be involved in this cancer evolution. Thus, the study of AR signaling pathways and
their collaborative factors will facilitate greater understanding of the mechanisms underlying the
progression of advanced prostate cancer as well as the development of novel drugs.
This article reviews the AR signaling pathway in CRPC as well as the development of novel
therapeutic medicines targeting AR collaborators, especially collaborative DNA binding transcription
factors (TFs).
2. AR Structure and Collaborating Factors in AR Signaling Pathway
The AR contains an N-terminal domain (NTD; 555 amino acids encoded by exon 1),
a DNA-binding domain (DBD; 68 amino acids encoded by exons 2 and 3), a hinge region, and a
ligand binding domain (LBD; 295 amino acids encoded by exons 4–8) [25]. The NTD includes the
activation function (AF) 1 element, which enables the transactivation of the AR [26]. The LBD is located
in the C-terminal region where androgens, such as DHT, bind in the first step of the androgen signaling
pathway. After activation by ligands, the AR translocates into the nucleus and then binds to specific
39
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DNA sequences, called androgen response elements (AREs). The DBD plays an important role at this
stage involving AR nuclear localization, homodimer formation, and specific DNA binding.
The increased frequency of functional AR mutations in CRPC enhances resistance to ADT.
In addition, ADT drugs mediate a conformational change in the AR [27,28]. The proportions of
AR mutations in prostate cancer are 40% in the NTD, 49% in the LBD, and 7% in the DBD [29].
Important mutations cause gain-of-function in the LBD [30], one of the most common of which is
T878A. Because this mutation broadens ligand specificity, the anti-androgen flutamide, as well as other
steroids, become partial agonists [31,32]. This mutation can be found in approximately one-third of
CRPC [33,34], whilst the other mutations appear to be rare [35].
Previous reports have shown that constitutively active AR isoforms (splice variants: ARVs) were
detected in CRPC cell lines and patient tissues [36]. These ARVs have common structural characteristics
of the NTD, encoded by exons 1 and 2 or exons 1 to 3, followed by a truncated C-terminal domain
(CTD) originating from introns 2 or 3. Among these ARVs, AR-V7, encoded by exons 1 to 3 with the
cryptic exons, is the most abundantly detected variant in prostate cancer [37]. Lacking the LBD in
the CTD, it is expected that: (1) enzalutamide is unable to bind to AR-V7; and (2) AR-V7 is activated
independently, despite the low androgen levels due to abiraterone acetate. A recent report showed
that positive AR-V7 expression in circulating prostate cancer cells was associated with the resistance to
enzalutamide and abiraterone acetate [38].
The regulation of AR-targeted gene expression requires the recruitment of coregulators to
regulatory regions of the AR protein. Coregulators promote (named coactivators), or inhibit (named
corepressors) AR transactivation. Although coregulators do not need to bind DNA, they recruit general
TFs associated with RNA polymerase II (Rpol II) to gene promoters [39]. The actions of AR coactivators
have been well characterized for PSA, a classical AR-regulated gene. The AR and coactivator complex
first occupies the PSA enhancer region and then bridges to the promoter, which allows Rpol II to track
to this region [40]. Since the discovery of steroid receptor coactivator-1 (SRC-1), more than 200 nuclear
receptor coregulators have been identified [39,41–43]. The elevated expression of SRC-1, 2 and 3 is
related to poor prognosis of patients with localized prostate cancer as well as CRPC [44].
In addition to AR coregulators, TFs that collaborate with AR are also important for androgen
responsive gene expression. Generally, most genes are packed and condensed into nucleosomes by
being wound around the four core histones [45]. Thus, nucleosomes prevent the AR from binding
to AREs. Some TFs make histone modifications to support AR binding to target regions. Wang et al.
identified 90 functional AR binding regions in chromosomes 21 and 22 using high-throughput
technologies [46]. Interestingly, they reported that the canonical ARE (AGAACAnnnTGTTCT) [47]
existed in only 10% of these AR binding regions, whilst 68% of the AR binding regions harbored
non-canonical, but functional AREs where motifs for three TFs, GATA binding protein 2 (GATA2),
forkhead box A1 (FOXA1), and octamer transcription factor (OCT1), were significantly enriched [46].
GATA and FoxA family members are known to play important roles in liver and gut development
in mouse embryos [48]. In vivo footprinting analysis revealed both families commonly bind to their
target gene elements first in nascent liver buds and gut endoderm to induce development [48,49].
Zaret et al. [48] proposed these factors as pioneer factors, which are able to bind DNA, even in
condensed chromatin, and facilitate DNA binding of other factors by opening the chromatin [50,51].
Consistent with the results of liver developmental studies, one member of the FoxA family,
FOXA1, works as a pioneer factor in the AR and estrogen receptor (ER) pathways in prostate cancer
and breast cancer cells [52–54]. Interestingly, although overexpression of FOXA1 is associated with
poor prognosis in prostate cancer [55], ERα-positive breast cancer with high FOXA1 expression shows
favorable sensitivity to endocrine therapy [56]. Lupien et al. [57] reported that FOXA1 is recruited
into target DNA regions according to the methylation of histone H3 lysine 4 (H3K4), which differs
between cell types. These data indicate that the pioneer factor FOXA1 is first recruited to a specific
DNA binding region, then facilitates the recruitment of other collaborating factors, and finally induces
cell type specific gene expression.
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GATA family proteins are also recruited to compact chromatin [54]. GATA2 and 3 are pioneer
factors for prostate cancer and breast cancer [48]. GATA2 is required for AR binding in prostate
cancer cells, whereas GATA3 is necessary for ER mediated gene expression in breast cancer [46,58].
High expression of GATA2 is related to high risk of prostate cancer [59]. Recent ChIP combined with
genome-wide studies have shown that GATA2 promotes the AR pathway by (1) binding to enhancer
regions before androgen stimulation; (2) modifying the histone code to allow the AR easy access;
and (3) establishing chromatin loop formation [60]. In addition, GATA2 cooperates with FOXA1 to
perform these actions regardless of the hormone status [60]. This means that GATA2 is functionally
similar to FOXA1 in the AR pathway. Like FOXA1, which induces chromatin looping for AR target
gene expression in CRPC cells, GATA2 establishes the loop via the recruitment of loop formation factor
mediator complex subunit 1 (MED1) [60–62]. These data indicate that GATA2 and FOXA1 correlate
with abundant AR hypersensitivity in CRPC cells.
OCT1 acts downstream of these pioneer factors. For prostate cancer cells, GATA2 and OCT1
work in a hierarchical network as GATA2 is recruited with AR, followed by OCT1 binding to its
motifs [46]. OCT1 is comprised of two DNA-binding domains that are connected to each other by
a flexible linker [63]. Previous reports showed that OCT1 is weakly recruited to some AR binding
regions, and OCT1 reduced TGM2 and C20orf77 expression by inhibiting AR activity [64,65]. These data
suggest that OCT1 recruitment is limited to specific AR regulated regions where it plays an OCT1
specialized function. Interestingly, some reports indicate that OCT1 is related to the cellular stress
response [66,67]. Tantin et al. [67] reported that fibroblasts deficient in OCT1 showed hypersensitivity
to radiation, doxorubicin, and hydrogen peroxide and harbored elevated levels of reactive oxygen
species. Kang et al. [66] showed that a large number of stress response-related genes were regulated by
OCT1. These stress response genes included DNA repair genes, such as poly(ADP-ribose) polymerase
1 (PARP1), and metabolic genes [68]. PARP1 plays an integral role in DNA repair, in addition,
a recent report showed that PARP1 was recruited to AR binding regions and promoted AR function in
advanced prostate cancer [69]. These data indicate that OCT1 might correlate with drug resistance in
prostate cancer by enhancement of the AR and DNA repair pathways. Consistent with these reports,
we previously reported that high OCT1 expression in prostate cancer tissues is related to poor prognosis
and high AR expression [70]. These data raise the hypothesis that the major downstream target genes
of the OCT1 and AR complex play an important role for prostate cancer progression. Using chromatin
immunoprecipitation sequencing (ChIP-Seq) and microarray techniques, we identified acyl-CoA
synthetase long-chain family member 3 (ACSL3) [71] as the most highly expressed gene regulated
by AR and OCT1 in LNCaP cells [72]. In addition, we also revealed that high ACSL3 expression in
prostate cancer tissues was associated with poor patient prognosis [72].
In addition to these primary factors, several groups have subsequently identified ETS
proto-oncogene 1, transcription factor (ETS1), ERG, ETS transcription factor (ERG), CCAAT/enhancer
binding proteins (C/EBPs), nuclear factor I (NFI), NK3 homeobox 1 (NKX3-1), runt related transcription
factor 1 (RUNX1), and forkhead box P1 (FOXP1) as other AR collaborative TFs [65,73–78]. The roles
of C/EBPs and NFI in the AR signaling pathway are still unknown. Both factors have various
subtypes (e.g., C/EBPα, β, NFIA, and NFIB), and each has different effects depending on AR response
genes [65,79,80].
ETS1 is a member of the ETS (v-ets erythroblastosis virus E26 oncogene) family. Massie et al. [73]
reported the enrichment of ETS consensus binding motifs and non-canonical AREs in about 70% of
AR binding promoter regions. ETS1 was known to activate AR, as well as multiple cancer-associated
pathways, which resulted in enhanced energy metabolism, cancer cell growth and survival [81,82].
Consistent with these data, Smith et al. [83] reported that increased ETS1 expression is related to
high-grade prostate cancer and the resistance to flutamide in prostate cancer cell lines. In addition,
ETS1 directly interacts with AR and stimulates NKX3-1 expression [73,84].
The NKX family belongs to the homeodomain class of TFs, which are critical regulators of
whole organ development [85]. The role of NKX3-1 in tumor progression is still controversial. Since
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the NKX3-1 gene region is frequently lost in prostate cancer and this leads to increase vascular
endothelial growth factor-C (VEGF-C) expression, NKX3-1 is known as a tumor suppressor gene [86,87].
On the other hand, a previous study showed that NKX3-1 is an AR response gene as well as an AR
collaborating TF [75]. This study suggested that NKX3-1 forms a positive autoregulatory loop with AR
and FOXA1, and mediates cancer cell survival via induction of RAB3B, a member of the RAS oncogene
family [75].
Similar to ETS1, ERG belongs to the class I ETS family (ERG, ETS1 and 2, ETS variant: ETV1–5,
ELK1, ELK3, ELK4, ETS2 repressor factor: ERF, FEV, Fli-1 proto-oncogene: FLI1 and GA binding
protein transcription factor alpha subunit: GABPα) and possesses oncogenic properties, which activate
the phosphoinositide 3-kinase (PI3K) pathway to promote prostate cancer progression [88,89]. On the
other hand, chromosomal rearrangements between TMPRSS2 and ERG (TMPRSS2:ERG), made by
AR binding to the “breakpoint ARE” in this region, occur in around 50% of prostate cancers [90–93].
Interestingly, Bowen et al. [94] recently reported that NKX3-1 bound to the region adjacent to the
“break point ARE” to prevent the TMPRSS2:ERG rearrangement and its expression.
Unlike ETS1, ERG has a unique role in the AR signaling pathway. Yu et al. [76] showed that
approximately 44% of AR binding sites overlap with ERG binding sites where ERG repressed AR
activity. Indeed, ERG represses a number of prostate epithelium-specific genes (PSA, solute carrier
family 45 member 3: SLC45A3, microseminoprotein beta: MSMB, and secretoglobin family 1D
member 2: SCGB1D2). In other words, these genes are prostate epithelial differentiation markers [95].
Yu et al. [76] suggest that TMPRSS2:ERG activates a malignant regulatory switch that inhibits
physiological AR signaling by induction of enhancer of zeste 2 polycomb repressive complex 2
subunit (EZH2). TMPRSS2:ERG expression decreases during ADT, but is reactivated in the castration
resistant state [96]. EZH2, which is a member of polycomb repressive complex 2 (PRC2), mediates the
trimethylation of H3K27 [97]. This means that EZH2 represses target gene expression, and facilitates
cellular dedifferentiation. For example, the tumor suppressive gene, DAB2 interacting protein (DAB2IP)
was inhibited by EZH2/PRC2 [98]. EZH2 is also overexpressed in hormone-refractory metastatic
prostate cancer, suggesting EZH2 promotes AR independent growth [97]. Furthermore, Xu et al. [99]
has shown that EZH2 works not only as a methyltransferase, but also as an activator of target
genes that cooperate with AR. Unlike ERG, we have reported that the AR response gene RUNX1
functions as an AR collaborative factor to maintain AR activity. In addition, EZH2 is recruited to
the RUNX1 promoter to repress its expression [77]. The RUNX1 expression level in clinical prostate
cancer tissues is negatively associated with EZH2 expression, and decreased RUNX1 expression is
correlated with poor prognosis [77]. These data indicate that long-term ADT and high EZH2 expression
in androgen-independent prostate cancer inhibits RUNX1 and the negative effect of RUNX1 on prostate
cancer progression. In addition to EZH2, Ma et al. [100] showed that the TMPRSS2:ERG activates SRY-box
9 (SOX9), which stimulates WNT signaling and tumor progression in a subset of prostate cancer.
Interestingly, previous reports have shown that high dose testosterone supplementation of
castrate-resistant cells inhibits their proliferation [101,102]. This negative feedback mechanism of the
AR signaling pathway might maintain prostate cancer in a well differentiated type of adenocarcinoma.
3. The Unique Features of Transcription Factors in Castration-Resistant Prostate Cancer
AR binding regions might keep changing with prostate cancer progression under a low
testosterone environment. Recently, Sharma et al. [103] elucidated the differences in AR binding
regions between ADT naïve prostate cancer and CRPC. Notably, 44% of genes with AR binding sites
unique to CRPC showed no response to androgen in prostate cancer cell lines [103]. These AR binding
sites are enriched in promoter regions and predominantly included E2F transcription factor (E2F),
v-myc avian myelocytomatosis viral oncogene homolog (MYC), and signal transducer and activator of
transcription (STAT) motifs compared to those in ADT naïve and prostate cancer cell lines [103].
E2F-1 activates genes related to G1–S transition and DNA synthesis and induces cell cycle
progression [104]. The expression of E2F-1 is regulated by the tumor suppressor gene RB transcriptional
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corepressor 1 (RB1). RB1 inhibits G1–S transition related gene expression by directly obstructing
the transactivation domain of E2F and the promoter activity of these genes [105]. Since RB1 loss
is frequently observed in CRPC, the RB1/E2F-1 complex could play a significant role in tumor
progression. A previous report suggested that loss of RB1 enhances AR activity via E2F-1 activation to
induce resistance to ADT [106].
c-MYC is known as an oncogenic transcription factor that regulates ribosomal RNA expression,
glutamine metabolism, and energy and reactive oxygen species [107–109]. Bernard et al. [110] reported
that c-MYC was regulated by the AR and was required for AR-dependent and AR-independent growth
in AR positive prostate cancer cell lines. Previous fluorescence in situ hybridization data showed the
specific amplification of the c-MYC gene in 72% of CRPC [111,112]. Some c-MYC repressed genes,
Bin1 and MXI1, were inactivated in advanced prostate cancer [113,114]. Consistent with the report by
Yu et al. [76] about the TMPRSS2:ERG/EZH pathway, Sun et al. [115] also reported that TMPRSS2:ERG
activates c-MYC and represses prostate epithelial differentiation genes.
STAT3 is regulated by the Janus kinase (Jak) family/interleukin 6 (IL-6) and is also oncogenic,
promoting cytosolic dimerization, nuclear translocation and DNA binding [116–118]. STAT3 activation
is observed in 82% of prostate cancer tissues compared to matched adjacent non-cancer tissues,
and elevated STAT3 activity was correlated with a malignant phenotype [119]. Interestingly,
Culig et al. [120] reported that IL-6 activates AR in androgen depleted conditions to promote the
growth of almost all prostate cancer cell lines. However, IL-6 stimulation inhibited LNCaP cell
proliferation regardless of STAT3 activation. In addition, a recent report showed that inhibition of
IL-6/STAT3 signaling in a phosphatase and tensin homolog (PTEN)-deficient prostate cancer model
promotes cancer progression [121]. These data indicate that the effect of STAT3 on prostate cancer
progression is still controversial. Reinforcing the report by Sharma et al. [103], a recent study shows
that the pluripotency transcription factor Nanog homeobox (NANOG) alters FOXA1 and AR target
genes during reprogramming of androgen-dependent prostate cancer cells to CRPC [122].
Collectively, these studies suggest that the role of the AR signaling pathway in prostate cancer
progression is more complicated than expected, because AR collaborating TFs are entangled with each
other and have differing effects on AR activity depending on testosterone levels and the duration of
anti-androgen drug treatment.
4. Development of Novel Drugs
4.1. Pyrrole-Imidazole Polyamide
Different classes of drugs are under investigation to inhibit AR collaborative TFs. In this section,
we review the development of one new class of compounds, pyrrole-imidazole (PI) polyamides,
before discussing specific examples of compounds that target AR collaborative TFs in the following
section. PI polyamides are small synthetic molecules made up of N-methylimidazole (Im) and
N-methylpyrrole (Py) amino acids, the side by side pairings of which recognize and attach to the minor
groove of DNA with high affinity and sequence specificity [123–125]. Im/Py pairs recognise G/C
nucleotides and Py/Py pairs bind to A/T and T/A nucleotides (Figure 1) [126,127].
In addition, the C-terminal β-alanine residue next to dimethylpropylamine (Dp) and the
γ-aminobutyric acid turns a unit, which enforces an antiparallel hairpin configuration and enhances
both DNA binding affinity and specificity [124,128,129]. Vector-assisted delivery systems are not
necessary for PI polyamide translocation to the nucleus. Following PI polyamide binding to DNA, the
minor groove is widened and the major groove is bent and compressed to block TFs binding [130].
Unlike most DNA targeted therapies, PI polyamides bind to DNA non-covalently without a drug
delivery system [131]. In addition, PI polyamides are fully resistant to biological degradation by
nucleases and do not induce unnecessary normal cell damage and carcinogenesis [132]. These are
advantages of PI polyamides compared to other chemical drugs.
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Figure 1. A schematic view of pyrrole-imidazole (PI) polyamide binding to a target DNA sequence.
Image of 1CVY [124] created with Open-Source PyMOL Molecular Graphics System, Version 1.7,
Schrödinger, LLC.
The pharmacokinetics of PI polyamides provide promise for future clinical applications.
Previous reports have shown that PI polyamides are not absorbed from the intestine [133].
After transvenous distribution in rat organs, PI polyamides were excreted into urine and bile without
any metabolism [133,134]. Matsuda et al. showed that PI polyamides accumulated in nuclei of kidney
cells in rats and were maintained for about two weeks without any drug delivery system [135,136].
Recently, Igarashi et al. [137] studied the possible clinical applications of PI polyamides using a primate
model. They developed an ointment including a PI polyamide targeting human transforming growth
factor beta (TGF-β) 1 and tested for hypertrophic scars in marmosets. The PI polyamide bound to
keratinocyte nuclei in marmosets and suppressed hypertrophic scarring without any side effects [137].
These reports are fundamental evidence for the clinical application of PI polyamides and increasing
interest in their use for AR and some AR collaborative TFs, such as OCT1 and ETS family genes.
4.2. Novel Drugs Targeting TFs Related to the AR Pathway
4.2.1. The Pioneer Factors (FOXA1 and GATA2)
Targeting the pioneer factor FOXA1 showed contradictory results for AR activity and prostate
cancer prognosis [138]. Increasing FOXA1 activity causes indiscriminate opening of closed chromatin,
attracting the AR to ARE half sites at the expense of genes with canonical ARE that promote prostate
cancer progression. Conversely, inhibition of FOXA1 reprogrammed the arrangement of the AR
and led to overexpression some androgen-responsive genes to promote CRPC cell growth [139].
We also reported that the AR/FOXA1 response gene FOXP1 acts as a negative AR collaborative
transcriptional factor, and represses tumor activity by binding to adjacent regions to AREs [78,140].
Interestingly, the EZH2 methyltransferase inhibitor, GSK126, promotes FOXA1 expression and inhibits
breast cancer growth via cooperation with BRCA1 [141]. Recently, Zhao et al. [142] elucidated
the dichotomous functions of FOXA1 in the AR signaling pathway. They indicated that FOXA1
reprograms the AR and GATA2 cistromes as a pioneer factor [142]. Whilst FOXA1 represses
AR binding to DNA, GATA2 positively collaborates with the AR in androgen-mediated gene
expression in prostate cancer [142]. Previous reports showed that GATA2 specific inhibition using
the low-molecular-weight compound K-7174 [143] suppressed AR expression and the proliferation of
CRPC cells [144]. Although it is not known whether this compound is suitable for clinical applications,
it is ingestible and possesses beneficial effects for haematological diseases [145–147].
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4.2.2. OCT1
Whilst many studies have focused on FOXA1 and GATA2, OCT1 is often overlooked, so we
have developed a novel drug targeting Oct1/AR using PI polyamides. A previous report showed
that a PI polyamide targeting AREs suppressed androgen-responsive gene expression in LNCaP
cells [148]. This sophisticated report showed that targeting canonical AREs was clearly effective;
however, it is possible that PI polyamides that also cover non-canonical AREs might block the
proliferation of CRPC even further. We identified the ACSL3 enhancer region, where AR and OCT1
regulate transcriptional activity, and developed a PI polyamide targeting OCT1 binding elements in
this region [72]. This PI polyamide suppressed ACSL3 expression and CRPC cell growth. In addition,
it specifically repressed global OCT1 chromatin association and AR signaling in prostate cancer
cells [72]. These data reinforce the evidence that OCT1 is also important for AR recruitment to
mediate global AR-response gene expression. Our study supports a novel therapeutic strategy using
PI polyamides in patients with CRPC.
4.2.3. ETS Family Genes
There is one report of an ETS-1 inhibitor using double-strand oligodeoxynucleotides (ODNs) that
represses gastric cancer cell proliferation [149]. ODNs mimic transcription factor binding sites and
act as decoys that compete with the original DNA binding sites in promoter regions [150]. Unlike PI
polyamides, ODNs require improvements to the drug delivery systems to target cells and greater
in vivo stability before they are suitable for clinical applications.
Since ERG was shown to be an oncogenic protein, ERG target drugs became attractive agents for
prostate cancer. PARP inhibitors, a direct ERG binding small molecule (YK-4-279), a DNA-binding
inhibitor targeting ETS consensus sites (DB1255), and a drug that enhances ERG ubiquitination
(WP1130) are all promising compounds for prostate cancer [151–154]. In terms of TMPRSS2:ERG,
we previously developed a PI polyamide targeting a common sequence in AR-related DNA break
points among TMPRSS2 and ERG gene loci to repress TMPRSS2:ERG expression and prostate
cancer cell growth [155]. Furthermore, a recent report showed that targeting AREs downregulated
TMPRSS2:ERG expression in VCaP cells and inhibited the growth of VCaP cells in vivo [156].
4.2.4. NKX3-1
Ren et al. [157] developed NKX3-1 targeting compounds using RNA activation (RNAa). RNAa is
system that uses small double-stranded RNA (dsRNA) that target selected gene promoter regions [158].
Transfecting the synthesized dsRNA into human cell lines causes induction of target gene expression.
Ren et al. showed that increased NKX3-1 expression by RNAa formulated in lipid nanoparticles
significantly inhibited prostate tumor growth both in vitro and in vivo [157].
4.2.5. C/EBP Family
Although the role of the C/EBP family in prostate cancer is still unknown, a recent report showed
that RNAa targeting C/EBPα repressed the proliferation of pancreatic ductal adenocarcinoma cells [159].
In addition, a phase I clinical study of RNAa targeting C/EBPα is underway for severe liver cancer
(NCT02716012).
4.2.6. E2F-1
Several studies of E2F-1 inhibitors have been reported. Kaseb et al. [160] studied the efficacy of a
herbal product, thymoquinone, extracted from Nigella sativa seeds for prostate cancer. Interestingly,
thymoquinone inhibited the tumor growth of CRPC xenografts and repressed E2F-1 and AR
expression [160]. Xie et al. [161] also developed a peptide binding to the E2F-1 consensus sequence.
Treatment of mice with this peptide encapsulated in PEGylated liposomes inhibited the growth of an
AR negative prostate cancer cell line without toxicity [162].
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4.2.7. c-MYC
Like ERG, there are several agents targeting c-MYC [163–166]. Recently, Rebello et al. [167]
reported the efficacy of a combination of RNA polymerase I (Rpol I) and proto-oncogene
serine/threonine-protein (PIM) kinase inhibitors (CX-5461 and CX-6258) for MYC-driven prostate
cancer. They showed that c-MYC is related to both Rpol I and PIM kinase activation, which were
significantly inhibited by both drugs in Hi-MYC mice [167].
4.2.8. STAT3
Leong et al. [168] showed that inhibiting STAT3 using ODNs repressed head and neck cancer cell
growth. In addition, Hedvat et al. showed favorable results in prostate cancer for a STAT3 inhibitor,
AZD1480, which is a potent ATP competitive inhibitor of Jak2 kinase [169]. However, Fizazi et al. [170]
reported an anti-IL-6 monoclonal antibody, siltuximab, inhibited STAT3 expression, but did not find a
survival improvement in patients with advanced prostate cancer.
The information about AR collaborative TFs and related drugs discussed in this section is
summarized in Table 1.
Table 1. AR collaborative TFs.






FOXA1 Pioneer factor Controversial GSK126 [141]
GATA2 Pioneer factor/Activator Promote + K-7174 [143,145–147]
OCT1 Activator Promote + PI polyamide [72]
ETS1 Activator Promote − ODNs [149,150]





NKX3-1 Activator Controversial + RNAa [157]
C/EBPs Repressor Unknown – RNAa [159]
NFI Diverse effects ongene regulation Unknown + -
RUNX1 Activator Inhibit − -
FOXP1 Repressor Inhibit + -
E2F Activator (CRPC) Promote − Thymoquinone/Peptide [160–162]
MYC Controversial(CRPC) Promote − CX5461/CX6258 [167]
STAT3 Activator (CRPC) Controversial − ODNs/AZD1480/Siltuximab [168–170]
FOXA1: forkhead box A1; GATA2: GATA binding protein 2; OCT1: octamer transcription factor; ETS1: ETS
proto-oncogene 1, transcription factor; ERG: ETS transcription factor; NKX3-1: NK3 homeobox 1; C/EBPs:
CCAAT/enhancer binding proteins: NFI: nuclear factor I; RUNX1: runt related transcription factor 1; FOXP1:
forkhead box P1; E2F: E2F transcription factor; MYC: v-myc avian myelocytomatosis viral oncogene homolog;
STAT3: signal transducer and activator of transcription; CRPC: castration resistant prostate cancer; ODN:
oligodeoxynucleotides; PI: pyrrole-imidazole; RNAa: RNA activation.
5. Conclusions
AR collaborators, such as collaborative TFs, are important in the extraordinary hypersensitivity of
the AR in CRPC. In addition, activation of AR-regulated genes promotes prostate cancer progression.
Over the last decade, sophisticated technologies for investigating transcriptional networks have
broadened our understanding of AR signaling in prostate cancer. Various functional studies,
including our own work, have elucidated the complicated influence that AR collaborators have
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on prostate cancer progression. These reports provide fundamental evidence to support the premise
that developing novel drugs against AR collaborators could provide promising strategies to treat
CRPC. Thus, further studies of these novel candidate compounds with pre-clinical drug screening
models will be crucial for developing new strategies to treat CRPC [24,171–174].
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Abstract: Prostate cancer progression is controlled by the androgen receptor and new blood vessel
formation, or angiogenesis, which promotes metastatic prostate cancer growth. Angiogenesis is
induced by elevated expression of vascular endothelial growth factor (VEGF). VEGF is regulated
by many factors in the tumor microenvironment including lowered oxygen levels and elevated
androgens. Here we review evidence delineating hormone mediated mechanisms of VEGF regulation,
including novel interactions between the androgen receptor (AR), epigenetic and zinc-finger
transcription factors, AR variants and the hypoxia factor, HIF-1. The relevance of describing the
impact of both hormones and hypoxia on VEGF expression and angiogenesis is revealed in recent
reports of clinical therapies targeting both VEGF and AR signaling pathways. A better understanding
of the complexities of VEGF expression could lead to improved targeting and increased survival time
for a subset of patients with metastatic castration-resistant prostate cancer.
Keywords: androgen receptor; AR; VEGF; angiogenesis; hypoxia; prostate cancer; CRPC
1. Introduction
Androgen Signaling and Angiogenesis
Hormones are known to regulate many genes involved in prostate cancer (PC) and prostate cancer
progression to castration-resistant prostate cancer (CRPC). Classical androgen signaling requires the
androgen receptor (AR) to bind to Dihydrotestosterone (DHT) or testosterone (T) and dissociate from
heat shock proteins. AR is then phosphorylated and translocated to the nucleus where it binds DNA
and other protein co-factors at dimeric AR recognition elements (ARE) and activates transcription of
androgen responsive genes such as PSA, TMPRSS2, Nkx3.1, and FKBP5 [1–6]. Many co-factors that
regulate AR signaling have been identified [7–10] including co-factors with chromatin remodeling
functions such as histone acetyltransferases, methyltransferases, and demethylases recruited by the
AR to regulate its signaling pathways.
Identification of hormone-activated targets of the AR has been fueled by the need for useful
markers of prostate cancer progression. While PSA remains the most widely used test for the presence
of cancer of the prostate, it provides a large percentage of false positive results [11]. Thus, evidence of
hormone responsive genes important in prostate cancer progression has been sought. One such
androgen mediated gene is vascular endothelial growth factor (VEGF), a mitogen secreted by tumor
cells that is essential for tumor angiogenesis and is necessary for tumor growth beyond 1–3 mm3 in
volume [12]. Patients with metastatic prostate cancer have greater VEGF plasma levels than those with
localized disease, as over-expression of VEGF contributes to tumor growth and metastasis [13]. VEGF is
regulated by multiple transcription factors (TFs), that respond to changes in the micro-environment
such as, HIF-1 (responsive to hypoxic conditions) [14], AR (responsive to hormone levels) [15–17],
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and other zinc-finger TFs that bind GC-rich promoter regions, e.g., Sp1 and WT1 [16,18]. This review
will outline what is known about mechanisms of androgen regulation of VEGF and the importance of
VEGF in angiogenesis in prostate cancer and prostate cancer progression. The relevance of delineating
the androgen and VEGF pathways in PC is demonstrated in recent clinical trials targeting both AR
and VEGF pathways (including HIF1-α) [19,20].
VEGF regulation is complex and occurs at both transcriptional and post-transcriptional
levels [21–23]. While the VEGF promoter lacks a TATA-binding site, it contains a GC-rich core
promoter region and additional distal enhancer sites including hypoxia response elements that bind
HIF1-α [24] (Figure 1A). Transcriptional and post-transcriptional regulation of VEGF has been well
studied and both genetic and epigenetic mechanisms have been identified. For nearly 20 years it has
been known that androgen up-regulates VEGF expression [17,25,26]. However, the mechanism of
activation, whether via classical or non-classical pathways, is not yet entirely understood. The VEGF
promoter lacks canonical androgen receptor (AR) DNA binding sites (ARE) either dimeric inverted or
direct repeats. Whether androgens may instead be activating VEGF through non-classical pathways
via src/MAPK is also unclear [27]. However, VEGF is activated via multiple pathways both in
normoxia and hypoxia conditions. Below we discuss the roles of epigenetic and transcription factors
AR, Sp1 (specificity protein 1), WT1 (Wilms tumor gene 1) and HIF1-α Hypoxia inducible factor 1-α)
in regulating VEGF expression in conjunction with hormone.
2. Androgen and Epigenetic Regulation of VEGF
2.1. VEGF Regulation by Histone Modifiers
AR co-factors either co-activate or co-repress AR target gene expression, and several of the
AR co-factors do so by modifying histone proteins. One well studied epigenetic modifier of AR
target gene expression is Lysine specific demethylase 1 (LSD1/KDM1A) which has been identified in
complexes with ligand bound AR [28]. LSD1 demethylates repressive histone marks and thereby can
increase AR dependent transcription [28,29]. However, since AR autoregulates its own expression,
it is noteworthy that AR recruitment of LSD1 to the AR promoter itself leads to a negative feedback
loop repression of AR transcription [30]. Thus, LSD1, like traditional transcription factors, acts to
regulate transcription, but the repressive or enhancing consequences are gene promoter context specific.
Nonetheless, LSD1 up-regulates VEGF-A expression in both hormone responsive PC cells such as
LNCaP, or non-responsive PC3 cells [29].
Recently, protein arginine methyltransferase 5 (PRMT5) has been shown to activate AR expression
and promote PC cell growth [31]. PRMT5 binds the proximal promoter of the AR gene in a complex
with Sp1 and the chromatin remodeling enzyme Brg1. Since VEGF is transcriptionally activated
by androgens, PRMT5 can be expected to indirectly up-regulate VEGF and angiogenesis as well.
This would be consistent with elevated PRMT expression observed in PC compared to BPH,
and suggestive of an oncogenic function [31]. Although epigenetic regulators of AR and VEGF
have been identified, evidence of their direct interaction with the AR on the VEGF promoter has been
limited to that described for LSD1 [29].
2.2. Post-Transcriptional Regulation of VEGF by mRNA Stabilizers
VEGF mRNA is typically short-lived with a half-life of 15–40 min [32], but VEGF mRNA message
stability is enhanced by low oxygen levels (hypoxia) through the binding of stabilizing proteins to
the 3’untranslated regions (3’UTR). Members of the ELAV family of RNA binding proteins, like HuR,
and heterogeneous nuclear ribonucleoprotein L (hnRNPL) bind to the AU-rich elements of the
3’UTR [33,34]. One potential mechanism for VEGF mRNA stabilization by HuR binding is that
these stabilizing proteins block binding by the de-stabilizing micro RNAs also known to bind the
3’UTR. Indeed the binding sites for HuR and miR-200b overlap and miR-200b can compete with HuR
binding to suppress VEGF mRNA expression [35]. Similarly, competition for 3’UTR binding between
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the hnRNPL and the γ-IFN-activated inhibitor of translation complex (GAIT) has been referred to as
a riboswitch [36]. Hypoxia elevates hnRNPL protein levels and they bind and stabilize VEGF mRNA
which acquires a secondary structure that blocks binding by the repressive GAIT complex [36].
As an example of the complexity of VEGF regulation, the riboswitch region is also a binding area
for several microRNAs that also compete with hnRNPL for binding at the VEGF 3’UTR [37]. Of note,
this is not an AU-rich but rather a CA-rich region (CARE). Overall, multiple miRNAs that bind to
the 3’UTR of VEGF have been identified (reviewed in [38]) but their sensitivity to androgen is not
known. Interestingly, the AR primarily up-regulates mi-RNAs considered to be oncogenic (oncomirs)
and but none of these have been reported to up-regulate VEGF. Recently, androgen has been shown
to suppress a miRNA cluster (miR-99a/let7c/miR-125b2), but this suppression still enhances PC cell
proliferation [39].
2.3. Translational Regulation of VEGF
The relative importance of the 3’UTR region of VEGF for post-transcriptional regulation of
VEGF is not greater than that of the 5’ UTR where two internal ribosome entry sites (IRES) permit
cap independent translation of two separate translation start sites (AUG and upstream CUG sites)
(reviewed in [38]). Of note, a sequence within the IRES-A promotes G-Quadruplex formation,
conferring a suppressive structure on the VEGF 5’UTR [40]. Importantly, the 5’UTR is a critical
regulatory area and in response to stress such as hypoxia, the IRES-B upstream of the CUG start sites
will promote cap independent translation of the L-VEGF form encoding a longer isoform, that after
proteolysis provides both an internal and the secreted VEGF peptide [41]. The clinical significance
of the IRES-B was suggested when a single nucleotide polymorphism (SNP) was identified that
suppressed the IRES-B function, reducing CUG translation initiation, and thereby decreasing L-VEGF
protein levels. This SNP was associated with an elevated risk of prostate cancer [42].
Although this review will not cover the diversity of alternative VEGF isoforms, clearly the
several alternative start codons, alternative splicing and the post translational proteolysis lead to
a large number of variant VEGF protein isoforms with alternative functions (Reviewed in [38]).
Use of the AUG translation initiation site is dependent upon specific exonic sequences that may be
deleted in some alternatively spliced transcripts. For example, the alternatively spliced transcript
encoding VEGF 121 (the diffusible form of VEGF lacking exons 6 and 7 encoding the heparin binding
domains) cannot be translated from the AUG initiation site, but rather its translation initiates from
an upstream CUG site [43]. The wide variety of VEGF isoforms have a variety of functions differentially
affecting angiogenesis, varying from distal activity (EGF 121), to locally restricted activity (VEGF 189),
to antiangiogenic activity (VEGF 165b). The role of androgen in altering VEGF isoform ratios is not yet
understood but can be expected to be of clinical significance.
3. Transcription Factors that Regulate Androgen Induction of VEGF Expression
3.1. Sp1
Androgen treatment of prostatic fibroblasts and LNCaP cells significantly increases VEGF mRNA
expression levels [15,16,44,45]. Additionally, VEGF protein levels have been demonstrated to be
up-regulated after treatment of LNCaP cells with hormone [17], and the androgen antagonist flutamide
blocks this up-regulation [46]. The mechanism of androgen-mediated regulation of VEGF expression,
however, is less well understood. Three potential monomeric ARE half-sites were predicted by
in silico analyses within the VEGF promoter, (Figure 1A) similar to sites reported in other gene
promoters [47–49]. Furthermore, the androgen analog R1881 was shown to up-regulate both the
proximal and distal VEGF promoter activity in 22Rv1 and LNCaP cells [18,24]. Taken together these
results indicate the VEGF promoter is hormone responsive.
Interestingly, regions in the VEGF promoter near predicted ARE half-sites contain G-rich
binding sites for other zinc finger transcription factors (ZFTF) such as Sp1, EGR1 (early growth
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response 1) or WT1 that could potentially interact with the AR. Non-classical AR half-sites were also
identified adjacent to G-rich WT1/EGR1/Sp1 sites in 8 of 11 promoters analyzed, including VEGF [50].
Co-transfection of WT1 expression plasmids enhances VEGF promoter activity [18,24], with addition
of the androgen analog R1881 increasing WT1 effectiveness, and mutation of a WT1 site reducing
VEGF promoter activity [18]. These results were consistent with chromatin immunoprecipitation of
WT1, Sp1 and AR at the VEGF promoter and co-immunoprecipitation of AR with Sp1 or WT1 [18,50].
Surprisingly, the ARE half-sites identified in the VEGF promoter are not required for hormone
induction of VEGF expression, as site directed mutagenesis failed to eliminate hormone response [16].
Rather a single GC-box in the core promoter is essential for hormone responsiveness of the VEGF
promoter [16]. This indicates that the AR is not bound to an ARE binding site, but rather is tethered
via a ZFTF, which is bound to the GC boxes (Sp1/Sp3 binding sites) (Figure 1B). This GC-rich VEGF
core promoter lacking ARE half-sites is responsive to androgen stimulation of PC cells, inhibited by
the anti-androgen casodex [16], and is also the region of estrogen responsiveness in breast cancer
cells [51,52]. In addition to lacking canonical dimeric ARE sites, the VEGF promoter also lacks canonical
estrogen receptor (ER) binding sites [51,52]. Similarly, VEGF regulation by estrogen in endometrial and
breast cancer cells involves interactions of ER-α and Sp1 (or Sp3) with GC boxes in the core promoter
region of VEGF [51,52]. VEGF mRNA levels are significantly induced in ZR-75 breast cancer cells
treated with estradiol, and the intact GC-rich core VEGF promoter region is required for such activation.
The relevance of Sp1 and Sp3 in estradiol regulation of VEGF in breast cancer was demonstrated by
binding assays in vitro (by EMSA) and in vivo (by ChIP) [51,52]. The VEGF core promoter contains
four Sp1 binding sites and mutation of only the Sp1 site closest to the transcription start site inhibited
androgen activation of VEGF in PC cells, while other adjacent sites were not required for hormone
response [16]. Together, these results indicate a mechanism of androgen-mediated induction of VEGF
expression in PC cells involving interaction of the AR with a specific, critical Sp1 binding site in the
VEGF core promoter region [16] (Figure 1B).
 
Figure 1. Androgen mediated regulation of vascular endothelial cell growth factor (VEGF) transcription.
(A) Promoter analysis of VEGF. The VEGF promoter (VEGFA accession number AB021221) was
downloaded from Ensembl and binding sites were predicted by MatInspector and located on the VEGF
promoter sequence [50]. Potential androgen receptor binding sites (ARE), HIF1α binding sites (HIF-1)
and zinc finger transcription factor binding sites (Sp1, Egr1, and WT1) thought to play a role in VEGF
regulation are color coded according to the legend; (B) Model of androgen regulation of VEGF in
prostate cancer showing the AR in a complex with Sp1 and bound to the GC-rich region of the VEGF
core promoter. Note that ligand binding replaces HSP binding in the cytoplasm, but within the nucleus
Sp1 binding recruits the AR to the core promoter region of the VEGF gene.
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3.2. Hypoxia (HIF-1α)
VEGF expression is up-regulated in response to hypoxia and this is mediated by the stabilization
of the transcription factor hypoxia-inducible factor 1 (HIF-1α) that up-regulates transcription of VEGF
via binding at HIF-Responsive elements. Importantly, HIF-1α itself is up-regulated by DHT both via
transcript stabilization [53] and via an autocrine loop involving EGF-R and AKT [46]. The clinical
importance of HIF-1α expression in prostate cancer has been demonstrated and HIF-1α has been
examined as a potential prognostic marker, being elevated in high grade PIN and not BPH [54].
Response to androgen deprivation therapy in mice with CWR22RV1 xenografts, suggests that AR may
regulate HIF-1α levels, as expression of both AR and HIF-1α target genes were affected even outside
of hypoxic tumor areas [55].
Conversely, substantial evidence exists for the effect of HIF-1α (and hypoxia) on AR signaling.
Combined hypoxia and hormone treatment synergistically increased PSA levels [56]. Hypoxia increases
transcriptional activity of ARE-luciferase reporters in low or high DHT conditions, but has no effect in
the absence of DHT [57]. Thus, androgen signaling is influenced by hypoxia, which itself up-regulates
VEGF expression. Overall, this suggests that VEGF response to hypoxia may be mediated in part by
HIF-1α but in the case of endocrine tumors, also by hormone effects on HIF-1α [53].
4. AR Variants
Currently, a family of AR splice variants are being identified that lack the LBD, but arise in patients
undergoing androgen deprivation therapy [58]. These splice forms lacking the LBD region have been
seen in BPH and localized prostate cancers, but are up-regulated in castration resistant prostate
cancer [59–61]. The presence of these variants is significant, as patients with a high level of AR-V7
and ARv567es expression have a shorter survival expectancy than CRPC patients lacking these AR
variants [59]. Additionally, AR-V7 (the AR-V most commonly expressed in clinical specimens) has been
shown to be involved in resistance to both enzalutamide and abiraterone in clinical studies [62,63].
Importantly in CWR22Rv1 cells, which contain AR splice variants (including AR-V7) [61,64,65],
we have shown that Sp1 and the AR interact to activate the VEGF promoter [16]. If AR variants
interact with Sp1 (either directly or through complex formation with full-length AR) they could
influence VEGF expression in response to hormone. Additionally, these AR variants can recruit
and form complexes with co-factors that have chromatin remodeling functions discussed above,
such as histone acetyltransferases, methyltransferases, and demethylases, potentially impacting the
epigenetic regulation of the AR and VEGF [29]. Thus, it will be important to determine if these
novel splice variants of the AR are involved in VEGF regulation in CRPC, particularly if improved
response is observed in clinical trials with CRPC patients being treated with both anti-androgens and
VEGF inhibitors.
5. Relevance of Dual Targeting of Hormone Signaling and VEGF in PC Tumor Angiogenesis
Metastatic PC is associated with higher VEGF levels than localized disease [66–68]. Thus,
anti-VEGF therapies have been the target of multiple clinical trials for treatment of men with CRPC.
Bevacizumab is a monoclonal antibody to VEGF-A which has been shown to decrease tumor volume in
many cancers. However, in clinical trials for treatment of CRPC, it has not improved the overall survival
time of patients getting chemotherapy (docetaxol) along with the immunosuppressant prednisone [69].
Therefore, it is thought that angiogenesis may play a smaller role in CRPC than other cancers and
current studies are investigating dual targeting of both androgen signaling and VEGF.
Studies targeting both the androgen signaling pathway (with bicalutamide or enzalutamide) and
VEGF (either directly with a VEGF inhibitor or indirectly through HIF1-α inhibition) have recently
been performed [19,20]. Figure 2 illustrates the steps at which dual drug targeting could impact both
(1) the androgen signaling pathway (through abiraterone blocking androgen synthesis, enzalutamide
binding to AR, or docetaxel inhibiting microtubule driven transport of AR-androgen complex) and
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(2) the angiogenic pathway (through bevacizumab blocking VEGF binding). The effects of targeting
both the AR signaling pathway and HIF-1α pathway have also been investigated and the authors
found that combinatorial targeting both of these pathways lead to greater inhibition of prostate cancer
cell growth than either one alone in both LNCaP and CWR22Rv1 cells [20]. Also, this study determined
that VEGF protein levels were significantly reduced in the presence of both enzalutamide and siHIF-1α,
suggesting that VEGF could be a biomarker for enzalutamide response [20].
A new phase II clinical trial of patients with recurring prostate cancer treated with or without the
VEGF inhibitor Bevacizumab after ADT revealed that ADT combined with Bevacizumab resulted in
an increased relapse free survival rate, although modestly, compared to ADT alone [19]. These results
suggested that combining ADT with Bevacizumab could prolong the off-ADT-cycle during intermittent
ADT and thus benefit a subset of patients that have hormone sensitive prostate cancer. These studies
demonstrate the need for understanding mechanistically the relationship between AR and VEGF and
how they interact in CRPC patients.
 
Figure 2. Targeting both VEGF induction of angiogenesis and androgen synthesis or AR signaling
inhibits two critical signaling pathways in prostate cancer (PC) progression. Note that hypoxia induced
VEGF can also be suppressed by targeting HIF1α with HIF1 inhibitors (not shown).
6. Conclusions
Treatment of CRPC involves targeting many factors and signaling pathways which are still being
uncovered, but dual targeting of both AR and VEGF signaling should result in better efficacy for
patients than either one alone. Mechanistically, it appears that androgen induction of VEGF is regulated
through AR complex formation with Sp1 in the core promoter region in prostate cancer cells and not
via ARE binding sites in the distal VEGF promoter. Therefore, addition of Sp1 or HIF-1α inhibitors
could further add to the significant effect seen by targeting AR signaling with enzalutamide and VEGF
with Bevacizumab. Further delineation of the mechanism(s) involved in the progression of CRPC and
the pathways utilized will help to produce even better treatment plans for this subset of patients.
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Abstract: Prostate cancer development and progression is the result of complex interactions between
epithelia cells and fibroblasts/myofibroblasts, in a series of dynamic process amenable to regulation
by hormones. Whilst androgen action through the androgen receptor (AR) is a well-established
component of prostate cancer biology, it has been becoming increasingly apparent that changes in AR
signalling in the surrounding stroma can dramatically influence tumour cell behavior. This is reflected
in the consistent finding of a strong association between stromal AR expression and patient outcomes.
In this review, we explore the relationship between AR signalling in fibroblasts/myofibroblasts and
prostate cancer cells in the primary site, and detail the known functions, actions, and mechanisms of
fibroblast AR signaling. We conclude with an evidence-based summary of how androgen action in
stroma dramatically influences disease progression.
Keywords: prostate cancer; stroma; fibroblasts; androgen; androgen receptor
1. Introduction
Histological assessment of solid tumours has been used in combination with clinical parameters for many
decades to inform both diagnosis and management decisions. In the emerging era of immunotherapeutics
and personalized medicine, histology and molecular assessment is playing an increasingly important
role in defining prognosis and individualised treatment options. Assessment now often includes
protein activity and mutation status in addition to extent and level within a tumour sample, as well
as markers of tumour activity, mitosis and turnover. For breast cancer, levels and extent of oestrogen
receptor (ER), progesterone receptor (PR, as a marker of ER function) and HER2 are used to broadly
categorize a tumour and inform on the benefit of anti-estrogen agents (e.g., tamoxifen) or tyrosine
kinase inhibitors. Similarly, assessment of colon cancer includes EGRF, KNAS and UHA1; of melanoma,
BRAF; of lung cancer, EGRF, ALK, KRAS and ROS-1; and of leukaemia a panel of markers for typing.
Prostate cancer remains an anomaly in this regard. Despite being the most common, non-skin, cancer,
and the leading cause of cancer related death, prognosis and treatment is generally defined using
clinical and pathological parameters established decades ago. The predominant histological patterns of
glandular disorganization are captured in the Gleason score, which together with clinical assessment
and/or medical imaging regarding the extent of disease within the prostate and any extracapsular
disease, are combined to provide prognostic information. Serum prostate specific antigen (PSA) testing
was introduced over 20 years ago, and although useful in stratification of patients for investigation,
risk of recurrence following definitive treatment and disease monitoring, is not a particularly useful in
a prognostic sense. Intriguingly, the lack of prognostic markers available to patients and clinicians
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is predicted to have led to both over and under treatment of patients, with financial and social
implications for both patients and the health care system. Currently, no histological markers are
routinely used to determine prostate cancer prognosis, or inform on the usefulness of androgen
ablation strategies. A key limitation in this regard is the multi-focal nature of most prostate cancers,
and the inherent heterogeneity within cancerous epithelia of individual patients. One alternative being
explored is the assessment of reactive changes occurring within the surrounding stroma.
Despite being generally regarded as a simple supportive structure for the specialised cells within
an organ, the stroma is actually vital to organ development and homeostasis, and plays a significant
role in both carcinogenesis and metastasis. The stroma is composed of a mixture of smooth muscle
cells, fibroblasts, immune cells, lymphatics, vasculature and extracellular matrix (ECM) as well as via
a rich array of secreted factors, hormones, enzymes and other soluble second messengers. Along with
direct cell-cell interaction, these factors mediate communication between stromal constituents and
bidirectional signalling between stromal and epithelial compartments, which is observed in all organs
and is vital for normal development. With carcinogenesis and with tumour growth, substantial changes
are found in stromal constituents and behaviour. Cancer stroma is characterised by a loss of smooth
muscle cells and a predominance of activated myofibroblasts, termed cancer associated fibroblasts
(CAFs), that enable carcinogenesis, stimulate tumour growth and contribute to invasion [1]. The CAFs
which surround the cancerous gland development from multiple sources, circulating marrow derived
progenitors, adipose tissue, and fibroblasts from distant organs, but a vast majority are reported to
develop from the resident fibroblast population [2,3]. Indeed, the extent of transformation of the
fibroblasts can associate with disease progression, potentially through providing paracrine cues to
disrupt and disaffect homeostasis. The prostate provides a compelling example of intra-compartmental
signalling that influences normal development and malignant cell behaviour. The growing appreciation
of the role played by prostate stroma in carcinogenesis, tumour behaviour and response to conventional
therapy is driving new innovation in research and treatment.
Prostate cancer remains the most commonly diagnosed non-skin malignancy and second leading
cause of cancer related death in US men, with invasion and metastasis from the primary site reducing
patient survival by 50%. Current clinical nomograms utilize imaging, clinico-pathological parameters
and serum leak of epithelial produced PSA to broadly stratify cancers according to risk of progression
following treatment, but cannot accurately predict tumour progression at the time of diagnosis, or the
timeframe in which progression might be clinically significant. As a consequence, it is believed
that many patients either incur treatments and their associated side effects unnecessarily, or are not
receiving the appropriate therapy or monitoring for aggressive disease.
Androgens are a key factor in prostatic development, homeostasis and malignancy. With respect
to the former, early in vivo studies showed that the absence of hormone responsive stroma prevented
epithelial cell differentiation and organ and glandular development [4,5]. Nonetheless, the vast
majority of androgen and androgen receptor (AR) research has been focussed on epithelial cancer cells
because of the response of these cells, and prostate tumours, to androgen deprivation. The purpose
of this review is to provide an emerging review of hormone signalling in the fibroblasts and
myofibroblasts of the prostate (the most prominent stromal cells in prostate cancer) and how it
controls stromal-epithelial interactions in the primary tumour setting, and to describe how changes in
this pathway are emerging as a key determinants of prostate cancer progression and outcome.
2. Stromal AR in Prostate Cancer Outcome
Continued growth of metastatic prostate cancer cells during complete androgen blockade, in both
clinical and experimental settings, is the result of mechanisms permissive for continued function of AR
and/or those of its activated pathways despite combined AR/androgen targeting. Although increased
AR expression in the epithelial cancer cells is one such mechanism, there is inconsistent evidence that it
contributes to development or progression of the primary tumour. As reviewed in Tamburrino et al. [6],
epithelial AR levels in primary prostate cancers has been inconsistently related to patient outcome,
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with 20% of studies suggesting high cancer AR as a prognostic marker of good outcome, 26% showing
high AR as a prognostic marker of poor outcome, and the majority showing no relationship (Table 1).
In comparison, for the smaller number of studies looking at stroma, a loss of stromal AR has universally
been related to the cancerous state, high risk clinical parameters, disease progression and/or poor
outcome (Table 2). In these studies, the term stroma refers to the cells directly adjacent to the epithelial
or cancerous cells, which are usually noted for their fibroblast appearance. In a study of twenty
patients, Mohler et al., showed lower intensity immunostaining of AR in cancer stroma compared
to regions of benign prostatic hyperplasia [7], but there was no correlation with cancer progression,
possibly due to the small cohort size. However, in larger studies, statistically significant associates
were made. In four studies, in cohorts of 53 patients (radical prostatectomy (RP) samples), 152 patients
(two separate cohorts, 78 transurethral resection of the prostate (TURP), and 74 biopsy), 96 patients
(RP), and 53 patients (RP), low stromal AP was significantly associated with biochemical relapse
and response to castration [8–11]. Other clinical parameters were also associated, including Gleason
score and disease stage. We have shown in a cohort of 64 patients that low stromal AR expression
inversely associates with patient outcome, to which we later added that the using FKBP5 as a marker
of AR activity could be combined with AR levels to for an even stronger inverse relationship with
patient outcome [12,13]. Importantly, this cohort had benign and cancers samples taken from each
patient, which showed that the loss of AR was specific to the cancer associated stroma. Overall,
all currently published patient-based studies indicate that lower AR in prostate cancer stroma is
associated with disease progression and/or worse outcome, implying that stromal AR is protective.
It will be important to know if this has prognostic significance, both in terms of patients most at risk
of developing advanced disease and the potential response of an individual tumour to androgen
deprivation. These findings are distinct from the potential beneficial effects of stromal AR in preventing
caner initiation and development, which is discussed further below.
Table 1. Expression of AR in cancerous epithelial tissue and association with outcomes. RP = Radical
prostatectomy; TURP = Transurethral resection of the prostate; IHC = Immunohistochemistry;
RT-PCR = Real time polymerase chain reaction.
Authors Specimens Cohort Size Methods Effect on Prostate Cancer Outcome
[14] Biopsies 62 IHC Higher AR, better prognosis
[15] Biopsy, RP and TURP 42 IHC Higher AR, better prognosis
[16] Biopsies 90 IHC Higher AR, better prognosis
[17] RP 197 IHC Higher AR, better prognosis
[18] RP 105 IHC Higher AR, better prognosis
[19] mixed RP, TURP, Biopsy 42 IHC Higher AR, better prognosis
[9] RP 96 IHC Higher AR, biochemical relapse
[20] RP 115 RT-PCR Higher AR, biochemical relapse
[21] RP 340 IHC Higher AR, biochemical relapse
[22] RP 52 IHC Higher AR, biochemical relapse
[8] RP 53 IHC Higher AR, biochemical relapse
[22] RP 52 IHC Higher AR, worse prognosis
[23] RP 640 IHC Higher AR, worse prognosis
[24] mixed RP/biopsy 66 IF Higher AR, worse prognosis
[11] RP 56 IHC Not prognostic
[25] RP 232 IHC Not prognostic
[26] TURP 68 IHC Not prognostic
[27] RP 64 IHC Not prognostic
[28] Biopsies 17 IHC Not prognostic
[29] RP 121 RT-PCR Not prognostic
[30] TURP and RP 81 IHC Not prognostic
[31] RP and metastases 119 IHC Not prognostic
[32] RP 2805 IHC and RT-PCR Not prognostic
[33] RP 172 IHC Not prognostic
[34] TURP 24 IHC Not prognostic
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Table 1. Cont.
Authors Specimens Cohort Size Methods Effect on Prostate Cancer Outcome
[10] TURP + biopsy 154 IHC Not prognostic
[35] RP 43 IHC Not prognostic
[7] RP 20 IHC Not prognostic
[12] TURP 64 IHC Not prognostic
[36] RP 53 branched chain DNA Not prognostic
[37] RP 10 IHC Unavailable
[38] Biopsies 39 IHC Unavailable
[39] RP 26 IHC Unavailable
[40] RP 50 IHC Unavailable
Table 2. Expression of AR in cancerous stroma and association with patient outcomes. RP = Radical
prostatectomy; TURP = Transurethral resection of the prostate; IHC = Immunohistochemistry.
Authors Specimens Cohort Size Methods Effect on Prostate Cancer Outcome
[41] RP 44 IHC Low AR, biochemical relapse
[8] RP 53 IHC Low AR, biochemical relapse
[9] RP 96 IHC Low AR, biochemical relapse
[12] TURP 64 IHC Low AR, PCSM
[10] TURP + biopsy 152 IHC Low AR, worse prognosis
[11] RP 56 IHC Low AR, worse prognosis
[7] RP 20 IHC (low AR, no association with Gleason)
3. Androgen Signalling
Androgens act primarily through their cognate receptor, the androgen receptor (AR), which is
a potent transcription factor with broad tissue distribution and a major mediator of cellular function and
homeostasis. Androgens are vital for growth and maturation of the prostate. However, the mechanism,
regulation, and outcomes of AR signalling are based primarily on whole body physiological responses,
and molecular studies in predominantly cancerous epithelial cells. AR signalling (Figure 1), in most
basic terms this starts with cellular internalization of circulating androgens such as testosterone
(T). Androgens then bind directly to the AR with variable affinity, or in the case of T may be
first metabolized to the more potent dihydrotestosterone (DHT) via the enzyme 5-alpha reductase.
Steroid binding to the AR occurs in the cytoplasm, where the receptor resides in an inactive state in
complex with molecular chaperones, such as HSP90, and other proteins. Binding and activation in the
initiation of genomic signalling pathways including PI3K-AKT, and ERK. Activation of AR also results
in alteration sin the interaction with chaperones, allowing for translocation to the nucleus via movement
along microtubules. Nuclearisation culminates in the interaction of the AR with chromatin, and
ultimately regulation of the cellular transcriptional profile. The transcriptional response to androgens
is modulated by the availability of steroid and the cellular complement of pioneer, coregulatory and
chaperone proteins.
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Figure 1. Schematic of androgen receptor (AR) signalling in fibroblasts/myofibroblasts. Serum testosterone
enters the cell, converts, via the 5α-reductase enzyme, into dihydrotestosterone (DHT). This then binds
to the AR which resides in the cytoplasm, bound to chaperones, causing a conformational change
and activation of the AR. The AR can then cause a series of non-genomic effects via kinase pathways,
but also shuttles via microtubules to the nucleus which it enters via nuclear pore complexes (NPC).
Concomitantly, activated AR also causes nuclear translocation of focal adhesion proteins such as Hic-5
(thus altering adhesiveness and movement of cells) which it uses as a co-regulator, along with a pool
of cofactors and other co-regulators (some of which are fibroblast/stroma specific) to combine with
transcriptional machinery and regulate gene expression.
4. How AR Signaling in the Stroma Works
Despite observations of AR in the stroma being important in all stages of prostate development
and carcinogenesis, until recently little was known about the mechanics of AR function in that cellular
71
Cancers 2017, 9, 10
compartment. In the benign prostate the predominant stromal cells are smooth muscle cells, a majority
of which strongly express AR. Myofibroblasts are the predominant cell type present in the tumour
stroma, and although they can be seen to express AR and show physiological and molecular responses
to androgens in vivo [12], primary human fibroblasts shed AR expression within 1–2 passages in
culture. To overcome this limitation, two engineered human prostate myofibroblast cell lines have
been developed, WPMY-1 and PShTert-ARs [41,42]. Of these two, only PShTert-AR cells stably
express AR, which has a similar AR binding patterns and gene regulation to primary and in vivo
mesenchyme [12,43], as well as being able to inhibit fibroblast proliferation replicative of in vivo studies
of human prostate, as well as being able to excite epithelial cells proliferation just as mesenchyme in
mouse recombination studies [12]. Furthermore, androgen action in these myofibroblast cells lines
validates in patient NPF and CAFs [12].
In general terms, the molecular action of AR function in fibroblast lineage cells appears to follow
the same general basic principles as AR in epithelial cells, but with some key differences that radically
alter the cellular response (Figure 1). At the front end, HSP90 appears to be equally essential for
AR function in both cell types [44], and the receptor traffics to the nucleus only following steroid
binding [45]. Importantly however, when we recently compared the global transcriptional response
to androgens, only around 10% of genes regulated by androgens in prostate myofibroblasts were
common with those regulated in epithelial cells [12]. This appears to be the result of lineage-specific
differences in the expression of co-regulators and pioneer factors. Cofactors are a diverse set of proteins
that exert their effects on AR by influencing stability, ligand binding, interaction with other proteins,
DNA interactions via modification to histone acetylation, methylation and sumoylation, recruitment
of the transcriptional machinery or baseline activity. The expression and ratio of co-regulators are
different between epithelial cells and non-epithelial cells of the prostate [46]. As an example, we
have shown that the mesenchymal specific co-regulator, Hic-5 affects regulation of over 50% of genes
targeted by androgen receptor in fibroblasts [45]. Pioneer factors are proteins that regulate targeting
and/or activity of transcription factors to specific regions of DNA. Unlike epithelial cancer cells that
utilize the forkhead protein, FOXA1 as the primary AR pioneer factor [47–50], we have shown that
prostate fibroblasts appear to use the AP1 complex, and JUN in particular, leads to regulation of distinct
molecular pathways in fibroblasts [43]. As one example, JUN driven fibroblast specific regulation of
licensing factor FBXO32 by AR results in a switch to inhibiting of fibroblast proliferation by androgens.
5. Stromal AR in Prostate Development
In the embryonic/developing prostate the urogenital mesenchyme (UGM) is comprised of
AR positive precursors to fibroblast and smooth muscle cells, similar to myofibroblasts [51–53].
Supporting a role for stromal androgen signalling throughout prostate development, expression of
the AR occurs higher and earlier in this compartment than in epithelia, and is maintained throughout
maturation. This has been demonstrated in tissue recombination models, where AR positive UGM
leads to normal growth and glandular differentiation of urogenital epithelia (UGE). In contrast, AR
negative mesenchyme from skin results in differentiation of UGE to stratified squamous epithelia [4,54]
(Figure 2A). Studies utilizing cells extracted from testicular feminized (Tfm) mice, which have a
non-functional AR, further clarify the importance of stromal androgen signalling. When wild type (WT)
UGM is combined with UGE from Tfm mice, prostatic structures develop normally. In contrast, tissues
generated from Tfm UGM and either WT UGE or Tfm UGE fail to generate glandular architecture [55]
(Figure 2A). Additional studies demonstrate poor differentiation of prostatic ducts and glandular
acini in mice that lack stromal AR [56] (Figure 2A). Although androgen signalling in the mature
prostate epithelia is primarily responsible for secretion of seminal fluid constituents, including prostate
specific antigen (PSA) [57], this process can also be modulated by the prostatic stroma [58,59]. In the
mature prostate, AR positive smooth muscle cells are the predominant cell type. In vitro, AR action
in fibroblasts increases epithelial AR activity, as measured by in vitro assays of AR activity [60], and
results in increased in epithelial PSA production [61]. Collectively, these findings implicate stromal
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AR activity in development, maintenance and biological function of adjacent epithelia. More broadly,
there appears to be a universal role for mesenchymal hormone signalling in the development of
both male and female reproductive organs, with expression of the appropriate hormone receptors
in adjacent stroma critical for subsequent organ-specific responses to oestrogen, progesterone, and
testosterone [62–65].
 
Figure 2. Impact of AR expression on prostate development and carcinogenesis. (A) Stromal AR is
required for prostate development. In mouse models combining embryonic urogenital epithelia (UGE)
with AR positive urogenital mesenchyme (UGM) results in normal epithelial structures, which doesn’t
occur when UGE is combined with AR negative or non-functionally AR containing mesenchyme;
(B) AR is needed in stroma for cancer initiation. When transformed BPH-1 cells are grown in mice
in the presence of AR positive mesenchyme cancer initiation and development can occur, but when
combined with AR negative stroma, only small, irregular, non-cancerous glands form.
6. Stromal AR in Carcinogenesis
The role of stromal androgen signalling in prostate carcinogenesis is becoming more and more
prominent [66–68]. Stromal AR activity is also required for tumour formation in prostatic epithelia in
recombinant mouse models [69]. AR negative initiated epithelial cells were implanted into castrate
mice flanks along with AR negative or positive UGM. Mice were then treated with or without androgen
and estrogen. In mice implanted with epithelia alone, there was no tumour formation under any
treatment condition. Where mice were implanted with initiated epithelium and AR positive UGM,
tumour formation occurred in 36% (n = 30/84) of hormone treated mice but <0.5% (n = 1/218) of
untreated mice [69]. Whilst that study did not specifically compare AR positive versus AR negative
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UGM, it did demonstrated the importance of stroma in early stage cancer, and the potential role
of stromal AR signalling in tumour formation. A role in early transformation was addressed more
recently by implantation of initiated prostate epithelia (via knockdown of tumour suppressors PTEN
and p53) with wild-type or Tfm mesenchyme [70]. When initiated, epithelia were combined with WT
mesenchyme, tumour formation occurred following hormonal stimulation (Figure 2B). In contrast,
when combined with the AR negative Tfm mesenchyme, the result was merely the development of
small non-invasive growths (Figure 2B). Significantly, the presence of AR in the epithelial cells did
not affect those processes [70]. Similarly, the spontaneous development of prostatic intraepithelial
neoplasia seen in PTEN+/− mice, was decreased in offspring bred with stromal AR knockout mice
(ARKO) [71]. Furthermore, inhibiting the AR chaperone, HSP90, in CAFs, thereby reducing the AR
activity, retards growth of patient derived cancer cell and CAF recombinant xenografts in mice [44].
AR positive stroma is also capable of inducing prostate tumour formation from grafted AR
negative benign prostatic hyperplasia (BPH)-1 cells [69], but is hindered in mice which lack stromal AR
in comparison to stromal AR positive mice [72]. Perhaps significantly, in men of African descent where
there is a higher incidence of prostate cancer compared to Caucasian men, there is reportedly higher
stromal AR expression [73]. Regardless, the evidence collectively supports stromal AR signalling acting
to induce prostate cancer cell proliferation and potentially play an important role in early prostate
carcinogenesis. Thus, it would appear that stromal AR plays an important and often overlooked role
in early prostate carcinogenesis. It is important, however, to distinguish this from the potential role of
decreased stromal AR in cancer progression and metastasis (see Section 2).
7. Why Is Stromal AR Lost?
Despite the relationship between clinical outcome and stromal AR loss highlighted in Table 2, the
mechanisms underpinning altered AR expression in this compartment in some, or perhaps all, prostate
tumours are unknown. One hypothesis is AR negative/low CAFs represent a subgroup of an initial
CAF population that undergoes clonal selection in some manner. We have previously reported that
AR action in myofibroblasts inhibits their intrinsic proliferation [12], which might provide a selective
pressure for the AR negative/low CAF population over those that highly express the receptor. A second
tier question is how variable AR expression occurs in stroma in the first place. Cellular variability in
ligand availability is one possibility. We know that AR signalling in stroma is less sensitive than in
epithelial cells, and thus more vulnerable to systemic changes in androgen levels, or on altered supply
based on local tumour microarchitecture and/or vascular supply. Decreased ligand availability will
manifest as decreased AR stabilization and increased receptor turnover. An alternative and relatively
unexplored possibility is that of stromal mutagenesis occurring distinct from genetic alterations within
the cancer cells themselves. Some studies using mixed prostate tumour samples have, for example,
paradoxically identified inactivating AR mutations that have been difficult to rationale in the context
of almost invariable AR driven epithelial disease [74]. It is tempting to speculate that some of those
mutations may have been captured from stromal components. Epigenetic regulation could also be
involved, as changes in methylation state are known to regulate AR expression [75]. Alternatively, p53
has been show to negatively affect AR interactions leading to receptor stabilization and activity [76],
and forms part of a stromal signature in prostate cancer associated with biochemical relapse [77].
However, down regulated genes weren’t assessed as part of that study, so it is currently unclear if
there is a direct relationship.
There is a clear need for a more contemporary analysis of cancer cells associated with high and low
stromal AR content, and to track mutational and transcription events within each compartment. It is
likely that events in one or both compartments of a tumour will can change the way cancer cells interact
with their microenvironment. Paracrine factors such as interleukins, interferons, and miRNAs have all
been reported to reduce AR levels [78–82]. Nitric oxide is a product of certain events within cancer
cells, inhibits AR expression and activity, and plays a role in cancer progression and metastasis [83–85].
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Given the potential prognostic importance of stromal AR expression, studies need to extend beyond
speculative hypotheses to address in real time how AR levels fluctuate within a tumour sample.
8. Possible Mechanisms for the Involvement of Stromal AR Signalling in Cancer Progression
and Outcome
The mechanisms by which stromal AR action influences response of adjacent epithelia are slowly
emerging. Secretion of factors by fibroblasts in response to androgens activate intracellular signalling
pathways in epithelia as well as post translational modification of AR, increased AR activity [12,86],
and stimulation of epithelial proliferation [87,88]. In contrast however, in transgenic adenocarcinoma
of the mouse prostate (TRAMP) mice co-inoculated with AR negative highly metastatic human prostate
cancer PC3 cells and human WMPY fibroblasts, knockdown of fibroblast AR with a specific siRNA
did not alter cancer cell proliferation based on Ki67 index [89]. Reconciling the paradox between
the apparent need for stromal AR signalling in the initial stages of cancer development versus the
apparent importance of lost stromal AR signalling with cancer progression and outcome may have
previously been problematic as there has been limited research into the function of AR in stromal cells.
This dichotomy can now be recognized as not mutually exclusive as detailed below and surmised in
Figure 3.
 
Figure 3. Potential mechanism for fibroblast AR influence on prostate cancer outcomes. AR signalling
in fibroblasts regulates growth factors, chemoattractants, cytokines and ECM production. By regulating
growth factors AR creates a hospitable environment for cancer, thus when AR is lost the local
environment may drive cancer cells to metastasise elsewhere. AR regulates chemoattractant production,
disruption of this may excite the migratory capacity of cancer cells. By regulating cytokine production,
AR signalling in fibroblasts my influence immune response which may have significant effects on
tumour cells. AR signalling in fibroblasts controls fibroblast production of ECM, when AR is lost, this
could dysregulate the ECM and enhance the migratory potential of cancer by providing a transversable
ECM microenvironment.
8.1. Loss of Stromal AR Creating Less Favourable Conditions
Fibroblasts produce a number of paracrine factors favourable for cancer cell growth (Table 3).
A number of these paracrine factors are reported to be influential in cancer initiation and growth and
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their inhibition in fibroblasts is reported to alter cancer progression in vivo [90,91]. We and others have
recently shown how fibroblast androgen action leads to regulation of a number of these paracrine
factors in vitro, at least at an RNA level (Table) [12,87]. During prostate development moreover,
androgen drives mesenchyme secretion of paracrine factors including FGFs, BMPs, WNTs, TGFBs
and EPHs [92]. Furthermore stromal specific AR knockdown reduces mesenchymal production of
key paracrine factors, IGF1, FGF7, FGF10, and HGF [56,71,93]. Indeed mouse models of androgen
deprivation therapy (ADT) have reported marked reduction in stromal expression of FGF2 Il6, IGF1
and TGFB [91,94–96], all of which are capable of significantly increasing cancer cell proliferation and
tumour growth [97], and acting to maintain terminal differentiation of the glandular epithelia [98].
An increased abundance of stimulatory growth factors by mesenchymal androgen action might
thus contribute to the tumourigenic process. For initiated cancer cells however, decreased in local
availability of paracrine mediators as the result of declining mesenchymal AR signalling could result
in (i) de-differentiation and/or epithelial-mesenchymal transition (EMT); (ii) reduced epithelial AR
function and PSA production that has implications for clinical monitoring via PSA and response to
androgen deprivation therapy; and (iii) a less hospitable environment for epithelial cells thus driving
pathways for epithelial movement and metastasis to more favourable sites.
Table 3. Stromal produced paracrine factors. Proliferative effect (P), Differential effect (D) supported
by [97,99,100]. Androgen regulation (Y = yes, regulated by androgen, N = no, not regulated by
androgen) determined from microarray data from [12,45,87].
Paracrine Factor Effect Androgen Regulation
CTGF P Y
FGF (2, 5, 7, 8, 9, 10) P, D Y (2, 5, 7), N (8), N/A (9, 10)
HGF P, D Y
IGF (1, 2) P, D Y (1, 2)
IL-6 P Y
PDGF P, D Y
TGFb (1, 2, 3) P, D Y (1, 2, 3)
VEGF (A, B, C) P Y (A,C), N (B)
WNT P Y
CXCL12 P N
EGF P, D N/A
TGFa P, D N/A
8.2. A Role for Stromal in AR Inflammatory Processes
A high abundance of inflammatory cells is associated with development of prostate cancer and
with poor outcome [101], and there is an association between age induced decline in testosterone
and increased prostatic inflammation [102–104]. Although an anti-inflammatory effect of androgens
has been demonstrated for the whole prostate [105], the role of fibroblasts, and indeed fibroblast AR
signalling, in this process is unclear. Significantly however, fibroblasts are known to interact with
inflammatory immune cells [106], and testosterone action in synovial fibroblasts has been suggested
to have an anti-inflammatory role by inhibition of pro-inflammatory cytokine production [107,108].
Moreover, CAFs themselves have been reported to activate immune responses via NFKB secretion,
while AR in prostatic fibroblasts is believed to modulate the release of pro-inflammatory cytokines that
affect initiation and development of BPH and PIN [71]. The above data are collectively compelling for
immune regulation in the prostate and a role in the tumour process, but the specific mechanisms and
role of fibroblast AR need direct elucidation.
8.3. AR in CAF Movement and a Subsequent Role in Cancer Invasion
Compared to normal fibroblasts, CAFs have been shown to modulate movement of cancer cells
through a variety of distinct mechanisms and effectors [90,109–113], and in themselves are more
migratory than NPFs [114]. On one level, changes in fibroblast maintenance of ECM can serve to
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enhance movement of cancerous epithelia directly via independent matrix interactions [115,116].
On another, the ability of fibroblasts to move, create guidance structures, and dictate cancer cell
movement may a key determinant in cancer progression and metastasis [115,117,118]. We have
previously reported in fibroblasts a non-genomic role for AR and its co-regulator, Hic-5, in controlling
fibroblast movement. With decreased androgen action, Hic-5 associates preferentially with the focal
adhesion complex to inhibit its activity, facilitating fibroblasts detachment from the extracellular matrix
and increased movement. It can be predicted therefore, that the loss of fibroblast AR might increase
fibroblast movement and stimulate direct guidance of cancer cells. Furthermore, chemotactic cues
are reported to outweigh any other conflicting stimuli, and drive migration [119]. Androgen also
regulates the fibroblast expression of the potent chemo attractant, CXC12 [12,87]. The role of CXCL12 in
controlling cancer cell movement is well known [120]. Additionally there are a host of other chemokines
produced by CAFs which may similarly be regulated any androgen [56,88,121,122], and could provide
an avenue by which disruption of AR signaling in fibroblasts may change the migrationary potential
of cancer cells thus affecting patient outcomes.
8.4. Stromal AR Regulation of ECM
We recently hypothesised that the inverse relationship between stromal AR level and prostate
cancer outcome is the result, in part, of changes in the production and regulation of fibroblast ECM [12].
The ECM is an intricate matrix of proteins and glycans that provide structural support for tissue
and organs, and acts as a repository of hormones, enzymes and second messengers. It has been
shown that the ECM can stimulate tumour growth and encourage cell cycle progression of cancer
cells through proliferative checkpoints [123]. The ECM can also drive cancer cell gene expression,
signal transduction, cell morphology, cell survival, and motility [124]. Changes in ECM can also cause
CAFs to secret pro-inflammatory markers, thereby enhancing cancer progression [125,126]. In physical
terms, it appears that the ECM can regulate cancer cell invasion via multiple parameters, including
density, orientation, stiffness, and organisation of the matrix fibres. Whilst the effects of these different
ECM characteristics can be interdependent or combine to create effects, it should be noted that they
are independently able to affect cancer cell behaviour [127].
The role of ECM density is potentially complicated as well as controversial. Accompanying the
switch from benign to malignant tissue for a number of different cancers is an increase in certain
ECM proteins such as collagen 1. However, these reactive changes also coincide with a change from
a mainly smooth muscle stroma that doesn’t produce much ECM, to one composed predominantly of
high-ECM producing/maintaining fibroblasts and myofibroblast. These changes occur with all solid
tumours, but nevertheless not every cancer will metastasise. In breast cancer, high collagen production
is associated with cancer development and is reported to excite tumourigenesis and proliferation,
and to alter intracellular processes to excite cancer cell movement [128–130]. While increased density
may contribute to cancer initiation, it might conversely oppose tumour progression. As an example,
hypoxia is a known driver of cancer progression and is associated with the ECM acquiring a loose
and porous phenotype [131]. Although early 2-D ECM models suggested a relationship between
density and cancer cell motility, more recent 3-D models show that cancer cells move more rapidly
and easily through low density ECM [132–134]. The idea of androgen regulation is confirmed in vivo
with a number of observations in ADT studies, noting changes in ECM volume [135–138] as well as
changes in MMP levels [138,139]. Furthermore androgen regulates ECM component genes expression,
and produces an ECM capable of altering cancer cell adhesion and migration [12].
The firmness or rigidity of the ECM fibres is also reported to affect cell movement. Traditionally,
increased stiffness was believed to enhance migration by encouraging mesenchymal-type cell
invasion [140], and by regulating cellular arrangement of integrins to control cell movement
processes [129]. Conversely, increased stiffness and rigidity inhibits the ability of ECM fibres to
be degraded by proteolytic enzymes such as MMP [141]. The recent move towards 3-D modelling
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has shed greater light on this process, specifically that maximal cell movement of cancer cells, such as
human prostate DU145 cells, occurs in matrices exhibiting lesser stiffness [142].
Another aspect of the ECM that is accruing evidence for a major role in cancer progression is
the orientation of the ECM fibres. In both in vitro and in vivo systems, cancer cells exhibit increased
invasion and metastasis if ECM is arranged linearly to provide tunnels and tracts for cell movement.
Similarly, the pore size, or space between ECM fibres can modulate cancer cell movement [132,134,143].
In in vitro 3D modelling, testing different poor sizes, widths, and arrangements, suggests that increased
density and constricted poor sizes have an inhibitory effect on cell migration [140,144].
In summary, movement of cancer cells appears to be the culmination of intrinsic changes within
the cell combined with the external influence and guidance of the ECM [145]. Fibroblasts AR has the
ability to regulate the ECM, which when lost will create an environment favourable for cancer cell
invasion and metastasis. This ability of AR signalling within fibroblasts to regulate the ECM may be
key factor in stromal AR correlation with outcome and worthy of further investigation.
9. Potential Importance of Stromal AR in Neoadujant Hormone Therapy
As prostate cancers progress to hormone refractory metastatic disease, usually under conditions
of androgen deprivation or complete androgen blockade, the epithelial AR is widely believed to
have acquired the capacity to drive tumour growth. In early stage disease however, it appears as if
the stromal AR is required in both tumour initiation and conversely as an inhibitor of progression
and metastasis, and unlike its epithelial counterpart holds prognostic information. Additionally,
in mouse recombinant models where patient cancer tissue is grown in the presence of either AR
positive or negative fibroblasts, the apoptotic response of cancer cells to castration is significantly
modulated by AR in the surrounding fibroblasts [12]. Given this dichotomy, we reviewed the use of
ADT in a neoadjuvant setting for primary prostate cancer (Table 4). Despite ADT not usually deemed
a standard treatment for organ confined prostate disease, the CaPSURE registry showed increasing
trends since 1990 for the use of ADT in a neoadjuvant setting either alone or in conjunction with
of other forms of treatment [146]. Neoadjuvant use of ADT does reduce primary tumour size by
25%–30% [147,148]. However, recent studies using pre-existing patient cohort information showed that
neoadjuvant ADT as a front-line therapy led to greater relative mortality when compared to surgery
or radiation in a cohort of 7538 prostate cancer patients [149]. In a second population-based study of
over 1900 men with T1–T2 prostate cancer, the use of ADT as primary therapy was associated with
a lower rate of prostate cancer-specific survival [150]. In a study of 16,000 men with well-to-moderately
differentiated tumours, the use of primary ADT within the first six months of diagnosis was associated
with worse rates of overall survival and prostate cancer specific mortality, regardless of any additional
treatment after this first 6 months [151]. A similar finding was reported by the European Organization
for Research and Treatment of Cancer (EORTC) clinical trial, which investigated immediate and
delayed use of ADT for treatment of locally defined tumours [152]. The use of ADT for localized
prostate cancer increased the subsequent need for chemotherapy [153]. Nonetheless, there have been
other reports suggesting either no or a slight beneficial effect of primary ADT [154,155], but these have
had significantly smaller cohorts of 176 and 57 patients, respectively. Likewise, in a larger study of
1006 patients with low to intermediate prostate cancer treated with low dose brachytherapy (LDB),
the use of ADT either three months prior to or concomitantly with LDB did not affect disease free
or overall patient survival [156]. Furthermore, studies that have reported unconventional forms of
primary ADT (i.e., diethylstilbestrol) have had inconsistent results with benefit for T2 tumours but
deleterious effects for T1 disease [157]. Overall, the evidence suggests that neoadjuvant use of ADT
may produce harmful effects through unknown mechanisms. However as discussed above, ADT is
of well proven benefit in metastatic disease so the adverse response of this treatment when used in
a primary setting must be due to adverse targeting/response of the early stage tumours. It is entirely
possible that this paradox is due to effects of androgen signalling in cancer fibroblasts associating with
the primary/early stage lesions.
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10. Future of Stromal AR
10.1. Prognostic Tool
There is growing appreciation for the influence of stroma in cancer, so much so that a number of
studies have looked to the stroma for prognostic utilisation. Morphological characterisation of prostate
cancer has used the degree of desmoplatic stroma to predict biochemical recurrence and cancer related
death [169–171]. Stromal signatures and protein profiles have been investigated, and have been used to
predict relapse post prostatectomy and clinical outcome [77,172–174]. Clinically, no protein expression
or gene profiles are used to aid prognosis, despite the various immunohistochemical markers used in
other cancers, such as breast cancer where oestrogen and progesterone receptors are used to inform on
disease coarse and management. Along these lines we, and others have studied the benefit of using
stromal AR in clinical settings. Despite inconsistent findings for the prognostic values for epithelial
AR, a loss of stromal AR is consistently associated with disease relapse and outcome [7–12,41] (Table 2).
We have also found using FKBP51 in addition to AR, as a marker of functional AR activity is even more
robust prognostic tool [13]. These studies have focus on tissue samples, development of serum markers
for stromal AR changes may also be useful tool. From whole genome studies we know a number of
genes targeted by AR fibroblasts code for secreted proteins so with further work there may be potential
for development of serum markers.
10.2. Therapeutic Targets
Just like in the prognostic setting, the cancer stroma is being investigated for its therapeutic
influence and even as a target. The important role of CAFs have led to monoclonal antibodies and drugs
which target the CAF marker, fibroblast activated protein (FAP) [175–177]. The stroma surrounding
the tumour is exposed to any serum administered therapeutic agent before said therapeutic agent
reacts with the cancer. Indeed it has been postulated that the stroma will mediate the influence of the
therapeutic agent [178].
Therapeutic antibodies and small molecule inhibitors delivered in nanoparticles as well as extracts
from natural compounds are being investigated for disrupting paracrine communication between the
stroma and cancer cells to treat solid cancers [179,180]. A number of stromal produced paracrine factors,
regulated by AR have been targeted therapeutically to varying degrees of success. Androgen regulated
paracrine factors such as TGFs, FGFs, EGF, HGFs produced by the stroma having agents capable
of targeting them [178]. FGF targeting has been reported to be effective in both in vitro and in vivo
studies for treating prostate cancer [181,182]. Similarly, agents targeting HGF in prostate cancer are in
different phases of clinical trial [183,184].
However, no therapeutic agents have been developed to specifically target stromal AR. Indeed in
cases of neoaduvent ADT or use of AR antagonists the effect on stromal AR and the subsequent
effects of stromal AR inhibition is rarely considered. In review of studies investigating the use of ADT
on primary prostate tumors, the neoadjuvant use of ADT predominantly produces worse outcomes
for the patients, with relapse free survival and overall survival reduced. Given the relationship
between reduced stromal AR and cancer related progression and death, it may be more important
to investigate either anti-androgen which affect only epithelial cells, or developing drugs which will
decrease epithelial AR but enrich stromal AR signalling. As we have previously shown a single
co-regulator can have vast effects on global gene expression with the cell. One way to ensure specificity
would be to target AR co-regulators and pioneer factors, a number of which are specific for one cell
type or the other [46]. In comparison of prostatic and skin fibroblasts to cancer cell lines, a panel
of 33 co-regulators were differentially expressed between the two cell types [46]. Cancer cell type
specific co-regulators included SP1, NCOA1, NCOA2, and PIAS1. Importantly these are potentially
targetable [185,186]. Pioneer factors are also targetable, and as we have shown FOXA1 is expressed
and active only in epithelial cells and not fibroblasts [43,186]. However targeting Hic-5, AP-1, or other
proteins which is also or highly expressed in the stroma should be avoided as inhibiting stromal AR
80
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may have detrimental side-effects. Taking into account stromal AR should become an important step
in future development of treatments targeting AR signalling, especially in a neoadjuvent setting.
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Abstract: Androgen receptor (AR) signaling remains the major oncogenic pathway in prostate cancer
(PCa). Androgen-deprivation therapy (ADT) is the principle treatment for locally advanced and
metastatic disease. However, a significant number of patients acquire treatment resistance leading
to castration resistant prostate cancer (CRPC). Epigenetics, the study of heritable and reversible
changes in gene expression without alterations in DNA sequences, is a crucial regulatory step in
AR signaling. We and others, recently described the technological advance Chem-seq, a method to
identify the interaction between a drug and the genome. This has permitted better understanding of
the underlying regulatory mechanisms of AR during carcinogenesis and revealed the importance
of epigenetic modifiers. In screening for new epigenomic modifiying drugs, we identified SD-70,
and found that this demethylase inhibitor is effective in CRPC cells in combination with current
therapies. The aim of this review is to explore the role of epigenetic modifications as biomarkers
for detection, prognosis, and risk evaluation of PCa. Furthermore, we also provide an update of
the recent findings on the epigenetic key processes (DNA methylation, chromatin modifications
and alterations in noncoding RNA profiles) involved in AR expression and their possible role as
therapeutic targets.
Keywords: epigenetics; prostate cancer; androgen receptor; methylation; acetylation; non-coding
RNA; biomarkers; novel treatments
1. Introduction
Prostate cancer (PCa) is the most prevalent cancer in men and the third cause of cancer-specific
mortality in Western countries [1]. To understand the cornerstone of prostate carcinogenesis, many
authors have pointed towards the central role of the androgen receptor (AR). AR, a member of the
nuclear receptor superfamily and located at chromosome Xq11-12, contains three major functional
domains. The first, highly unstructured, and largest domain is the N-terminal domain (NTD), which
comprises the activation function 1 (AF1) motif. The DNA binding domain (DBD) is the second
AR-region and contains two zinc fingers that cooperate with the androgen-response element (ARE),
and allow dimerization. The hinge region is a bridge between the DBD and the ligand binding domain
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(LBD), which accommodates the second activation function (AF2) motif [2]. It is well established that
sustained AR activity is inexorable from PCa cell survival and disease progression, even following
androgen deprivation therapy (ADT) [3,4]. Since the discovery in the 1940s that PCa is dependent
on androgens [5], the central therapy for patients with locally advanced or metastatic disease targets
the AR. After an initial period of therapeutic response, PCa become insensitive to these therapies
and progresses to the castration resistant prostate cancer (CRPC) [6]. To date, in addition to the
well- known genetic mutations, epigenetics is considered fundamental in the molecular pathogenesis
of PCa. Epigenetics has been described as “the stable transmission of cellular information due to
a modification of the DNA without a change in DNA sequence” [7,8]. It has been demonstrated
that alteration of epigenetic marks may determine cancer initiation, development, and subsequent
progression [9,10]. This review focuses on the role of epigenetic processes such as histone methylation,
histone acetylation and non-coding RNA that play a central role in the regulation of AR in PCa
pathogenesis and progression and discusses further modalities of treatment.
2. Histone Methylation
Histone methylation is an important and complex method of transcriptional control mediated by
histone methyltransferase (HMT) and histone demethylase (HDM) enzymes. Methylation changes to
the local chromatin encourage or repress transcription according to the site of modification [11].
For example, methylation of lysine residues 4 and 36 in histone H3 (H3K4, H3K36) generally
preserves euchromatic domains [12,13] whereas the modification of H3K9 and H3K27 [14,15] forms
heterochromatic regions. Arginine methylation is an alternative method of histone modification.
Protein arginine methyltransferase (PRMT) family members such as PRMT6 [16] and coactivator
associated arginine methyltransferase 1 (CARM1) [17], are enzymes responsible for histone methylation
at arginine residues. Several articles [2,18] suggest that the histone methylation of AR can regulate the
transcriptional activity of AR.
One of the most extensively studied HMT enzymes in PCa is SET9, which seems to improve
gene expression by inducing histone H3K4me1 and obstructing histone H3K9 methylation and the
nucleosome remodeling deacetylase (NURD) complex [19–21]. Different groups have observed
elevated levels of this enzyme in malignant epithelial cells from PCa patients [22,23]. To explore
its role in the regulation of the AR, many works describe that SET9 is responsible for N–C inter-domain
cooperation that is important for AR transcriptional activity [24–26]. It was subsequently found
that the hinge region of AR contains a motif (KLKK) that is comparable to the sites modified by
the methyltransferase SET9 in other proteins [22,23]. Even if SET9 was shown to methylate AR,
a consensus could still remain elusive about the sensitivity of this interaction. It is also unclear which
Lys is methylated; one study shows Lys 630 [23] and another Lys 632 [22].
The nuclear receptor-binding SET domain-protein 2 (NSD2) is a histone methyltransferase that
cooperates with the DBD of the AR [27]. High levels of NSD2 are related to the expression of PSA
(prostate specific antigen) [27]. A paper by Asangani et al. reported that high levels of NSD2 correlate
with aggressive characteristics in PCa [28]. The mechanism of action is linked to the enhancer of zeste
homolog 2 (EZH2), a component of Polycomb repressive complex 2 (PRC2) [4]. The enhancement of
EZH2 leads to the transcriptional inhibition of miR-203, miR-31 and miR-26, which are repressors of
NSD2. This complex mechanism facilitates an over expression of NSD2 with the generation of the
active histone mark, H3K36me2. Moreover, the study by Yang et al. [29] shows that NSD2 acts as
a transcriptional coactivator of NF-κB for activation of target genes, such as IL-6, IL-8, VEGFA and
survivin in CRPC cells.
Historically, EZH2 has been considered an AR transcriptional repressor. This peculiarity has been
related to the ability of EZH2 to catalyze two repressive histone markers, H3K27me3 and H3K4me3,
via AR recruitment [30]. Other works with conflicting findings have established a strong correlation
between increased EZH2 and more aggressive [31], neuroendocrine [32] or metastatic [33] PCa. The role
of EZH2 as an AR coactivator has been described to be AKT dependent. In fact, the phosphorylation
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of EZH2 serine 21 mediated by PI3K/AKT obstructs the methylation of H3K27 [34]. Xu et al. [35]
confirmed these previous reports and showed that the phosphorylation of EZH2 at serine 21 defines the
oncogenic function of EZH2 as a coactivator of AR in advanced PCa. This mechanism is independent of
PCRC2 and H3K27me3 and suggests that EZH2 can methylate other proteins or other histone residues.
Another methyltransferase involved in PCa growth is PRMT6 [36]. PRMT6 has a high affinity
for H3 and provides H3R2me2, a well-known repressive mark [36] but at the same time it was
widely detected in a cohort of patients affected by PCa [37]. Almeida-Rios et al. [38] recently showed
that PRMT6 silencing in PC-3 cells downregulates the PI3K/AKT/mTOR pathway and increases
AR signaling.
A relevant enzyme for the AR regulation is the lysine specific demethylase 1 (LSD1). It has been
targeted for its dual ability to suppress or stimulate AR expression [18]. The explanation of its role
as a transcriptional coactivator can be the de-methylation of H3K9me1,2 [39]. The activity of this
methyltransferase could be regulated by other post-transcriptional modifications. For example, it was
discovered that H3 phosphorylation mediated by the protein kinase C-related kinase 1 (PRK1) [40]
and the protein kinase C 1 (PKC1) [41] changes the substrate of LSD1 from H3K4me1,2 to H3K9me1,2
with an enhancement of AR related gene expression. Recently, Yang et al. [42] described an alternative
mechanism of LSD1 that involves the generation of ROS leading to DNA damage. The authors report
that this ROS generation occurs after androgen stimulation, which determines the demethylation
of H3K4me1,2 on ARE regions, resulting in DNA damage. This DNA damage releases DNA and
facilitates DNA loop formation, which is critical for miRNA expression and transcription. Subsequently,
OGG1 and APEX1, DNA damage repair factors, are recruited to these ARE regions in an androgen
and LSD1 dependent manner, suggesting that LSD1-mediated AR targets transcription relies on H3K4
demethylation and DNA oxidation [42].
Historically, despite its aforementioned role as coactivator, LSD1 has been considered a corepressor.
LSD1 acts as a demethylase for H3K4me1,2 [43] enhancing the recruitment of corepressor complexes.
Moreover, has been reported that LSD1 can reduce the expression of several genes such as the
AR gene or AKR1C3 and HSD17B6, two genes responsible for the androgen synthesis [18,44].
The overexpression of AKR1C3 have been correlated with PCa progression and aggressiveness [45,46]
and recent findings describe the activation of AKR1C3 as a mechanism of resistance to Enzalutamide
and Abiraterone [47,48].
Furthermore, it has been shown that other HMT enzymes such as the lysine demethylase 4B
(KDM4B) [49], KDM4C [50], and KDM3A [51] can enhance the AR transcription activity. KDM4B,
an enzyme that can de-methylate H3K9me3, has a duplex function. It can stimulate the AR activity
directly through the demethylation of H3K9me3, or indirectly reducing the ubiquitylation and
degradation of AR [49].
It is well known that one of the tumorigenic mechanisms in PCa cells is the fusion gene
TMPRSS2-ERG [52] and several works highlight the causal relationship between the AR signaling and
these genomic rearrangements [53]. Androgen stimulation facilitates the co-recruitment of the AR and
the topoisomerase II beta (TOP2B) at TMPRSS2 and ERG loci near genomic breakpoints, leading to
TOP2B-mediated DNA double strand break formation [54].
Yu et al. [55], through the use of a chromatin precipitation (ChIP) technique, discovered that
ERG expression increases the recruitment of EZH2 which may then mediate the repression of AR
transcription activity through H3K27 methylation [55]. Using a global proteomics approach to unravel
the mechanism that might control androgen-dependent TMPRSS2-ERG fusion, Metzeger et al. [56]
showed that the di-methylation of K114 mediated by LSD1 is executed by the histone mehylatransferase
EHMT2. LSD1-K114me2 allows for interactions with the chromodomain helicase DNA-binding
protein 1 (CHD1). The complex (EHMT2-LSD1 K114me2-CHD1) controls chromatin binding of AR,
and it was found to play an important role in regulating the TMPRSS2-ERG oncogenic fusion [56].
The mechanisms of action of the principal methyltransferases and demethylases involved in the
regulation of AR gene expression are presented in Figure 1.
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Figure 1. Schematic overview of AR histone 3 methylation status. SD70 inhibits the demethylase activity
of KDM4C and is effective in CRPC cells both in vitro and in vivo. NURD: nucleosome remodeling
deacetylase complex; EZH2: enhancer of zeste homolog 2; LSD1: lysine specific demethylase 1; NSD2:
nuclear receptor-binding SET domain-protein 2; PRMT6: protein arginine methyltransferase 6; KDM4B
and KDM4C: Lysine Demethylase 4B and 4C.
3. Histone Acetylation
The histone acetyltransferases (HAT) and histone deacetylases (HDAC) are two groups of
enzymes that regulate acetylation and deacetylation [57]. In general, active euchromatin is relatively
hyperacetylated whereas inactive heterochromatin is hypoacetylated [58]. In 2000, Fu et al. discovered
within the flexible hinge region of AR a short sequence (KLKK), with the property of an acetylation
motif [59].
As described in other reviews [18,60–62], the histone acetylation status is a reversible process
of placing and removing covalent acetyl groups that can improve or reduce the AR transcriptional
activity, respectively. To study the fundamental role of AR acetylation, several groups used two
different models in which the acetyl acceptor sites were mutated to be non-functional or acetylation
mimetic. In these two scenarios, when the AR is non-functional, the AR takes on a repressed form,
which increases binding to co-repressor proteins including NCoR [59,63,64]. In the other case, when
the acetylation acceptor mutated sites mimic acetylation, we can observe a completely different result;
an improvement of the transcriptional activity and a reduction of the interaction with co-repressor
proteins [60,63].
3.1. AR Activation Mediated by Histone Acetylation
Many works have described several co-regulators of the AR transcription machinery with a HAT
activity such as p300/CAF [59], p160/SRC [65], Tat-interactive protein, 60 kDa (TIP60) [66], and
N-acetyltransferase arrest-defect 1 protein (ARD1) [67].
CBP and p300 are proteins with HAT activity, and they are able to regulate transcription [68,69].
It was discovered that AR is acetylated by p300 and p300/cAMP-response element-binding protein
associated factor (PCAF) both in vitro and in vivo [59]. Recently, Zhong et al. [70] explained an
interesting pathway involving PTEN and AKT. The authors show that the inactivation or deletion of
PTEN and the subsequent phosphorylation of AR at the serine 81 stimulates the acetylation of the AR
by p300. Furthermore, it has been described that p300 can affect the AR activity indirectly. In fact,
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the acetylation of b-catenin provided by p300, determines a different interaction with the AR leading
to an enhanced AR transcription [71].
The Steroid Receptor Coactivator-1 (SRC1) is responsible for the activation of AR due to its HAT
domain [72]. Moreover, it has not only been shown that SRC1 can interact directly with AR, but it can
recruit other coactivators (p300/CBP) in order to stimulate the transcriptional activity of the AR [73].
A recent study describes the possible role of the SCR1/p160 binding site as a novel therapeutic target.
In fact, using two overlapping SRC1 peptides the authors show an inhibition of AR-dependent genes,
such as PSA and TMPRSS2 [74].
As previously suggested in another review [60], in addition to androgens, various other factors
can stimulate the levels of AR acetylation mediated by CBP/p300 or SRC1. Despite the fact that
the mechanism of action is not well-understood, it has been proposed that bombesin, via Src and
PKC signaling pathways, can activate p300 activity. This interaction leads to enhanced acetylation
of AR resulting in increased expression of AR-regulated genes (PSA) [75]. At the same time, IL-4
increases CBP/p300 protein expression and enhances interaction of AR with CBP/p300 proteins
through a recruitment of p300 protein to the androgen responsive elements (AREs) in the promoters of
androgen responsive genes [76]. IL-6 is another cytokine important for cell growth and survival in PCa
both in vitro and in vivo [77], and it has been reported that SRC-1 can improve its ligand independent
stimulation of AR by IL-6 via MAPK [78].
TIP60, an AR factor acetyl transferase (FAT), has a specificity for the LBD of the AR [79].
More recently, it has been shown that TIP60 may be directly responsible for the acetylation of AR
and it can interplay with HDACs at the PSA promoter gene. The equilibrium between these can
lead to activation or suppression of AR transcription [80]. Shiota et al. [81] explained that TIP60
overexpression facilitates the acetylated form of AR and, consequently, the AR localization in the
nucleus in absence of an androgen enriched environment.
Arrest defective-1 protein (ARD1) is another acetyltransferase [82] which has important functions
in several types of cancer through acetylating different target proteins [83–85]. Wang et al. [67] reported
that the level of ARD1 is consistently higher in PCa, and recently, a work by DePaolo et al. [86] revealed
that ARD1 not only acetylates AR at lysine 618 but also creates a ternary complex with AR and HSP90,
playing a role in the AR-HS90 dissociation.
Interestingly, another study suggests that the levels of AR potentiate the recruitment of AR and
the components of the transcription machinery to chromatin in order to enhance the acetylation on
H3K9 and on H3K14 in CRPC cells even in an androgen deprivation environment [87]. These finding
are in line with other works [88], which report how an enhanced acetylation in cells that overexpress
AR is linked to the development of a castration resistant condition.
3.2. AR Inhibition Mediated by Histone Acetylation
As mentioned above, acetylation of particular residues determines the enhancement of the AR
activity, and it is normal to expect that the opposite process can lead to inhibition. Within the HDAC
family, we encounter several proteins with a similar enzymatic activity. For example, HDAC1 interacts
with the PSA promoter and suppresses AR signaling [66] while HDAC7 has the similar ability to
inhibit AR, but in this case the mechanism of action is independent of AR acetyl acceptor sites [89].
Moreover, several studies describe that HDAC6 regulates the correct folding of the AR mainly via
modulating HSP90 acetylation. The acetylation of HSP90 results in a destabilization of the AR and
subsequently in its degradation by the proteasome [90].
Sirtuin 1 (SIRT1), a NAD-dependent deacetylase, has been described as a repressor of AR
activity [91]. Fu et al. extended precious observations and established a role for SIRT1 in regulating
cellular growth by repressing and deacetylating the AR directly [91]. Moreover, the same group
highlighted a “functional antagonism” between SIRT1 and p300 at the same site of the hinge region
avoiding the N-C terminal interaction [61,91]. Figure 2 depicts the molecular communication between
AR and acetylation status in order to enhance or reduce AR gene expression.
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Figure 2. Graphic representation of the balance between acetylation and deacetylation in the regulation
of androgen receptor (AR) gene expression. The mechanism of action of histone deacetylase inhibitors
(HDACi) such as romidepsin and panobinostat is related to the heat shock protein-90 (HSP90).
NTD: N-terminal domain; DBD: DNA binding domain; LBD: ligand binding domain; AF1 and AF2:
activation function 1 and 2; PKC: protein kinase C; SRC1: steroid receptor coactivator-1; TIP60:
Tat-interactive protein, 60 kDa; ARD1: N-acetyltransferase arrest-defect 1; SIRT1: Sirtuin 1; PCAF:
p300/cAMP-response element-binding protein associated factor.
4. Non-Coding RNA
In the last decade, several articles corroborated by the use of new technologies to reveal that
a major portion of the non-coding genome is transcribed with many regulatory functions. This brought
about a change in thinking that non-coding RNA can have a role in cancer [92]. Non-coding RNAs
(ncRNAs) are divided into two major groups based on their size: small ncRNA (<200 bp) and long
ncRNA (>200 bp) [93].
4.1. MicroRNA and AR
MicroRNAs (miRNAs) are a class of small non-coding RNAs with an important role in cell
development, differentiation and signal transduction. Generally, miRNAs cause mRNA translational
repression or mRNA degradation by binding to the 3′ untranslated region (3′-UTR) [94]. Furthermore,
recent studies have reported that the 5′-UTR of mRNAs might be involved in the gene regulation by
miRNA, and it has been shown that miRNA can activate gene expression rather than repress it [95,96].
Based on the central role of AR signaling in the normal and neoplastic growth of the prostate cell,
many reports describe the existence of feedback loops between miRNAs and AR [97].
4.1.1. Androgen Regulation of miRNA Expression
In 2011, Waltering et al. presented one of the first miR microarray studies to examine androgen
regulation of miRNAs [98], and they showed that dihydrotestosterone (DHT) positively modulates
17 miRNAs in VCaP cells whereas castration causes high levels of 42 miRNAs. The work of several
independent groups demonstrates that miRNAs such as miR-19a, miR-148, and miR-27a are androgen
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inducible miRNAs [99–101]. Indeed, androgen-mediated overexpression of miR-27a results in the
reduction of prohibitin, a well-known tumor-suppressor gene and co-repressor of the AR, with a
subsequently increased expression of AR genes and increased PCa cell growth [101].
Genome-wide screenings of androgen target genes have identified miR-125b as androgen-inducible
miRNA [102] and in particular have been shown that androgens carry out this action by binding the
promoter region of the miR-125b gene. Moreover, Sun et al. [103] reported that AR targets the
miR-99a/let7c/125b-2 cluster genes region LNC00478 and subsequently represses the level of this
cluster. The authors also explain the role of two chromatin modifiers EZH2 or JMJD3, that can suppress
or enhance the levels of the miR-99a/let7c/125b-2 cluster depending on the presence or the absence of
androgen [103]. The downregulation of the miR-99a/let7c/125b-2 cluster has been shown to protect
many of their target mRNAs from degradation. On the contrary, when miR-125b is overexpressed,
it cooperates with the insulin-like growth factor 1 (IGF1R) to enhance PCa cell development [103].
MiR-125b has been reported to stimulate the PCa cells growth without androgen stimulation through
down-regulating the expression of Bak1 (Bcl-2 homologous antagonist/killer 1) [104] and by targeting
the Bcl-2-binding component 3 (BBC3) and p53 [105–107]. MiR-125b, as described in another work [108],
is connected to Her2-AR pathway and could have a function in inducing CRPC.
MiR-135a has been found to be upregulated in androgen sensitive PCa cells and AR, as previously
reported for miR-125, directly activates transcription by using a functional ARE in the miR-135a
promoter region [109]. To explore the biological effects of miR-135a in prostate cells, the researchers
overexpressed miR-135a in LNCaP cells and demonstrated that miR-135a can down-regulate the
expression of the Rho-associated protein kinase 1 (ROCK1) and ROCK2 (implicated in cytoskeleton
regulation) at mRNA and protein levels [109]. Coarfa et al. [110] also found AR recruitment to
the ARE in the promoter region under androgen stimulation. They additionally identified stronger
co-recruitment of AR and coactivators to a region immediately downstream of the miR-135a-5p
gene without the addition of androgen. Combined with the inhibitory effect of miR-135a-5p on
expression of AR and its coactivators, this suggests a negative feedback loop that can de-repress AR
axis transcriptional output upon androgen deprivation. A recent study by Wan et al. [111] describes a
downregulation of miR-135a in CRPC. The authors found that RB-associated KRAB zinc finger (RBAK)
and matrix metalloproteinase 11 (MMP11), two genes involved in migration pathway, are controlled
by miR-135a. They showed that PCa progression is associated with low levels of miR-135a and high
levels of RBAK and MMP11.
MiR-32 is also reportedly an androgen-regulated miRNA. The transfection of pre-miR-32 into
LNCaP cells confers significant cell growth and reduces apoptosis. In CRPC, miR-32 is regulated by
androgen through targeting the B-cell translocation gene 2 (BTG2), a member of the antiproliferative
(APRO) gene family [112]. BTG2 regulates several cellular mechanisms such as cell cycle progression,
DNA damage repair, and apoptosis, and thus it has been shown that its levels are suppressed in many
human cancers [113].
AR acts as a stimulus for miR-21 transcription by targeting miPPR-21, the miR-21 promoter [114].
AR is not the only enhancer of miR-21. In fact, mir-21 can be stimulated by two other transcriptional
factors, the activator protein 1 (AP-1) and the signal transducer and activator of transcription 3
(STAT3) [115,116]. Furthermore, Mishra et al. [117] described a positive feedback loop between miR-21
and AR. The AR and miR-21 axis negatively alters the TGFBR2 pathway, and in this way inhibits the
tumor-suppressive activity of TGFβ. Mir-21 is implicated even in the regulation of the cell cycle, and
the same group further revealed that miR-21 is not only able to reduce the level of a cyclin-dependent
kinase inhibitor p57Kip2, but it is also able to attenuate p57Kip2-mediated responses [118].
MiR-221 and miR-222 are encoded on the X chromosome [119], but curiously they are
downregulated by AR in an androgen enriched environment [112]. A recent review by Shih et al. [97]
highlighted the mutual interaction between miR-221 and AR. Even though miR-221 has been
extensively studied, we still do not have a clear idea on what its expression pattern in PCa is.
For example, work by Gordanpour et al. [120] shows low levels of miR-221 in aggressive PCa with
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an inverse association with the Gleason Score, clinical recurrence, and metastasis. On the other hand,
another study revealed a linear correlation between miR-221 expression and the pathological stage,
lymph node involvement, Gleason Score, and biochemical recurrence (BCR) [121]. Yang et al. [122]
confirmed that miR-221 and miR-222 are highly expressed in an androgen insensitive cell line (PC-3),
and the experimental down-regulation of miR-221 or miR-222 inhibits migration and increases
apoptosis in PC-3 cells. At the same time, the authors describe that the expression of SIRT1, a histone
deacetylase, is increased in PCa cells after the inhibition of miR-221 and miR-222, suggesting that
SIRT1 may play a suppressive role against the tumorigenic action of these miRNAs. To explore another
possible mechanism of action of miR-221, a systematic biochemical and bioinformatical study has
been performed [123]. It reveals two miR-221 targets, HECT domain E3 ubiquitin protein ligase 2
(HECTD2) and member RAS oncogene family (RAB1A). In this study, downregulation of HECTD2
affected androgen related transcription, and downregulation of HECTD2 and RAB1A altered the
expression of many cell cycle genes and pathways, promoting tumor metastasis and leading to the
development or maintenance of the CRPC phenotype.
4.1.2. MiRNA Regulation of Androgen Signaling
Many investigations have been conducted for documenting the role of miRs in controlling the AR
pathway. By using a miR library in 2011, Ostling et al. demonstrated the ability of 71 unique miRs
(52 decreasing and 19 increasing) to influence the AR [124]. Since then several miRNAs have been
described as having a role in the regulation of AR activity directly or through co-regulators [97,125].
MiR-205 is deregulated in PCa compared to benign prostate tissues, it is inversely associated
to advanced disease and short life expectancy, and miR-205 levels exhibit a negative correlation to
AR [126]. Moreover, miR-205 was also found to be lower in CRPC patients in comparison with men
who had not initiated ADT. Hagman et al. [126] reported that mir-205 directly targets AR and reduces
both AR transcript and proteins. The role of miR-205 is not only related to AR, but it has been found
that this miRNA can regulate several genes. Some of these genes (IL-8 and EDN1) are responsible for
improving the expression of the AR, and others are involved in the MAPK/ERK, mTOR, and IL-6
signaling pathways [97].
MiR-34 family includes three miRNAs that have been previously reported to suppress
tumorigenesis by different mechanisms, including modulation of cell cycle, epithelial to mesenchymal
transition, or metastasis [127]. In PCa, all miR-34 family members are downregulated, and the
expression of miR-34a or miR-34c correlates with the tumor grade, advanced disease, and life
expectancy [128,129]. This down-regulation has been linked to several mechanisms such as methylation
of the CpG islands in the promoter region of this miRNAs, regulation by p53 in response to DNA
stress, and a mechanism involving the p38- MAPK/MK2 pathway [129–132]. As reported in the study
by Ostling et al., in PCa cells a statistically significant inverse association exists between miR-34a and
AR [124]. Recently, Fang et al. [133] demonstrated that the long non-coding RNA PlncRNA-1, known
to be enhanced by AR, can preserve AR from miR-34c-mediated suppression in PCa cells. According
to the theory of competing endogenous RNAs, some kind of RNAs may “titrate” other ribonucleic
acids such as miRNAs [133].
LET7 levels are frequently decreased in human cancers [134,135]. The most important and well
known targets of this miRNA are the oncogenes RAS and MYC [136,137]. A work by Nadiminty et al.
explain that LET7c determines PCa tumor suppression through AR, and this mechanism is linked
to the ability of this tumor-suppressing miRNA to target c-MYC, a molecule required for the correct
transcription of AR [138]. In detail, the same group also found that LET7c reduces AR activity and
decreases growth of C4-2B cells, and it can be attributable to the association of this miRNA with c-MYC
3′-UTR and the subsequent reduction of AR transcription [138]. These results are corroborated by
other studies. Gao et al. [139] reported that the suppression of the AR and c-MYC diminishes PCa cell
proliferation, but at the same time, an ectopic overexpression of c-MYC mitigates the tumor progression
due to AR suppression, supporting an intense molecular relation between the AR and c-MYC.
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Not only do miRNAs have direct effects, but they can also use other pathways to control androgen
signaling. Two of these pathways are mediated by the ERBB-2 and PI3K/AKT. The tyrosine receptor
ERBB-2 is often elevated in PCa, whereas the activation of PI3K/AKT signaling is linked to proliferation,
metastasis, apoptosis resistance and angiogenesis in PCa [140]. A work by Epis et al. demonstrates
that the ERBB-2 mRNA 3′-UTR contains two specific miR-331-3p target sites and that miR-331-3p
suppresses ERBB-2 expression at both the transcript and protein levels. MiR-331-3p expression was
found to be lower in ERBB-2 overexpressing PCa tissue compared to normal adjacent tissue. The same
group also explained that miR-331-3p is involved in the downstream PI3K/AKT signaling in multiple
PCa cell lines. Interestingly, it has been shown that miR-331-3p acts specifically to decrease PSA
promoter activity and PSA levels without reducing AR expression [140].
MiR-488* directly targets AR by targeting the AR in 3′-UTR. MiR-488* down-regulates AR
protein expression in both androgen-sensitive and insensitive PCa cells, inhibiting cellular growth and
increasing apoptosis as observed after the transfection of miR-488* [141].
MiR-17-5p has been shown to target PCAF, a coactivator of AR, and to support PCa
development [142]. The authors found that the overexpression of PCAF in PCa cells is inversely
associated with miR-17-5p levels, suggesting that low levels of miR-17-5p can enhance AR signaling in
PCa cells indirectly by modulating PCAF expression. Moreover, circulating miRNAs of the miR-17
family have been recently associated with a reduction of PSA levels and overall survival in CRPC
patients [143].
MiR-124 has been described as a tumor suppressor miRNA in several cancer types including
PCa [144–146]. In accordance with its role in many biological processes, different authors examined
the mechanism of action of miR-124. As reported in a recent review [97], the reduction of miR-124
levels in PCa cells is due to hypermethylation of the promoter. As a consequence of this event, both cell
lines or clinical prostate samples showed an elevation in AR expression. Mechanistically, the presence
of the miR-124-binding site in the AR 3′-UTR seems to explain the reason why miR-124 is involved
in the negative regulation of the AR [147]. Moreover, Shi et al. reported that miR-124 can induce the
upregulation of p53, causing cell death and apoptosis in AR-positive PCa cells [147].
The same authors propose an explanation of this phenomenon. The upregulation of p53 may in
part be due to the capacity of miR-124 to inhibit the AR/miR-125b signaling pathway or by targeting
the 3′-UTR of the high mobility group A (HMGA) gene which, as previously reported, can inactivate
p53 [147]. A recent study shows that miR-124 can inhibit AR expression and suppress PCa cells
proliferation and, on the other hand, that miR-124 is an androgen/AR responsive gene [148].
Finally, in the same class of small ncRNA we can include miR-145. MiR-145 has consistently been
found to be downregulated in several types of cancer, including PCa [149,150], and it is inversely
correlated with metastasis, survival and ADT response [151]. The reason for its downregulation is not
completely clear. It could be due to the methylation of the miR-145 promoter, to the mutation of p53
that is a transcriptional activator of miR-145, or to the effect of IL-6 [151]. Larne et al. [151] theorized
that miR-145 may determine a reduction of the AR and its target genes, PSA and TMPRSS2, at both
transcription and protein levels by direct binding because the AR 3′-UTR contains a predicted miR-145
binding site. Moreover, using clinical prostate specimens the authors confirmed the same promising
results, suggesting a future role of this miRNA as a novel therapeutic intervention. Our findings
regarding the role of miRNAs in AR transcriptional activity are summarized in Figure 3.
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Figure 3. Mutual regulatory model of miRNAs and androgen receptor (AR). The graphic also shows
MRX-34, the first miRNA based therapy for cancer. BBC3: Bcl-2-binding component 3; IGF1R:
Insulin-like growth factor 1; Bak1: Bcl-2 homologous antagonist/killer 1; HER2: human epidermal
growth factor receptor 2; p57Kip2: cyclin-dependent kinase inhibitor; AP-1: activator protein 1;
STAT3: signal transducer and activator of transcription 3; HMGA: high mobility group A gene; PCAF:
p300/cAMP-response element-binding protein associated factor; PI3K: phosphatidylinositol-3-kinases;
PlncRNA-1: prostate cancer-up-regulated long noncoding RNA 1.
4.2. Long Non Coding RNA and AR
Given the growing body of evidence documenting the role of long non coding RNA (lncRNA)
in controlling various biological processes or having a central role in various cancers [152–154], it is
reasonable to assume that lncRNAs may have a significant role in PCa as well. Several investigations
in PCa suggest that specific lncRNAs can modulate AR activity through various mechanisms [97].
In 2000, Srikantan et al. [155] characterized the prostate cancer gene expression marker 1
(PCGEM1). PCGEM1 is overexpressed in more than half of PCa tissues [156], and its upregulation
has been associated with high-risk PCa [157]. Moreover, the ectopic expression of PCGEM1 may be a
cause of resistance to doxorubicin-induced apoptosis [158], and this can explain why a gene expression
analysis found its levels upregulated in CRPC [159]. The prostate cancer noncoding RNA1 (PRNCR1)
is transcribed from the “gene desert” region of chromosome 8q24. It is a 13 kb intron less lncRNA, and
although the role of PRNCR1 is not well known, its knockdown reportedly inhibits cell viability [160].
Several works confirm that PCGEM1 is an androgen-regulated prostate-specific gene [155,161] and that
PCGEM1 [162] as well as PRNCR1 [160] are involved in prostate carcinogenesis through AR activation.
An elegant study performed by Yang et al. [156] discovered a particular chromatin mechanism
for AR transactivation mediated by PRNCR1 and PCGEM1. The authors explain that binding of
PRNCR1 to the AR enhancer region and its association with DOT1L is fundamental for the enrollment
of PCGEM1. As reported in the article, PCGEM1 needs the recruitment of Pygo2 to form a selective
looping of the enhancer region in order to induce transcription of the target genes. Moreover,
the authors state that PRNCR1 and PCGEM1 are indispensable for the activation of both truncated
and full-length AR. Confirming these results, the knockdown of these lncRNAs in the CRPC cell line
strongly suppresses the growth of the cancer in a xenograft model [156].
Nevertheless, the efficacy of these findings has been questioned. In fact, Prensner et al. [163]
disagreed with these reports because they found that only PCGEM1 is associated with PCa. Moreover,
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using a large cohort of high-risk PCa patients, they showed the lack of an association of these lncRNAs
with poor disease outcomes.
Recently, Ho et al. [164] described a new mechanism through which PCGEM1 can regulate AR
expression in CRPC. They demonstrate that androgen deprivation induces the elevation of PCGEM1
through p54/nrb (engaged in RNA splicing and gene regulation) leading to expression of the splice
variant AR3 and castration resistance disease.
The lncRNA PCA3, one of the most important prostate-specific genes, has been extensively
studied as a tumor biomarker [165] due to its specific expression in both PCa and high-grade prostatic
intraepithelial neoplasia [166]. PCA3 has been demonstrated to have a role in the regulation of AR
signaling. Several experiments silencing PCA3 showed a reduction of AR target genes and a higher
number of cells in the sub G0/G1 phase of the cell cycle [167]. Lemos et al. recently explained that
PCA3 can be considered a significant marker to detect the “epithelial to mesenchymal transition”
process [168].
Another lncRNA named CTBP1 antisense (CTBP1-AS) has been identified as a promoter of the
AR transcriptional activity [169]. To explore the function of CTBP1, the authors use an antisense
non-coding RNA. Thanks to this, it has been shown that CTBP1-AS works by repressing CTBP1 in
two different scenarios. Firstly, CTBP1-AS acts with the RNA-binding transcriptional repressor PSF
to recruit the HDAC–Sin3A complexes to CTBP1 promoter in cis with the loss of activating histone
marks. Secondly, in the trans-regulatory pathway, CTBP1-AS also enhances PSF complexes to the
regulatory regions of target genes, leading to the transcriptional repression of suppressive genes [169].
Despite the fact that its mechanism of action has been elucidated, we have opposing results regarding
the effective levels of CTBP-1 in PCa. Takayama et al. [169] revealed the suppressive role of CTBP1
in AR-positive PCa cells, but there is another work describing not only that CTBP1 is upregulated in
metastatic PCa but also that CTBP1 has a sort of stimulatory effect in PCa cells [170]. As suggested by
the authors, this debate can be solved by analyzing tumor samples or cell lines used in these works.
In fact, the experiments of Wang et al. were performed predominantly in AR-negative cells while
Takayama et al. showed that CTBP1 exerts tumor suppressive effects in AR-positive PCa cell lines.
Cui et al. [171] firstly demonstrated that the expression of PlncRNA-1 is significantly higher in
PCa cells compared to normal cells but also, more interestingly, that PlncRNA-1 silencing decreases
AR mRNA- and AR-related genes. The authors give the same results in both androgen-dependent
(LNCaP) and androgen-independent cell lines (LNCaP-AI). As above mentioned, the same group
recently discovered that PlncRNA-1 can deregulate the expression of miR-34c and miR-297. At the
same time, these two miRNAs have the ability to reduce PlncRNA-1 expression, creating a reciprocal
inhibitory feedback loop [133].
The lncRNA HOTAIR is a 2.2-kb-long transcript localized to the boundaries of the HOXC gene
cluster [172]. Tsai et al. [173] elucidated the role of HOTAIR as a scaffold protein that interacts at the
5′ domain with PRC2 and at the 3′ domain with the LSD1/CoREST/REST complex. This allows the
concomitant methylation of H3K27 and the demethylation of H3K4 [173]. Zhang et al. [172] recently
investigated the role of HOTAIR interacting with the AR. They discovered high levels of HOTAIR
after ADT and further confirmed that its knockdown decreased cell proliferation. In the same work,
one of the possible mechanisms underlying the effect of this lncRNA has been explained. HOTAIR
seems to limit the AR ubiquitination and degradation, reducing the interaction between AR and the
E3 ubiquitin ligase MDM2, and this can explain why the overexpression of HOTAIR can led to a CRPC
condition [172].
Prostate cancer transcript-associated 18 (PCAT18) is a lncRNA reported to be prostate specific
and up-regulated in PCa compared to other tumors [174]. An RNA sequencing on paired
metastatic/non-metastatic PCa xenografts derived from clinical specimens showed the upregulation
of PCAT18 in metastatic PCa. Furthermore, the same group discovered not only that AR can improve
PCAT18 overexpression but that this lncRNA can be involved in PCa cell proliferation, cell migration
and cell invasion [174].
101
Cancers 2017, 9, 9
Another novel lncRNA, PCAT29, was recently discovered, and its relationship to the AR explained.
Malik et al. [175] described a different behavior of this lncRNA in presence or in absence of androgens.
Specifically, PCAT29 is suppressed by dihydrotestosterone (DHT) and increased after ADT. Low
or repressed levels of PCAT29 show an improvement in proliferation and migration of PCa cells;
whereas PCAT29 overexpression confers the opposite effect and attenuates growth and metastasis
of prostate tumors [175]. Moreover, Sakurai et al. [176] proposed a mechanism of regulation for this
lncRNA based on an equilibrium between different molecules. In androgen-dependent cells, androgen
stimulates AR to bind to the PCAT29 locus suppressing its expression. On the contrary, FOXA1 and
NKX3-1 can balance the effect mediated by AR and prevent the repression of PCAT29. Interestingly,
in castration resistant cells low levels of FOXA1 and NKX3-1 together with an anomalous activation of
AR determine the decrease of PCAT29 [176].
5. Novel PCa Biomarkers
Prostate specific antigen (PSA) is the most important screening technique used for PCa diagnosis
and tumor monitoring. Despite being organ specific, PSA is not cancer specific, and its level changes in
the presence of several conditions such as prostatitis, hyperplasia, prostate biopsies and surgeries [177].
All of these pitfalls may determine over-diagnosis and over-treatment especially for low or very
low-risk PCa patients [178–180]. Despite the fact that in the last decade innumerable molecules have
been discovered, the inconsistency of some findings, the difficulty of reproducibility, and the lack of
clinical studies with a significant number of patients can explain the reason why only a very small
number of these markers have been used in clinical practice.
The epigenetic alterations in PCa, as in part described above, can provide effective biomarkers
for early detection and cancer relapse, for prognosis and, finally, to predict then response to specific
therapies [181]. In this section, we present the epigenetic biomarkers with a consistent role and use in
clinical practice.
5.1. Epigenetic Signature as Biomarkers
Several reviews report the role of the DNA methylation asset as a biomarker for PCa
detection/diagnosis or prognosis and response to therapy [181,182].
One of the most frequent epigenetic alterations in PCa is the aberrant promoter methylation
of the glutathione S-transferase pi 1 (GSTP1) gene. In fact, GSTP1 has been considered one of the
most promising candidates for a DNA methylation biomarker because it appears in more than 90% of
cases [183].
In 2011, Wu et al. [184] published a meta-analysis on GSTP1 methylation in body fluids. The
authors highlight an excellent specificity (86.8%–100%) but a lower sensitivity in urine (18.8%–83.2%)
and serum or plasma (13.0%–71.9%) samples. These findings suggest the possible role of GSTP1
methylation as a biomarker for PCa diagnosis [185]. In 2014, a review by Strand et al. [186] studied the
ability of GSTPI methylation as a biomarker for disease prognosis. In this case the authors did not find
strong evidence for the use of this gene in cancer tissues for predicting early disease outcomes [185].
In order to enhance the predictive power of this biomarker, several gene panels have been studied.
The combination of GSTP1 with other DNA methylation biomarkers showed an improvement in the
detection rate (86% for urine and 42%–47% for serum) [181].
Moreover, the combination of the methylation pattern of three genes (GSTP1, APC, and RARB2)
has been evaluated in a prospective study named ProCaM [187]. The test performed on urine
samples collected after DRE presented a higher predictive accuracy than simply using PSA and
clinical characteristics [188].
A methylation marker genetic test, ConfirmMDx (MDxHealth, Inc., Irvine, CA, USA), is a
tissue-based assay that studies the epigenetic alteration surrounding the tumor lesions. This test
identifies the methylation pattern of three genes (GSTP1, APC, and RASSF1) in men with a low risk for
disease after a negative biopsy. ConfirmMDx, after a validation in a European and a US population,
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achieved a negative predictive value of 88%–90% [189,190]. Furthermore, the 2016 Clinical Guide of
the National Comprehensive Cancer Network [191] recommended this test for the early detection of
PCa in patients with an elevated PSA and prior negative biopsy.
To explore the biological role of DNA methylation alterations and to understand the utility of
these epigenetic modifications as future biomarkers or as therapeutic targets, Aryee et al. [192] used a
genome-scale analysis of DNA methylation among metastatic PCa patients. Although a consistent
inter-individual heterogeneity in DNA methylation alterations was found, the authors showed that
the methylation signatures are preserved in each patients’ metastases. This interesting intra-individual
homogeneity is a promising finding in the development of personalized treatments against all lethal
metastatic PCa cell clones [192].
5.2. Long Non-Coding RNA as Biomarkers
Prostate cancer antigen 3 (PCA3) is a prostate cancer-specific antigen mapped to chromosome
9q21-22 [193]. It is a lncRNA of unknown function identified by Bussemakers et al. in 1999 [194].
More than 95% of PCa specimens show PCA3 over-expression [194], and in addition to cancer tissue,
PCA3 transcripts have also been identified in urine samples of patients with benign enlargement and
malignant disease of the prostate [165]. The Progensa PCA3 test (Hologic Gen-Probe, Marlborough,
MA, USA), an in vitro amplification test, attained Conformiteé Européenne (CE) in 2006, and it was
approved by the US FDA in 2012 for use in men older than 50 years old with one or more negative
biopsies [195].
The PCA3-test involves collection of a urine sample after DRE to mobilize prostatic cells.
The PCA3 score is a mathematical operation, and it can be acquired by dividing PCA3 RNA by
PSA RNA levels in order to normalize PCA3 signals.
Despite these suggestive findings, the best cut-off to use is still controversial. A urine PCA3 score
more of than 35 has been linked with a sensitivity comprised between 47%–57% and a specificity
around 70% [196,197]. A recent meta-analysis by Lu et al. describes a sensitivity and specificity of
72% and 53%, respectively, with a PCA3 score cut-off of 20 [198]. Crawford et al. in a large multicenter
study showed that a cut-off of 35 is correlated with a large number of false negatives, even though it
can reduce the number of re-biopsies by 77% [199]. Controversial results have been reported regarding
the relationship between PCA3 score and aggressive features. Some studies describe a correlation with
the Gleason Score, the tumor volume, and extracapsular extension [200,201], but others didn’t find
any correlation with the aggressiveness of the tumor [202,203]. Despite these conflicting results, PCA3
score has been considered a more specific indicator with a better predictive value than the PSA [204].
In 2013, GenomeDx Biosciences (Vancouver, BC, Canada) and Mayo Clinic (Rochester, MN,
USA) co-developed and validated a tissue-based genomic classifier that is able to evaluate the risk
of developing clinical metastases at 5 years postoperatively named Decipher [205]. The authors
used a high-density transcriptome-wide microarray to assess the expression of over 1.4 million
markers including protein-coding genes and ncRNAs in 545 PCa patients samples including 213
who experienced early metastasis [205]. This test, whose result is expressed as a continuous risk score
ranging from 0 to 1, is based on 22 RNA biomarkers related to cell proliferation, differentiation, motility,
immune modulation and AR signaling. Decipher has been studied by several groups with varying
cohorts of patients [206]. Karnes et al. [207] evaluated the prognostic role of Decipher in 219 high-risk
PCa patients with a median follow up of 6.7 years after surgery. On multivariable analyses, higher
decipher scores resulted in the highest prognostic predictor of metastasis with an area under the curve
(AUC) of 0.79. 85 high-risk patients with PSA failure after radical prostatectomy (RP) were evaluated
by Ross et al. in 2014 [208]. The genomic classifier showed an AUC of 0.82 compared to 0.64 of Gleason
Score and 0.69 of PSA doubling time. The prognostic value of Decipher has also been studied in PCa
patients undergoing adjuvant or salvage radiation therapy following RP. Den et al. [209] demonstrated
that the AUC of this genomic test is 0.78 and 0.80 to predict BCR and metastasis, respectively, in a cohort
of 139 patients treated by RP and adjuvant radiotherapy. Patients with a higher genomic score mainly
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benefit from this adjuvant treatment. With a median follow-up of 10 years, the same group followed
188 patients from two different institutions treated with RP and adjuvant or salvage radiotherapy [210].
Decipher predicts the occurrence of metastases on multivariable analyses and confirmed the previous
results suggesting that adjuvant radiotherapy should be taken into consideration for PCa patients with
high genomic score. Approved in the United States for patients with positive margins, pT3 disease,
or PSA failure after surgery [211], Decipher could help physicians in the clinical decision making in
order to improve accuracy in predicting patient outcomes.
5.3. MicroRNA as Biomarkers
Several studies suggest the use of miRNAs in the clinical setting and many reviews have been
published about the argument [97,212,213]. The exploitation of different technological platforms,
the examination of different samples (tissues, sera, urine), the retrospective design of many studies,
the use of endogenous or exogenous controls, and the presence of contaminating non-neoplastic cells
are all potential explanations for controversial results reported until now. Despite these obstacles,
miRNAs have been reported to have a promising role as novel biomarkers in PCa. In the last few
decades, many miRNAs profiles have been presented, but there is not a large consensus in the
expression of a single signature in different groups. For this reason, many efforts have been undertaken
to discover a panel of small RNAs in order to reduce the inter-individualities between several settings.
Larne et al. [149] focused their attention on a combination of four miRNAs. These four
discriminatory miRNAs (miR-96-5p, miR-183-5p, miR-145-5p, and miR-221-5p), characterize the
miR index quote (miQ). This test seems to predict PCa (AUC = 0.931) after a validation in four external
cohorts. In addition, miQ was investigated to predict the manifestation of metastases (AUC = 0.827)
and unfavorable disease behavior (AUC = 0.895).
As mentioned above, several miRNAs, regulated by or involved in AR transcriptional activity,
are able to predict biochemical failure, clinical relapse, and castration resistant status. Interestingly,
the overexpression of miR-21 has been reported in patients with castration-resistant disease [214],
and it is reported to be an independent predictor of BCR in patients with a Gleason Score of 6 [215].
In the same way, miR-221 and miR-222 have been found to be upregulated in CRPC patients [216],
and other studies demonstrate that miR-221 is also able to predict both recurrence and cancer related
death [217,218].
6. Novel Treatments
Androgen deprivation therapy (ADT) is the principle treatment for advanced PCa and induces
remission in 80%–90% of patients [219]. Despite an initial response, cancer cells are able to escape,
and they subsequently continue to proliferate. This condition is termed castration resistant prostate
cancer (CRPC), and it reportedly has a median overall survival rate of 23–37 months from the
start of ADT [220]. The mechanisms governing the reactivation of AR despite castrated levels of
testosterone have been widely studied. Although several alternative pathways have been observed
and reported [221,222], the predominant mechanisms for cancer cell proliferation under deprivation
conditions are due to reactivation, overexpression or mutation of the AR [223]. Therefore, therapies
aimed to block the AR or to block the crosstalk of this steroid receptor with other molecular
pathways are considered promising approaches to treat CRPCs. Here, we present three examples
of how the regulation of AR epigenomic mechanisms could offer a novel therapeutic target to limit
PCa proliferation.
6.1. Demethylase Inhibitor
Uncovering the locations of proteins throughout the genome helped physicians to understand the
biology of both healthy and tumoral prostates. Chromatin immunoprecipitation (ChIP) followed by
high-throughput DNA sequencing (ChIP-seq) is considered a novel technique to discover transcription
factor binding sites, chromatin regulators, and the identification of genomic histone marks. Moreover,
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mapping the interactions of small molecules with chromatin, a technique named Chem-seq, has not
only helped build the understanding of novel mechanisms underlying the biology of diseases but in
discovering new specific treatments [224].
Chem-seq, ChIP-seq, and RNA-seq methods were used to evaluate the role of a small molecule,
termed SD70, originally recognized as an inhibitor of DHT and chromosomal translocations events in
PCa [225]. The 8-hydroxyquinoline domain of SD70 has been found to be similar to other molecules
considered as competitive inhibitors of the histone demethylase KDM4 family and in particular
KDM4C [226]. A biotinylated derivative of SD70 (B-SD70) has been observed as having the ability to
bind the AR regulatory enhancers in an androgen-dependent manner. Further experiments show that
SD70 was able to suppress DHT-regulated gene transcriptions in androgen dependent and independent
cell lines, but at the same time, AR localization was not altered. As a consequence of its structure and
analogy with other histone demethylase inhibitors, SD70 was found to inhibit the demethylase activity
of KDM4C (Figure 1). KDM4C, as aforementioned above, plays a role in AR transcriptional program,
mainly regulating the histone H3K9me3/me2 demethylase activity [50,227,228]. Using a Chem-seq
assay on AR target gene enhancers, the authors reveal that KDM4C is located on the same gene
enhancers that are co-occupied by B-SD70.
RNA-seq analysis in KDM4C knockdown cells confirmed the central role of KDM4C on AR
target-gene regulation. Moreover, a Chip-seq in androgen dependent cells revealed that SD70 represses
the methylation activity of KDM4C at the AR-regulated enhancers [225]. In consideration of the fact
that “in vivo” experiments with a xenograft model unveiled a conspicuous inhibitor effect of SD70 on
tumor cell growth without any particular toxicity, SD70 should be considered a potential candidate
therapy in PCa patients.
6.2. Deacetylase Inhibitor
Histone deacetylase inhibitors (HDACi) are a group of molecules with anticancer activity against
hematologic and solid tumors [229]. Different classes of HDAC, as previously described, modulate
the acetylation profile of numerous genes including AR. Several studies have reported that HDAC
inhibitors, such as trichostatin A (TSA), suberoylanilide hydroxamic acid (SAHA), and valproic acid,
may reduce AR expression [230–232], but their mechanisms of action are not completely clear. One of
them is undoubtedly correlated to the heat shock protein-90 (HSP90). HSP90 is a chaperone protein
indispensable for molecular stability and the right folding and function of steroid hormone receptors
such as the AR [233,234] (Figure 2).
A recent review [235] extensively reported the activity of several HDACi as novel therapeutic
options in CRPC but here we might focus our attention on the efficacy of HDACi which mainly affect
the HSP90-AR signaling.
Romidepsin is a cyclic depsipeptide, enhancing the acetylation of HSP90, that reportedly
interferes with the correct folding of AR determining its degradation [236]. Despite these encouraging
pre-clinical data and two phase I clinical trials that did not show a particular toxicity, a phase II study
(NCT00106418) unveiled a very low clinical activity in 35 metastatic CRPC patients. In particular,
only two enrolled patients displayed a PSA reduction more than 50% in a period of time longer than
6 months. Moreover, a substantial proportion of patients (31%) interrupted the trial due to several
toxic effects [237]. As suggested by the same authors, these data do not support the use of single-agent
romidepsin in unselected CRPC patients.
Panobinostat is a cinnamic hydroxamic acid class molecule with an HDACi activity. In vivo
studies in AR-positive PCa cell lines showed a significant degradation of the AR mediated by the
acetylation and subsequent inhibition of the HSP90 chaperone function [238]. In 2010, Rathkopf et al.
reported the first results of a phase I clinical trial (NCT00663832) of oral panobinostat versus oral
panobinostat plus docetaxel in patients with advanced disease. Despite the fact that all patients
being solely treated with panobinostat displayed a clinical progression, 63% of patients treated with
a combination therapy exhibited a biochemical response greater than 50% [238]. The same group
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examined the effect of intravenous panobinostat in a phase II trial (NCT00667862). Of the 35 enrolled
patients, none of them exhibited a significant PSA reduction [239]. Again, despite promising preclinical
data and a strong scientific rationale, panobinostat has not shown a sufficient level of clinical activity
as a single agent in metastatic patients.
6.3. Non Coding RNA Therapy
In the last decade, several findings have documented the role of miRNAs as new oncogenes or
tumor suppressor genes, thus supporting their use as therapeutic tools. Artificial miRNA mimics
and inhibitors are considered a good way in which to “block or boost” the production of several
proteins [240]. MiRNA mimics have been used to reintroduce tumor suppressor miRNAs, and miRNA
inhibitors serve to reduce the levels of oncogenic miRNAs. Interesting results from preclinical studies
using mouse models demonstrate the possible therapeutic application of miRNA mimics in PCa [241].
The bi-univocal correlation between p53, one of the most important tumor suppressor genes, and
miR-34 highlighted the role of this miRNA as an encouraging therapy for cancer [242]. MiR-34a seems
to be a promising target in PCa because “in vivo” studies proved that its reintroduction decreases
the growth of prostate xenografts [243]. In April 2013, a liposome-formulated miRNA34a mimic
(MRX34), sponsored by Mirna Therapeutics (Austin, TX, USA), was tested in a phase I clinical trial
(NCT01829971) [244] (Figure 3). This was the first attempt to use a miRNA as an innovative therapy
for cancer.
7. Conclusions
The androgen receptor is the central regulator of nominal and tumor prostate biology. Prostate
carcinogenesis is a complex event due to genetic mutations and epigenetic alterations. In the past
decade, the role of epigenetic regulation has become evident, and considerable progress has been
made defining its role in the onset and progression of prostate cancer. In this review we focused
our attention mainly on the AR epigenetic alterations. A better understanding of AR transcriptional
pathway is indispensable to develop diagnostic and therapeutic procedures exploiting these epigenetic
changes. Although PSA remains the prevalent test for prostate cancer screening and prognosis,
the new generation of biomarkers can help physicians in their clinical decisions. The PCA3 test
is widely used in clinical practice but chromatin remodeling marks and miRNA panels, as well as
genomic tests, are becoming new promising predictive tools. New technologies for global epigenomic
analyses and integration with genomic and transcriptomic data are extending our knowledge on
prostate tumorigenesis. A new approach named “Chem-seq” permitted us to uncover the site and the
mechanism of action of a small molecule named SD70. The demethylase SD70, targeting a key regulator
of AR function, is effective in CRPC cells in combination with current therapies. Furthermore, the
optimization of the stability of miRNAs and the improvement of the efficacy of HDAC inhibitors are
also challenges for the future treatment of prostate cancer. Knowing the specific molecular mechanisms
underlying tumors will be desiderable for the identification of more effective approaches allowing to
personalize therapy.
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Abstract: Prostate cancer (PCa) is one of the most common cancers and among the leading causes
of cancer deaths for men in industrialized countries. It has long been recognized that the prostate
is an androgen-dependent organ and PCa is an androgen-dependent disease. Androgen action is
mediated by the androgen receptor (AR). Androgen deprivation therapy (ADT) is the standard
treatment for metastatic PCa. However, almost all advanced PCa cases progress to castration-resistant
prostate cancer (CRPC) after a period of ADT. A variety of mechanisms of progression from
androgen-dependent PCa to CRPC under ADT have been postulated, but it remains largely unclear
as to when and how castration resistance arises within prostate tumors. In addition, AR signaling
may be modulated by extracellular factors among which are the cysteine-rich glycoproteins WNTs.
The WNTs are capable of signaling through several pathways, the best-characterized being the
canonical WNT/β-catenin/TCF-mediated canonical pathway. Recent studies from sequencing
PCa genomes revealed that CRPC cells frequently harbor mutations in major components of the
WNT/β-catenin pathway. Moreover, the finding of an interaction between β-catenin and AR
suggests a possible mechanism of cross talk between WNT and androgen/AR signaling pathways.
In this review, we discuss the current knowledge of both AR and WNT pathways in prostate
development and tumorigenesis, and their interaction during development of CRPC. We also review
the possible therapeutic application of drugs that target both AR and WNT/β-catenin pathways.
Finally, we extend our review of AR and WNT signaling to the mammary gland system and breast
cancer. We highlight that the role of AR signaling and its interaction with WNT signaling in these
two hormone-related cancer types are highly context-dependent.
Keywords: androgen receptor; AR; WNT; prostate; prostate cancer; castration-resistant prostate
cancer; CRPC; mammary gland; breast cancer
1. Introduction
For the men in the United States, prostate cancer (PCa) is not only one of the most commonly
diagnosed cancers, but also one of the most predominant causes of death from cancer [1,2].
The American Cancer Society estimates that in 2016, there will be 180,890 newly diagnosed cases and
26,120 deaths due to PCa in the United States, making it the second leading cause of cancer death in
men [3]. Since the prostate gland development depends on androgens and androgen receptor (AR)
signaling [4,5], human PCa initially responds to androgen-deprivation therapy (ADT) [6,7]. However,
the cancer often reappears, and is accompanied by rising levels of serum prostate-specific antigen
(PSA) [8,9]. PSA (KLK3) is encoded by an androgen-dependent gene, and increased expression of PSA
in an environment of castrate levels of circulating androgens indicates that adaptive androgen signaling
has emerged in the tumor [10,11]. Accordingly, in the majority of cases, an initially hormone-sensitive
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PCa will evolve to a lethal castration-resistant prostate cancer (CRPC) [12–15]. The underlying
molecular basis for how PCa cells escape from the growth control by exogenous androgens remains
poorly understood. Recent studies, however, pointed to the AR and its actions as a key factor in many
CRPCs, despite the reduction in circulating testosterone. The mechanisms involved in this change
include increased expression and stability of the AR protein, activating mutations in this receptor
that alter its ligand specificity, and changes in the expression of transcriptional co-regulators of the
AR [16,17]. In addition, AR and its cognate ligands interact with potent oncogenic systems, such as
WNT signaling, to elicit changes in cellular adhesion and oncogenesis [18–21].
WNT signaling is an evolutionary highly conserved signaling system throughout the eukaryotic
kingdom. During embryonic and postnatal development, WNT signaling controls many cellular
processes, including proliferation, survival and differentiation [22–26]. Deregulation in WNT signaling
leads to an imbalance of such processes, often resulting in aberrant development or disease [27,28];
in particular, deregulated WNT signaling is common in human cancers, including malignancies of the
intestine [29–31], liver [32–35], skin [36,37], breast [38–41] and prostate [42,43].
The term Wnt is an amalgam of Wg and Int [44], as the genes Wingless (Wg) and integration 1 (Int1)
are homologues in Drosophila and mouse, respectively [45,46]. Wg was genetically characterized
as a segment polarity gene in Drosophila in 1980 by Nüsslein-Volhard and Wieschaus [47].
The proto-oncogene Int1 was first identified in 1982 by Nusse and Varmus as a preferential site for
proviral integration of the mouse mammary tumor virus (MMTV) in a mouse mammary cancer
model [48]. Since the identification of Wnt1, genome sequencing has revealed the existence of
19 Wnt genes in mammals. All WNT proteins share common features that are essential for their
function, including a signal peptide for secretion, many potential glycosylation sites, and WNT
ligands interact with seven-pass transmembrane receptors of the Frizzled (FZD) family and/or
single-pass transmembrane co-receptors, such as lipoprotein receptor-related protein 5/6 (LRP5/6),
ROR2, and RYK [49–54]. Co-factors such as R-spondin and Wise also take part in WNT-receptor
complex activity [55–57]. R-spondin/LGR (leucine-rich repeat-containing G-protein coupled-like
receptor) complexes and WNT ligands directly interact with FZD-LRP-receptor complexes on target
cells to activate downstream signaling. This leads to the activation of various intracellular signaling
cascades that can be cross-connected or act independently. The intracellular signaling activated
by WNT proteins is organized into two categories: canonical and non-canonical. Canonical WNT
signaling is often referred to as the WNT/β-catenin pathway, as it relies on β-catenin-dependent
transcriptional activation triggered by WNT-stimulated signals. In contrast, non-canonical WNT
pathways, including the WNT/Ca2+ (calcium) and WNT/JNK (c-Jun N-terminal kinase), WNT/Rho
pathways, are β-catenin-independent and activate a variety of downstream intracellular signaling
cascades [26,58–60]. These mechanisms have been the subject of numerous reviews [22–26], and
therefore will only be briefly described here.
In this review, we will discuss the multifaceted manner with which both the canonical and
non-canonical WNT pathways influence and modulate AR signaling in CRPC development. We will
consider the possible therapeutic application of drugs that target both pathways. We will also discuss
these under the context of recurrent mutations in both pathways identified from PCa genomes. Finally,
we will extend our review of these two pathways to the mammary gland system and breast cancer.
2. An Overview of the Canonical and Non-Canonical WNT Signaling Pathways
The known molecular components and the cascade of the canonical WNT signaling pathway are
summarized in Figure 1. Canonical WNT signaling strictly controls the level of the cytoplasmic protein
β-catenin. β-Catenin, encoded by the CTNNB1 gene [61], is a member of the armadillo family of
proteins. β-Catenin consists of an N-terminal region of 149 amino acids, followed by a central domain
of 515 residues composed of 12 armadillo repeats, and a C-terminal region of 108 residues [62].
The N-terminal region contains phosphorylation sites recognized by GSK3β and CK1α and an
α-catenin binding site, whereas the C-terminal region works as a transcriptional co-activator-binding
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domain (CBD) that interacts with histone modifiers such as histone acetyltransferases CBP/P300 [63].
β-Catenin has dual functions. It acts as a transcription cofactor with the T cell factor/lymphoid
enhancer factor (TCF/LEF) in the WNT pathway [64–67]. It is also a structural adaptor protein that
binds E-cadherin and α-catenin through its Armadillo repeats and N-terminal domain, respectively
(E-cadherin is a core transmembrane adhesion protein, and α-catenin is a protein that binds actin
and other actin-regulators) [68–72]. The multifaceted functions of β-catenin are regulated by three
cellular pools of this molecule that are under strict regulation: a membrane pool of cadherin-associated
β-catenin, a cytoplasmic pool, and a nuclear pool [73]. Canonical WNT signaling works in the
following fashion: in the absence of WNT signals, β-catenin is efficiently captured by scaffold proteins,
the AXINs, which are present within a destruction complex containing glycogen synthase kinase
(GSK3β), adenomatous polyposis coli (APC) and the casein kinase-1 (CK1). The resident CK1
and GSK3β protein kinases sequentially phosphorylate conserved serine and threonine residues
in the N-terminus of the captured β-catenin, generating a binding site for an E3 ubiquitin ligase.
Ubiquitination targets β-catenin into proteasomes for rapid degradation [74–77]. Therefore, in the
absence of WNT, cytoplasmic β-catenin levels remain low, and the transcription factors LEF1 and
TCF interact with Grouchos in the nucleus to repress WNT pathway-specific target genes [78,79].
In contrast, upon the interaction of canonical WNT ligands to its receptors, FZD, and co-receptor,
LRP5/6, the destruction complex is disassembled through phosphorylation of LRP5/6 by CK1γ
and binding of AXIN to LRP, which prevents β-catenin degradation [80,81]. The inactivation of the
destruction complex allows cytoplasmic stabilization and translocation of β-catenin to the nucleus,
where it interacts with members of the TCF/LEF family [64–66] and converts the TCF/LEF proteins
into potent transcriptional activators. It achieves this by displacing Grouchos [82] and by recruiting
other co-activators such as B-cell lymphoma 9 (BCL9) [83,84], Pygopus [85,86], CREB-binding protein
(CBP) [87,88] or Hyrax [89], ensuring efficient activation of WNT target genes encoding c-Myc [90],
Cyclin D1 [91,92], urokinase-type plasminogen activator (uPA) [93], CD44 [94], Cox-2 and Cox-9 [95],
and the AR gene [96,97], as well as genes that encode key components of the WNT pathway (e.g., FZDs,
DKKs (Dickkopf), LRPs, AXIN2, β-TrCP and TCF/LEF) (Figure 1). These WNT target genes then
influence cell cycle regulation, stem cell function and development, as well as invasion and metastasis
of cancer cells. For an updated overview of the WNT pathway and its target genes, see the WNT
homepage at http://www.stanford.edu/group/nusselab/cgi-bin/wnt/.
In addition to promoting the WNT activity, a series of biochemical experiments indicated that
R-spondins (RSPOs) are able to synergize with the WNT pathway in the presence of canonical WNT
ligands [98]. Similar to the WNT proteins, RSPOs are also cysteine-rich. However, unlike WNTs, the
cysteine residues found in RSPOs are organized into two adjacent furin-like domains, which have
been suggested to be sufficient for inducing β-catenin stabilization [98]. Recently, LGR4, LGR5 and
LGR6, three closely related LGR proteins, have been identified as receptors for RSPOs. LGR5 is a
WNT target gene and although originally discovered as an intestinal stem cell marker [99], it has also
become an ideal candidate marker for understanding stem cell and cancer biology of other epithelial
cell types in mice and human [56,99–101]. The LGR5 protein had previously been identified as an
orphan receptor, among LGRs. The LGR family is defined by a large extracellular N-terminal domain
composed of a string of leucine-rich repeat units, a 7-transmembrane domains (7TM) and a cytoplasmic
region. Specifically, LGR5, together with LGR4 and LGR6, belong to the B-class LGRs [100,102]. Close
relatives are the LGRs for the follicle stimulating hormone (FSH), the luteinizing hormone (LH) and
the thyroid-stimulating hormone (TSH), which are true G-protein coupled receptors. Recently, it was
found that instead of binding hormones, the LGR4/5/6 receptors interact with RSPOs and do not
activate G-proteins; instead, they promote WNT/β-catenin signaling. Specifically, the interaction of
RSPOs and LGR5 has been assessed in cell surface binding assays, cell-free co-immunoprecipitation
and tandem affinity purification mass spectrometry [55,102,103]. As their potentiating ability depends
on the presence of a WNT ligand, the WNT secretion machinery can thus indirectly affect their role on
WNT signaling.
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Figure 1. Schematic diagram of the canonical WNT signaling pathway. (left panel) the “WNT-Off” state:
In the absence of a WNT signal, β-catenin levels in the cytoplasm are kept low through proteosomal
degradation induced by the β-catenin destruction complex. Grouchos (transcriptional co-repressors)
interact with TCF/LEF proteins and prevent the expression of WNT target genes. (right panel) the
“WNT-On” state: When WNT ligands bind to their receptors Frizzled (FZD) and LRP5/6, the receptor
complex can recruit components of the β-catenin destruction complex, resulting in accumulation of
β-catenin in the cytoplasm. β-catenin will then translocate into the nucleus, replace Grouchos and
recruit transcriptional co-activators to form the transcription complex with TCF/LEF proteins, which
eventually promote expression of the WNT target genes.
The activation of canonical WNT signaling can also be blocked by extracellular proteins.
These include the sFRP family (secreted frizzled related protein; sFRP1, 2, 4, and 5) [104], WIF
(Wnt inhibitory factor) [105], the DKK family of proteins (DKK1–4 and DKKL1) [106], and the cysteine
knot family proteins SOST [107] and WISE [108]. These soluble inhibitors bind to WNT, the FZD
receptor in the case of sFRP, or to the co-receptor LRP5/6 in the case of DKK1 and SOST/WISE, thereby
interfering with ligand–receptor complex formation and blocking WNT signaling [109].
While the canonical WNT signaling pathway has been extensively dissected biochemically
and at the molecular level, non-canonical WNT signaling has been less focused on. The best
characterized non-canonical WNT pathways include the WNT/Ca2+ pathway, which was first
described in vertebrates [58], and the planar polarity pathway (PCP), which was first identified
in Drosophila [110]. Other non-canonical pathways include WNT/JNK and WNT/Rho signaling [111].
In the WNT/Ca2+ pathway, the interaction of non-canonical WNT ligands and receptors
recruits Dishevelled (DVL) and G protein, which activates phospholipase C (PLC), leading to
production of 1,2-diacylglycerol (DAG); 1,2-DAG then activates protein kinase C (PKC), and inositol
1,4,5-triphosphate (IP3), thereby triggering intracellular calcium release from the endoplasmic
reticulum [112,113]. Calcium release activates calcineurin (CNA) and Ca2+/calmodulin-dependent
protein kinase II (CAMKII), which increase expression of nuclear factor of activated T cells
(NFAT)-dependent genes and inhibit canonical WNT signaling through nemo-like kinase (NLK),
respectively [114,115]. Activated NFAT may boost the expression of several genes in neurons,
cardiac and skeletal muscle cells, prostate, and pro-inflammatory genes in lymphocytes [116–118].
In the WNT-PCP pathway, FZD receptors activate a signaling cascade that involves the small
GTPases Rho and Rac and c-Jun N-terminal kinase (JNK) [119]. In contrast to calcium-regulated
non-canonical signaling, WNT/JNK signaling uses ROR2-dependent circuitry to activate downstream
effectors of the activating protein-1 (AP-1) family of transcription factors [59,60]. In addition, a
new β-catenin-independent aspect of WNT signaling was recently reported in proliferating cells:
WNT signaling was found to peak at the G2/M phase of the cell cycle to produce the so-called
WNT-dependent stabilization of proteins (WNT/STOP) [120,121]. This appears to be a dominant mode
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of WNT signaling in several cancer cell lines, where it is required for cell growth. Of note, boundaries
of both canonical and non-canonical WNT pathways are not stringent and there are considerable
degrees of overlapping between them [122].
3. WNT Signaling in Prostate Development and Stem Cells
In both human and rodents, the prostate gland surrounds the urethra at the base of the bladder
and functions by contributing secretory proteins to the seminal fluid. In men, the prostate gland is a
walnut-sized tissue with a zonal architecture, corresponding to central, periurethral transition, and
peripheral zones, together with an anterior fibromuscular stroma [123]. Importantly, the outermost
peripheral zone occupies the most volume, and harbors the majority of prostate carcinomas. In contrast,
benign prostatic hyperplasia (BPH), a common nonmalignant condition found in older men, arises
from the transition zone [124]. Unlike the human prostate that is a compact gland, the mouse prostate
includes four paired lobes situated circumferentially around the urethra: anterior (AP), dorsal (DP),
lateral (LP), and ventral (VP) prostate. The DP and LP are sometimes collectively referred to as the
dorsolateral lobes of the prostate (DLP). At birth, each lobe of the VP consists of 1–3 main ducts
with secondary and tertiary branches, whereas the more complex DLP initially has 9–12 unbranched
proximal main ducts on each side [125,126].
In all species, formation of the prostate gland initiates during embryogenesis. During
mid-gestation, the primitive urogenital sinus (UGS) is separated from the terminal region of the hindgut
through division of the cloaca by the urorectal septum. The most rostral region (vesiculo-urethral part)
of the primitive UGS forms the urinary bladder, whereas the most caudal region (phallic part) forms
the penile urethra. The prostate gland originates from a sub-compartment of the lower urogenital
tract (LUT), known as the definitive UGS [127,128]. The endodermal UGS is surrounded by embryonic
connective tissue called urogenital sinus mesenchyme (UGM). Prostate development, growth and
function is androgen dependent; however, other steroid receptors, such as estrogen receptors (ER) and
retinoid receptors (RARs and RXRs), also contribute to prostate morphogenesis and differentiation.
Prior to sexual differentiation of the UGS, UGM expresses AR in both sexes and thus acquires the
capacity to undergo masculine development [129–131]. Over 30-year of research by Cunha and
colleagues has shown that an AR-dependent signal from the urogenital mesenchyme is required for
prostate formation, while AR is not initially required in the urogenital epithelium (UGE) for prostate
organogenesis, but is subsequently necessary for epithelial differentiation and secretory protein
expression [124,132–134]. In mouse, the prostatic ducts start to form after embryonic day 17 (E17) as
solid epithelial buds formed from the UGE that invades the surrounding UGM [126]. During perinatal
and neonatal development, prostatic buds undergo primary, secondary, and tertiary branching
morphogenesis in a pattern unique to each pair of the DP, VP, LP, and AP lobes in rodents [125]. The rate
of new VP ductal tip formation in Balb/c mice, a hallmark of branching morphogenesis, peaks at about
postnatal day 5 (P5). Concurrent with branching morphogenesis, epithelial buds canalize in a proximal
to distal direction along the developing ducts, giving rise to two distinct cell layers: a superficial
layer of secretory columnar luminal epithelium lining prostatic ducts and a deep layer of basal
epithelium including the rare neuroendocrine cells [135,136]. Basic prostatic architecture is established
during puberty, upon an androgen-driven increase in prostate gland size. After that the prostatic
epithelium reorganizes into a layer of outer cuboidal basal cells and inner tall columnar luminal cells.
Human prostate development proceeds by a similar series of morphogenetic events, but gives rise
to a mature prostate that contains a single capsulated structure divided into peripheral, central, and
transitional zones. The basal cells express cytokeratins 5 and 14, and p63 and are localized along the
basement membrane, but express AR at low or undetectable levels [137]. The luminal cells express
cytokeratins 8 and 18 as well as high levels of AR [138]. In humans, mature luminal cells constitute
the exocrine part of the prostate and secrete PSA and PAP (prostate acid phosphatase) [139,140].
The third epithelial cell type in the prostate is the androgen-independent neuroendocrine cell, which
makes up only a small proportion of the prostate epithelial cells and is characterized by expression of
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functional markers such as chromogranin A and synaptophysin [141,142]. In addition, intermediate or
transit-amplifying cells that express both the basal and luminal lineage markers are detectable during
the developmental stage, under pathological conditions in adults, or when prostate epithelial cells are
cultured in vitro [137,143–146].
The use of transgenic mice combined with molecular analyses have demonstrated the importance
of several developmental signaling pathways during prostate organogenesis, including bone
morphogenetic protein (BMP), transforming growth factor beta (TGFβ), Notch, sonic hedgehog
(SHH), and WNT pathways [147]. Evidence that WNT signaling is involved in prostate morphogenesis
comes from studies by Zhang et al. [148]. By creating six LongSAGE libraries at three key stages
of prostate organogenesis: E16.5 UGS (i.e., a stage just before the first prostate buds are formed),
P0 prostates (i.e., a stage when branching morphogenesis has begun), and 12-week adult prostates
(i.e., a time of relative growth quiescence), Zhang and colleagues evaluated sex and cell-type specific
genes associated with prostate induction and found expression changes of multiple WNT-related
genes, such as Sfrp2, Wnt4, Wnt5a, Wnt11, Fzd1, Fzd7, Fzd10, Lrp5, Axin1, Lef1, Nkd1, and RhoA [148,149].
Accordingly, in vivo studies using Sfrp1-overexpressing transgenic mice and Sfrp1-null mice confirmed
that this WNT modulator stimulates prostate branching morphogenesis, epithelial cell proliferation and
secretory gene expression [150]. Additionally, in vitro studies by Prins and colleagues showed that the
WNT signaling inhibitor DKK1 also stimulated growth and branching of cultured newborn rat VP lobes
over a four-day period, suggesting that canonical WNT signaling suppresses prostate growth [147].
This was supported by another recent study where WNT3A, a canonical WNT ligand, reduced ductal
branching of cultured neonatal rodent (rat) prostates and active canonical WNT signaling in epithelial
progenitor cells maintaining their undifferentiated state [151]. In addition, Wnt5a was found to be
indispensable during the UGS development. High levels of Wnt5a expression has been observed at the
distal tips and along the centro-distal periductal mesenchyme during the period of postnatal branching
morphogenesis, with a rapid decline thereafter in the VP but not the DP and LP [152]. Another study
further demonstrated that loss of Wnt5a impeded buds branching during morphogenesis [153].
β-Catenin has been identified in both epithelial and mesenchymal structures that undergo
a budding program; its activation is necessary and/or sufficient for specification of hair follicle,
mammary gland and tooth buds [154–156]. Of note, an absolute requirement for this protein has
been shown in prostatic induction. While conditional expression of a constitutively active form of
β-catenin in developing prostate epithelium prevents epithelial differentiation [136,157], conditional
deletion of the β-catenin gene (Ctnnb1) in the mouse prostate during embryonic stages results in
significantly decreased prostatic budding and abrogates prostatic development [158]. Furthermore,
a recent study by Mehta et al. demonstrated the importance of WNT-activators RSPOs in murine
prostatic bud formation [136]. By in situ hybridization (ISH), Mehta et al. unveiled the expression
pattern of R-spondin1-4 (Rspo1-4) in developing and neonatal mouse LUT. They found that Rspo3,
together with Wnt4, Wnt10b, Wnt11 and Wnt16, appear to be more abundant in male versus female
UGS and they stimulate prostatic development [136].
Although development of the adult prostate is largely completed at puberty, it must possess
a mechanism to assure the homeostasis of its epithelium. To achieve this, prostate, similar to
other epithelial organs, sets aside a life-long reservoir of somatic stem cells that retain self-renewal.
The regenerative capacity of prostate epithelial stem cells (PSCs) has been shown in the experiment
with repeated rounds of androgen ablation and restoration; thus PSCs are androgen-sensitive but not
dependent, are capable of self-regeneration, and give rise to transit-amplifying cells that differentiate
into various specialized epithelial cells of the prostate [159]. To date, the best approach to identify and
characterize murine and human PSCs is to combine flow cytometry with functional assays, such as
genetic lineage tracing experiments, tissue culture and renal capsule implantation. Specifically, first
prostate epithelial cells are fractionated based on their surface antigenic profiles and then functional
assays are used to determine whether different subpopulations possess stem cell activity or not. Based
on this approach, the basal cell subpopulation appeared to be bipotent, i.e., capable of generating
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both luminal and basal lineages, thus indicating that basal cells have stem cell-like potential [160–162].
Independent studies by the two laboratories of Witte and Wilson showed that makers such as CD49f,
Trop2 and CD166 could enrich prostate cells for the PSC activity among the Sca-1+ cells [145,163–167].
Similarly, Richardson et al. isolated human prostate cells expressing a stem cell marker CD133
and showed that α2β1integrin+CD133+ basal cells also correspond to an enriched stem cell fraction
in the human prostate epithelium [168]. Finally, Leong et al. reported successful regeneration
of prostatic tissues from single Lin−Sca-1+CD133+CD44+CD117+ cells, which are predominantly
basal in mice and are exclusively basal in humans [169]. In addition to the cellular hierarchy of the
prostatic epithelium in mice, Wang et al. showed in the lineage tracing experiments that rare luminal
cells (i.e., castration-resistant Nkx3-1 expressing cells (CARNs)) are bipotential and can self-renew
in vivo [170]. Nevertheless, a full understanding the properties of prostate luminal epithelial cells has
been hampered by the lack of suitable in vitro model systems. In comparison to the basal epithelial cells,
luminal epithelial cells are indeed more sensitive for tissue dissociation, after which they fail to survive
in explant culture or grafts [170,171]. To circumvent this technical difficulty, three-dimensional (3D)
organoid culture was developed recently [172]. By using testosterone-responsive culture conditions,
Karthaus et al. confirmed that human prostate luminal cells have potential to generate both basal and
luminal lineages. Moreover, they showed that basal and luminal cells can each generate a complete
multilayer prostate organoids, suggesting that both lineages have stem cell-like potentials [173].
Of note, the 3D organoid system, although mimicking a testosterone-naïve environment for the single
stem cells, relies also on the addition of LGR4/5 ligand R-spondin1, a potent WNT/β-catenin agonist.
This might shed a new light on the role of WNT activity in the maintenance and expansion of PSCs
and their progeny. In fact, evidence of the importance of WNT activity in the maintenance of PSCs
and their progeny was provided in two consecutive studies by the laboratory of Wilson; in one study,
Blum et al. determined the transcriptional profiles of four populations of prostate cells: (i) urogenital
epithelium from 16-day embryos, that represent fetal PSCs; (ii) Sca-1High cells, enriched in adult PSCs;
(iii) Sca-1Low cells, that represent transit-amplifying cells; and (iv) Sca-1Negative cells representing
terminally differentiated population with no regenerative potential [174]. Upregulation of WNT
signaling was observed in both fetal and adult PSCs. However, WNT signaling acts differently in
these two populations, as the fetal PSC population is highly proliferating, whereas the adult PSC
population is quiescent [174]. In another work, the same group reported that WNT receptors such as
FZD6 and ligands such as WNT2 and WNT4 also control the stem cell niche activity [175]. Similarly,
other WNT ligand has been shown to be critical in controlling self-renewal of PSCs in a prostasphere
culture system [94]. Interestingly, activation of canonical WNT pathway through WNT3A results in a
significant increase of the expression of nuclear β-catenin [94]. This is consistent with other reports
showing that WNT3A signaling can preserve an undifferentiated phenotype in CD133+ human cord
blood-derived cells [176] and it supports embryonic stem cell self-renewal [177]. Furthermore, the
importance of β-catenin in the self-renewal of Lin−Sca−CD49fhigh mouse prostate stem and progenitor
cells has been provided in the study by Lukacs et al. [178]. This group reported that cells expressing
the BMI-1 (polycomb group) protein require constitutively active β-catenin for increased self-renewal.
This suggests that BMI-1 may be a mediator of WNT/FZD signaling in normal PSCs [178].
4. An Overview of AR and AR Signaling
The most critical molecular component of the androgen signaling pathway is the AR protein.
Upon activation by androgens, AR mediates transcription of target genes that modulate growth and
differentiation of prostate epithelial cells. AR plays a vital role in the development of male reproductive
organs. Of note, its dysregulation contributes to the male pattern of baldness, development of prostatic
hyperplasia, and later in life to PCa.
The AR gene is located on chromosome Xq11-12. It consists eight exons that encode an 110 kDa
nuclear receptor that is a unique member of the nuclear steroid receptor gene family (Figure 2) [179,180].
The AR protein has four functional domains (Figure 2). The N-terminal domain (NTD) is the most
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variable and least conserved domain; it is needed to form a transcriptionally active molecule. Precisely,
the NTD contains the activation function 1 (AF-1) domain that includes two overlapping transcription
activation units (TAUs): TAU-1 (amino acids 1–370), which supports AR transcriptional activity
upon stimulation by full agonist, and TAU-5 (amino acids 360–528), which confers a constitutive
activity to the AR in the absence of its ligand-binding domain (LBD) (Figure 2) [181–183]. Next to
the NTD lies the DNA-binding domain (DBD), which is the most conserved region in this protein.
This DBD consists of two zinc finger modules that are responsible for binding to the hormone response
elements [184,185]. The carboxy-terminal end of AR contains the LBD and the activation function 2
(AF-2) domain [183]. Lastly, the region between the DBD and LBD of AR is termed the hinge region
(HR) (Figure 2). It provides the main portion of the nuclear translocation signal and regulates the
transactivation potential as a result of posttranslational modifications. Interestingly, it serves as an
integrator for signals coming from different pathways [185].
Figure 2. Schematic representation of the androgen receptor (AR) gene and protein, with indications of
its specific motifs and domains. The AR gene is located on human X chromosome and is composed
of 8 exons. The domains and motifs in the AR protein include: the N-terminal domain (NTD), the
DNA-binding domain (DBD), the hinge region, and the ligand-binding domain (LBD), as well as the
activation function 1 (AF-1) domain and the activation function 2 (AF-2) domain, and two transcription
activation units (TAUs): TAU-1 and TAU-5.
In mammalian cells, AR is sequestered in the cytoplasm and is bound to heat shock protein
complex consisting of Hsp70 (hsc70), Hsp40 (Ydj1), Hop (p60), Hsp90 and p23. The main role of
this complex is to maintain AR in a conformation capable of ligand binding and to protect it from
proteolysis [182,186–188]. Upon binding to testosterone or dihydrotestosterone (DHT), the chaperone
heterocomplex mediates AR translocation to the nucleus (Figure 3). In the canonical genomic pathway,
once in the nucleus, AR, as a homodimer, interacts with androgen response elements (ARE); by
recruiting co-regulators to form a pre-initiation complex and together with the basal transcriptional
machinery, it initiates transcription of its target genes (Figure 3A) [189–191]. Of note, nuclear targeting
of AR is influenced by its HR, where a deletion markedly reduces ligand-induced nuclear translocation,
but does not totally block signaling [192–194]. Subsequently, loss of bound ligand allows the nuclear
export signal (NES) to coordinate AR shuttling to the cytoplasm where AR can be tethered again to
cytoskeletal proteins in preparation for ligand binding [195,196].
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Figure 3. Schematic representation of AR signaling in normal prostate tissue and prostate cancer.
(A) The AR is complexed to heat shock proteins (HSPs), principally HSP90, in the absence of steroid
hormones. Upon binding to dihydrotestosterone (DHT), AR dimerizes and translocates to the nucleus.
In the nucleus, AR binds to DNA via the androgen-responsive element (ARE). This occurs both by
direct binding to DNA and by association with other transcription factors and co-regulators, leading to
expression of its target genes that control growth and differentiation of prostate cells; (B) In PCa cells,
AR signaling is maintained through other mechanisms such as AR amplification, AR mutations, or AR
alternative splicing. AR can also be transactivated in the absence or under very low levels of androgens.
In the nucleus, AR can drive expression of oncogenes such as those encoding the ETS transcription
factors (e.g., ERG, ETV1), as a consequence of gene rearrangements (e.g., TMPRSS2-ERG gene fusion);
it also controls expression of its target genes that support proliferation and survival of PCa cells.
Regulation of the AR activity occurs, in part, by posttranslational modifications, such as
phosphorylation at several serine residues with or without a bound ligand [197]. Precisely, AR is
phosphorylated at serine residues (Ser80, Ser93 and Ser641) that are believed to function by protecting
AR from proteolytic degradation [196,198]. Degradation of AR plays a pivotal role in the regulation
of AR function. AR is a direct target for MDM2-mediated ubiquitylation and proteolysis [199].
The NEDD4 ubiquitin ligase recruiting protein PMEPA1 may also play important roles in this
pathway [200,201].
5. The Emergence of Castration Resistance
Although the preferred ligand for AR is DHT (Figure 3A), it has been reported that mutations
frequently detected in both human PCa and in PCa cell lines may alter the ligand specificity of
AR, leading to its promiscuous activity in the presence of alternative steroid ligands that do not
bind to the wild-type AR [202,203]. In addition to mutations of AR found in PCa, important recent
studies have shown that AR can drive expression of oncogenes such as those encoding the ETS
transcription factors (e.g., ERG, ETV1) as a consequence of gene rearrangements [204]. The most
common form of these rearrangements creates a TMPRSS2-ERG gene fusion, resulting in expression
of an N-terminally truncated ERG protein under the control of the androgen-responsive promoter of
TMPRSS2 (Figure 3B) [204,205]. Furthermore, a recent whole-genome chromatin immunoprecipitation
(ChIP) analysis showed that ERG could bind to AR downstream target genes and disturb AR signaling
in PCa cells through epigenetic silencing [206]. By characterizing human PCa cell lines and knockin
mouse models ectopically expressing ERG or ETV1, we demonstrated that ERG negatively regulates
the AR transcriptional program, whereas ETV1 cooperates with AR signaling by favoring activation of
the AR transcriptional program [207].
Prostate gland development and PCa are critically dependent on AR signaling. The ADT remains
the most widely used treatment for patients with advanced PCa. In fact, androgen deprivation causes
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reduced AR expression, apoptosis and decreased tumor cell volume; however most PCas eventually
develop the capacity for recurrent growth in the absence of testicular androgen (i.e., CRPC) [208–210].
The postulated mechanisms to explain the emergence of CRPC can be separated into three general
categories, most of which center on AR signaling, including AR amplification, AR mutation, and
overexpression of AR splice isoforms (Figure 3B). Another mechanism for increased AR signaling
activity is the endogenous expression of androgen synthetic enzymes by tumor tissues, which leads
to de novo androgen synthesis or conversion of weaker adrenal androgens into testosterone and
DHT [124,211–214]. Up to 80% of CRPCs display a marked increase in AR mRNA and protein [215–218].
Studies by Kim et al. have shown that AR protein expression is increased in recurrent tumor samples
compared to paired androgen-sensitive samples in tumor xenograft models [210]. Specifically, in
CWR22 xenograft tumors, castration initially induced growth arrest in tumor cells. However, foci
of Ki-67 immunopositive cells were detected by 120 days after castration [210]. In nearly one-third
of patients progressing after castration or antiandrogen treatments, the mechanism for increased AR
expression is through amplification of the AR gene at Xq11-12 [183,215,216,219–221]. Additionally, the
most recent analysis of whole-exome sequencing of 150 metastatic CRPC (mCRPC) biopsies revealed
63% of AR gene amplification and mutation in comparison to that of 440 primary PCa tissues [222].
This amplification leads to an increase in AR gene expression and enhances AR activation by low levels
of androgens. It remains unclear, however, whether amplification of the AR gene in hormone-refractory
tumors results in an increase in AR protein levels. In fact, contradicting results have been obtained.
Studies by Koivisto et al. have shown that hormone-refractory prostate tumors carrying an amplified
AR express a higher level of AR mRNA compared to untreated primary tumors with a single copy of
AR per cell [220]. In contrast, studies by Linja et al. have revealed that hormone-refractory tumors
carrying AR amplification were not found to express a higher level of AR mRNA than those with a
normal AR copy number [217]. Therefore, the significance of AR amplification in PCa remains unclear.
In addition, alternative splicing of AR mRNA is another mechanism implicated in progression to
CRPC. Multiple aberrantly spliced AR variants (ARV) that miss the C-terminal LBD were detected in
CRPCs [222–224]. Importantly, all ARVs retain the amino-terminal transactivation and DNA-binding
domains. AR-V7 (AR1/2/3/CE3 variant) is constitutively active and the most abundant variant
detected to date in CRPC [225]. Interestingly, elevated AR-V7 induces expression of a unique set of
target genes [225]. Furthermore, recent findings suggested that AR-V7 could have value as a predictive
biomarker in CRPC. Antonarakis et al. showed that AR-V7 mRNA in circulating tumor cells (CTCs)
might be enhanced by AR-directed therapies including abiraterone acetate and enzalutamide, and its
expression was associated with poor prognosis [226]. Of note, the full-length AR and AR-Vs appear to
almost always coexist in PCa cells; thus, it remains highly challenging to dissect their corresponding
roles in driving AR signaling in translational studies of clinical specimens [183].
6. Interaction between AR and WNT Signaling in Prostate Cancer
The paradigm that PCa development and emergence of therapy resistance are a consequence of
the restoration of embryonic developmental programs (e.g., WNT signaling) has shed a new light on
understanding the molecular mechanisms underlying epithelial invasion in prostate development and
development of CRPC. While the (aberrant) AR signaling pathway is considered as the most critical
player in CRPCs, as intracellular signaling pathways are often interconnected, other pathways, in
particular, the WNT pathway, can also play key roles. As noted in the previous section, considerable
evidence indicates that the WNT pathway plays a central role in the development of prostate tissues, by
providing developmental growth inductive signals during embryonic/neonatal organogenesis. In PCa,
studies by Schaeffer et al. have reported that androgen exposure regulates genes previously implicated
in prostate carcinogenesis; these genes included those related to developmental pathways, such as
WNT signaling, along with cellular programs regulating such “hallmarks” of cancer as angiogenesis,
apoptosis, migration and proliferation [227]. This observation was in line with the previously published
data showing that aberrant activation of the WNT/β-catenin pathway contributes to progression
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of several other major human cancer types [27,30,35,56,90,100,228]. The prime example is colorectal
cancer, in which approximately 85% of cases display loss-of-function mutations in the tumor suppressor
APC gene [229–232]. APC protein recruits β-catenin to the degradation complex and its loss leads to
upregulation of β-catenin signaling (Figure 1). In addition, mutations of serine/threonine residues
within the N-terminal domain of β-catenin suppress β-catenin degradation, leading to constitutive
activation of WNT signaling even in the absence of WNT ligands. In PCa, mutations in the APC or
CTNNB1 (β-catenin) genes, which lead to constitutive activation of WNT signaling, similar to those
found in colon cancer, have also been identified [202,233–236].
Accumulating evidence has supported that the WNT/β-catenin pathway plays an important role
in CRPC, by interacting with AR signaling [234,237–239]. Several groups have focused on studying the
role of β-catenin in CRPC compared to hormone-naïve PCa. Findings of a protein-protein interaction
between AR and β-catenin have supported the biological significance of β-catenin in PCa cells. In 2000,
Truica et al. showed that β-catenin could directly bind to AR to enhance its transcriptional activity
stimulated by androgen, androstenedione, or estradiol, in LNCaP cells [240]. In 2002, Yang et al.
demonstrated that β-catenin preferentially and directly bound to the LBD of AR in the presence of
DHT over several other steroid hormone receptors [241]. Further studies revealed that β-catenin
bound to the AF-2 region of the AR LBD, and modulated the transcriptional effects of the AR NTD
as well as the p160 coactivator transcriptional intermediary factor 2 (TIF2); importantly, a single
AR lysine residue (K720) has been shown to be necessary for the AR/β-catenin and TIF2/β-catenin
interactions [242,243]. In β-catenin, early mapping experiments suggested that the NH2 terminus
and the first six armadillo repeats of β-catenin were involved in its interaction with AR. In particular,
deletion of repeat 6 fully abolished the physical interaction between AR and β-catenin, suggesting a
key role of this repeat in the interaction [241]. Phenotypically, transient over-expression of β-catenin in
AR+ PCa cell lines CWR22-Rv1 and LAPC-4 enhanced AR-mediated transcription of its target genes,
in an androgen-dependent manner [244]. Hence, β-catenin (wild-type or mutated) is considered as
a ligand-dependent co-activator of the AR-driven transcription (Figure 4). Binding of β-catenin to
ligand-engaged AR also facilitates the movement of β-catenin into the nucleus [245]. Furthermore,
it was shown that WNT/β-catenin signaling could increase AR gene expression via the TCF/LEF-1
binding sites in the AR promoter [246]. Thus, in hormone-naïve PCa, WNT/β-catenin signaling serves
as a positive regulator of AR signaling in an androgen-dependent manner (Figure 4A).
Figure 4. A simplified model of interaction between WNT and AR signaling during PCa development
and progression. (A) In hormone naïve PCa cells, AR signaling inhibits the transcription of
WNT/β-catenin target genes, while WNT/β-catenin signaling promotes transcription of AR target
genes. Relative levels (i.e., anti-correlation but may reach to an equilibrium) of WNT (blue) and AR
(red) signaling are indicated; (B) In CRPCs, AR and WNT/β-catenin signaling pathways stimulate each
other to activate specific target genes for promoting androgen-independent growth and progression of
PCa cells. Relative levels (i.e., positive correlation) of WNT (blue) and AR (red) signaling are indicated.
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In the other hand, the effect of AR signaling on WNT/β-catenin signaling is more complicated.
Early studies in gonadotropin-releasing hormone neuronal cells showed that in the presence of DHT,
liganded AR repressed β-catenin/TCF-responsive reporter gene activity [247]. In androgen-dependent
LNCaP PCa cells, androgen treatment repressed target genes of WNT/β-catenin, whereas inhibition
of AR activity enhanced WNT/β-catenin-responsive transcription; this data suggested that under the
hormone-naïve condition, AR signaling could repress β-catenin/TCF-mediated transcription induced
by androgen [96] (Figure 4A). Mechanistically, as β-catenin interacts with TCF4 to control transcription
of WNT/β-catenin target genes, this could be due to preferential interaction of β-catenin with AR rather
than TCF4 in hormone-naïve PCa cells. While WNT/β-catenin pathway is repressed by AR in the
androgen-dependent LNCaP cell line, upon repression of AR activity or in the androgen-independent
subline of LNCaP cells (LNCaP-abl), the WNT/β-catenin responsive transcription appeared to be
largely activated, suggesting a likely role of WNT signaling in PCa progression to CRPC [96] (Figure 4B).
This could be due to an increased interaction of β-catenin with TCF4 (rather than AR), which could
promote WNT/β-catenin-target gene expression [96]. Therapeutically, pharmacological and genetic
inhibition of the WNT/β-catenin pathway (using siRNA against β-catenin or a small molecule
β-catenin inhibitor) in LNCaP-abl cells re-established their sensitivity to enzalutamide, a synthetic
non-steroidal antiandrogen [96]. Thus, this study implies that inhibition of the WNT/β-catenin
pathway may be translated into an effective therapeutic approach to treat enzalutamide-resistant CRPC.
To add another layer of the complexity of interaction between AR and WNT/β-catenin signaling,
it was shown that when PCa cells had been adapted to the low androgen environment (e.g., upon ADT),
β-catenin could act as a co-activator of AR as well to enhance AR transcriptional activity in the presence
of androstenedione, a weaker adrenal androgen remaining present in CRPC patients [239,241–243].
This direct interaction between AR and β-catenin seemed to elicit a specific expression of a set of target
genes in low androgen conditions in CRPC, which is consistent with the previous finding that target
genes regulated by AR signaling are different in CRPC cells compared to those in hormone-naïve
PCa cells [248]. Thus, it seems the effect of AR signaling on WNT/β-catenin signaling is PCa
stage-dependent: it suppresses WNT/β-catenin signaling in hormone-naïve PCa, but in CRPC, both
AR signaling and WNT/β-catenin signaling work together to positively support each other and to
control a unique set of genes for sustaining CRPC cells (Figure 4). Lastly and most importantly, the
significance of WNT/β-catenin and AR pathways in CRPCs was further demonstrated in studies by
Robinson et al [222]. Their clinical sequencing analysis of PCa genomes has revealed that the majority
of individuals with CRPCs harbor molecular alternations in the AR gene, as well as in genes encoding
the main components of the WNT/β-catenin pathway, such as APC, β-catenin and R-spondins, leading
to overactivation of WNT/β-catenin signaling [222].
As described in the previous section, WNT ligands are highly conserved secreted molecules that
play critical but pleiotropic roles in cell-cell signaling during embryogenesis. Interestingly, expression
levels of several WNT ligands were found to be up- or down-regulated in advanced PCa. For instance,
Chen et al. demonstrated that high levels of WNT1 and β-catenin expression were associated with
advanced, metastatic, hormone-refractory prostate carcinoma, in which they could serve as markers for
disease progression [236]. In two independent studies, another WNT ligand, WNT3A, has been shown
to modulate growth of PCa cells [20,249]. Importantly, the activity of AR signaling in the presence
of low concentrations of androgens was increased by application of purified WNT3A, suggesting an
important role of the canonical WNT3A signaling on the AR program [20]. As to the non-canonical
WNT pathways, elevated levels of WNT5A have been found to increase free intracellular calcium and
CaMKII in PCa cell lines, indicating that the WNT/Ca2+ pathway operates via CaMKII in PCa [250].
Yamamoto et al. showed that WNT5A overexpression enhanced invasion of the PC3 PCa cell line, and
the invasion activity required the expression of WNT receptors FZD2 and ROR2 [251]. Interestingly,
the very recent clinical studies by Miyamoto et al. have shown the importance of non-canonical
WNT in the maintenance of metastatic CRPC [252]. In details, they used RNA-in-situ hybridization
(RNA-ISH) to identify the source of WNT production in tumor specimens and CTCs. Metastatic tumor
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biopsies from patients with CRPC had readily detectable WNT5A and WNT7B. Similarly, WNT5A
or WNT7B mRNA was detected by RNA-ISH in a subset of CTCs from patients with CRPC [252].
This demonstrates that a subset of PCa cells express non-canonical WNT ligands, which may provide
survival signals in the context of AR inhibition. Furthermore, elevated expression of another WNT
ligand, WNT11, has also been detected in PCa tissues versus normal samples [21]. Interestingly,
WNT11 induced expression of neuroendocrine differentiation (NED) markers NSE and ASCL1, while
silencing of WNT11 in androgen-depleted LNCaP and androgen-independent PC3 cells prevented
NED and resulted in apoptosis [19].
Secreted WNT antagonists, including the sFRP family, DKK family, and Wnt inhibitory factor-1
(WIF1), are negative modulators of WNT signaling [239,253–255]. Thus, their expression is expected to
be downregulated in advanced PCa. Indeed, a recent study reported downregulation of sFRP2
in PCa [256]. WIF1 mRNA appears to be downregulated in a considerable percentage of PCa
samples [257]. Interestingly, laboratories of Zi and Hoang have demonstrated that ectopic expression
of sFRP3 (FRZB) or WIF1 in a CRPC cell line PC3 caused a reversal of epithelial-to-mesenchymal
transition and inhibition of tumor growth by inhibition of the canonical WNT pathway [258,259].
The role of the DKK family of WNT antagonist (e.g., DKK1) in PCa is arguably even more complex
than that of the sFRP family or WIF1. DKK1 inhibits WNT signaling by disrupting the binding of LRP6
to the WNT/FZD ligand-receptor complex [239,255]. Although DKK1 is upregulated in early PCa,
it is downregulated during progression from primary tumor to metastasis; however, its expression
can also inhibit WNT-induced osteoblastic activity and thus reduces bone metastases [260,261].
Altogether, these results suggest that WNT ligands and antagonists may play different roles during
PCa progression in a context-dependent manner.
7. Therapeutic Applications for Targeting WNT/β-catenin-AR Interactions in CRPC
Cancer stem cells (CSCs) have been proposed to contribute to therapy resistance and cancer
recurrence [262]. In addition to its higher activity in CRPC, the WNT/β-catenin signaling pathway
has also been linked to prostate CSCs. For instance, Jiang et al. showed that activation of the WNT
pathway via inhibition of GSK3β promoted LNCaP C4-2B and DU145 cell-derived xenograft tumor
growth, as well as C4-2B cell-derived bone metastasis [263]. Interestingly, they reported an increase of
the ALDH+/CD133+ CSC-like subpopulation in these PCa cell lines. Previous studies have shown
that PCa cells with these markers exhibited tumor-initiating and metastasis-initiation cell properties,
although it was not absolutely clear whether the ALDH+/CD133+ subpopulation represented CSCs
definitively [263–265]. In a recent study [266], it was shown that knockdown of a prostate tumor
suppressor, DAB2IP, transformed normal prostate epithelial cells into CSCs, which exhibited enriched
CD44+/CD24− populations. Interestingly, they reported that it was the WNT/β-catenin signaling
pathway that mediated upregulation of CD44 by DAB2IP knockdown. In this setting, CD44 not
only served as a marker for CSCs, but also played a key role in facilitating the onset of prostate
CSCs and increasing their chemoresistance [266]. Importantly, combination therapy based on WNT
inhibitors (e.g., LGK974) and conventional drugs (e.g., docetaxel) synergistically enhanced their
efficacy and robustly inhibited growth of xenograft tumors [266]. In another study, Rajan et al.
reported a gene expression profiling study of seven patients with advanced PCa, with paired samples
before and after ADT [267]. By using RNA sequencing combined with bioinformatic approaches, the
authors identified alterations in the WNT/β-catenin signaling pathway following ADT. Additionally,
they showed that the tankyrase inhibitor XAV939 (which promotes β-catenin degradation) reduced
growth of the androgen-independent LNCaP-abl cell line, compared with the androgen-responsive
LNCaP cells [267]. Similarly, Lee et al. demonstrated that iCRT-3, a novel compound that disrupts
both β-catenin/TCF and β-catenin/AR protein-protein interactions, inhibited PCa growth in vivo and
blocked bicalutamide-resistant prostate sphere-forming cells [268]. Overall, it seems that targeting
CSCs via inhibition of WNT signaling may have the potential to reduce the self-renewal and aggressive
behavior of PCa [162].
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As to the non-canonical WNT pathway, the most recent clinical studies by Miyamoto et al.
have shown that activation of this pathway in CTCs from patients with metastatic CRPC correlates
with reduced effectiveness of antiandrogen treatment [252]. In particular, significant enrichment of
non-canonical WNT signaling was observed in CTCs from patients whose PCa progressed in the
presence of enzalutamide, particularly among CTCs with reduced glucocorticoid receptor expression.
To test whether activation of non-canonical WNT signaling modulates enzalutamide sensitivity, they
ectopically expressed the ligands for non-canonical WNT signaling, including WNT4, WNT5A,
WNT7B, or WNT11, in LNCaP PCa cells, which express these ligands at low endogenous levels.
They found that ectopic expression of a range of these WNT proteins in androgen-sensitive LNCaP
cells enhanced their survival in the presence of enzalutamide, with WNT5A to be particularly effective
in this regard [252]. Conversely, its knockdown resulted in reduced cell proliferation. This data
suggests that the non-canonical WNT signaling pathway may serve as a potential new therapeutic
target in PCa that is resistant to antiandrogen therapy.
Taken together, WNT signaling interacts with AR signaling using distinct mechanisms at
different stages of PCa progression. In hormone-naïve PCa cells, WNT/β-catenin signaling promotes
transcription of AR target genes, whereas AR signaling inhibits the transcription of WNT/β-catenin
target genes (Figure 4A). However, in CRPCs, the AR and WNT/β-catenin signaling pathways
stimulate each other to activate a unique set of target genes for promoting androgen-independent
growth and progression of PCa cells (Figure 4B). The interaction between AR and WNT signaling
provides a growth advantage to PCa cells at the castration level of androgens. Inhibition of the
WNT/β-catenin pathway would thus offer a novel therapeutic strategy to target CRPC cells and
CSCs [239].
8. AR and WNT Signaling in Mammary Gland Development and Breast Cancer
8.1. AR and WNT Signaling in Mammary Gland Development
WNT signaling plays key roles in both mammary gland development and breast cancer (BCa),
largely through regulating mammary stem cell maintenance and basal mammary epithelial cell fate
determination. An excellent review for this topic was published in this journal recently [41]. As to
the AR signaling pathway, AR-mediated androgen actions play a direct or indirect role in mammary
physiology (Figure 5). AR can interact with estrogen receptor alpha (ERα) and their interactions have
inhibitory effects on their transactivational properties [269]. AR can also compete with ERα for binding
to specific estrogen-responsive element (ERE) [270]. Thus, the effect of AR signaling in mammary gland
development may be largely related to its effect on estrogen signaling. In fact, androgen treatment
could inhibit estrogen-induced proliferation of mammary epithelial cells, particularly during puberty,
leading to retarded mammary ductal extension and reduced expression of ERα [271–273]. Conversely,
inactivation of AR resulted in accelerated mammary ductal growth and increased expression of ERα
during puberty [273]. However, in addition to its inhibitory role on the ERα pathway, the role of AR
signaling in mammary epithelial cells may be also mediated by inhibition of WNT/β-catenin signaling,
a mechanism similar to that in hormone-naïve prostate cells (Figure 4). This is supported by the finding
that loss of AR led to activation of the WNT/β-catenin pathway in the pubertal mammary gland [273].
In adult females, inhibition of AR signaling could also increase mammary ductal branching and
mammary epithelial cell proliferation; however, this phenotype was not due to changes in serum
estradiol levels or ERα expression, but was attributed to increased AR expression and consequently an
increase in the ratio of AR to ERα (as ERα level remained constant) [271]. Relating to BCa, disruption
of the inhibitory influence of androgen/AR signaling on mammary epithelial cells at either puberty or
adult stage, as well as the crosstalk between AR signaling and estrogen or WNT signaling, are likely to
have important implications for breast tumorigenesis [270,273].
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Figure 5. Proposed roles of AR and WNT signaling in mammary gland development and breast cancer.
In breast cells, activated androgen/AR binds to ARE or ERE in its target genes. In ERα+ cells, it largely
works as a tumor suppressor by inhibiting estrogen/ERα signaling and/or WNT signaling; in ERα−
cells or even in ERα+ cells that have become resistant to hormone therapy (targeting the estrogen/ER
pathway), AR may function as an oncoprotein by activating WNT signaling and/or other oncogenic
pathways. Under different cellular contexts, AR may utilize different co-regulators (e.g., LSD1, or other
co-regulators remain to be defined (X?, Y?, or Z?)) to control distinct downstream programs.
8.2. AR Signaling in Breast Cancer
Unlike PCa, our understanding of AR signaling in BCa is still at its infancy. Some studies
report that overexpression of AR is associated with better outcomes in BCa, while others illustrate a
positive correlation of circulating androgens with high risk, recurrence and metastasis of BCa [274–279].
Historically, therapeutics targeting AR were considered beneficial for women diagnosed with
advanced BCa [280]. In the “older generation” of androgen-related therapy for the treatment of BCa,
including DHT, testosterone, and fluoxymesterone, certain clinical efficacies were observed [281–283].
However, androgen-related therapy gradually lost its attraction for the treatment of BCa, due to
aromatization of androgens to estrogens, inconsistent clinical trials, undesirable virilizing side effects,
and the broad utilization of estrogen-targeted therapy such as tamoxifen [284–287]. With improved
preclinical interpretation of heterogeneity toward mammary epithelial cells and BCa subtypes, AR
signaling-directed therapies, and resistance mechanisms of anti-estrogen therapies, there have been
renewed enthusiasms in utilizing androgens and targeting AR for BCa [280,288].
In breast tissues, androgen can be converted to DHT, which subsequently activates AR.
The liganded AR direct or indirectly (possibly together with distinct co-regulators under different
ERα settings) interacts with either ARE or ERE in its target genes (Figure 5). In the presence of
comparable levels of AR and ERα, AR competes with ERα, leading to inhibition of the estrogen/ER
pathway [270,274]. In the absence of ERα (or under the conditional of resistance to hormone therapy),
the ratio of AR to ERα increases and AR functions as an oncoprotein by recruiting different co-factors
(e.g., lysine-specific demethylase 1 (LSD1)), leading to regulation of a different set of target genes, which
may contribute to BCa cell proliferation and/or epithelial–mesenchymal transition (EMT) [270,289]
(Figure 5).
BCa is often classified clinically into four subtypes based on expression of ER, progesterone
receptor (PR), and human epidermal growth factor receptor 2 (HER2, also known as ERBB2):
ER+/PR+/HER2−, ER+/PR+/HER2+, ER−/PR−/HER2+, and ER−/PR−/HER2− (also known as
triple negative breast cancer, TNBC). Relating to the ER status, AR likely plays distinct roles in BCa in
a subtype-specific manner.
Positive expression of AR was clinically defined as immunohistochemical (IHC) nuclear staining
≥1% or ≥10% according to various studies [281,290–292]. AR is highly expressed in both primary
(~80%) and metastatic (~60%) breast tumors [280]. AR expression varies in BCa across different
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subtypes; the prevalence of AR is approximately 70%–95%, 50%−81%, and 10%–53%, in ER+,
ER−/HER2+, and TNBC subtypes, respectively [275,281,282,293–298].
Modulation of AR signaling, either inhibitory or stimulatory, exhibits somewhat contradictory
observations in different subtypes of BCa, particularly when interacting with ER signaling [283,299].
When prescribed to non-selected BCa patients, testosterone contributed to a response rate of about
20%–25%; due to broad side effects, this strategy has quickly been replaced by multiple ER-directed
therapies [300–303]. However, a retrospective study reported a promising tumor control rate of 58.5%
(tumor regression and stableness, n = 53) with testosterone therapy in patients with metastatic ER+
BCa [304]. Androgen, together with tamoxifen, synergically increased response rates when treating
advanced ER+ BCa, but this study is still at the beginning stage [280,305]. Recently developed
AR antagonists have demonstrated more potent and better clinical efficacies than those of the
early-generations, which have generally been disappointing for combating BCa [280,288,306,307]. Here
we will highlight the key AR-based therapeutics for treatment of BCa, in a subtype-specific manner.
8.2.1. AR in ER+ Breast Cancer
AR is highly expressed in ER+ BCa with a frequency of ~70%–95% [281,295,296,298,308].
In this BCa subtype, ER signaling functions as a dominant oncogenic driver; thus, clarifying its
functional relationship with AR signaling would be beneficial for exploring the role of anti-estrogen
therapies [309]. AR and ER can interact (and interfere) with each other functionally by sharing
(and competing for) similar cofactors and nuclear binding sites [274,310]. AR expression may have
contradicting functional consequences in ER+ BCa in a treatment-dependent manner: some studies
indicated that higher AR expression is associated with better therapy outcomes, whereas others have
reported that AR plays an oncogenic role in tamoxifen-resistant subjects [294,311–314]. Nevertheless,
AR signaling may mainly play an anti-proliferative effect in ER+ BCa initially, due to its ability to
antagonize the growth-promoting role of ER signaling [302]. Accordingly, androgens and androgen
agonists have been evaluated for the efficacies of treating ER+/AR+ BCas [302]. But combination
therapy based on enzalutamide (antiandrogen) and agents that target ER signaling (e.g., exemestane,
anastrozole, or fulvestrant) has also been tested in clinical trials for potentially overcoming resistance
to hormone therapy [294].
8.2.2. AR Signaling in ER−/HER2+ Breast Cancer
AR is highly expressed in ER− BCa and the functional crosstalk between AR and HER2 is critical
for the tumor cell survival and expansion [282,297,315]. In this subtype of BCa, the proliferative role of
AR signaling has been well investigated [275,280]. Mechanisms underlying this functional interplay
include direct transcriptional upregulation of HER2 signaling by AR via its heterodimer HER3, which
in turn activates AR transcription in a positive feedback loop [297,316,317]. AR signaling also induces
ligand-dependent stimulation of WNT signaling, via direct transcriptional upregulation of WNT7B,
which activates β-catenin, resulting in HER3 transcriptional activation [297]. HER2 signaling is the key
oncogenic driver in this subtype of BCa and effective HER2-targeted therapies are crucial for treating
patients with this BCa subtype. As AR antagonists can efficiently reduce cell proliferation [297,318],
clinical trials are ongoing to explore whether combination of AR and HER2-directed therapies could
result in any synergic outcomes [318].
8.2.3. AR Signaling in TNBC
The frequency of AR expression in TNBC is around 10% to 53% [281,296,298]. A molecular
subtype of BCa referred to as the molecular apocrine subtype, which included those non-basal-like
ER− breast tumors that were also AR+, was defined based on microarray expression profiling [319].
Later on, also based on gene expression profiling data, TNBCs were classified as six subtypes and those
with AR expression were defined as the luminal androgen receptor (LAR) subtype [298]. Differentially
expressed genes that characterize this subtype are heavily enriched in hormonally regulated pathways,
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including steroid synthesis, porphyrin metabolism, and androgen/estrogen metabolism [298,320]. AR
signaling in TNBC was reported to maintain cell proliferation and AR also acted as a biomarker for
sensitivity to both PI3K and ERK inhibition [318,321]. The functional role of AR in TNBC was further
established based on the finding that LAR BCa cells were sensitive to AR antagonists and Hsp90
inhibitors [322]. An encouraging case for using AR-targeted therapy for treatment of AR+ TNBC was
reported recently, in which a patient with this BCa subtype had progressive disease following six cycles
of cytotoxic chemotherapy, but attained a 100% response to bicalutamide (an antiandrogen) [323]. With
the development of potent AR-directed therapies and promising combined therapeutic approaches,
more clinical trials targeting AR+ TNBC are being developed [318,321].
8.3. Interaction between AR and WNT Signaling in Breast Cancer
Overexpression of WNT induces aberrant activities of the WNT signaling pathway, which is a
main driving force in BCa progression [297,324]. WNT ligands are associated with normal mammary
gland development and overexpression of WNT1 is oncogenic for BCa [325]. The interplay of AR and
WNT signaling has been mainly studied in the ER−/HER2+ BCa subtype. Using gene set enrichment
analysis (GSEA), Ni et al. observed that androgen (DHT)-stimulated genes in ER−/HER2+ BCa cells
were mainly those involved in WNT signaling [297]. Furthermore, they found that AR upregulated
WNT7B transcription in a ligand-dependent manner. WNT7B is a canonical WNT ligand and may
play roles in the normal mammary gland development during the stages of ductal formation and
involution [326,327]. Elevated expression of WNT7B has been found in ~10% of BCa cases [328].
In addition to activation of WNT signaling via the androgen/AR-WNT7B pathway, Ni et al. showed
that similar to PCa, AR and WNT/β-catenin signaling also cooperated functionally; in this case,
β-catenin cooperated with AR to promote the progression and maintenance of ER−/HER2+ BCa cells
by upregulating HER3, which encodes a key co-receptor of HER2 in HER2+ BCa [297]. Importantly,
by targeting the AR pathway using bicalutamide, the growth of DHT-stimulated ER−/HER2+ breast
tumor cells in vivo was inhibited [297].
Thus, in both PCa and BCa, AR signaling appears to regulate distinct sets of target genes in
hormone-dependent cancers (i.e., hormone-naïve PCa, ER+ BCa) and hormone-refractory cancers
(i.e., CRPC, ER− BCa, hormone therapy-resistant ER+ BCa). Accordingly, both AR agonists and AR
(and/or WNT) antagonists may be beneficial for BCa therapy, but in a BCa subtype and therapy
stage-dependent manner. In particular, as both the AR and WNT signaling pathways drive progression
and maintenance of AR+ TNBCs, inhibitors for these two pathways may prove to be useful for
targeting this TNBC subtype. In addition, AR antagonists and anti-HER2 agents may also be used in
combination to treat ER−/HER2+ BCa with AR expression, and inhibitors for WNT signaling may
offer another therapeutic opportunity, particularly when ER−/HER2+ BCa cells develop resistance to
the anti-HER2/AR agents.
9. Concluding Remarks
As two key pathways regulating both normal development and tumorigenesis in
hormone-responsive prostate and mammary glands, the context-dependent interplay of AR and
WNT signaling pathways provides a unique opportunity to explore therapeutic options for treating
prostate and breast cancers, particularly when under the setting of therapeutic resistance. As both
CRPCs and ER− BCas (i.e., TNBC and ER−/HER2+ BCa, or even ER+ BCas that become resistant to
hormone therapy) are refractory or unresponsive to hormone therapy, a better understanding of roles of
AR and WNT pathways and their interactions in these hormone-refractory diseases should open a new
avenue for improving their treatment and for combating the inevitable challenge of therapy resistance.
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Abstract: Androgen receptor (AR, a member of the steroid hormone receptor family) status has
become increasingly important as both a prognostic marker and potential therapeutic target in breast
cancer. AR is expressed in up to 90% of estrogen receptor (ER) positive breast cancer, and to a lesser
degree, human epidermal growth factor 2 (HER2) amplified tumors. In the former, AR signaling
has been correlated with a better prognosis given its inhibitory activity in estrogen dependent
disease, though conversely has also been shown to increase resistance to anti-estrogen therapies
such as tamoxifen. AR blockade can mitigate this resistance, and thus serves as a potential target
in ER-positive breast cancer. In HER2 amplified breast cancer, studies are somewhat conflicting,
though most show either no effect or are associated with poorer survival. Much of the available
data on AR signaling is in triple-negative breast cancer (TNBC), which is an aggressive disease with
inferior outcomes comparative to other breast cancer subtypes. At present, there are no approved
targeted therapies in TNBC, making study of the AR signaling pathway compelling. Gene expression
profiling studies have also identified a luminal androgen receptor (LAR) subtype that is dependent
on AR signaling in TNBC. Regardless, there seems to be an association between AR expression
and improved outcomes in TNBC. Despite lower pathologic complete response (pCR) rates with
neoadjuvant therapy, patients with AR-expressing TNBC have been shown to have a better prognosis
than those that are AR-negative. Clinical studies targeting AR have shown somewhat promising
results. In this paper we review the literature on the biology of AR in breast cancer and its prognostic
and predictive roles. We also present our thoughts on therapeutic strategies.
Keywords: AR signaling; AR/PARP interplay; AR/BET interplay; breast cancer
1. Introduction
Androgen receptor (AR) signaling has become increasingly important in understanding the
biology of breast cancer, and serves as a potential therapeutic target in the era of precision medicine.
Previously, breast cancer has been categorized based on hormone receptor (HR) status, and the
presence or absence of human epidermal growth factor 2 (HER2) amplification. More recently,
it has become apparent that the AR pathway is associated with breast tumor carcinogenesis, with
differing mechanisms dependent on co-expression of HR or HER2 amplification [1,2] Although
our understanding is still early, this signaling pathway has important prognostic and therapeutic
implications. This review will aim to further clarify the complexities of the AR pathway in relation
to breast cancer tumorigenesis, prognostic associations in relation to HR expression and HER2
amplification and potential therapeutic options.
2. AR Pathway in Breast Cancer
The AR is a steroid-hormone activated transcription factor belonging to the nuclear receptor
superfamily, a group that also includes the estrogen receptor (ER) and progesterone receptor (PR).
Cancers 2017, 9, 21 154 www.mdpi.com/journal/cancers
Cancers 2017, 9, 21
Upon binding of its androgen ligand, the protein translocates to the nucleus where it stimulates
transcription of androgen-responsive genes [2,3]. More recently, non-genomic actions of the AR
signaling pathway have been described and are still being investigated in both normal female tissue
and in tumor carcinogenesis [4]. AR binds androgens that are produced in a normal physiological
manner from the female adrenal glands and ovaries, and in descending order of concentration include
dehydroepiandrosterone sulphate (DHEAS), dehydroepiandsoterone (DHEA), androstenedione (A),
testosterone (T), and dihydrotestosterone (DHT) (Figure 1) [5,6]. Only testosterone and DHT bind
directly to AR, and are primarily formed by peripheral conversion of DHEAS, DHEA, and A in adipose
tissue, liver and skin [5,7]. It is important to note that although testosterone can itself bind to AR, or be
converted to the more potent DHT via 5α reductase, it can also be converted to estradiol (E2) via the
aromatase enzyme that is found in numerous tissues including the breast [8–10]. This conversion to
estradiol is important, as estradiol serves as the primary ER ligand for both ERα and ERβ receptors
in breast cancer. ERα has been shown to have proliferative effect on tumors, while ERβ has been
associated with anti-proliferative effect, though these mechanisms are complex and our understanding
remains limited [11–14].
 
Figure 1. Abbreviated androgen and estrogen pathway. Arrows represent direction of enzymatic conversion.
AR is found in up to 70%–90% of all breast cancers, making it more abundant than ER or
PR activity [15–19]. However, identifying exact percentages of AR expression among the various
breast cancers—HR-positive, HER2-positive, or triple negative breast cancer (TNBC)—is somewhat
challenging due to considerable variability in methodology, including differing locations of expression
(cytoplasmic versus nuclear), cut off points for immunohistochemical (IHC) receptor expression (≥1%,
≥5% or ≥10%), and the antibody used in staining. One very large systematic review aimed to address
AR expression in ER-positive versus ER-negative breast cancers by analyzing 19 studies, including
7693 patients, and found AR co-expression with ER-positive disease to be 74.8% [20]. AR was also
found in ER-negative tumors at a lower rate of 31.8% from the same study, although other studies
show significant variability in this percentage depending on HER2 or TNBC status [20]. For example,
HR-negative and HER2-positive breast cancers seem to express AR in the range of 50%–60%; TNBC is
generally between 20% and 40% [15,16,21–28]. AR is also variably expressed in certain histologically
distinct subsets of mammary epithelial cells, including invasive apocrine carcinomas, with molecular
apocrine cells uniformly expressing AR but not ER or PR [29,30]. Luminal epithelial cells have also
been found to express AR in up to 30%, often with co-expression of ER and PR [31].
Gene expression profiling has also led to distinct molecular subtyping that is sometimes used
to classify breast cancer, and these tumors seem to show variable rates of AR expression [32,33].
For example, the luminal A and luminal B subtypes, as defined by ER positivity seem to express AR
anywhere from 50% to 90% depending on the study. The HER2-positive molecular subtype expresses
AR between approximately 20%–60%, and TNBC molecular subtype between 20% and 50% [34,35].
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In regards to AR activity in breast cancer carcinogenesis, multiple in vitro studies using several
laboratory breast cancer cell lines (i.e., MCF-7, T47-D, and BT20) have shown an anti-proliferative
effect of AR antagonism [1,36–39]. Interestingly, in the presence of ERα, the AR pathway can be
either antagonistic or agonistic to tumorigenesis, and at least partially is influenced by the level of
receptor expression and availability of their respective ligands [40–43]. Alternatively, ERα-negative
and AR-positive breast cancers fall into a category termed the “molecular apocrine” subtype, with
typically distinct histological features of eosinophilic and granular cytoplasm [44]. Within this subtype,
a preclinical study by Doane and colleagues utilizing the cell line MDA-MB-453 found the absence of
ER but continued dependence on hormonally regulated transcription, which was previously thought
to be solely the product of ER activation. Further gene expression profiling revealed the presence of
AR, and incubation of the cell line with synthetic androgen led to proliferation that could be blocked
by the anti-androgen flutamide [45]. The proliferative activity of AR seems to be consistent in the
presence of HER2, with at least partial “cross-talk” between the receptor pathways, and in TNBC as
well [46–48]. This heterogeneity of AR signaling in relation to co-expression of ERα, HER2 and in
TNBC will be discussed in further detail in their respective sections of this paper.
3. AR Pathway in ER+ Breast Cancer
Like AR, ER is a steroid hormone receptor. There are naturally two receptors expressed in normal
breast tissue, ERα and ERβ, which are involved in the development of reproductive organs, bone
density, cell cycle regulation, DNA replication and variety of other processes that occur through both
genomic and non-genomic mechanisms. Its ligand is estradiol, and in normal breast tissue ERβ is the
dominant receptor. In breast cancer, ERα expression increases and is implicated in tumorigenesis [49].
The function of AR depends largely on the level of co-expression of ERα in HR-positive breast cancer
(i.e., luminal breast cancer). Interestingly, many pre-clinical studies show differing proliferative versus
anti-proliferative effects in ERα and AR-positive breast cancer that correlates with variation in the
ratio of these steroid receptors and the availability of their respective ligands (i.e., estradiol and DHT).
As noted earlier in this paper, androgens can be peripherally converted to estradiol (Figure 1), making
the interplay between androgens and estrogens in patients expressing both AR and ER quite complex.
Early in vitro studies have tried to elucidate the complex relationship between AR and ER expression
and the variable responses to hormones and their antagonists in breast cancer cells.
Some studies show AR agonists to actually have anti-tumor effect in the setting of ERα. This has
been demonstrated through in vitro modeling in which higher levels of AR confer anti-proliferative
effects in the MCF-7 cell line [41]. Some older in vitro studies show increased apoptotic activity with
the use of androgens, as well as down regulation of the bcl-2 proto-oncogene, which could be reversed
with the addition of the anti-androgen hydroxyflutamide [50,51]. There are even some older clinical
trials that have demonstrated that treatments with exogenous androgens can successfully treat certain
breast cancers, with regression rates of approximately 20% [42]. These early clinical studies, though,
did not categorize the receptor status of treated patients.
Overexpression of AR in the MCF-7 breast cancer cell line, as postulated by Britton and
colleagues, is thought to be due to cross talk between ERα and the EGFR/MAPK pathway, which
leads to a self-propogating autocrine growth-regulatory loop through ERα mediated development
of AR [52]. Yeast and mammalian two-hybrid systems found ER and AR co-expression led to ER-AR
heterodimerization, rather than ER-ER or AR-AR homodimerization, and thus a decrease in AR
transactivation by 35% [43]. This fell in line with other older studies, which showed a dose-dependent
decrease in AR transcriptional activity in the presence of ER co-expression and estradiol [53]. Another
potential way AR down-regulates ERα activity is by competing for and binding to estrogen response
elements (EREs) on DNA [54]. Chromatin immunoprecipitation sequencing (ChIP-seq) and gene
microarray analysis of the ZR-75-1 luminal breast cancer cell line identified that increased presence of
one respective steroid hormone ligand (DHT versus estradiol) over the other leads to antagonism of
the other pathway, specifically at the level of transcription by binding to DNA response elements [40].
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For example, if AR binds to EREs it leads to an anti-proliferative effect rather than the proliferative
effect of ERα binding to ERE and vice versa for ERα binding to androgen response elements (AREs).
In certain studies, ER and AR interplay actually leads to increased resistance to traditional endocrine
targeted therapies [55,56].
ER expression serves as a primary target for therapy and one of the first treatments targeting this
pathway was the anti-estrogen tamoxifen, which was FDA approved in 1998. It is a selective estrogen
receptor modulator (SERM) that has differential ER agonist and antagonist activity depending on the
target tissue, and acts as a competitive inhibitor of estradiol [57]. Tamoxifen-resistance can occur in
HR-positive breast cancers and AR signaling has been implicated in this process, leading to some
clinical insight into the relationship between ER and AR signaling pathways. Toth-Fejel and colleagues
noted the androgen DHEA-S induced growth in the AR and ER-positive cell line T-47D by 43.4%,
but inhibited the AR-positive and ER-negative cell line HCC1937 by 22% [58]. They also found that
pre-treatment of the cell lines with tamoxifen in T-47D cells could increase the inhibitory activity of
DHEA-S, presumably though increased activity at the level of the AR receptor.
A somewhat conflicting pre-clinical model to that of Toth-Fejel and colleagues noted in the MCF-7
cell line that overexpression of AR made ERα-positive breast cancer cells resistant to the inhibitory
effects of tamoxifen in xenograft and nude mice studies, and that treatment with anti-androgen therapy
could overcome this resistance [59]. The postulated mechanism was an AR-associated increase in
tamoxifen agonist activity on ER, rather than an antagonistic effect [58,59]. A more recent preclinical
study found that the agonist activity of tamoxifen on ER signaling in the presence of high levels of AR
leads to activation of epidermal growth factor receptor (EGFR), which could be blocked by use of the
non-steroidal anti-androgen enzalutamide and/or the anti-EGFR therapy gefitinib [60]. Additionally,
tamoxifen-resistant cancers in which AR is present tend to have both higher levels of AR expression
and in one study, higher AR to ER nuclear expression [56].
4. Prognostic Implications of AR in ER+ Breast Cancer
Several larger studies and meta-analyses reviewing the prognostic implications of AR-positive
breast cancer report their findings without discussion of AR in relation to co-receptor status, or male
breast cancer. Given the size of these studies, and the unique look into male breast cancer, they remain
important and will be discussed briefly here prior to reviewing the significance of AR in relation to ER
in this section, and HER2 co-expression versus TNBC in later sections. The largest meta-analysis to
date presented by Vera-Badillo and colleagues encompassed 19 studies and 7693 patients with stage
I-III disease [20]. Specifically, this study looked at the odds ratios for overall survival (OS) and disease
free survival (DFS) at 3 and 5 years for patients with AR expression, in which 4658 patients (60.5%) had
breast cancers that were notably AR-positive. Independent of ER expression, patients with AR-positive
breast cancers were found to have statistically significant improvements in OS and DFS at both 3 year
and 5 year time points, including a 13.5% absolute improvement in 5 year OS and 20.7% in DFS [20].
Another meta-analysis reviewing DFS and OS by Qu et al. evaluated 12 studies and 5270 patients
that met their criteria. The combined hazard ratio for DFS of all included studies was 0.52, which
was statistically significant, indicating a lower risk of recurrence for patients with AR-positive breast
cancers. However, although showing a trend toward improvement, the difference in OS was not
statistically significant [61]. Aleskandarany et al. performed a retrospective cohort study of stage I-III
patients (n = 1141) with tumors ≤5 cm from 1987 to 1997 [62]. High AR expression was associated
with longer breast cancer specific survival (BCSS) and was an independent predictor of better outcome
regardless of tumor size, grade and nodal stage. Moreover, low AR expression was associated with
increased risk of distant metastasis [62]. The Nurses’ Health Study (NHS) showed similar results in a
prospective analysis of stage I-III patients conducted from 1976 to 2008 of postmenopausal women.
AR-positive tumors were associated with small tumor size (≤2 cm), lower histologic grade, and stage.
Breast cancer survival rates at 5 and 10 years were 88% and 82% for AR-negative patients, and 95%
and 88% for AR-positive patients [63].
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Regarding male breast cancer, these cases comprise only approximately 1% of all breast cancer.
In a Chinese study analyzing 116 patients from 1995 to 2008, men were found to have poorer outcomes
if their breast cancers were AR-positive [64]. Unlike comparable studies in female breast cancer,
AR expression was not correlated with pathologic T stage, histologic grade, or HR expression. Likewise,
in contrast to the studies outlined above, OS and DFS rates were significantly shorter with 5 year OS
at 54% versus 72%, and 5 year DFS at 39% versus 61%, for AR-positive versus AR-negative cancers
respectively, echoing the results of an earlier Polish study [65,66]. However, AR signaling in male
breast cancer remains poorly understood with conflicting results, largely due to the relatively small
series available. Where one study indicates a lack of correlation between AR expression and male
breast cancer, another indicates decreased AR expression is correlated with earlier development of
cancer [67,68]. Further studies are necessary to help clarify this patient population further.
In relation to ER-positive breast cancer, several studies have established that AR positivity has
prognostic value. AR and ER co-expressing breast cancers generally have better outcomes in terms of
time to relapse (TTR), as well as disease specific survival (DSS) as noted from a study by Castellano
and colleagues [69]. The study analyzed 953 ER-positive patients from 1998 to 2003 treated with
chemotherapy, hormone therapy or both, of which 859 were evaluable for AR expression and 609 were
positive (70.9%). The median TTR was 11.72 years versus 13.22 years and the DSS was 12.33 and 13.91
respectively. Regarding clinical and pathologic features, the study established a correlation with AR
positivity and smaller tumor size (<2 cm), absence of lymph node metastases and PR expression [69].
A Swedish population-based prospective cohort study assessing patients from 2002 to 2012
also showed a statistically significant improvement in DFS (at 6 years, approximately 90% versus
78%) in breast cancers co-expressing AR and ER [70]. Tsang et al. reviewed data from 3 Chinese
institutions from the years 2002 to 2009 and showed AR and ER co-expression to be associated with
lower pathologic T stage, lower tumor grade, PR positivity and better outcomes, and postulated that
the favorable result could be due to the inhibitory effect of the AR signaling [34,58]. The Nurses’ Health
Study noted the best survival rates in AR and ER co-expressing breast cancers were in postmenopausal
women with stage I-III breast cancer, with an overall 30% reduction in breast cancer mortality [63]. Jiang
and colleagues also noted a significantly better DFS in the ER-positive molecular luminal (A and B)
subtypes [71].
Reduced AR expression in ER-positive disease can predict for an increased risk of relapse,
breast-cancer associated death and worse DFS as well [71]. A study of 215 invasive ductal carcinoma
samples noted that breast cancers with higher expression (median of 75% nuclear positivity by the
AR-U407 IHC assay), was associated with a 3 fold increased risk of relapse and 4.6 fold increased risk
in breast cancer related death, as well as a statistically significant decrease in OS [54].
5. AR Pathway in HER2 Amplified Breast Cancer
The HER2 receptor in breast cancer was first noted in the late 1980s. Historically, it has been
associated with poorer outcomes and is amplified in approximately 15%–25% of invasive breast
cancers [72,73]. HER2 amplified breast cancers have lower rates of ER co-expression, ranging from
28% to 49%, with typically better outcomes when ER is present [73,74]. Previous molecular studies
have distinguished a group of patients with ER-negative but HER2-positive disease that did not easily
fall into a pre-defined category. An important study by Farmer et al. in 2005 aimed to better define
ER-negative, HER2-positive disease by tissue microarray and found an increase in AR signaling [44].
These cells in further review were notable for apocrine differentiation when exposed to high amounts
of androgens in the in vitro setting, and became known as molecular apocrine with separate distinct
characteristics than traditional apocrine tumors [44,75]. One early pre-clinical study postulated that
the molecular apocrine subtype was associated with cell proliferation in the presence of androgen
due to complex interactions between AR and the HER2 signal transduction pathway in the absence
of interference by the ER pathway [45]. A related investigation in prostate cancer found that HER2
kinase signaling is required for full activity of AR at low androgen concentration. In particular, HER2
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signaling led to increased binding of AR to the appropriate DNA targets to promote transcription, and
protected AR from ubiquitin associated degradation [76].
This interplay was further elucidated by Naderi and Hughes-Davies, who showed in the cell
lines MDA-MB-453 and MDA-MB-361, and in fresh tumor samples, that there is cross-regulation
of certain genes between AR and HER2. In particular, there was increased expression of steroid
response genes FOXA1, XBP1 and TFF3, as well as, increased cell proliferation when either AR or
HER2 were stimulated. When exposed to the anti-androgen flutamide, or HER2 inhibition there were
pro-apoptotic effects, which was notably additive when given in combination [46]. Later, the same
group in a study by Chia et al., further identified a positive feedback loop between the AR and
extracellular signal-regulated kinase (ERK) signaling pathways, in which HER2 is a transcriptional
target of AR, and leads to increased ERK activity [77]. The ERK pathway was also found to increase
AR expression, which could be down-regulated both with the androgen targeting flutamide, or the
ERK pathway targeting MEK inhibitor in an in vivo mouse model [77]. Similar models have been
described in prostate cancer, and serve as potential therapeutic targets [78].
To further add to the complexity of AR in HER2 amplified disease, a study by Ni and colleagues
looking at the AR cistrome in the MDA-MB-453 breast cancer cell line, had several interesting
findings. They noted that forkhead factor binding motif FOXA1, was highly expressed in HER2 and
AR-positive breast tumors, which is similar to AR-positive prostate cancers and seems to be involved
in recruitment of ER and AR to their transcription regulatory elements [28,79,80]. AR mediated
activation of HER2/HER3 signaling led to increased activity of MYC gene activity, which increased
transcriptional activity of androgen-response genes in ER-negative and AR-positive molecular apocrine
breast cancers [81]. In an earlier study, this same group showed DHT stimulation, likely through
AR promotion of FOXA1 and wnt/B-catenin pathway led to up-regulation of HER2 and HER3
phosphorylation and activation of the phosphoinositide 3-kinse (PI3K) pathway in the MDA-MB-453
cell line.
Also identified by another group is that AR activates the Wnt/β-catenin pathway, which leads to
upregulation of HER3 and has been previously implicated in breast oncogenesis [82]. Exposure to the
androgen DHT led to increased growth signaling activity of AR, HER2/HER3 and as a downstream
event, and activation of PI3K/AKT pathway and these events could be blocked with the addition
of the anti-androgen bicalutamide in an in vivo mouse model [28]. It should be noted that the cell
line used in this study has been found to have a homozygous deletion of TP53, a homozygous PTEN
missense mutation, and an oncogenic mutation in PI3K that might confound this data [83–85].
6. Prognostic Implications of AR in HER2 Amplified Breast Cancer
The prognostic significance of AR in HER2 amplified breast cancer seems to either show no
association with survival, or indicate poorer outcomes. However, many of these studies are limited
by smaller sample sizes. One analysis looking at prognostic variables in AR expressing breast cancer
showed no association with BCSS or distant metastasis free interval, though this only comprised a
sample of 59 patients [62]. A large prospective study assessing postmenopausal women notably had
1154 samples with AR-positive disease, but only 81 patients with HER2 amplification and noted no
differences in survival [63].
Other studies, including a retrospective analysis by Park et al. analyzed 931 breast cancer tissue
samples in stage I–III disease without prior therapy. Forty-nine patients with AR-positive, HER2
amplified breast cancer were categorized as molecular apocrine subtype, and survival analysis revealed
a trend toward poorer OS, though this did not reach statistical significance [23]. Along these lines,
Schippinger and colleagues in a study looking at 232 specimens of metastatic breast cancer noted that
DFS in patients with AR expression and HER2-amplification was 9.07 months compared to 17.51 in all
patients with AR expressed disease, though again not statistically significant. Moreover, the median
survival after recurrence (SAR) in this population was only 10.89 months, which was similar to the
11.99 months in patients with AR-negative disease [86].
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7. AR Pathway in TNBC
TNBC, as defined by lack of expression of ER and PR and a lack of HER2 amplification, comprises
between 10% and 20% of all breast cancers [48,87,88]. Traditionally, outcomes in TNBC have been
poor with a median overall survival in metastatic disease of approximately 13 months, as well as a
shorter time from recurrent disease until death compared to other breast cancers [89,90]. Pathologic
features include higher mitotic indices and an increase in BRCA1 mutations [91]. Demographically,
TNBC has been associated with higher proportion of African American and Hispanic patients based
on population studies and tend to occur at a higher frequency in younger patients [92–95]. Despite
these common characteristics, TNBC remains a biologically variable disease and thus a common
signaling pathway that could serve as a target for therapy has proven elusive [96]. Traditional cytotoxic
chemotherapy remains the main approach to treatment in these patients, but significant research at
the molecular level is being conducted to identify at least subsets of TNBC that might benefit from
treatments focused on driver pathways such as AR signaling.
Gene expression profiling has increasingly been used to classify invasive cancer subtypes over the
last 15 years. In TNBC, the majority of cases fall into a category of basal-like subtype, first described
by Perou, et al. in 2000 [32]. Expanded studies on the basal-like subtype have identified that this
heterogeneous group comprises approximately 16% of all breast cancers [97]. The basal-like subtype
has several common and more aggressive clinical features, including higher histologic grade and
mitotic indices, as well as earlier disease recurrence that lead to poorer outcomes [33,98–100]. Many
of these features have clinical overlap with the broader category of TNBC. Depending on the study,
the basal-like subtype is found in anywhere from 56% to 95% of cases and has sometimes been used
synonymously with the term TNBC [101–104]. With improved methods in molecular biology and gene
expression profiling, the heterogeneity of TNBC is becoming increasingly understood.
Lehmann et al. initially categorized TNBC into 6 separate subtypes, including basal-like 1 (BL1),
basal-like 2 (BL2), immunomodulatory (IM), mesenchymal (M), mesenchymal stem-like (MSL), and
luminal androgen receptor (LAR), each with distinct gene signatures predicting for driver signaling
pathways that could potentially serve as therapeutic targets [48]. Specifically, the LAR subtype was
found to be enriched in mRNA expression of AR signaling, as well as multiple downstream AR targets
with in vitro studies showing increased sensitivity to the AR antagonist bicalutamide [48]. Lehmann
and colleagues later adjusted their classification in 2016, utilizing more refined techniques, to include
only 4 subtypes with the omission of the IM and MSL categories [105]. Regardless, the LAR subtype
remains validated within the Lehmann lab and among other research groups, including Yu et al., and
more recently Jezequel and colleagues who found the subtype to account for approximately 22% of
TNBC [106,107]. Moreover, Lehmann’s group later noted that all commercially available AR expressing
TNBC cell lines also had PIK3CA mutations. They performed Sanger sequencing on 26 AR-positive
and 26 AR-negative TNBC clinical cases, and found clonal PIK3CA mutations were significantly higher
in AR-positive (40%) versus AR-negative (4%) tumors [108]. Further analysis of 5 LAR cell lines
revealed activating PIK3CA mutations and sensitivity to PI3K inhibition suggesting interplay between
these pathways as well [48,108].
Even non-LAR TNBC cell lines SUM159PT, HCC1806, BT549, and MDA-MB-231 seem to have a
role for AR signaling. Gene microarray and ChIP-seq analysis shows AR mediated up-regulation of
the EGFR ligand amphiregulin, which promotes proliferation via the EGFR pathway. This proliferative
activity appeared to be blocked with the anti-androgen enzalutamide [47].
8. Prognostic Implications of AR in TNBC Breast Cancer
AR positivity has been associated with more favorable prognoses in TNBC. There are several
studies that show AR is associated with lower Ki-67 proliferative marker, lower mitotic score,
lower histologic grade and lower clinical stage [23,27,63,109–112]. Interestingly, TNBC has been
associated with the poor prognostic TP53 mutation in up to 80% of patients, but at least one
study has shown that patients with AR-positive TNBC have a lower rate of TP53 mutations as
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well [109,113]. This improvement in histological and genetic features seems to translate to clinical
benefit and AR-positive TNBC have both improved DFS and OS versus AR-negative [110,114,115] One
retrospective study analyzing tissue microarrays from 287 patients with operable TNBC breast cancer
found a statistically significant decrease in lymph node positivity in AR-positive disease. The same
study showed a significant difference between AR-positive and AR-negative disease in which 5 year
DFS was 87% versus 74.2% and 5 year OS was 94.2% versus 82.3% [114]. A prospective study by
Loibl and colleagues that was linked to the German GeparTrio trial noted AR expression predicted
a significantly better 5 year DFS of 85.7% compared to 65.5% and 5 year OS of 95.2% compared
to 76.2% [116]. Other studies have also shown that lack of AR expression is associated with an
increased risk of recurrence and distant metastases, especially in patients with lymph node positive
disease [111,112].
Other analyses have shown either no difference or worse outcomes for AR-positive TNBC.
McGhan et al., looking at 119 patients with resectable disease, found patients with AR-positive cancers
trended toward more advanced stages (stage II and III) breast cancer, with no differences in DSS
or OS [21]. Mrklic in a retrospective study analyzing 83 patients with TNBC found no difference
in DFS and OS in patients with AR-positive disease versus AR-negative, though only 27 cancers
were AR-positive [27]. Pistelli in a similar study analyzing 81 cancers with only 15 positive for AR
showed no difference in DFS and OS, and the same was the case for Park and colleagues, in which 21 of
156 TNBC samples expressed AR and no survival differences were noted [117,118]. Another study with
97 AR-positive TNBC cases failed to find a difference in relapse free survival (RFS) or OS compared to
AR-negative disease [119]. The large prospective NHS study previously referenced was also evaluated
for the prognostic significance of AR in TNBC and found that in 78 out of 211 AR-positive TNBC
there was a statistically significant 83% increase in overall mortality compared to AR-negative in a
multivariate model [63]. This data conflicts with most other studies as noted above, which generally
show improved to no differences in outcomes.
More recently, pathological complete response (pCR) has become a surrogate marker for outcome
in patients treated with neoadjuvant therapies [120]. In terms of chemosensitivity in AR-positive TNBC,
a limited number of studies have shown a lower rate of pCR. Loibl and colleagues in the GeparTrio
trial showed AR-positive disease to have a pCR of 12.85% (n = 358), compared to AR-negative tumors
at 25.4% (n = 315). In multivariate analysis, AR independently predicted pCR. Interestingly, though
patients with AR-negative disease had a higher chance of achieving pCR, those with AR-positive
disease had similar DFS and OS whether or not pCR was achieved [116]. Specifically, patients
who achieved a pCR and had AR-negative cancers had a 5 year DFS of 77.9% and 5 year OS of
87% compared to patients who did not achieve a pCR and were AR-positive in which DFS was
77.5% and OS 88.6% [116]. The patients in the GeparTrio trial received a regimen of doxorubicin,
cyclophosphamide and docetaxel (TAC), and if considered a non-responder, went on to receive either
more TAC or vinorelbine and capecitabine prior to surgical intervention [116]. Another retrospective
study by Asano and colleagues examined 177 patients with resectable early stage breast cancer treated
with neoadjuvant fluorouracil, epirubicin, and cyclophosphamide (FEC100) followed by paclitaxel.
Sixty-one patients were found to have TNBC, with 23 (37.7%) of these with AR positivity. Though the
numbers were quite small, the pCR rates were lower in AR-positive versus negative disease at 17.4%
(n = 4) compared to 63.2% (n = 24) [121]. Notably, the latter AR-negative pCR response was particularly
robust in comparison to the Loibl study, and likely contributed to improved OS and non-recurrence
free survival in AR-negative TNBC in their population [121].
Also, of interest and somewhat opposite to the above studies looking at pCR is a recent article
by Jiang and colleagues in which whole exome sequencing was performed on 29 biopsy samples
obtained prior to treatment of patients who were found to have either a pCR (n = 18) or extensive
residual disease (n = 11) after neoadjuvant chemotherapy with adriamycin, cyclophosphamide and
paclitaxel (ACT). Pathway databases were used to predict the impact of somatic mutations on certain
pathways associated with cancer. Though no single mutation was found to be predictive of response
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to chemotherapy in TNBC, they did find tumors with mutations in the AR pathway and FOXA1
transcription factor networks had a significantly higher pCR (94.1% vs. 16.6%) compared to those
that did not carry such mutations [122]. The FOXA1 transcription factor is thought to be activated by
AR signaling [123]. It should be noted that the study did not designate if the samples with somatic
mutations in the AR or FOXA1 pathways expressed AR by IHC, which is the surrogate marker of AR
pathway activity in most studies.
9. Treatment Options in AR+ Breast Cancer
9.1. Bicalutamide
As previously described, the mechanism of AR-signaling in breast cancer is quite complex
and depends on the presence or absence of other signaling mechanisms in concert (Figure 2).
Early pre- clinical models have shown both a proliferative effect of androgens on cell activity
and an anti-proliferative effect, leading to studying the therapeutic effects of anti-androgen
medications. Bicalutamide is a non-steroidal peripherally selective anti-androgen that binds AR
as an antagonist [124]. One study showed that in MCF-7 cells transfected with an AR vector, androgens
prevented the cells from proliferating, while the addition of the synthetic anti-androgen bicalutamide
actually reversed this effect, leading to continued proliferation [41]. Another study by Toth-Fejel
and colleagues further differentiated cell lines into ER and AR-positive versus ER-negative and
AR-positive disease. They found ER-negative and AR-positive cells were inhibited by 22% with the
addition of androgen, but that this could be reversed with pre-treatment with bicalutamide. However,
bicalutamide was not studied in the cell line that was ER and AR-positive, thus it was unclear what
effect it might have on cell proliferation (i.e., inhibition of cell proliferation?) [58]. De Amicis and
colleagues studied the interplay between AR expression and response to the anti-estrogen tamoxifen in
the ER and AR-positive MCF-7 cell line. They found in tamoxifen-resistant cells an elevated level of AR
and reduced ER mRNA, essentially showing that AR overexpression was associated with tamoxifen
resistance, possibly by enhancing its agonistic effects rather than antagonist. This resistance could
be overcome with the addition of bicalutamide, which offers interesting therapeutic implications in
tamoxifen resistance cancers in which AR is expressed [59]. Further studies assessing bicalutamide in
treatment of tamoxifen resistance, or as prophylaxis to resistance, in ER and AR-positive disease are
certainly warranted.
There are not many studies that have assessed the role of bicalutamide activity in HER2 amplified
disease. Ni and colleagues though, did show an in vivo ability to block stimulation by androgen and
induce apoptosis with the use of bicalutamide in ER-negative, AR and HER2-positive breast cancer,
giving further evidence of the possible therapeutic effects of anti-androgens in certain AR-positive
breast cancers [28].
Bicalutamide has been studied in TNBC. In addition to identifying the molecular LAR subtype,
Lehmann and colleagues found this subtype to be quite sensitive to bicalutamide [48]. Zhu and
colleagues showed in MSL TNBC cell lines MDA-MB-231 and Hs578T that androgens induce cell
proliferation and inhibits apoptosis in vitro and in vivo and that bicalutamide promotes apoptosis, as
well as other inhibitory effects [125]. Another study aimed at understanding the interplay between
the transcription factor ZEB1, which plays a role in cancer progression by regulating the epithelial
to mesenchymal transition (i.e., increased tumor migration and invasion) in breast cancer, and AR
signaling in TNBC noted that by inhibiting ZEB1, AR expression was decreased and perhaps more
importantly, inhibition of AR signaling with bicalutamide suppressed ZEB1 expression [126]. Mehta
and colleagues analyzed the TNBC cell line MDA-MB-453, which in addition to AR positivity, also
has PTEN and p53 mutations [127]. They identified 10 genes as AR targets using RT-qPCR and ChIP
sequencing techniques and found that androgens promote cell proliferation and decrease apoptosis via
these gene targets. They found that the addition of the anti-androgen bicalutamide could reverse this
effect. Additionally, they hypothesized that the reason for poorer response to adjuvant or neoadjuvant
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chemotherapy in AR-positive TNBC was due to an AR-mediated resistance to apoptosis. The effects
of paclitaxel, 5-fluorouracil and cyclophosphamide in AR-positive TNBC were studied and cells
were found to have significant increases in cell survival and decreased apoptosis in the presence of
androgen and that this could be reversed with the addition of bicalutamide [127]. As previously noted,
patients with TNBC receiving neoadjuvant chemotherapy have been found to have lower pCR rates
when AR-positive and this study provides rationale that perhaps targeting the AR pathway may help
improve pCR rates [116].
 
Figure 2. Drug targets in AR signaling pathway.
Evaluation of the correlation between membrane tyrosine kinase receptors and expression of
AR in TNBC has shown a positive correlation with EGFR, and platelet derived growth factor beta
(PDGFRβ) [128]. The same study found increased PI3K/Akt activity in AR-positive TNBC and found
that co administration of bicalutamide with agents targeting EGFR, PDGFRβ, PI3K/ mammalian target
of rapamycin (mTOR), and ERK pathways led to synergistic activity and provides some rationale to
further evaluate combination therapy in AR-positive TNBC [128]. To further the argument that dual
blockade of AR and PI3K/mTOR inhibition can lead to synergistic effects, is a study by Lehmann and
colleagues. They noted a much higher rate of concurrent clonal phosphatidylinositol-4,5-bisphosphate
3-kinase, catalytic subunit alpha gene (PIK3CA) mutations (40%) in AR-positive TNBC versus
AR-negative (4%), and also that targeting dual targeting of PI3K and AR had an additive inhibitory
effect on tumor growth [108].
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An alternative combination target may include the use of cyclin-dependent kinases 4 and 6 (CDK4
and CDK6). These kinases are activated by cyclin D, and promote cell cycle entry by phosphorylating
proteins that drive the transition from G1 to the S1 phase and when disrupted can lead to unrestricted
cell proliferation in breast cancer [129,130]. Certain preclinical models have shown that resistance
to anti-androgen therapy is linked to a F876L mutation in AR, leading to a change from antagonist
activity to agonist. CDK4/6 inhibitors have been shown to restore activity of anti-androgen treatment
by antagonizing AR F876L [131]. There is currently a phase I/II trial of palbociclib in combination
with bicalutamide for the treatment of metastatic AR-positive TNBC which is accruing (NCT02605486)
(Table 1) [132].
Table 1. Ongoing breast cancer clinical trials.
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Preclinical studies led to a phase II clinical trial evaluating bicalutamide in metastatic ER-negative
and AR-positive cancers as a proof of concept study led by Gucalp and colleagues. Patients with >10%
nuclear expression of AR by IHC were included and treated with bicalutamide 150 mg daily, with
the primary endpoint being clinical benefit rate (CBR) defined as the total number of patients who
showed a complete response (CR), partial response (PR) or stable disease (SD) > 6 months. The study
found the CBR to be 19% for the 26 study participants, driven by SD as there were no CRs or PRs,
and a median progression free survival (PFS) of 12 weeks. Though HER2 status was not an exclusion
criteria, only 1 of the 26 patients had HER2 amplified cancers and 1 of the 5 patients with SD had
initial negative HER2 status that was later considered positive after undergoing a curative intent
mastectomy [133]. A more recent case reported by Arce-Salinas of a patient with recurrent AR-positive
metastatic TNBC, molecular apocrine subtype, had a CR with use of bicalutamide despite heavy
pretreatment with palliative chemotherapy, showing that a CR with anti-androgen therapy alone
does seem to be possible [134]. Briefly, it should be noted that the older nonsteroidal anti-androgen
flutamide, which is less potent than bicalutamide, was studied in two phase II clinical trials in 1988 in
patients with metastatic breast cancer. Neither of these studies yielded promising results, though were
conducted in a patient population unselected for AR, ER, PR or HER2 status [135,136].
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9.2. Enzalutamide
Enzalutamide is a newer generation nonsteroidal anti-androgen that binds the androgen receptor
with greater affinity than bicalutamide, decreases nuclear translocation, and impairs binding to
androgen response elements and co-activators [137]. An interesting study by Cochrane and colleagues
examined the effects of enzalutamide in AR-positive breast cancer in both ER-positive and ER-negative
tumors. The study found both in vitro and in vivo that enzalutamide inhibits androgen mediated
growth in both ER-positive and ER-negative cancers expressing AR. Interestingly, enzalutamide also
inhibited estrogen-mediated growth in ER-positive, AR-positive cells, whereas previous preclinical
studies have shown bicalutamide to increase cell proliferation in this cell population [56]. A more
recent study by D’Amato and colleagues had similar results, and found AR inhibition reduced estradiol
mediated proliferation in ER-positive and AR-positive disease [138]. These studies suggest that the AR
signaling pathway may be a potential target in ER-positive disease as well, which has not been shown
with bicalutamide. Along these lines, a number of studies have shown that when ER is expressed in
breast cancer, AR positivity is associated with tamoxifen-resistance. Ciupek and colleagues suggest
that in the presence of AR, tamoxifen leads to AR-mediated EGFR activation as a mechanism of
resistance. This could be blocked with the use of enzalutamide and the EGFR inhibitor gefitinib and
may provide a viable preventive or salvage therapy in ER-positive, AR-positive disease treated with
tamoxifen [60].
In TNBC, an in vivo study by Barton and colleagues analyzed 4 TNBC cell lines (SUM159PT,
HC1806, BT549, and MDA-MB-231) and noted that the anti-androgen enzalutamide was not only
active in the LAR molecular subtype, but also in the M, MSL and BL2 subtypes. They noted that
AR activation up-regulates the EGFR pathway, as in ER-positive disease noted above, which could
be blocked by enzalutamide and makes it potentially applicable to a broader range of TNBC [47].
Combination therapy with anti-androgens and mTOR inhibition has shown some promising results
and Robles and colleagues found additive anti-proliferative effect in the LAR molecular subtype in the
MDA-MB-453 cell line and LAR xenograft model [139]. Given that mTOR is downstream from PI3K,
this further strengthens the rationale that the PI3K is important in TNBC and a possible target with
concurrent enzalutamide as well. There is currently a phase IB/II clinical trial that is in process, which
is assessing the CBR at 16 weeks of the PI3K inhibitor taselisib in combination with enzalutamide in
advanced TNBC (NCT02457910) [140].
Also of importance is that enzalutamide has been associated with immunogenic modulation,
which may increase the susceptibility of tumor cells to immune-mediated cell death [141]. A study
by Kwilas et al. showed growth inhibition with enzalutamide and abiraterone in breast cancer cells,
with improved immune mediated lysis. They found this increase in immune mediated activity to be
associated with increased cell surface expression of tumor necrosis factor-related apoptosis-inducing
ligand (TRAIL) and reduction in expression of osteoprotegerin (OPG) [142]. Enzalutamide and
the anti-androgen abiraterone acetate, which inhibits the CYP17A1 enzyme involved in androgen
biosynthesis, decreased cell proliferation and enhanced immune mediated lysis in AR-positive disease.
Even more interesting, both of these medications enhanced immune mediated lysis even in AR-negative
disease [142]. An earlier study by Kwilas and colleagues also showed increased immune activity
when a pox viral based cancer vaccine was combined with enzalutamide in in vivo mice models, and
furthers the idea that this medication increases immunogenic modulation and may have importance in
newer immunotherapy trials [143]. There is currently an ongoing phase II clinical trial evaluating dual
therapy with enzalutamide and the monoclonal antibody trastuzumab in HER2 amplified, AR-positive
metastatic breast cancer with a primary endpoint of CBR at ≥24 weeks (NCT02091960) [144]. Although
it would be difficult to tease out the immunogenic modulation of enzalutamide in this study, it may
boost the effect of trastuzumab. Enzalutamide is also currently being assessed in several AR-positive
TNBC clinical trials, either alone or in combination, which will be discussed below.
Traina and colleagues shared preliminary results of a phase II clinical trial assessing enzalutamide
in AR-positive metastatic TNBC [145]. The single-arm, non-randomized phase II trial assessed patients
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with TNBC who screened for AR positivity as defined by AR expression greater than 0% by IHC.
A total of 118 women were enrolled in the trial, with a majority of patients treated in the first or second
line setting. The primary end point was CBR at 4 months, which was 35% at that time point, and
29% at 6 months. The median PFS was 14 weeks, and included 2 CRs and 5 PRs and the medication
was well tolerated without any new safety concerns [145]. As a side benefit, the study also led to the
development of a predictive assay termed PREDICT AR, in which they noted patients who responded
to enzalutamide had a distinct gene expression profile, and had a better CBR of 36% at 24 weeks
compared to 6% in patients who were PREDICT AR-negative [145,146].
As previously discussed, patients with AR-positive TNBC have a relatively low pCR rate of
12.85% [116]. Aimed at this group is a phase IIB clinical trial in the neoadjuvant setting looking at
the use of enzalutamide with weekly paclitaxel with a primary endpoint of pCR that is meant to
hopefully improve the response rate (NCT02689427) [147]. There is also a feasibility study accruing
that is looking at the use of 1 year of adjuvant enzalutamide for the treatment of patients with early
stage, AR-positive TNBC (NCT02750358) [148].
9.3. Abiraterone
Abiraterone acetate is a selective, irreversible and potent inhibitor of 17α-hydroxylase and
17,20-lyase (CYP17) enzymatic activity and is commonly used in castration-resistant prostate cancer
(CRPC) [149]. It has also been studied in ER-positive metastatic breast cancer with at least part of the
rationale being that CYP17 inhibition decrease the synthesis of both androgens and estrogens and
may be more effective than an AI alone. A phase II, randomized open-label clinical trial assessing
297 patients with metastatic ER-positive breast cancer looked to clarify the role of abiraterone, though
AR positivity was not a stratification factor. Eligibility required sensitivity to an aromatase inhibitor
(AI) prior to disease progression and AR positivity was reportedly balanced between treatment
arms, including abiraterone plus prednisone, versus abiraterone with exemestane versus exemestane
alone with primary end point of PFS. Abiraterone either in combination with prednisone or with
exemestane did not improve PFS, compared to exemestane [150,151]. Another phase II clinical trial
assessed the safety and efficacy of abiraterone plus prednisone in molecular apocrine AR-positive
metastatic breast cancer with a primary endpoint of CBR at 6 months. The CBR was found to be 20%,
which included 1 CR and 5 SD, although the overall response rate was only 6.7% with a median PFS
2.8 months [152]. At the time of analysis, five patients remained on treatment with clinical benefit
ranging between 6.4 and 24 months. There are currently two other clinical trials assessing abiraterone in
breast cancer. A phase I/II UK study evaluated abiraterone in postmenopausal women with advanced
metastatic ER or AR-positive breast cancer. This study is no longer recruiting, and results are awaited
(NCT0075585) [153]. A phase I, open-label, multicenter trial evaluating abiraterone in combination
with the PI3K inhibitor AZD8186 in a variety of solid malignancies, including TNBC, is still recruiting
patients (NCT01884285) [154].
9.4. Newer Anti-Androgens
A number of other novel nonsteroidal anti-androgen agents are currently under analysis.
Orteronel (TAK-700) is a reversible, selective CYP17 inhibitor, similar to abiraterone with a higher
specificity for 17,20 lyase inhibition and known activity in CRPC [155,156]. This agent is being studied
in a phase II clinical trial in patients with AR-positive metastatic breast cancer, with 2 separate cohorts
assessing ER-positive disease and TNBC (NCT01990209) [157]. Seviteronel (VT-464) is a similar newer
generation CYP17 inhibitor, with a current phase I/II study accruing patients with advanced breast
cancer with separate cohorts for ER-positive disease and TNBC (NCT02580448) [158]. There are more
potent and novel anti-androgens in development. A recent study by Kandil and colleagues showed up
to 30 to 50 fold improvement in activity with the use of pure novel AR antagonists with 7-substituted
umbelliferone derivatives over enzalutamide and bicalutamide respectively [159]. These agents clearly
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require further testing, but purer compounds may be important in AR-positive TNBC in the future if
current clinical trials confirm a significant signal.
9.5. SARMs
Somewhat contradictory to other studies presenting therapeutic options, Narayanan and
colleagues demonstrated in the MDA-MB-231 cell line that nonsteroidal, tissue selective androgen
receptor modulators (SARMs), rather than anti-androgens could inhibit breast cancer growth [160].
They chose the genomically stable MDA-MB-231 TNBC cell line, in which they transfected an AR
plasmid, over the often used MDA-MB-453 cell line as the latter is known to express mutated AR, PTEN
and p53 that could potentially confound results. Both in vitro and in vivo, they found the addition of
SARMs inhibited intratumoral expression of genetic pathways that promote breast cancer development,
metastasis-promoting paracrine factors (i.e., IL6, MMP13) and cell proliferation [160]. Based largely
on this study, a phase II, multicenter clinical trial investigating the efficacy and safety of the SARM
enobosarm (GTx-024) in advanced AR-positive TNBC is currently underway (NCT02368691) [161].
9.6. Other Drugs
Poly ADP-ribose polymerase (PARP) inhibitors are a group of agents aimed at the PARP1 protein
that acts to repair single strand breaks in DNA. These breaks occur frequently in the cell cycle, and
rely on mechanisms such as PARP1 activity to resolve the errors via the base excision repair pathway.
Patients with breast cancer susceptibility gene 1 (BRCA1) and 2 (BRCA2), as well as partner and
localizer of BRCA2 (PALB2) mutations are susceptible to DNA double strand breaks, as these genes
normally function to correct such breaks. In patients with these underlying mutations, the addition of
a PARP inhibitor leads to cell death due to dysfunction of both repair pathways [162]. In regards to
AR signaling and PARP inhibition, there is minimal data. However, Park and colleagues identified
that BRCA1 increased ligand-dependent AR transactivation, as well as synergistically combined
with co-activators of the AR pathway, leading to increased efficacy. They postulated that lack of the
BRCA1 gene would reduce AR-dependent signaling [163]. Shin et al. found non-mutated BRCA2
synergizes with the co-activator p160 to enhance AR-mediated transcription, similar to BRCA1, and
was associated with an anti-proliferative effect [164]. A small study evaluated 41 patients with BRCA1
mutations and 14 with BRCA2 mutations and analyzed AR status by IHC and found only 12% of
BRCA1, and 50% of BRCA2 mutated tumors expressed AR [165]. Another study found AR positivity
in 13 of 43 (30%) BRCA1 and 14 of 18 (78%) of BRCA2 mutated tumors [166]. At present, there have
been no preclinical or clinical studies looking at PARP inhibition specifically in AR-positive disease.
Although PARP inhibition has become an important tool in breast cancer treatment, especially in
BRCA1, BRCA2 or PALB2 mutated cells, its activity needs to be better defined in relation to the AR
pathway in preclinical models before we can identify if there is significant rationale for their use in
AR-positive disease.
Bromodomain and extraterminal (BET) signaling has emerged recently as an important pathway
in AR signaling. These proteins, which are expressed by the majority of cancer cells, are involved
in epigenetic activity and chromatin “reading” and include BRD2, BRD3, BRD4 and BRDT [167].
BRD4 has a significant role in RNA polymerase II transcription by helping to recruit the positive
transcription elongation factor P-TEFb [168,169]. Previous studies established the anti-cancer
activity of BET inhibitors that target BRD4, which was further evaluated in CRPC by Asangani
and colleagues [167]. They found BET inhibition with the small molecule JQ1 to induce G0-G1 cell
cycle arrest, apoptosis and transcriptional down-regulation of anti-apoptotic BCL-xl in AR-positive
cells. Moreover, they noted a direct AR-BRD4 interaction, which was inhibited by JQ1 leading to a
more robust anti-proliferative effect than enzalutamide [167].
BET signaling has been studied in breast cancer as well. The ER-positive MCF-7 breast cancer
cell was noted to have increased T-bet activity associated with insulin exposure, which also was
associated with tamoxifen-resistance [170]. Feng and colleagues furthered this understanding by
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noting that ER signaling was positively associated with WHSC1, a histone methyltransferase recruited
to the ERα gene by BET proteins. They found this pathway could be blocked with BET inhibition
with JQ1 and overcome tamoxifen-resistance in cell culture and xenograft models [171]. Further,
Sengupta et al. noted JQ1 suppression of estrogen-induced growth and transcription in MCF7 and
T47D cell lines [172]. BET signaling has been studied in HER2 amplified breast cancer, using the
cell lines HCC1954 and MD-MBA-361 in which it was shown that BET inhibition could overcome
lapatinib resistance associated with kinome reprogramming [173]. Other studies have found that
resistance to PI3K inhibitors and mTOR inhibitors is associated with feedback activation of tyrosine
kinase receptors in metastatic breast cancer and can be overcome with dual use of PI3K and BET
inhibition or mTOR and BET inhibition [174,175]. Borbely and colleagues noted activity of combination
therapy with a histone deacetylase (HDAC) inhibitor and BET inhibitor JQ1 by increasing activity
of ubiquitin-specific protease 17 (USP17), which down-regulated the Ras/MAPK pathway and thus
reduced cell proliferation in 2 separate TNBC (MDA-MB-231 and BT549) and 2 ER-positive (MCF7
and T47D) cell lines [176]. Synergy with the chemotherapeutic agents docetaxel, vinorelbine, cisplatin
and carboplatin has been shown with JQ1 in preclinical evaluation of several breast cancer cell
lines [177]. An association with hypoxia responsive genes and angiogenesis has been noted, which
can be down-regulated with BET inhibition in cell culture and xenograft models [178]. Finally, Sahini
and colleagues noted that BET inhibition results in growth suppression of TNBC independent of their
intrinsic molecular subtype [179]. BET signaling certainly is an exciting area in breast cancer. However,
a limitation to all the above mentioned studies regarding BET and breast cancer is that none of them
further clarify the role of AR signaling in the effects that are being described. Given the findings in
prostate cancer showing clear activity with AR signaling and the BET pathway, it is important to clarify
the role of AR and BET signaling in breast cancer in order to identify its role as a therapeutic target.
Currently, there are three early phase clinical trials assessing BET inhibitors in TNBC along with other
malignancies [180–182].
10. Discussion
Our study aimed to describe advances in understanding of the complex AR signaling pathways
in relation to co-receptor signaling, as well as prognostic and therapeutic implications. However, there
are some inherent limitations to the data presented. In particular, several of the above-mentioned
pre-clinical studies utilize commercially available breast cancer cell lines. Though there are advantages
to the use of these classic cell line models, over time multiple cycles of cell cultures can select for
certain subclones that can create variability in genetic and phenotypic expression across labs [183].
For example, in one study the cell line MDA-MB-453 notably had a homozygous deletion in TP53,
a homozygous PTEN missense mutation and a PI3K mutation and it is unclear if these are preserved
changes in the cell line or unique to the specific version from that particular lab [127]. Several studies
do utilize cells fresh tumor samples to help corroborate their findings, but many do not and thus
reproducibility of the findings is a question.
Additionally, most in vitro studies do not distinguish whether the cell line, or cells from fresh
biopsy material are early stage or metastatic in origin. Independent review of commercially available
cell lines reveals that most are metastatic in origin, and often from malignant pleural fluid, which some
might argue indicates particularly aggressive biology that does not reflect the general population [183].
Lobular carcinoma represents approximately 10% of all invasive breast cancer, and none of the above
studies looking at AR signaling studied these tumors, raising concerns of the generalizability of
findings in these patients. In terms of co-receptor expression, ERα is known to be proliferative in
breast cancer but ERβ is less understood, especially in relation to AR. It is possible that ERβ, as another
steroid receptor, might have importance given the competitive activity between AR and ER as steroid
hormones. There is also controversy over what constitutes IHC positivity of AR expression, with cut
off values of ≥1%, ≥5% or ≥10% depending on the study. This lack of consensus guidelines makes it
difficult to interpret prognostic value of AR expression in comparison between studies. Lastly, several
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of the larger studies and meta-analyses do not distinguish differences in prognostic value of AR in
relation to co-receptor expression of ER, HER2 or in TNBC. These are somewhat offset by the multiple
studies reviewed that do distinguish between these different subtypes of breast cancer.
AR remains an area of study that is rapidly evolving. The current study is a comprehensive
review of the available data regarding the pathophysiology of AR-positive breast cancer, and makes
important efforts to discuss the nuanced differences between AR-positive breast cancers in relation to
co-receptor status. Also, prognostic implications of AR are discussed in the same manner, noting clear
differences in ER-positive, HER2 amplified and TNBC. Therapeutic targets along the AR pathway are
discussed with emphasis on novel agents and combination therapy with promising results. As our
understanding of the complexities of AR signaling in regards to tumorigenesis becomes more refined,
we will better be able to use AR expression as a prognostic marker and therapeutic target.
11. Conclusions
The identification of the AR signaling pathway in breast cancer has led to an interesting and
growing field, especially in regards to basic and translational research. Not only have we identified
important prognostic associations with ER-positive, HER2 amplified and TNBC, but also potential
therapeutic targets either with monotherapy or in unique combinations. Clearly, there is still significant
room to expand the field and grow our understanding of these complex pathways, but early work
is encouraging regarding the ability to use targeted therapies in new and exciting ways and we look
forward to future of the field.
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Abstract: Molecular and histopathological profiling have classified breast cancer into multiple
sub-types empowering precision treatment. Although estrogen receptor (ER) and human epidermal
growth factor receptor (HER2) are the mainstay therapeutic targets in breast cancer, the androgen
receptor (AR) is evolving as a molecular target for cancers that have developed resistance to
conventional treatments. The high expression of AR in breast cancer and recent discovery and
development of new nonsteroidal drugs targeting the AR provide a strong rationale for exploring it
again as a therapeutic target in this disease. Ironically, both nonsteroidal agonists and antagonists for
the AR are undergoing clinical trials, making AR a complicated target to understand in breast cancer.
This review provides a detailed account of AR’s therapeutic role in breast cancer.
Keywords: androgen receptor; breast cancer; selective androgen receptor modulator (SARM);
estrogen receptor; triple-negative breast cancer (TNBC)
1. Introduction
Over 240,000 women will develop breast cancer and ~40,000 will die from the disease in the
United States in 2016 [1]. Globally, about 1.7 million women were diagnosed with breast cancer in
2012, emphasizing the urgent need for effective and safe therapeutic approaches [2]. Although the
majority of breast cancers are slow growing or indolent [3], a subset acquires an aggressive phenotype
due to a variety of reasons. Molecular, genotypic, and phenotypic studies clearly provide evidence for
the heterogeneity of breast cancer with multiple subtypes and classifications [4,5].
2. Breast Cancer Classification
For therapeutic purposes, breast cancer has been historically classified based on the expression or
lack of expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth
factor receptor (HER2) [6]. Breast cancers expressing these three targets are classified as triple-positive,
while those that lack their expression are classified as triple-negative (TNBC).
In 2000, Perou et al. completed a genome-wide molecular analysis of patient specimens to classify
breast cancer based on cell-type and molecular signature [4]. Breast cancer specimens that expressed
keratin 8/18, markers of luminal epithelial cells, were classified as luminal breast cancers, while those
that expressed keratin 5/6, markers of basal epithelial cells, were classified as basal breast cancer.
Further, using gene expression signatures, breast cancers were classified into luminal A, luminal B,
HER2-enriched, and basal-like (BLBC).
The luminal A subtype is characterized by the expression of ER, lack of HER2, and a lower
expression of the proliferative marker, Ki67 (ER+/HER2-/Ki67 low). The luminal A subtype is an
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indolent disease that is typically treated with hormonal therapies that either antagonize or degrade ER
or inhibit aromatase, an enzyme critically involved in biosynthesis of estradiol.
The luminal B subtype is characterized by the expression of ER, lack of HER2, and high Ki67
(ER+/HER2-/Ki67 high). Although luminal B is predominantly HER2-negative, a subset of it expresses
HER2 while still retaining other characteristics of HER2-negative luminal B. Markers of proliferation
such as cyclin B1 (CCNB1), Ki67 (MKI67), and Myb proto-oncogene like 2 (MYBL2) [7,8] and
proliferative growth factor signaling [9,10] are highly expressed in the luminal B subtype. The luminal
B subtype is associated with high recurrence, poor disease-free survival [7] with much lower five- and
ten- year survival rates than the luminal A subtype [7,11,12], and failure to respond consistently to any
existing treatments [13].
The HER2 subtype is comprised of tumors that are ER-negative and HER2-positive [4].
This subtype is treated with HER2 inhibitors such as traztuzumab. The HER2 subtype frequently
metastasizes to brain [14], escaping further inhibition by HER2-targeting antibodies that seldom cross
the blood-brain barrier due to their large size.
The BLBC subtype is the most aggressive subtype of breast cancer and is associated with high
mortality in women. While 75%–80% of the basal subtype is TNBC, the remaining 20%–25% express
ER and/or HER2 [15]. It is still regarded as TNBC for therapeutic purposes and treated with a cocktail
of chemotherapeutic agents that provide a pCR of about 40%–45% [16]. The cancer genome atlas
(TCGA) studies indicate that the basal subtype has several features, including a high percentage of
p53 mutations that confer an ovarian cancer phenotype rather than breast cancer [17].
3. TNBC Sub-Classification
Genome-wide studies to understand the underlying mechanisms for the aggressive phenotype of
TNBC and to identify new therapeutic targets led to the classification of TNBC into six subtypes [5],
including: Basal-like (BL1 and BL2) subtypes that are enriched in genes representing cell cycle,
cell division, and DNA damage response. These two subtypes also express high levels of Ki67 at
about 70% compared to 42% for other subtypes. Immunomodulatory (IM) subtype that is enriched in
genes representing immune cell signaling. Mesenchymal (M) and mesenchymal stem cell like (MSL)
subtypes that are enriched in pathways involved in cell motility, kinases, and differentiation. Luminal
Androgen Receptor (LAR) subtype with high expression of Androgen Receptor (AR) mRNA and
enrichment of hormonal signaling.
This subtyping provides an opportunity to develop focused therapeutics and conduct clinical
trials in which the subjects belong to a particular subtype.
4. Androgen Receptor
The AR is a member of the nuclear hormone receptor family of ligand-activated transcription
factors that is activated by androgen (i.e., testosterone or its locally synthesized and more potent
metabolite, dihydrotestosterone (DHT). The AR gene is located on the X chromosome at q11 and
contains eight exons encoding for an N terminus domain (NTD), a DNA binding domain (DBD), a hinge
region, and a ligand binding domain (LBD). The NTD contains the activation function 1 domain (AF-1)
that retains most of the AR activity [18]. The DBD contains two zinc finger motifs that recognize
consensus androgen response elements (AREs) and anchoring of the AR to recognized sequences [19].
The hinge region is responsible for nucleo-cytoplasmic shuttling of the AR and the LBD that contains
the ligand binding pocket is important for ligand recognition. The LBD of the AR contains 11 helices
(unlike other receptors that contain 12 helices as the AR lacks helix 2) and the AF-2 domain [20].
The unliganded AR is maintained in an inactive complex by heat shock proteins, HSP-70 and
HSP-90. Upon ligand binding, the HSPs dissociate from the AR enabling it to translocate into the
nucleus and bind to DNA elements that are located both proximal and distal to the transcription
start site [21]. Once bound to DNA, the AR recruits coactivators and general transcription factors
to alter the transcription and translation of the target genes. While agonists recruit coactivators to
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augment transcription and translation of target genes, antagonists either recruit corepressors, prevent
coactivators from associating with the AR, or retain the AR in the cytoplasm resulting in inactive AR.
5. Prognostic Value of the AR in Breast Cancer
Perhaps surprisingly, the AR is the most widely expressed nuclear hormone receptor in breast
cancer with about 85%–95% of the ER-positive and 15%–70% of the ER-negative breast cancers
expressing AR. In a study conducted with 2171 patient specimens, AR was found to be expressed in
77% of invasive breast carcinomas [22]. About 91% of the luminal A subtype tumors were positive
for the AR, while 68% of the luminal B and 59% of the HER2 subtypes were positive for the AR.
In addition, 32% of BLBCs expressed the AR in this cohort of 2171 patient specimens [22]. Interestingly,
the study found an inverse correlation between the AR expression and tumor size, lymph node status,
and histological grade. A higher proportion of the AR-positive tumors had smaller size compared
to AR-negative tumors (24.6% vs. 15.8% for tumors less than 1 cm). Similarly, the majority of the
AR-negative tumors were histological grade 3 tumors, while AR-positive tumors typically were
histological grades 1 and 2 [22].
A review of a database containing data from 19 studies with a total of 7693 women demonstrated
that the AR is expressed in 61% of the patients [23]. While 75% of the ER-positive tumors expressed
AR, only 32% of the ER-negative breast cancers expressed the AR [23]. Tumors that expressed the AR
were associated with improved overall survival (OS) and disease-free survival (DFS) compared to
AR-negative tumors [23]. Considering the significance in this finding, the authors recommended that
the AR be considered as one of three prognostic markers to classify breast cancers as triple-positive
(ER, HER2, and AR-expressing) or triple-negative (ER, HER2, and AR-negative). Since PR is an
ER-target gene, PR is most likely to align with ER expression pattern and hence was logical to exclude
from the list of prognostic markers. These results were reproduced in other studies conducted in
different patient cohorts around the world [24–29], including one clearly showing that expression
of the AR was associated with reduced recurrence of the disease and reduced incidence of death in
TNBC [28].
Noh et al. included 334 ER-negative HER2-positive or -negative breast cancers in a study to
evaluate the expression of AR and clinical outcome [30]. Most of the AR-negative breast cancer patients
were younger and had higher Ki67 compared to AR-positive breast cancer patients. While 27% of the
TNBC patients were AR-positive, 53% of the ER-negative HER2-positive patients were AR-positive.
Metabolic markers such as carbonic anhydrase (CAIX), which are associated with shorter DFS and OS,
were significantly lower in AR-positive TNBC and ER-negative tumors [30].
One of the breast cancer subtypes where AR’s prognostic value was debated is the molecular
apocrine type [31]. Molecular apocrine breast cancers, which constitute about 5%–10% of the
breast cancers, are ER- and PR- negative [31,32]. The lack of these hormone receptors makes
them unresponsive to associated hormonal therapies. One of the unique features of the molecular
apocrine breast cancers is that they express AR, potentially making AR a valuable prognostic and
therapeutic target [5]. Since AR and androgens increase the proliferation of a molecular apocrine
breast cancer cell line, MDA-MB-453, it is widely perceived, albeit falsely, that AR is an unfavorable
therapeutic target and prognostic marker in molecular apocrine subtype [33,34]. However, a study
compared 20 molecular apocrine cancers with 26 non-apocrine cancers for AR expression and other
clinical features [35]. All apocrine carcinomas were AR-positive, while all non-apocrine tumors
were AR-negative. While apocrine tumors had grades between G1 and G3 and low T stage (TNM
classification where T corresponds to tumor size), all non-apocrine tumors were G3 and high T stage.
In addition, 80% of the apocrine tumor patients showed no disease-related mortality. These results
present additional evidence to support the idea that the AR is a good prognostic marker with potentially
favorable function in breast cancer.
In addition to measuring AR expression, some studies measured the expression of androgen-
synthesizing enzymes such as 17βHSD5 (also known as AKR1C3) and 5α-reductase. 17βHSD5 converts
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the weaker androgen, androstenedione, to a more potent testosterone, while 5α-reductase further
amplifies the activity by converting testosterone to the more highly potent DHT [36]. McNamara et al.
evaluated 203 TNBC specimens from Thailand and Japan in a study to measure the expression
of the AR and androgen-synthesizing enzymes [37]. While 25% of the patients were AR-positive,
72% were 5α-reductase-positive and 70% were 17βHSD5-positive. AR expression inversely correlated
with Ki67 staining. Co-expression of the AR and androgen-synthesizing enzymes negatively correlated
with Ki67 staining. Although no significant improvement in OS and DFS was observed in the AR- and
5α-reductase- positive cohort, the AR-negative 5α-reductase-positive cohort had worse survival in
an 80 month follow-up.
A recent study evaluated the expression of AR and other genes in 1141 patient specimens [38].
Nuclear AR expression, which is an indirect measure of activated AR, was associated with favorable
prognosis such as smaller tumor size, lower grade, and overall survival, suggesting that AR activation
is favorable in breast cancer [38]. These observations were more pronounced in the luminal breast
cancer subtypes [38].
An overwhelming number of publications demonstrate that the AR is a favorable prognostic
marker (i.e., that the AR is a protective protein), regardless of the tumor subtype, and suggest that in
most, if not all, cases AR expression is inversely proportional to tumor size, aggressiveness, pathological
grade, and directly proportional to DFS, progression-free survival (PFS), and OS. However, a few
reports have identified a subset of cancers where AR expression is directly proportional to Ki67 staining
and correlates with poorer OS and DFS [39,40]. For example, a study conducted in a Chinese cohort
of 450 breast cancer patients [40] showed that AR expression correlated with an increase in DFS in
luminal breast cancer patients but a decrease in DFS in patients with TNBC. These results further
illustrate the complex role of the AR in breast cancer. This information is summarized in Table 1.
Table 1. Summary of studies showing the prognostic value of androgen receptor (AR) expression in
breast cancer.
Reference Ref Summary
Pistelli et al., 2014 [29] • AR expression in TNBC (n = 81) was inversely correlated with Ki67 (p < 0.0001).
Vera-Badillo et al.,
2014 [23]
• A review of data from 19 studies that included 7693 women.
• AR expression was associated with improved OS and DFS (both in ER + ve and
TNBC) at both 3 and 5 years p < 0.001).
Noh et al., 2014 [30]
• 334 ER − ve (HER2 + ve or −ve) cases were included in this study.
• AR − ve Her2 − ve patients were younger and had higher ki67 than
AR + ve patients.
• Metabolic markers such as CAIX, which are associated with shorter DFS and OS,
were lower in AR + ve Her2 − ve cancers
Sultana et al., 2014 [24]
• Patients (in a study that included 200 women) with AR + ve tumors had higher OS.
• AR + ve ER-ve women had a trend for longer OS and encountered only 2 deaths
(n = 16). On the other hand, AR − ve ER − ve women had shorter OS and had
10 deaths (n = 37).
McNamara et al., 2014 [25]
• AR expression was associated with lower ki67, mostly TNBCs.
• AR was the only correlative marker for ki67 staining (lower)
McNamara et al., 2013 [37]
• 25% (51 samples) of 203 TNBC patients were AR + ve, 72% for 5-α reductase and
70% for 17βHSD5.
• AR negatively correlated with ki67.
• Co-expression of AR and androgenic enzymes negatively correlated with
ki67 staining.
• AR − ve 5αR group had worse survival in an 80 month follow up.
Luo et al., 2010 [26]
• Of 137 TNBC patients 38 were AR + ve. Of 132 non-TNBC patients 110 were AR + ve.
• AR + ve correlated with 5 year survival in TNBC, but not in non-TNBC.
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Table 1. Cont.
Reference Ref Summary
Agoff et al., 2003 [28]
• 89% of ER + ve (n = 19) and 49% of ER − ve (n = 69) tumors were AR + ve.
• Patients with ER − ve and AR + ve tumors were older than AR − ve patients.
AR − ve tumors had higher ki67 staining.
• ER − ve AR + ve tumors were lower grade, smaller and Her-2/neu over-expression.
• In ER + ve tumors AR positivity correlates with PR positivity.
• 84% of ER − ve, AR + ve patients were disease free after treatment, while only
53% of ER − ve, AR − ve patients were disease free after treatment.
• None of the ER-negative, AR-positive patients died, while 4 of ER-negative,
AR-negative patients died.
Qu et al., 2013 [27]
• 109 breast cancer (ER + ve, ER − ve, TNBC) were included in this study.
• AR + ve breast cancers (all types) had better OS and DFS.
• AR was also associated with lower risk of recurrence.
6. AR as Predictor of Therapeutic Response
While the above studies strongly suggest that AR expression predicts favorable prognosis, AR
expression also provides information on the treatment response. In a study evaluating 913 patients,
AR expression was associated with a favorable outcome to treatment [41]. Patients with tumors that
expressed ER, but not AR, failed aromatase inhibitor (AI) therapy earlier. Since aromatase converts
testosterone to estradiol, inhibiting the enzyme will potentially increase intracellular testosterone, an
AR agonist. This observation suggests that activation of the AR is an important factor for sustained
therapeutic outcome with AI. In addition to the above study, an interesting observation [42] indicated
that patients with AR-positive tumors benefited from tamoxifen treatment, whereas patients with
AR-negative tumors had worse outcome.
Loibl et al. evaluated 673 core primary breast cancer biopsies from patients who have received
neoadjuvant chemotherapy [43]. AR was detected in 53% of the entire cohort with 67% in luminal
A and 21% in TNBC. Similar to several other studies, AR expression correlated with better DFS and
OS in both luminal breast cancer and TNBC. However, the pathological complete response (pCR) in
the AR-positive group was only 13%, which is similar to rates observed for the luminal A subtype,
compared to 25% in the AR-negative cohort, which is similar to rates observed in the luminal B or
TNBC subtype. This data indicates that the AR-negative cohort had a better chance of attaining pCR
and provides evidence that, regardless of the breast cancer subtype and ER/PR/HER2 expression,
AR-expressing tumors appear to retain the characteristics of the luminal A subtype when responding
to chemotherapeutic agents. This hypothesis was corroborated by other studies. Lehmann et al. in
their TNBC sub-classification study found that the LAR subtype of the TNBC expressed a luminal
gene expression pattern including luminal markers such as FOXA1, KRT18, and XBP1 [5]. Indolent
AR-positive luminal A subtype has a pCR of only 10% in response to chemotherapeutic agents, while
the BLBC or TNBC tumors have approximately 50% pCR [16,44]. In addition, out of the six molecular
subtypes in TNBC, basal-like is the only subtype that provided a significant association between pCR
and survival after chemotherapy [45].
7. Role of Intracrine Androgen Synthesis in Breast Cancer
Intracrine hormone synthesis in breast and prostate cancers has been recognized in the recent years
as a vital but previously unrecognized driver of continued tumor growth [46–48]. Fernand Labrie’s
elegant work in this area for over two decades shed light on how, why, when, and the extent to which
intracrine hormone synthesis occurs [46,47,49,50]. Studies have shown that estradiol concentrations
were significantly higher intra-tumorally compared to serum and that the levels did not differ between
pre- and post- menopausal women [51]. Also, estradiol concentration was >2 fold higher in breast
carcinoma tissues than in surrounding normal tissues [52]. Recchione et al. determined the serum
and tumor levels of estradiol, testosterone, and DHT in 34 patient specimens [53]. While the levels of
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testosterone were comparable between serum and tumor tissues, the concentration of estradiol and
DHT was much higher in the tumor tissues than in blood [53]. In addition, cancers of the breast and
prostate overcome pharmacological inhibition by synthesizing hormones through unconventional
pathways [54–58]. These data support the importance of intracrine hormone synthesis in breast cancer.
The activation and inactivation of steroid hormones are influenced by a class of enzymes called
hydroxysteroid dehydrogenases (HSD), which catalyze the NAD(P)(H)-dependent oxidoreduction of
the hydroxyl/keto groups of androgens, estrogens and their precursors [59,60] and thereby regulate the
intracellular availability of steroid hormone ligands to their receptors [61]. HSDs modify the 3, 5, 11, 17,
or 20 positions of the steroid backbone [61–63]. Fourteen of these enzymes are classified as mammalian
17β-HSDs [59]. Between 75% and 100% of circulating estradiol in pre- and post- menopausal women,
respectively, is synthesized from adrenal precursors by steroidogenic enzymes (i.e., the 17-βHSD
family and aromatase) [46,64]. One of the fourteen 17-βHSDs important for the activation of adrenal
precursors is aldo keto reductase 1C3 (17-βHSD5 or AKR1C3). AKR1C3 converts estrone to estradiol,
androstenedione (A′dione) to testosterone, and progesterone to 20α-hydroxy progesterone [65–67]
(Figure 1).
Figure 1. Intracrine synthesis of androgens, estrogens, and progesterone. AI: aromatase inhibitor;
?: functional importance in clinical breast cancer is not clear.
Estrogens in pre-menopausal and post-menopausal women are synthesized from their adrenal
androgen precursors, dihydroepiandrosterone sulphate (DHEAS) and dihydroepiandrosterone
(DHEA) [46]. DHEAS and DHEA are converted to androstenedione (4′dione) and then to highly
active androgens and estrogens in peripheral tissues. Tumor protective functions have been attributed
to these adrenal androgen precursors. On one hand, low circulating levels of DHEA and DHEAS
have been found in patients with breast cancer [68]. On the other hand, administration of DHEA and
maintenance of serum DHEA levels similar to that of healthy pre-menopausal women resulted in
significant inhibition of mammary carcinogenesis in rats [69]. Further, DHT was detected at higher
concentrations in breast cancer tissues [53], supporting the hypothesis that a combination of AR
expression and higher DHT levels are associated with a favorable prognosis in AR-expressing breast
cancer tissues.
Together, these lines of evidence suggest that intracrine androgen synthesis, higher androgen
concentrations, and AR expression are strongly associated with a better prognosis, favorable
therapeutic outcome, and a reduction in tumor in patients with AR-positive breast cancers.
8. AR as Therapeutic Target for Breast Cancer
Steroidal androgens were the mainstay of clinical treatment for breast cancer before the discovery
of tamoxifen or other ER antagonists and AIs [70,71]. Early preclinical evidence for the anti-proliferative
effects was generated in 1950s when Huggins and colleagues showed shrinkage of chemically-induced
mammary tumors by ovariectomy or by the administration of DHT, long before either the ER or
AR had been cloned [72–74]. However, the use of androgens was discontinued after the discovery
of ER antagonists or selective estrogen receptor modulators (SERMs) and AIs, owing largely to
the undesirable masculinizing effects of steroidal androgens and the commercial promise of the
newer therapies.
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Despite or perhaps because of plentiful historical evidence, a controversy remains with respect to
whether an AR agonist such as an androgen or an AR antagonist will be effective in treating breast
cancer. The conflict is primarily due to the skewed outcome of experiments performed with preclinical
immortalized cell line models. Below we summarize the clinical and preclinical evidence supporting
the use of both AR agonists and antagonists as treatment options for breast cancer.
9. Preclinical Evidence Supporting the Beneficial Effects of AR agonists in Breast Cancer
Preclinical models to evaluate the role of the AR in breast cancer are highly variable. ZR-75-1 is an
ER-positive luminal A breast cancer cell line that expresses high levels of the AR. Treatment of this cell
line with DHT resulted in significant growth inhibition [75]. DHT inhibited both estradiol-dependent
and estradiol–independent growth completely [75]. Unlike other cell lines, ZR-75-1 responds to
physiologically relevant concentrations of DHT. These anti-proliferative effects were reversed by
hydroxyflutamide, an AR antagonist. These in vitro results were extended in vivo in ovariectomized,
estradiol-supplemented, nude mice bearing ZR-75-1 tumors [76]. In this study, DHT completely
inhibited the tumor growth and even regressed the tumors. Due to very slow growth properties
of ZR-75-1 cells, which is characteristic of ER-positive luminal A tumors, it is difficult to conduct
xenograft studies in this model.
Tilley and colleagues using MCF-7 and T47D ER- and AR- positive luminal breast cancer cell lines
demonstrated that two steroidal androgens (DHT and mibolerone) inhibited the cell proliferation [77].
Although the inhibition of proliferation was not as robust as that obtained in ZR-75-1 cells, the inhibition
was also reversed by AR antagonists [77]. The differences in the magnitude of effects between cell
lines could be due to the level of AR expression. MCF-7 cells have relatively lower AR expression
compared to ZR-75-1 cells. Studies have also shown that androgens induce apoptosis in MCF-7
cells. On the other hand, some studies have also reported growth-stimulatory effects of androgens
in modified MCF-7 cells [78]. Although these results define the variability in cell-based models,
predominantly anti-proliferative effects were observed with androgens in ER- and AR-positive cells.
More convincing results evolved from the dimethylbenzanthracene (DMBA)-induced mammary
carcinogenesis rat model [76]. Rats bearing DMBA-induced mammary tumors regressed significantly
when treated with either strong androgens such as DHT or with weak androgen precursors such
as DHEA, DHEAS, or 4′dione [69,76]. All these in vitro and in vivo results in multiple models
unequivocally prove that AR agonists are inhibitors of ER-positive luminal breast cancers.
When analyzing the preclinical data in TNBC or BLBC models, the landscape is complex and
inconclusive. Most of the data were generated in one ER-negative apocrine breast cancer cell line,
MDA-MB-453. The proliferation of MDA-MB-453 cells or growth of MDA-MB-453 xenografts are
stimulated by androgens and inhibited by AR antagonists [33,79]. It is yet unclear if the mutation in
the AR LBD, p53, and PTEN, and constitutive activation of PIK3CA contribute to this phenotype of the
cells [34,80]. However, ectopic expression of wildtype AR in MDA-MB-231 ER-negative cells restored
the growth inhibitory effects of steroidal androgens and selective androgen receptor modulators
(SARMs), which could be partially reversed by AR antagonists [79].
Barton et al. used TNBC cell lines to evaluate the effect of DHT [81]. Treatment of SUM159PT,
HCC1806, BT549, and MDA-MB-231 cells with 10 nM DHT increased the proliferation of only
SUM159PT, but not the other cell lines, while the proliferation of all cell lines was inhibited by
enzalutamide, a nonsteroidal AR antagonist. The induction of proliferation by DHT in SUM159PT
cells was modest. For unknown reasons, the proliferation of BT549 cells, which express AR at a level
comparable to that of SUM159PT, was not induced by DHT. Growth of all cell lines was inhibited by
AR antagonist enzalutamide or AR siRNA.
Ince and colleagues evaluated the effect of DHT in various ER-negative and TNBC cell lines [82,83].
While 10 nM DHT inhibited the proliferation of AR-positive CAL-148, MFM-223, and BT-474 in
8–10 days, DHT failed to inhibit the proliferation of AR-negative MDA-MB-468, SUM-159PT, or BT-20
cells. This group also evaluated the AR antagonist enzalutamide in these cell lines; some of which
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express the AR and some of which do not express the AR [82]. While enzalutamide inhibited the
proliferation of prostate cancer cell lines with a 5-fold difference in IC50 values between AR-positive
and -negative prostate cancer cell lines, it inhibited TNBC cell lines at comparable concentrations
regardless of the AR expression. These results suggest that the effect of AR antagonist enzalutamide in
TNBC cell lines could be AR independent.
Multiple lines of evidence suggest that the AR is a favorable prognostic indicator in breast
cancer and that AR agonists would be the preferred approach for choice of androgenic treatment for
ER-positive breast cancer. However, data is conflicting in TNBC. With multiple players involved in
TNBC, the action of the AR in TNBC appears to be influenced by cross-talk with other pathways that
differ between cell types and cancer subtypes.
10. Clinical Evidence Supporting the Use of AR Ligands in Hormone-Receptor-Positive
Breast Cancer
Clinical evidence supporting the use of steroidal androgens for breast cancer dates back to the
1940s when testosterone and DHT were used to treat women with breast cancer [71,84]. Several studies
using natural androgens demonstrated that the breast cancers regressed by 30%–50% in pre- and
in post-menopausal women and that these effects were predominant in breast cancers expressing
the AR [85–88]. Tumor growth regression with androgens was also observed after the removal of the
pituitary, establishing that the effect of androgens is mediated directly through the AR expressed in
the breast cancer tissue rather than through an effect on the hypothalamus pituitary hypogonadal
axis [85].
Initial evidence of synthetic steroidal androgens showing growth inhibitory effects in breast
cancer came from the use of fluoxymesterone (Halotestin™) and medroxyprogesterone acetate [89–91].
These synthetic androgens were not only effective in eliciting breast cancer regression, but were also
effective in providing additive effects in combination with tamoxifen, providing a survival advantage
to patients [92]. Although medroxyprogesterone has PR activity, it was effective in TNBCs that do not
express PR, suggesting that the effects were achieved by through the ability of medroxyprogesterone
to activate the AR [93].
Despite the historic and positive clinical results achieved with androgens in breast cancer, there
have been few controlled clinical trials. As such, it remains unclear which subtypes respond best to
androgens and the magnitude of response that can be expected. Ongoing clinical trials with newer
nonsteroidal SARMs and nonsteroidal antiandrogens are poised to fill this knowledge gap. DHT,
testosterone, and fluoxymesterone are steroidal androgens that have androgenic effects not only in
breast, but also in other tissues including uterus, ovaries, skin, and hair follicles. SARMs were first
reported in the late 1990s and subsequently shown to tissue selectively activate the AR in breast,
muscle, and bone, without side effects associated with steroidal androgens [94–98]. Clinical trials with
enobosarm (a nonsteroidal SARM being developed by GTx, Inc., Memphis, TN, USA) are ongoing to
evaluate its efficacy and safety in breast cancer [94,95]. A phase II proof-of-concept clinical trial in 18
ER- and AR-positive breast cancer demonstrated a favorable response of stable disease in 42% of the
evaluable patients. Since all the patients had bone-only disease, partial response or complete response
could not be achieved. These results were presented at the San Antonio Breast Cancer Conference
in 2015. Currently, enobosarm is being tested in Phase II clinical trials in subjects with ER-positive
breast cancer and TNBC (NCT02463032 and NCT02368691, respectively). These early clinical results
corroborate the clinical utility of androgens in breast cancer and suggest that nonsteroidal SARMs
without the side effects commonly associated with steroidal androgens could provide a new avenue of
hormonal therapy for certain subtypes of breast cancer.
Abiraterone acetate is an inhibitor of Cyp17A1 enzyme, an enzyme upstream in the
steroidogenesis pathway. An intriguing result was obtained in a clinical trial with abiraterone in
ER-positive breast cancer patients [99]. The central hypothesis for the study was that a complete
inhibition of androgen and estrogen signaling would provide a better response in breast cancer. In this
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trial, 297 patients were stratified into three arms; with one arm receiving 1000 mg abiraterone plus
5 mg prednisone, one arm receiving 25 mg exemestane alone and one arm receiving exemestane
and abiraterone [99]. The primary end-point was PFS. No significant difference in PFS was observed
when abiraterone was combined with exemestane. The investigators found an increase in serum
progesterone levels, which they believe could have contributed to the lack of clinical activity with
abiraterone. However, recently a publication reported a protective effect of progesterone in breast
cancer [100]. This has to be mechanistically further evaluated to understand why abiraterone did not
provide a better outcome in both ER-positive breast cancer and in TNBC, while enzalutamide did in
a TNBC clinical trial.
11. Clinical Evidences Supporting the Use of AR Ligands in ER-Negative Breast Cancer
The results obtained in MDA-MB-453 cells provided an impetus to evaluate antagonists in breast
cancer, TNBC in particular. Two AR antagonists, bicalutamide and enzalutamide, and a CYP17A1
inhibitor, abiraterone, are currently used in the clinical treatment of prostate cancer. Repurposing
these drugs to treat TNBC should prove straightforward if they are found to be effective in the
clinic. An investigator-initiated clinical trial was conducted to evaluate the efficacy and safety of
bicalutamide [101]. Out of the 424 patients with TNBC screened to determine the AR expression,
only 51 were found to express AR. The trial treated 26 subjects with 150 mg bicalutamide daily.
Although there were no partial or complete responses in the study, stable disease was observed in
two patients for up to 6 months and five patients for greater than 6 months with a clinical benefit rate
(CBR) of 19%. Although a modestly favorable response to bicalutamide was observed, it was interesting
that subjects with tumor specimens that stained strongly for the AR were the least responsive to the
drug while subjects with tumor specimens that stained very weakly for AR demonstrated the most
durable responses.
A follow-up case report of one patient with AR-positive TNBC who relapsed after chemotherapy
and progressed after multiple treatments and surgery and responded to treatment with 150 mg
bicalutamide has also been published [102]. The patient achieved a complete response according to
RECIST 1.1 criteria after 4 months of treatment and responded as long as 12 months when the report
was published.
Based partially on the modest success achieved with bicalutamide, clinical trials in TNBC and
ER-positive breast cancer were initiated with a second generation AR antagonist, enzalutamide.
Enzalutamide has a unique mechanism of action where it blocks AR nuclear translocation and is more
potent than bicalutamide [103]. Although no publications have come out on the trial, data presented in
San Antonio breast cancer conference in 2014 and 2015 and in American Society for Clinical oncology
(ASCO) 2015 annual meeting indicated a favorable response, including partial and complete responses,
in approximately 40% of the patients. Details will emerge when the data are published.
Abiraterone, the CYP17A1 inhibitor, was tested in 34 AR-positive TNBC patients [104]. Patients
were treated with 1000 mg abiraterone combined with 5 mg prednisone. At 6 months a CBR of 20%
was achieved, which included one complete response and five subjects with stable disease of greater
than 6 months. The overall response rate was 6.7% with median PFS of 2.8 months, which was far less
than that observed with enzalutamide. Table 2 has a summary of clinical data.
Table 2. Summary of clinical data on AR agonists and antagonists in breast cancer.
Reference Ref Summary
Hermann and Adair, 1947,
1946 [71,84]
• Treatment of patients with breast cancer with testosterone propionate showed
significant regression of cancer and disappearance of metastases.
• Four out of 11 breast cancer patients treated with testosterone propionate
exhibited favorable response.
Bines et al., 2014 [88]
• Clinical trial with Megesterol acetate, a synthetic progestin that also has
AR agonistic activity was conducted in ER-positive breast cancer patients.
• Clinical benefit rate of 40% was achieved with a duration of clinical benefit of
10 months.
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Table 2. Cont.
Reference Ref Summary
Hermann and Adair, 1947,
1946 [71,84]
• Treatment of patients with breast cancer with testosterone propionate showed
significant regression of cancer and disappearance of metastases.
• Four out of 11 breast cancer patients treated with testosterone propionate
exhibited favorable response.
Bines et al., 2014 [88]
• Clinical trial with Megesterol acetate, a synthetic progestin that also has
AR agonistic activity was conducted in ER-positive breast cancer patients.
• Clinical benefit rate of 40% was achieved with a duration of clinical benefit of
10 months.
Tormey et al.,1983 [90]
• Combination of halotestin and tamoxifen was tested in a clinical trial
conducted in ER-positive breast cancer patients.
• Combination was more effective with 38% partial and complete remission
rates, while tamoxifen had only 15%.
• The duration of response was also longer in the combination group than in
the tamoxifen group.
Gucalp et al., 2013 [101]
• Clinical trial with an AR antagonist, bicalutamide, was performed in
ER-negative breast cancer patients.
• The 6 month clinical benefit rate was 19% and the median PFS was 12 weeks.
The drug was well tolerated.
Arce-Salinas et al., 2016 [102]
• Case report of a patient with ER-negative breast cancer treated
with bicalutamide.
• The patient showed a complete response and the response was also durable
for over a year.
Bonnefoi et al., 2016 [104]
• A clinical trial with abiraterone+prednisone in 30 AR-positive TNBC patients
was performed.
• A clinical benefit rate of 20% was observed in this trial with an overall
response rate of 6.7%.
O’Shaughnessy et al.,
2016 [99]
• Abiraterone acetate was tested alone or in combination with exemestane in
patients with ER-positive breast cancer.
• There was no significant difference in the PFS in the combination arm
compared to the exemestane arm.
12. Mechanisms of Action of the AR in Breast Cancer
Studies from several groups support the concept that AR elicits anti-proliferative effects in
ER-positive breast cancers by antagonizing ER action. Data also suggests that the AR in the presence of
agonists binds to estrogen response elements (EREs) by competing for common binding regions [105]
(Figure 2). Likewise, gonist-activated AR may compete for the limited coactivator pool, thereby
inhibiting ER function by sequestering coactivators from the ER.
Figure 2. Mechanism for inhibition of estrogen receptor (ER)-positive breast cancer by the Androgen
receptor (AR). (A) ER, in the presence of estrogens, binds to estrogen response elements (ERE)
and activates the transcription and translation of target genes. AR, when activated by androgens,
displaces ER and binds to EREs to form an inactive transcriptional complex, leading to inhibition of
ER-target genes; (B) On the other hand, the AR, when activated by androgens, competes with ER for
a limited pool of coactivators. This competition inhibits ER target genes and activates AR target genes.
(Modified version of the figure published by McNamara et al. [25]).
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While the mechanism is, safe to say, modestly clear in an ER-positive setting, it is still ambiguous
in TNBC, especially considering that only one cell line MDA-MB-453 was used for mechanistic studies.
The AR has been shown to cross-talk with several proteins in MDA-MB-453 cells. FOXA1 regulates AR
and ER DNA binding and has significant overlapping binding regions in MDA-MB-453 [106]. Similarly,
androgens were shown to increase extracellular signal-regulated kinase (ERK) and HER2 signaling in
TNBC. Evaluation of PIK3CA kinase mutation in TNBC specimens showed that 40% of the AR-positive
and 4% of the AR-negative specimens had mutations and concurrent amplifications [107,108].
Considering that the MDA-MB-453 cell line also contains a PIK3CA mutation, combination of the AR
antagonist and PI3K/mTOR inhibitors provided additional effects [108]. Androgens in the presence of
the AR have also been shown to abrogate the interaction between epithelial cells and mesenchymal
stem cells to inhibit the paracrine metastatic factors [79].
13. Conclusions
The AR is a favorable prognostic marker and a promising therapeutic target in breast cancer.
In ER-positive breast cancer, the landscape is clear suggesting that androgens and in particular
nonsteroidal AR agonists may provide beneficial effects. On the other hand, data on TNBC is conflicting
with historical data favoring the use of agonists, data from enzalutamide clinical trials supporting
antagonists, and data from abiraterone clinical trials suggesting that inhibition of AR signaling is not
beneficial. This is likely to come down to the subtypes in TNBC where a subtype might respond to
agonists, while another subtype might respond to antagonists. A clear picture can be obtained only
with new preclinical translational models such as the patient-derived xenografts (PDXs) that will
provide clarity. Even in this case, the outcome and mechanisms might vary between patient specimens
and exposure to prior treatments. In addition, the evolving AR splice variants (AR-SVs) have to be
taken into consideration while planning a strategy [109]. Considering that splice variants lack the
LBD, neither agonists nor antagonists that bind to the LBD are likely to provide a meaningful outcome.
Similar to prostate cancer, prolonged treatment of patient’s specimen with enzalutamide resulted in an
increase in the AR-SVs [109]. The AR-SVs in breast cancer is a nascent field requiring additional data
before any direction could be chartered.
Overall the next few years, when results from clinical trials with enobosarm and enzalutamide
will be available, are critical to provide greater clarity on the role of the AR in ER-positive and –negative
breast cancers. Considering that new agonists and antagonists for the AR are available, the emergence
of nonsteroidal drugs targeting the AR as a new hormonal treatment for breast cancer is almost
certainly on the horizon.
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Abstract: Background: Triple-negative breast cancer (TNBC) has a poor prognosis because of frequent
recurrence. Androgen receptor (AR) is involved in the pathogenesis of breast cancer, but its role is
not clearly defined. The aim of this study was to explore the expression of AR and its relationship
with clinicopathologic features in TNBC. Methods: This study investigated 1036 cases of sporadic
invasive breast carcinoma. Immunohistochemical assays were performed to determine the expression
of AR in 190 TNBC samples. The relationships between AR expression and clinicopathologic data
and prognosis were analyzed. Results: In 190 TNBC cases, the prognosis of AR-positive patients
was significantly better (p = 0.019, log-rank) than AR-negative patients, and in multivariate analysis,
AR expression was an independent indicator of good prognosis (p = 0.039, hazard ratio = 0.36).
In patients with disease relapse, AR positivity was significantly correlated with better prognosis
(p = 0.034, log-rank). Conclusions: AR expression may be useful as a subclassification marker for
prognosis in TNBC.
Keywords: triple-negative breast cancer; androgen receptor; prognostic marker; individualized
treatment; intrinsic subtype
1. Introduction
Breast cancer is a highly diverse disease that can be classified into subtypes comprising different
clinical or cellular characteristics. It is commonly subclassified into five subtypes including luminal A,
luminal B, human epidermal growth factor receptor 2 (HER2)-enriched, basal-like, and normal-like,
according to the mRNA expression profile; these breast cancer types are frequently referred to as
the “intrinsic subtype” [1–4]. The basal-like subtype almost always coincides with estrogen receptor
(ER)-negative, progesterone receptor (PR)-negative, and HER2-negative triple-negative breast cancer
(TNBC) [3,5,6]. However, compared to the basal-like classification that is based on a molecular
approach, classifying a tumor as a TNBC is based on an immunohistochemical approach that is
easy to use in actual clinical practice. TNBC is an intractable breast cancer because of its highly
malignant biological potential, including aggressive tumor growth and rapid dissemination to
important organs [7–9]. Patients with TNBC often require systemic anti-cancer therapy to manage
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the progression of the disease. Endocrine and anti-HER2 therapies are ineffective against TNBC as
they lack the molecular targets (ER and HER2, respectively), and chemotherapy is considered the only
remedy for TNBCs [10,11].
However, recent research indicates that TNBC can be further classified according to its genetic
profile. Androgen receptor (AR)-positive TNBC is one of these subtypes [12]. AR-positive TNBC
shows preserved androgenic signaling that could be a possible therapeutic molecular target similar to
ER-positive breast cancer [10,13]. Additionally, AR expression has been identified in 70%–90% of breast
tumors, similar to the frequency of ER expression in breast tumors [14]. Although previous reports
indicated that androgens inhibit the progression of breast cancer [15–17], the precise mechanisms
and clinical significance of AR in breast cancer remain unclear. International phase II studies
aiming to develop a novel individualized treatment strategy against TNBC are currently underway
in AR-positive TNBC [13]. There have been several reports investigating the clinical features of
AR-positive TNBC [10,18–22]; most have found non-aggressive characteristics with a favorable
prognosis compared with AR-negative TNBCs [18,22,23]. However, some reports have suggested
positive correlations between AR positivity and progressive disease or poor prognosis [19]. Thus,
controversies still exist concerning the clinical significance of AR expression in TNBC [24].
In this study, we classified 190 cases of breast cancer with the triple-negative phenotype
from 1036 breast carcinomas. We addressed the significance of clinicopathologic features and AR
expression in order to identify additional prognostic markers that can help identify tumors with more
aggressive behavior.
2. Materials and Methods
2.1. Patient Background
This study investigated a consecutive series of 1036 patients with primary infiltrating breast cancer
who underwent operations at the Osaka City University Hospital from 2000 to 2006. Additionally,
190 patients with TNBC treated at the Osaka City General Hospital were included. All of the patients
who had undergone conservative breast surgery received postoperative radiotherapy to the residual
breast. TNBC patients received adjuvant chemotherapy by either an anthracycline-based regimen
(doxorubicin or epirubicin) or a 5-fluorouracil (5-FU)-based regimen, depending on the stage or risk
of recurrence, in accordance with the National Comprehensive Cancer Network guidelines or the
guidelines for breast cancer in Japan. The median follow-up time was 6.6 years (range, 0.2–8.0 years).
Relapse-free survival (RFS) was defined as the interval between the date of surgical removal of
the primary tumor and the date at which relapse was confirmed or the date of the last follow-up
(for censored patients). Cancer-specific survival (CSS) was the time, in years, from the date of the
primary surgery to the time of breast cancer-related death. Tumors were confirmed histopathologically
and staged according to the TNM classification. This research conformed to the provisions of
the Declaration of Helsinki in 1995. All patients were informed of the investigational nature of
this study and provided their written, informed consent. The study protocol was approved by the
Ethics Committee of Osaka City University (#926).
2.2. Immunohistochemistry
Immunohistochemical studies were performed as previously described [25]. The tumor specimens
were fixed in a 10% formaldehyde solution and embedded in paraffin, after which they were cut into
4-μm thick sections and mounted on glass slides. The slides were deparaffinized in xylene and heated
in an autoclave for 20 min at 105 ◦C and 0.4 kg/m2 in Target Retrieval Solution (Dako, Carpinteria,
CA, USA). The specimens were then incubated with 3% hydrogen peroxide in methanol for 15 min to
block endogenous peroxidase activity, and then incubated in 10% normal goat or rabbit serum to block
nonspecific reactions.
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Primary monoclonal antibodies directed against ER (clone 1D5, dilution 1:80; Dako),
PR (clone PgR636, dilution 1:100; Dako), HER2 (HercepTest™; Dako, Carpinteria, CA, USA),
Ki67 (clone MIB-1, dilution 1:100; Dako), and AR (clone AR441, dilution 1:100; Dako) were used.
The tissue sections were incubated with antibody for 70 min at room temperature or overnight at
4 ◦C (HER2: 70 min; ER, PgR, Ki67, AR: overnight), and were then incubated with horseradish
peroxidase-conjugated anti-rabbit or anti-mouse Ig polymer as a secondary antibody (HISTOFINE
(PO)™ kit; Nichirei, Tokyo, Japan). The slides were subsequently treated with streptavidin–peroxidase
reagent and incubated in phosphate-buffered saline-diaminobenzidine and 1% hydrogen peroxide
(v/v), followed by counterstaining with Mayer’s hematoxylin. Positive and negative controls for each
marker were used according to the supplier’s data sheet.
2.3. Immunohistochemical Scoring
Immunohistochemical scoring was performed by two pathologists who specialized in mammary
gland pathology using the blind method to confirm the objectivity and reproducibility of the diagnosis.
In line with previous studies, the cut-off value for ER and PR positivity was set at ≥1%, and the
same cut-off was adopted for AR positivity. HER2 expression was graded according to the accepted
grading system as 0, 1+, 2+, or 3+. The following criteria were used for scoring: 0, no reactivity or
membranous reactivity in <10% of cells; 1+, faint/barely perceptible membranous reactivity in ≥10%
of cells or reactivity in only part of the cell membrane; 2+, weak to moderate complete or basolateral
membranous reactivity in ≥10% of tumor cells; 3+, strong complete or basolateral membranous
reactivity in ≥10% of tumor cells. HER2 was considered positive if the grade of immunostaining
was 3+, or 2+ with gene amplification via fluorescent in situ hybridization (FISH). In the FISH
analysis, each copy of the HER2 gene and a reference gene (centromere 17; CEP17) was counted.
The interpretation followed the criteria of the American Society of Clinical Oncology (ASCO)/College
of American Pathologists (CAP) guidelines for HER2 immunohistochemistry classification for positive
breast cancer if the HER2/CEP17 ratio was higher than 2.0 [26]. A Ki67-labeling index of ≥14% was
classified as positive [27]. Immunohistochemical scoring of AR expression was evaluated as previously
described [28–30]. AR expression was semi-quantitatively analyzed according to the percentage of cells
showing nuclear positivity: 0, 0%; 1+, 1%–29%; 2+, 30%–69%; 3+, ≥70%. Scores ≥1 were considered
positive, and a score of 0 was negative (Figure 1) [28–30].
Figure 1. Immunohistochemical determination of androgen receptor. Androgen receptor (AR)
expression was semi-quantitatively analyzed according to the percentage of cells showing nucleus
tipositivity: 0, 0% (A); 1+, 1%–29% (B); 2+, 30%–69% (C); 3+, ≥70% (D). AR expression was considered
positive when scores were ≥1, and negative when scores were 0. (×400).
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2.4. Statistical Analysis
Statistical analysis was performed using the SPSS® version 19.0 statistical software package
(IBM, Armonk, New York, NY, USA). Categorical data are reported with numbers and percentage,
and continuous data as median and range. The association between TNBC and other clinicopathologic
variables and the significance of different prognostic markers were analyzed using the chi-squared test
(or Fisher’s exact test when necessary). Association with survival was analyzed by the Kaplan-Meier
plot and log-rank test. The Cox proportional hazards model was used to compute univariate and
multivariate hazard ratios (HRs) for the study parameters with 95% confidence intervals (95% CIs).
In all of the tests, a p-value of less than 0.05 was considered statistically significant. Cutoff values for
different biomarkers included in this study were chosen before statistical analysis.
3. Results
The prognoses of 1036 patients with breast cancer who underwent surgery were analyzed
retrospectively according to pathological subclassification. Among these, 190 (18.3%) were diagnosed
with TNBC, and 846 (81.7%) with non-TNBC. Adjuvant chemotherapy was provided to 138/190 (72.6%)
TNBC patients; 60 patients received an anthracycline-based regimen and 78 received a 5-FU-based
regimen. Patients with TNBC had a significantly higher relapse rate compared to those with non-TNBC
(p < 0.001, log-rank) (Supplemental Figure S1A). Furthermore, patients with TNBC also had a
significantly poorer CSS rate than those with non-TNBC (p < 0.001, log-rank) (Supplemental Figure S1B).
Fifty-six of 190 (29.5%) TNBC tumors expressed AR. No correlation was found between
clinicopathologic characteristics and AR expression (Table 1). Additionally, no significant difference
was observed in RFS rates between patients with AR-positive and -negative TNBC (p = 0.348, log-rank)
(Figure 2A). However, the patients with AR-expressing tumors had significantly better prognoses than
those with non-AR-expressing tumors (p < 0.001, log-rank) (Figure 2B). A statistical analysis of clinical
factors demonstrated that advanced disease stage, tumor diameter ≥2 cm, positive axillary lymph
node metastasis, higher histological grade, and negative tumor AR expression correlated significantly
with poorer RFS. A multivariate analysis demonstrated that positive axillary lymph node metastasis
was an independent and the strongest factor indicating higher risk of recurrence in patients with TNBC
(p = 0.011, HR = 3.30). In addition, AR expression was found to be an independent factor indicating
favorable prognosis in patients with TNBC (p = 0.039, HR = 0.36) (Table 2).
 
Figure 2. Cancer specific and relapse-free survival of patients based on AR expression in triple-negative
breast cancers. AR expression cases had significantly good prognosis compared to the non-expression
cases (A), but no significant difference in relapse-free survival rate was observed between AR-positive
and negative triple-negative breast caluncer (TNBC) cases (B).
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Table 1. Correlation between clinicopathological features and androgen receptor expression in 190
triple-negative breast cancer.
Parameters
Androgen Receptor p Value
Positive (n = 56) Negative (n = 134)
Age at operation
≤55 27 (48.2%) 57 (42.5%)
>55 29 (51.8%) 77 (57.5%) 0.473
Stage
1 16 (28.6%) 43 (32.1%)
2–4 40 (71.4%) 91 (67.9%) 0.633
Tumor size (cm)
≤2 21 (37.5%) 54 (40.3%)
>2 35 (62.5%) 80 (59.7%) 0.719
Lymph node status
Negative 34 (60.7%) 81 (60.4%)
Positive 22 (39.3%) 53 (39.6%) 0.973
Lymphatic invasion
Negative 44 (78.6%) 91 (67.9%)
Positive 12 (21.4%) 43 (32.1%) 0.140
Vascular invasion
Negative 56 (100.0%) 129 (96.3%)
Positive 0 (0%) 5 (3.7%) 0.171
Histologic type
IDC 48 (85.6%) 116 (86.6%)
Special type 8 (14.3%) 18 (13.4%) 0.876
Histological grade
1–2 28 (50.0%) 55 (41.0%)
3 28 (50.0%) 79 (59.0%) 0.257
Ki67
Negative 24 (42.9%) 57 (42.5%)
Positive 32 (57.1%) 77 (57.5%) 0.968
IDC, invasive ductal carcinoma.
Table 2. Univariate and multivariate analysis with respect to progression free survival in
190 triple-negative breast cancers.
Parameters
Univarite Analysis Multivariate Analysis
Hazard Ratio 95% CI p Value Hazard Ratio 95% CI p Value
Androgen receptor
0.34 0.13–0.87 0.025 0.36 0.14–0.95 0.039Positive vs. Negative
Pathological stage
2.54 1.04–6.22 0.041 0.40 0.62–2.54 0.329I vs. II and III
Tumor size (cm)
2.46 1.11–5.45 0.027 2.71 0.63–11.77 0.183≤2 vs. >2
Lymph node status
3.39 1.67–6.88 0.001 3.30 1.32–8.25 0.011n0 vs. n1, n2, n3
Lymphatic invasion
1.94 0.99–3.75 0.054 1.23 0.65–2.66 0.565ly0 vs. ly1, ly2, ly3
Histological grade
2.36 1.01–5.21 0.034 1.78 0.79–4.01 0.1621, 2 vs. 3
Among 43 patients who suffered from disease relapse, 10 (23.3%) had AR-positive TNBC.
When CSS after the relapse was investigated, patients with AR-positive TNBC had a significantly better
prognosis than those with AR-negative TNBC (p = 0.034, log-rank) (Figure 3). However, there were
no clinical features or pathological characteristics observed that may have influenced the increased
survival rate in patients with AR-positive TNBC in comparison with those with AR-negative TNBC
(Table 3).
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Figure 3. In relapse cases of TNBC. AR-positive TNBC had significantly good prognosis compared to
negative cases.
Table 3. Correlation between clinicopathological features and androgen receptor expression among
43 relapsed cases in 190 triple-negative breast cancer.
Parameters
Androgen Receptor p Value
Positive (n = 10) Negative (n = 33)
Age at operation
≤55 5 (50.0%) 20 (60.6%)
>55 5 (50.0%) 13 (39.4%) 0.551
Stage
1 2 (20.0%) 8 (24.2%)
2–4 8 (80.0%) 25 (75.8%) 0.575
Tumor size (cm)
≤2 3 (30.0%) 9 (27.3%)
>2 7 (70.0%) 24 (72.3%) 0.579
Lymph node status
Negative 5 (50.0%) 14 (42.4%)
Positive 5 (50.0%) 19 (57.6%) 0.673
Lymphatic invasion
Negative 6 (60.0%) 14 (42.4%)
Positive 4 (40.0%) 19 (57.6%) 0.269
Vascular invasion
Negative 10 (100.0%) 31 (93.9%)
Positive 0 (0%) 2 (6.1%) 0.585
Histologic type
IDC 10 (100.0%) 28 (84.8%)
Special type 0 (0.0%) 5 (15.2%) 0.247
Histological grade
1–2 3 (30.0%) 8 (24.2%)
3 7 (70.0%) 25 (75.8%) 0.504
Ki67
Negative 1 (10.0%) 11 (33.3%)
Positive 9 (90.0%) 22 (66.7%) 0.149
Relapse and metastases
Locoregional 6 (60.0%) 19 (57.6%)
Distant 4 (40.0%) 14 (42.4%) 0.594
IDC, invasive ductal carcinoma.
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4. Discussion
In recent studies, it has been determined that TNBC may further be classified into seven
subtypes according to its gene expression profile [10,11], and the subtypes may respond differently
to standardized therapeutic efforts [31]. According to previous studies, AR expression is commonly
found in tumors that also express ER, and the prevalence of AR expression in TNBCs is reported less
frequently, ranging from 13.7% to 64.3% (total 317/1227; 25.8%) [8,30,32–34]. This variability may be
caused by differences in the techniques or criteria used to define AR positivity [8,29,30,32–34]. For AR
positivity, many studies have adopted the standardized criteria for determining ER and PR positivity
in breast cancer, defined as >1% positive cancer cells, which was also used in our study [29,30].
We found 30% of TNBCs expressed AR, which was in line with previous reports. Our study included
as many as 190 TNBCs, although we did not examine the genetic profiles of each AR-positive tumor
to determine which of these tumors could be classified into the luminal androgen receptor (LAR)
subtype [30]. However, we did demonstrate that AR-positive TNBCs had different characteristics than
AR-negative TNBCs. Thus, we believe that most of the AR-positive TNBCs could be categorized as
the LAR subtype, and the population of the LAR subtype in TNBC would not be rare, as has been
described by Lehmann et al. [10]. As with the luminal A and B (ER+) subtypes, overexpression of
FOXA1 is observed as in LAR subtype TNBCs [10]. Breast tumors with FOXA1 overexpression have
been reported to have a good prognosis, and we expect that the expression of FOXA1 will be tested in
AR-positive TNBCs in the future.
As has been suggested in previous reports, we observed a significant difference in disease-free
survival between patients with AR-positive and -negative TNBC [30,32,34]. Patients with AR-positive
TNBC had disease recurrence later, by approximately 2 years, compared with those with AR-negative
TNBC. Previous studies have shown that AR-positive tumors are associated with lower Ki-67 index [33],
postmenopausal status, positive nodal status [30], higher tumor grade, and development of distant
metastasis [8]. However, in our samples, the profiles of the patient or the initial disease did not differ
between AR-positive and -negative TNBC. We also observed no difference in the site of recurrence
(loco-regional or distant). These observations suggested that AR-positive TNBC has similar clinical
characteristics to AR-negative TNBC. There have been consistent results concerning the difference in the
population of TNBC and AR positivity according to race. AR-positive TNBCs in Japanese women may
have unknown characteristics distinct from TNBCs as a whole that could contribute to the longer time
to disease relapse. Signals generated by AR expression have been confirmed to display adverse effects
on cellular proliferation in some breast cancer cell lines treated with 5-alpha-dihydrotestosterone [35].
These molecular mechanisms could be involved in delaying disease relapse.
AR expression also had a significant effect on CSS. Patients with AR-positive TNBCs survived
longer after recurrence than those with AR-negative TNBCs. This clearly suggests a difference in
malignant potential between AR-positive and -negative TNBC. However, we could not identify any
specific factor responsible for this increase in survival. This was a retrospective study, and thus we
could not alter the treatment strategies as the result of AR expression for any patient. Therefore,
the difference in survival might be caused by differences in sensitivity to conventional treatments or
by the innate nature of the AR-positive TNBC phenotype. Further investigation is required to identify
the precise characteristics of AR-positive TNBCs. We have previously reported that TNBCs that are
positive for AR expression have a significantly lower rate of pathological complete response (pCR) in
neoadjuvant chemotherapy (NAC) and are chemotherapy-resistant [28].
A study examining treatment with AR antagonists in AR-expressing breast cancers is currently
underway for clinical application [36]. There have been several agents that have been shown to have
adverse effects on AR-positive cancer cells, and two clinical studies have already been conducted using
targeted agents in AR-positive breast cancer [13]. The administration of bicalutamide to patients with
metastatic AR-positive TNBC resulted in stable disease for 24 months in 19% of patients. These agents
could become important treatment options for AR-positive TNBC in the near future [37].
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In this study, we carried out protein expression analysis on TNBCs using immunohistochemical
staining and investigated the clinical significance of AR expression. Although we observed no
significant difference in the RFS rate between AR-positive and -negative TNBC cases, many late
relapse cases (4 or more years to recurrence) showed luminal type relapse. Thus, we believe that
AR-positive TNBC has biological properties different from those of the basal-like TNBCs that display
a high degree of malignancy, and that are more similar to the hormone receptor-positive luminal
subtypes. We believe that among the TNBC subtypes, the biological malignancy of AR-positive TNBC
is lower than other subtypes.
5. Conclusions
We conclude that AR expression may be useful as a subclassification marker for good prognosis
in TNBC, and that AR-positive TNBCs may be responsive to anti-androgen endocrine therapy.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/9/1/4/s1.
Figure S1: Correlation between the triple-negative phenotype and cancer specific survival and relapse-free survival.
The patients with triple-negative breast cancers had a significantly poorer outcome in all breast cancers (A,B).
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Abstract: Emerging preclinical findings have indicated that steroid hormone receptor signaling
plays an important role in bladder cancer outgrowth. In particular, androgen-mediated androgen
receptor signals have been shown to correlate with the promotion of tumor development and
progression, which may clearly explain some sex-specific differences in bladder cancer. This review
summarizes and discusses the available data, suggesting the involvement of androgens and/or the
androgen receptor pathways in urothelial carcinogenesis as well as tumor growth. While the precise
mechanisms of the functions of the androgen receptor in urothelial cells remain far from being fully
understood, current evidence may offer chemopreventive or therapeutic options, using androgen
deprivation therapy, in patients with bladder cancer.
Keywords: androgen; androgen receptor; anti-androgen; carcinogenesis; tumor progression;
urothelial cancer
1. Introduction
Urinary bladder cancer, mostly urothelial carcinoma, is the second most common genitourinary
malignancy, with an estimate of 429,800 new cases and 165,100 deaths in 2012 worldwide [1].
Despite significant advances in diagnostic technologies as well as surgical techniques and
adjuvant/neoadjuvant treatment strategies, the prognosis of patients with bladder cancer has remained
largely unchanged over the last few decades. Thus, patients with a non-muscle-invasive bladder
tumor still carry a life-long risk of recurrence with occasional progression to muscle invasion
following transurethral surgery, while those with a muscle-invasive tumor are at a high risk of
metastasis following radical cystectomy. Indeed, current non-surgical conventional treatments, such
as intravesical pharmacotherapy and systemic chemotherapy, do not result in complete prevention
of tumor recurrence or significant reduction in mortality [2,3]. Of note, mainly due to the life-long
need for monitoring for recurrence, bladder cancer has been reported to have the highest lifetime costs
per patient among all malignancies [4,5]. As a result, further studies are urgently needed to better
understand the molecular mechanisms for bladder cancer development and progression, which may
not only provide effective targeted therapy but also contribute to the reduction of treatment costs.
Men are at a significantly higher risk of bladder cancer than women in the US as well as
virtually all countries/regions, while there is an approximately 10-fold variation in its incidence
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internationally [1,6]. Cigarette smoke and exposure to industrial work-related chemicals—well-
established risk factors for bladder cancer—were thought to contribute to the sex-disparity. However,
men are still 3–4 times more likely to develop bladder cancer than women even after controlling these
environmental or lifestyle factors [1,6–8]. Accordingly, intrinsic factors are likely to play a critical role
in urothelial carcinogenesis. Meanwhile, preclinical evidence has strongly suggested the involvement
of androgen receptor (AR) signaling in bladder tumorigenesis and cancer progression.
Previous studies have thus demonstrated that AR activation generally correlates with the
promotion of the development and growth of urothelial cancer. In this article, we review these
available data and highlight underlying molecular mechanisms.
2. Androgens, AR Signaling, and Their Physiological Functions in the Bladder
Androgens, first discovered in 1936, are a class of steroid hormones, mainly secreted by the
testis, ovary, and adrenal cortex. These include testosterone and its metabolite via 5α-reductase in
certain tissues, dihydrotestosterone (DHT), as well as adrenal androgens, dehydroepiandrosterone,
androstenediol, and androstenedione. In males, androgens can stimulate the differentiation and
maturation of the sex organs and the development of secondary sex characteristics as well as maintain
sexual activity and reproductive function [9,10]. The physiological functions of androgens are mainly
dependent on their binding to AR in target cells to stimulate a series of post-receptor biochemical
changes [9–12].
The AR, a 110 kD protein composed of 919 amino acids, is a member of the nuclear receptor
superfamily that functions as a ligand-inducible transcription factor and mediates the biological effects
of androgens in a wide range of physiological and pathological processes [11–13]. The human AR gene
locates on the X chromosome (Xq11–12) and contains eight exons and seven introns with the total length
exceeding 90 kb. The AR encodes four distinct functional domains: the N-terminal transactivation
domain, the DNA-binding domain (DBD), a hinge region, and the C-terminal ligand-binding domain
(LBD) [13]. It usually locates in the cytoplasm coupling with heat shock proteins. Upon binding of
androgens at the LBD, AR is released from heat shock proteins and is translocated into the nucleus in
the form of a phosphorylated homodimer. Then, AR binds to androgen response elements (AREs) in
the genome as well as to a variety of co-regulators, leading to a series of specific activation or repression
of gene transcription [13,14]. An alternative mechanism of AR activation independent of androgen
binding includes its phosphorylation via kinases [e.g., epidermal growth factor receptor (EGFR)] in,
for instance, prostate cancer cells [15–17]. Truncated AR isoforms that lack the LBD have also been
found and are constitutively active in the absence of androgens [18].
Male internal genitalia, including the prostate and bulbourethral gland as well as urothelium, are
derived from the urogenital sinus endoderm. Simultaneously, it is well known that the differentiation of
the prostate and its development require the induction of AR signaling [19]. Thus, we can infer that AR
signaling also contributes to bladder development. Meanwhile, AR expression has been documented
in a variety of human or rodent tissues [20,21]. AR has also been found to be present in urothelium as
well as bladder submucosa, such as smooth muscle cells and neurons [20–24]. However, physiological
functions of AR in some of the organs, including the bladder, remain far from being fully understood.
Animal studies have shown that AR is involved in the regulation of urine storage and urinary tract
functions. Castration in male animals resulted in significant decreases in the activity and expression of
tissue enzymes closely related to cholinergic and non-cholinergic nerve functions [25,26]. Androgen
supplementation in castrated male rats also re-augmented the thickness of urothelium, the quantity
of smooth muscle fibers, and the number of vessels in their bladders [27]. In addition, androgen
deficiency was found to induce bladder fibrosis and reduce the bladder capacity and compliance in
male rats [28]. Thus, androgens appear to contribute to improving/maintaining bladder functions.
It has indeed been shown in a few clinical studies that testosterone treatment is beneficial to men with
lower urinary tract symptoms [29,30]. Conversely, testosterone was shown to inhibit neurogenic and
chemogenic responses in the rat bladder, resulting in the reduction of detrusor muscle contraction [31].
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To the best of our knowledge, there are no recent clinical studies further assessing the efficacy of
androgen treatment in those with lower urinary tract symptoms.
3. Alterations of AR in Bladder Cancer
Prior to its cloning, a binding assay suggested higher levels of AR content in bladder tumor
(49.5 Fm/mg) than in normal bladder mucosa (17.2 Fm/mg), as well as in male (68.0 Fm/mg) or
low-grade (43.8 (male)/27.7 (female) Fm/mg) tumors than in female (27.7 Fm/mg) or high-grade
(32.4 Fm/mg) tumors, respectively [32]. Thereafter, immunohistochemical studies in surgical
specimens have assessed the expression status of AR in different grades/stages of bladder tumors,
in comparison with normal/non-neoplastic urothelial tissues in some of them [33–44] (Table 1).
Of note, a PCR-based method could detect the AR gene in all 33 superficial bladder cancer specimens
examined [45].
Table 1. Immunohistochemical studies showing correlations between androgen receptor (AR)
expression in bladder cancer and clinicopathological features.
Study [Reference] N
AR Positivity
Non-tumor vs. Tumor Patient Gender Tumor Grade Tumor Stage
Non-tumor Tumor Male Female Low High NMI MI
Zhuang et al., 1997 [33] 9 NA 44.4% 50.0% 33.3% NA NA 20.0% 75.0%
Boorjian et al., 2004 [34] 49 86.5% 53.1% 61.1% 30.1% 88.9% 48.5% 75.0% 21.4%
Boorjian et al., 2009 [35] 55 NA 43.6% NA NA NA NA 59.1% 33.3%
Mir et al., 2011 [37] 472 NA 12.9% 14.0% 8.1% 12.2% 13.1% 9.0% 15.1%
Tuygun et al., 2011 [38] 139 0% 51.1% 66.7% 61.5% 63.9% 37.3% 60.4% 21.2%
Zheng et al., 2011 [39] 24 NA 33.3% NA NA 40.0% 31.6% NA NA
Miyamoto et al., 2012 [40] 188 80.1% 42.0% 41.9% 42.5% 55.4% 36.4% 50.5% 33.0%
Jing et al., 2014 [41] 58 NA 53.4% 56.8% 42.9% 55.0% 50.0% 48.9% 69.2%
Mashhadi et al., 2014 [42] 120 0% 21.7% NA NA NA NA NA NA
Nam et al., 2014 [43] 169 NA 37.3% 38.5% 30.8% 39.2% 32.7% NA NA
Williams et al., 2015 [44] 297 NA 24.6% NA NA NA NA 33.6% 19.5%
N: number of cases; NMI: non-muscle-invasive; MI: muscle-invasive; NA: not applicable.
The positive rates of AR expression immunohistochemically detected in bladder tumor tissues
involving more than 40 cases range from 13% to 55%, which are significantly lower than those in
non-neoplastic urothelial samples in some studies [34,36,40]. In contrast, at least two studies have
demonstrated no detectable AR in normal urothelial tissues examined [38,42]. These conflicting
findings may have resulted from differences in tissue preservation (e.g., formalin fixation), staining
protocol (e.g., antibody), and/or signal scoring. In addition, the so-called cancer field effect may have
affected the immunoreactivity because normal-appearing tissues from patients with bladder cancer
were used in most of these studies. Nonetheless, these immunohistochemical studies have failed
to reveal significant sex-related differences in AR expression in male versus female tissues (normal,
tumor). A significant decrease in the AR positive rate was also reported in urothelial carcinomas of the
upper urinary tract, compared with corresponding non-neoplastic urothelial tissues [46].
Some of these studies have compared the rates of AR positivity in low-grade or
non-muscle-invasive tumors versus high-grade or muscle-invasive tumors. Similar to the AR
positivity in bladder tumors compared with non-neoplastic bladders, its significant or insignificant
down-regulation is observed in high-grade and/or muscle-invasive tumors [34–36,38,40,43]. Similar
findings were observed in upper urinary tract tumors [46–48]. Thus, AR expression appears to be
down-regulated or lost during steps of tumorigenesis and tumor progression in spite of the promoting
effects of AR signals as described below. In contrast, a few other studies showed slight increases in AR
positivity in high-grade and/or muscle-invasive bladder tumors [37,41].
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Prognostic values of AR expression in bladder cancer patients have also been assessed, and the
findings remain controversial. Two studies indicated a correlation between AR positivity and a lower
risk of tumor recurrence [38,43]. Meanwhile, AR expression was shown to correlate with the risk of
tumor progression [40,42]. Other studies have failed to show prognostic significance of AR expression
in bladder or upper urinary tract tumors [36,37,46,47]. It has also been suggested that muscle-invasive
bladder cancers are initially androgen-sensitive for their growth, which is eventually lost due to the
activation of certain genes possessing an ARE in their promoter region in an androgen-independent
manner—as seen in prostate cancer—and induces metastatic potential of tumor cells [49]. Thus, AR
expression may not necessarily serve as a prognosticator in patients with bladder cancer.
In addition to the differential expression of AR protein, genetic alterations involving the AR
gene have been documented in bladder cancer. Loss of heterozygosity at the AR locus was identified
in muscle-invasive tumors and concurrent lesions of carcinoma in situ from female patients [50].
In addition, several studies have demonstrated differences in the number of polyglutamine (CAG)
repeats within exon 1 of the AR gene, which in general is inversely correlated with its transcriptional
activity, between bladder tumors and controls or different grades/stages of bladder tumors. Men and
women who had 23 (odds ratio = 2.09) and 44 (cumulative; odds ratio = 4.95) CAG repeats were found
to have a significantly elevated risk of urothelial carcinoma, compared to those with longer CAG [51].
A significantly shorter CAG repeat length was also identified in 95 male patients with bladder cancer
(mean: 19.8), compared with 94 control males (mean: 21.1) [52]. Moreover, there appeared to be a link
between shorter CAG repeat length and more aggressive features of bladder cancer in a relatively small
number of cases [53]. Short CAG repeat lengths (20 in UMUC3 and 22 in TCCSUP) were also identified
in two AR-positive human bladder cancer cell lines [35]. Meanwhile, although no somatic mutations
in the AR gene were found in 99 cases of bladder cancer [54], a molecular profiling data search [55,56]
identified them in up to 4% (2 of 50) of urothelial carcinomas of the bladder as well as in 6.1% (2 of 33)
of plasmacytoid urothelial carcinomas. AR isoforms (i.e., 90 kDa, 60 kDa) were also detected in some
of tumor specimens [33], suggesting the presence of its splice variants in bladder cancer.
4. Role of AR Signaling in Urothelial Carcinogenesis
The gender-specific difference in the incidence of bladder cancer as well as AR expression in
benign and cancerous urothelium suggests the involvement of AR signaling in urothelial tumorigenesis.
High incidence of high-grade prostatic intraepithelial neoplasia and prostatic adenocarcinoma—in
the development of both of which, AR plays a critical role—in cystoprostatectomy specimens
undergone for bladder urothelial carcinoma (e.g., 24.4% for the latter in a meta-analysis involving
13,140 patients [57]) may also support the presence of common tumorigenesis signals between these
two malignancies. Based on these observations, previous studies using various approaches have
assessed the role of androgens and/or AR in urothelial carcinogenesis.
A chemical carcinogen, N-butyl-N-4-hydroxybutyl nitrosamine (BBN), which is known to induce
a bladder tumor effectively in experimental rodents and more rapidly in male animals than in
females [58], has been used to assess the effects of androgens, AR, and anti-AR treatment on bladder
carcinogenesis. In 1975, it was shown that testosterone treatment in female rats increased the incidence
of BBN-induced bladder tumors while a synthetic estrogen diethylstilbestrol in males decreased
it [59]. In 1997, hormonal treatment with a gonadotropin-releasing hormone analogue as chemical
castration or an anti-androgen flutamide was shown to prevent the development of BBN-mediated
tumors in male rats [60]. Subsequently, BBN was found to fail to induce bladder cancer in male
or female AR knockout (ARKO) mice [45]. Testosterone treatment and surgical orchiectomy were
also shown to increase and decrease, respectively, the incidence of bladder tumors in male rats with
administration of another carcinogen N-nitrosobis(2-oxopropyl)amine [61]. Thus, androgen-mediated
AR signals appeared to play a critical role in bladder carcinogenesis induced by chemical carcinogens.
However, a subset of male ARKO mice treated with BBN and supplemented with DHT developed
bladder tumors [45], suggesting the involvement of androgen-mediated non-AR pathways in bladder
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tumorigenesis. Otherwise, because only DBD in exon 2 of the AR gene was disrupted in the ARKO
mice [62], the androgen effect on bladder tumorigenesis might be mediated through the truncated AR
protein that is unable to bind to DNA. An additional possibility was that the second zinc finger of
the DBD in exon 3 had residual DNA binding activity. More recently, BBN was also found to fail to
induce bladder tumors in male mice having normal levels of testosterone yet lacking AR specifically in
the urothelium [63]. Similarly, the incidence of a BBN-induced bladder tumor in a transgenic mouse
model where AR is conditionally expressed in the bladder urothelium was higher than that in age
and sex matched controls [64]. In addition, castration inhibited the development of bladder tumors in
another transgenic mouse model in which constitutive active β-catenin in the urothelial basal cells
spontaneously induced high-grade urothelial cancer [65]. These observations further suggest a critical
role of urothelial AR, but not ARs in other organs, in bladder carcinogenesis.
Several recent retrospective cohort studies have supported these findings in animals indicating
that AR activation correlates with the induction of bladder tumorigenesis. First, men undergoing
androgen deprivation therapy (ADT) for their prostate cancer were shown to have a considerably lower
risk of subsequent development of bladder cancer (0/266 (0%)), compared with those undergoing
surgery alone (5/437 (1.1%)) or radiotherapy (14/631 (2.2%)) [66]; second, in 162 men with a history
of prostate and bladder cancers, ADT used for the treatment of the former strongly prevented the
recurrence of the latter, compared with those without ADT [67]. In this cohort, AR expression in their
bladder tumors was also found to be an independent predictor of the preventive effects of ADT on
tumor recurrence [68]; third, in 228 men with a history of bladder cancer, ADT (for their prostate
cancer) or a 5α-reductase inhibitor dutasteride treatment (for their benign prostatic hyperplasia)
resulted in significant reduction in the rate of bladder tumor recurrence, compared with 196 control
patients without hormonal treatment [69]; finally, in a prospective cohort study involving 72,370 men,
treatment with a 5α-reductase inhibitor finasteride primarily prescribed for their symptomatic benign
prostatic hyperplasia significantly reduced the risk of bladder cancer development (hazard ratio = 0.634;
p = 0.0004) [70], although a preclinical study failed to show a significant inhibitory effect of finasteride
on a BBN-induced bladder tumor [60].
Androgens have been shown to modulate the activity and/or expression of certain
enzymes via the AR pathway. These enzymes include cytochrome P450 (e.g., CYP4B1) and
UDP-glucuronosyltransferase (e.g., UGT1A subtypes) that are known to involve the activation and
detoxification, respectively, of bladder carcinogens, such as aromatic amines. The levels of CYP4B1 gene
expression in male mouse bladders were found to be higher than those in female mouse bladders, and
castration in males resulted in a decrease in its expression [71]. Similarly, the expression levels of mouse
Ugt1a subtypes were elevated in the bladders from intact female or ARKO male mice, compared
with those from intact/control male mice [72]. In addition, orchiectomy [72] or ovariectomy [73]
up- or down-regulated, respectively, the expression of some Ugt1a subtypes in the mouse bladders.
Meanwhile, in SVHUC human normal urothelial cells stably expressing wild-type full-length AR,
DHT treatment resulted in considerable decreases in the expression of all UGT1A subtypes, and an
anti-androgen hydroxyflutamide blocked the DHT effects [72]. Moreover, in a mouse model, castration
was shown to reduce bladder susceptibility to a carcinogen 4-aminobiphenyl via modulating UGT1A3
in the liver [74].
GATA3 is a zinc-finger transcription factor and is highly expressed in urothelial cells. Loss of
GATA3 expression in a subset of bladder cancers, especially high-grade and/or muscle-invasive
tumors [75], as well as its correlation with the induction of tumor cell migration and invasion
in vitro [76], suggests the role of GATA3 as a tumor suppressor. Indeed, in an in vitro transformation
model using SVHUC cells, GATA3 silencing resulted in the induction of malignant transformation
as well as down- or up-regulation of the expression of tumor suppressors (e.g., p53, p21, p27, PTEN,
UGT1A) or oncogenic molecules (e.g., c-myc, cyclin D1/D3/E, FGFR3), respectively [77]. In SVHUC
sublines with or without undergoing neoplastic transformation induced by carcinogen challenge, AR
overexpression or androgen treatment considerably reduced GATA3 expression [77]. In addition,
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orchiectomy increased and ovariectomy decreased the levels of GATA3 expression in the mouse
bladders [77]. Thus, in non-neoplastic urothelial cells, AR activation appears to correlate with the
down-regulation of the expression of GATA3 that prevents neoplastic transformation.
5. Role of AR Signaling in Urothelial Cancer Progression
In addition to its involvement in urothelial carcinogenesis, there have been a variety of studies
suggesting that androgens and/or AR promote bladder cancer progression. As seen in prostate cancer
cells, androgens could induce AR expression and its nuclear translocation as well as ARE promoter
activity in bladder cancer cells [39,41,45,78–83]. In some of these studies, AR antagonists, such as
flutamide, bicalutamide, and enzalutamide, were shown to block the effects of androgens on AR
expression or transcription.
Using cell viability or colony formation assays, androgens have been shown to induce the
growth of AR-positive bladder cancer cells [39,45,79,80,82–89]. Accordingly, AR knockdown as well as
treatment with AR antagonists inhibited the cell proliferation of bladder cancer lines cultured with
androgens. In an earlier study using the R198 transplantable bladder cancer line, tumor growth in
male mice was facilitated by DHT administration [90]. Subsequent studies using mouse xenograft
models for bladder cancer demonstrated that orchiectomy or treatment with anti-AR compounds
could considerably inhibit tumor growth [41,45,84,86–88,91]. In a transgenic mouse model expressing
SV40 large T antigen specifically in urothelium (via uroplakin II) and spontaneously developing
bladder cancer, castration after tumor formation retarded its growth, which was restored by DHT
supplement [92]. Similarly, in vitro assays have demonstrated that androgen-mediated AR signals
promote the migration and invasion of bladder cancer cells [41,82,83,88]. Then, AR knockdown or
anti-androgen treatment was shown to inhibit them [41,83,86–88]. Additionally, in the uroplakin
II-SV40T transgenic model, castration reduced microvessel density in bladder tumors and increased
the expression of an anti-angiogenic factor TSP-1 [92], indicating the promotion of angiogenesis by AR
activation in bladder cancer.
In AR-positive bladder cancer cells, androgens are able to modulate the expression or activity
of various molecules/pathways. Those known to involve bladder cancer cell proliferation/
migration/invasion as well as angiogenesis/metastasis include β-catenin/Wnt signaling and its
downstream targets c-myc/cyclin D1 [65,81,84,86], CD24 [80,88], EGFR family and its downstream
AKT/ERK [39,79], ELK1 [82], matrix metalloproteinases (MMPs) [45,65,83,86,88,93], and vascular
endothelial growth factor [45,88]. Androgen-mediated AR signals were also shown to induce
epithelial-to-mesenchymal transition via modulating the expression of Slug and the activity of
β-catenin/Wnt signaling in bladder cancer cells [41,87]. More recently, in vitro assays demonstrated
that bladder cancer cells could recruit B cells [94], T cells [95], and neutrophils [93], leading to the
induction of cell invasion as well as the expression of AR and MMPs. These observations may
represent underlying molecular mechanisms for the promoting effects of androgens on bladder
cancer progression.
As seen in prostate cancer cells, non-androgens, such as epidermal growth factor (EGF), could
increase AR transcriptional activity in bladder cancer cells, which was blocked by AR antagonists [79].
EGF could also induce AR-positive bladder cancer cell proliferation in the absence of androgens [79,85].
More interestingly, EGF and DHT appeared to show synergistic effects on the proliferation as well as
phosphorylation of EGFR, AKT, and ERK in bladder cancer cells [39,79].
Recent in vitro studies have suggested a correlation between AR activity in bladder cancer cells
and chemosensitivity. AR-positive cell lines were more resistant to cisplatin than control AR-negative
or AR knockdown cells cultured in the presence of androgens [96]. Furthermore, androgen or
anti-androgen treatment resulted in a decrease or an increase, respectively, in sensitivity to cisplatin in
AR-positive bladder cancer cells, presumably via modulating the activity of a key factor of cisplatin
resistance NF-κB [96]. Similarly, bladder cancer cells overexpressing AR or those treated with DHT
were found to be more resistant to doxorubicin, an anti-cancer agent often used for intravesical
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pharmacotherapy, than respective control cells [84]. However, there were no significant differences
in sensitivity to 5-fluorouracil [84] or gemcitabine [96] between AR-positive versus AR-negative
bladder cancer cells or between AR-positive cells with versus without androgen treatment. In addition,
enzalutamide treatment or AR knockdown was shown to inhibit the growth of gemcitabine-resistant
bladder cancer cells, while whether it could increase chemosensitivity was not tested [89]. Of note,
in these studies, AR expression was shown to be considerably elevated in “resistant” cell lines after
long-term culture with cisplatin [96], doxorubicin [84], or gemcitabine [89], compared with control lines.
6. AR Co-Regulators in Bladder Cancer
As aforementioned, androgen-mediated AR transcriptional activity can be further enhanced by
co-activators. Indeed, several AR co-regulators have been implicated in the modulation of bladder
cancer cell growth. A cross-talk between AR-co-regulators and other signaling pathways in bladder
cancer cells may further promote urothelial tumorigenesis and tumor progression.
Immunohistochemistry in tissue samples showed the expression of NCOA1, NCOA2, NCOA3,
CREBBP, and EP300, in 85%–100% of bladder tumors—some of which even lacked AR expression [35].
Furthermore, of these AR co-activators, only NCOA1 expression was significantly down-regulated in
tumors, compared with non-neoplastic urothelial tissues. Meanwhile, knockdown of each co-activator
led to significant reduction in cell proliferation of AR-positive bladder cancer lines, although,
inconsistent with the findings in prostate cancer cells, androgen treatment failed to up-regulate
the expression levels of these co-activators in these cells [35]. Therefore, distinct mechanisms may
underlie co-regulator functions in bladder cancer versus other AR-positive malignancies such as
prostate cancer.
Immunohistochemistry in radical cystectomy specimens also showed strong correlations of the
expression of JMJD2A and LSD1, both of which were shown to mediate AR transactivation via
histone-lysine demethylation mechanisms, with that of AR [36]. Moreover, significant down- and
up-regulation of JMJD2A and LSD1, respectively, were found in bladder cancer specimens, compared
with benign urothelial tissues. Loss of JMJD2A was also associated with lymphovascular invasion
or worse overall survival, but not cancer-specific mortality. Remarkably, pharmacological inhibition
of LSD1 resulted in significant decreases in the growth and androgen-induced AR transcription in
bladder cancer cells [36].
Altered expression of β-catenin is well known to correlate with the progression of bladder cancer
and poor patient outcomes [41,81,97]. Additionally, as described above, constitutive active β-catenin
in mouse bladder cells could induce urothelial tumorigenesis [65]. In AR-positive bladder cancer
cells, androgens have also been shown to activate β-catenin/Wnt signaling [65,81]. Moreover, AR
and β-catenin co-express at the nuclei of bladder cancer cells and form a complex with T-cell factor, a
co-factor of β-catenin and a downstream component of Wnt signaling, in the presence of androgens [81].
Thus, androgen-mediated AR signals appear to synergize with β-catenin in bladder cancer cells and
may thereby promote tumor growth.
7. Concluding Remarks
Current evidence indicating correlations of AR activation with the promotion of urothelial
tumorigenesis and tumor progression supports that bladder cancer is a member of endocrine-related
tumors. It is thus likely that at least AR and its associated signaling pathways, as depicted in
Figure 1, play an important role in the pathogenesis of bladder cancer, which also helps explain the
sex disparities, especially its incidence between men and women. However, underlying mechanisms
of how AR and related signals regulate bladder cancer outgrowth still need to be elucidated. It also
remains unclear whether androgen-mediated AR signals are the central pathway in modulating
bladder carcinogenesis. Accordingly, further mechanistic studies are required to determine the precise
functional role of AR signaling in the development and progression of bladder cancer.
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Figure 1. AR signaling in bladder cancer. A, androgen; AR, androgen receptor; ARE, androgen
response element; Co-R, co-regulator; EGF, epidermal growth factor; EGFR, epidermal growth factor
receptor; HSP, heat shock protein.
Again, current non-surgical conventional treatments, such as intravesical pharmacotherapy and
systemic chemotherapy, often fail to completely prevent the recurrence of superficial bladder tumors
or significantly reduce the mortality rate in patients with advanced bladder cancer. Moreover, no
approved targeted therapy for bladder cancer is available. As aforementioned, AR signals likely
promote the development and progression of urothelial cancer. We therefore anticipate that AR
inactivation—even via available options clinically used for the treatment of, for instance, prostate
cancer—offers an effective chemopreventive or therapeutic approach for urothelial cancer. Indeed, two
phase II clinical trials are being conducted to assess the preventive effects of enzalutamide on tumor
recurrence in patients with non-muscle-invasive bladder cancer (NCT02605863) and the therapeutic
effects of abiraterone—an androgen biosynthesis inhibitor prescribed in men with castration-resistant
prostate cancer—in patients with advanced bladder cancer (NCT02788201). In addition, a phase I trial
(NCT02300610) assessing the combination effects of enzalutamide with gemcitabine and cisplatin in
patients with urothelial cancer is recruiting participants. Further prospective cohort studies of anti-AR
treatment in patients with bladder cancer are thus encouraged.
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Abstract: Salivary gland cancers comprise a small subset of human malignancies, and are classified
into multiple subtypes that exhibit diverse histology, molecular biology and clinical presentation.
Local disease is potentially curable with surgery, which may be combined with adjuvant radiotherapy.
However, metastatic or unresectable tumors rarely respond to chemotherapy and carry a poorer
prognosis. Recent molecular studies have shown evidence of androgen receptor signaling in
several types of salivary gland cancer, mainly salivary duct carcinoma. Successful treatment with
anti-androgen therapy in other androgen receptor-positive malignancies such as prostate and breast
cancer has inspired researchers to investigate this treatment in salivary gland cancer as well. In this
review, we describe the prevalence, biology, and therapeutic implications of androgen receptor
signaling in salivary gland cancer.
Keywords: salivary gland cancer; androgen receptor; salivary duct carcinoma; androgen-deprivation
therapy (ADT)
1. Introduction
Salivary gland cancers (SGCs) are a group of uncommon, heterogeneous tumors that account for
0.3% of all malignancies and 6% of head and neck cancers in the United States [1]. The majority of SGCs
are found in the parotid gland (59%–81% of cases), but they also arise in the submandibular gland
(6%–21%), or in minor salivary glands (7%–22%) that populate the upper aerodigestive tract [2–4].
The World Health Organization classifies 24 subtypes of SGC, which show significant variation in
histological and clinical features [1]. SGC is generally treated with surgery and, in selected cases,
adjuvant radiotherapy (RT) [5]. Systemic therapy has not been adequately tested in many SGC
subtypes, and cytotoxic chemotherapy has shown a limited effect in SGCs in general. As a consequence,
the prognosis of recurrent or metastatic SGC can be poor [2,6,7]. However, recent studies have
investigated the molecular landscape of several types of SGCs, such as adenoid cystic carcinoma (ACC),
mucoepidermoid carcinoma (MEC), polymorphous low grade adenocarcinoma (PLGA), secretory
carcinoma and salivary duct carcinoma (SDC), and uncovered molecular targets of interest in selected
patients [8–13].
The androgen receptor (AR) is a nuclear steroid hormone receptor that is physiologically expressed
at low levels in many human tissues [14]. Its main ligands are testosterone and 5α-dihydrotestosterone
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(DHT). AR regulates the transcription of multiple effector genes through direct DNA binding or
interaction with other transcription factors, leading to increased cell growth, differentiation, and
survival [15]. Overactive AR signaling is an important oncogenic driver in several tumor types,
including prostate cancer and a subset of breast cancers [16,17]. Androgen-deprivation therapy (ADT)
has been used in patients with prostate cancer since the 1940s [18], and has more recently gained interest
in a growing number of malignancies [17,19–21]. ADT may be achieved by direct inhibition of AR
(known as anti-androgen therapy), or by downregulating the gonadotropin-releasing hormone (GnRH)
receptor signaling output, which leads to reduced serum testosterone levels (known as chemical
castration). These two methods are often combined to achieve what has been termed maximum or
complete androgen blockade [22].
2. AR Expression in SGC
Nuclear AR expression based on immunohistochemistry (IHC) is the most widely used marker of
active AR signaling, and correlates with the response to ADT in prostate cancer [23]. The prevalence of
AR expression varies substantially between different subtypes of SGC (see Table 1 for a summary of
published IHC data). AR overexpression is most frequently associated with salivary duct carcinomas
(SDC), the majority of which are positive for AR. Several studies have shown AR immunoreactivity in
64%–77% of cases [8,24–30], whereas a recent large report detected AR expression in as many as 98%
of SDCs [31]. In that study, several tumors initially diagnosed as AR-negative SDCs were reclassified
as other tumor entities after a second evaluation by salivary pathologists. Also, for tumors with
conventional SDC morphology and a negative first AR IHC, the staining was repeated and showed
AR expression the second time in several cases. This may suggest that the prevalence of AR-positive
SDC was previously underestimated due to technical issues or diagnostic difficulties.
Our group recently identified AR positivity by IHC in 75% of SDCs, and RNA sequencing
confirmed extremely low but detectable levels of AR mRNA in AR IHC–negative cases, all of which
had typical SDC morphology at the time of pathologic re-evaluation [8]. Interestingly, three of four
AR IHC-negative cases showed AR signaling activity at levels equivalent to AR IHC-positive cases,
as measured by expression of AR-regulated genes. Both AR-negative and AR-positive SDCs showed
global gene expression patterns highly similar to AR-positive (also termed molecular apocrine) breast
cancers. This raises the possibility that some SDCs with low levels of AR may have acquired alternative
mechanisms to activate AR signaling pathways. Furthermore, the remarkable biological similarity
between the two cancer types may suggest that treatment results in patients with molecular apocrine
breast cancer could be of interest for the design of clinical trials in SDC.
The prognostic relevance of AR expression in SDC is difficult to assess, due to the rarity of
the disease and the low number of AR-negative cases. Some investigators have identified a trend
suggestive of better disease-free survival in AR-positive compared to AR-negative SDC patients [26,29],
but this association has not been identified by other groups [8,24,25]. Similarly, one study detected a
higher prevalence of AR expression in men than in women with SDC [30], a finding that has not been
replicated in other reports [8,26].
In other subtypes of SGC, nuclear AR expression is found at lower rates. Adenocarcinoma, not
otherwise specified (AC NOS) and acinic cell carcinoma (AcCC) are AR-positive in 26% and 15% of the
cases, respectively [28,32–35]. On the other hand, only a small subset of MEC and ACC have detectable
expression of AR [27,28,32–34,36,37], and some of these cases show weak AR expression (5%–15%
stained nuclei) which may not be relevant for the biology of the tumors [32]. Among the rare types
of SGC, AR expression has been reported in PLGA and basal cell adenocarcinoma (BCAC) [28,32],
whereas all published cases of myoepithelial carcinoma (MECA) have been AR-negative [28,33].
Five cases of AR-positive epithelial-myoepithelial carcinoma (EMC) were reported and suggested
to represent a specific variant of the disease, denoted apocrine EMC [38]. However, one study of six
unselected EMCs did not detect AR [28], and the prevalence of AR expression in EMC is unknown.
Given the challenging nature of salivary gland pathology, it is possible that some of these AR-positive
entities in fact represent SDC.
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A subset of SGCs result from the malignant transformation of a pre-existing pleomorphic adenoma
(PA). PA is the most prevalent salivary gland tumor, and is typically benign and non-metastatic. Around
6% of PAs develop into different types of carcinoma, denoted carcinoma ex-PA [39]. Whereas PAs are
AR-positive in 30% of the cases, 90% of carcinoma ex-PAs express AR. This difference may suggest that
AR expression is a risk factor for the malignant transformation of PAs. Alternatively, overexpression of
AR may act as an oncogenic event in some carcinomas ex-PA [40].
Table 1. Prevalence of positive AR immunoreactivity in different types of SGC.
Histology AR Positivity 1 Reported Range 2 References
SDC 615/713 (86%) 43%–100% [8,24–31,33,34,41–45]
AC NOS 11/43 (26%) 21%–33% [28,33,34]
AcCC 6/40 (15%) 0%–31% [28,32,34,35]
MEC 7/135 (5%) 0%–20% [27,28,32–34,36]
ACC 7/145 (5%) 0%–20% [28,32–34,36]
EMC 0/6 (0%) N/A [28]
MECA 0/7 (0%) N/A [28,33]
BCAC 2/2 (100%) N/A [32]
PLGA 1/2 (50%) N/A [28]
1 Number of AR-positive cases/total number of cases, in all studies combined; 2 Range of prevalence detected in the
different studies. SDC, salivary duct carcinoma; AC NOS, adenocarcinoma not otherwise specified; AcCC, acinic
cell carcinoma; MEC, mucoepodermoid carcinoma; ACC, adenoid cystic carcinoma; EMC, epithelial-myoepithelial
carcinoma; MECA, myoepithelial carcinoma; BCAC, basal cell adenocarcinoma; PLGA, polymorphous low
grade adenocarcinoma.
3. Expression of AR Splice Variants
The full-length AR (AR-FL) gene consists of eight exons, of which exons 4–8 encode the
ligand-binding domain. Expression of alternative AR isoforms lacking the ligand-binding domain
(which normally serves as a binding site for anti-androgens, such as enzalutamide) is associated with
ADT resistance in prostate cancer [46–50]. AR-V7, a constitutively active AR splice variant that includes
only exons 1–3 and a cryptic exon 3, is detected in 37%–50% of SDCs (Figure 1) [8,26]. On average,
AR-V7 is expressed at around 5% of AR-FL RNA levels [8], which is similar to the AR-V7/AR-FL
ratio seen in prostate cancer [16]. Another AR isoform, AR-V3, including only exons 1, 2 and a cryptic
exon 2, is also found in SDC but at lower rates and only in male patients [26]. AR-45, which lacks the
majority of exon 1, including the N-terminal domain that mediates ligand-independent transactivation
of AR [51], is detected in a minority of SDCs [26]. However, the association between the alternative
AR isoforms and response to ADT in SDC, and the prevalence of AR-V7, AR-V3, and AR-45 in other
types of SGC, remains unknown.
 
Figure 1. Reported prevalence of AR splice variant expression in SDC. References:
For AR-FL, [8,24–31,33,34,41–45]; for AR-V7, [8,26]; for AR-V3 and AR-45, [26].
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4. Genetic Alterations Affecting AR Signaling
An extra copy of chromosome X, which includes the AR gene, is found in almost 40% of SDCs.
This may contribute to overexpression of AR, although some of the tumors with an extra chromosome
X are negative for AR in IHC [26]. Unlike in prostate cancer, focal amplification or protein-altering
somatic mutations of AR have not been found in SDC or ACC [8,9,26].
Forkhead box protein A1 (FOXA1) is a transcription factor that mediates the transcription of AR
target genes by facilitating the AR/chromatin interaction [52]. FOXA1 mutations may potentially be
associated with ADT resistance in prostate cancer, although this is being actively investigated [53].
In a recent exome sequencing study reported by our group, we identified alteration (either somatic
mutations in the DNA-binding domain or high-level amplification) of FOXA1 in four of 12 AR-positive
SDCs. Conversely, no FOXA1 alterations were found in four AR-negative SDCs [8].
Fatty acid synthase (FASN) is an enzyme that controls fatty acid synthesis and has been shown to
promote the growth of prostate cancer as a result of AR signaling. Experimental studies suggest that
FASN overexpression can mediate resistance to ADT in prostate cancer, although no clinical data are
yet available [54]. In our exome study of SDC, alterations (missense mutations, a frameshift insertion,
and high-level amplification) of FASN were found in four of 12 AR-positive but not in AR-negative
tumors [8].
In ACC, which rarely expresses AR, no significant genetic alterations affecting AR signaling
have been detected [9]. In other subtypes of SGC, the prevalence of AR-related genetic alterations
is unknown.
5. Anti-Androgen Therapy in Patients with SGC
Several ADT drugs have been developed and tested clinically, mainly in patients with prostate
cancer. Abiraterone is a CYP17A1 inhibitor which reduces circulating levels of androgen by ultimately
blocking the conversion of pregnenolone to DHT. Bicalutamide and flutamide are competitive
inhibitors of the AR ligand-binding domain, as is enzalutamide, which was developed more recently
and has greater AR affinity compared to the earlier anti-androgens, and may inhibit AR activity via a
variety of different mechanisms [55]. Triptorelin and goserelin are GnRH agonists which eventually
cause downregulation of luteinizing hormone (LH) and thereby reduced serum testosterone levels [22].
Inspired by results from other cancers [17,56] and functional studies showing AR-dependency in
cultured SGC cells [26,57], a number of patients with AR-positive SGC have been treated with different
ADT regimens (see Table 2 for a summary of reported cases). In a retrospective analysis of 17 patients
with recurrent or metastatic AR-positive SGC, of which the majority had SDC or AC NOS, the overall
response rate was 65%. Treatment was generally well tolerated in these patients, both men and women.
However, relapse was commonly seen, leading to a three-year progression-free survival (PFS) of 12%,
and a five-year overall survival of 19% [58]. Smaller studies of AR-positive SDC patients have reported
somewhat less favorable outcomes, with an overall ADT response rate of 25%–50% [8,59]. Several case
reports have shown a good effect of ADT alone in patients with AR-positive SDC or AC NOS, including
stable disease for several months as well as cases of complete remission [43,60,61]. A few patients
with SDC or AC NOS, who initially responded to a combination of bicalutamide and triptorelin but
had a relapse, then showed a response to subsequent abiraterone, suggesting resistance mediated by
the reactivation of AR signaling during ADT treatment [62,63]. ADT has also been combined with
either definitive RT or palliative chemotherapy with robust responses in several single case reports of
SGC [64,65].
Patients with AC NOS have been found to respond well to ADT, with partial or complete response
in 10 of 11 reported cases, and a median PFS of 20 months. SDC patients appear to have a lower
response rate, with partial or complete response in 11 of 26 (42%) reported cases and a median PFS of
eight months (Table 2).
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Table 2. Reported cases of ADT treatment in patients with AR-positive SGC.
Patient ID 1 Histology Sex Age 2 ADT Agents Response PFS (Months) Ref.
1 AC NOS m 73 Bicalutamide + triptorelin CR N.K. [60]
2 AC NOS m 72 Bicalutamide + triptorelin CR 2 [58]
3 AC NOS m N.K. Goserelin PR N.K. [61]
4 AC NOS m 59 Bicalutamide + triptorelin PR 12 [63]
5 AC NOS m 44 Bicalutamide + triptorelin PR 25 [63]
6 AC NOS m 67 Bicalutamide + triptorelin PR 22 [58]
7 AC NOS m 67 Bicalutamide + triptorelin PR 22 [58]
8 AC NOS m 46 Bicalutamide + triptorelin PR 58 [58]
9 AC NOS m 49 Bicalutamide + triptorelin PR 7 [58]
10 AC NOS m 62 Bicalutamide + triptorelin PR 9 [58]
11 AC NOS m 69 Bicalutamide + triptorelin SD 20 [58]
12 Cyst AC m 79 Bicalutamide + triptorelin PR 14 [58]
13 Cyst AC f 68 Triptorelin + cyproterone PD 0 [58]
14 Poor diff. m 54 Bicalutamide + triptorelin PD 0 [58]
15 SDC f 87 Bicalutamide + leuprolide 3 CR 24 [64]
16 SDC m 44 Bicalutamide + triptorelin CR 39 [58]
17 SDC m 67 Bicalutamide + triptorelin CR 11 [58]
18 SDC m 66 Bicalutamide PR 14 [43]
19 SDC m 50 Bicalutamide PR 8 [59]
20 SDC f 83 Bicalutamide PR 26 [59]
21 SDC m 45 Goserelin PR 4 [62]
22 SDC m 45 Bicalutamide + goserelin PR 10 [62]
23 SDC m 45 Abiraterone + goserelin PR 10 [62]
24 SDC m 51 Bicalutamide + triptorelin PR 6 [58]
25 SDC m 67 Bicalutamide + triptorelin PR 7 [58]
26 SDC f 68 Bicalutamide + leuprolide SD 17 [8]
27 SDC m 57 Bicalutamide SD 14 [59]
28 SDC m 56 Bicalutamide + goserelin SD 12 [59]
29 SDC m 67 Bicalutamide + goserelin SD 8 [59]
30 SDC m 75 Bicalutamide + triptorelin SD 8 [58]
31 SDC m 54 Bicalutamide + triptorelin SD 10 [58]
32 SDC m 68 Bicalutamide + triptorelin SD 23 [58]
33 SDC f 48 Bicalutamide + leuprolide PD 0 [8]
34 SDC f 69 Bicalutamide + leuprolide PD 0 [8]
35 SDC m 77 Bicalutamide + leuprolide PD 0 [8]
36 SDC m 73 Bicalutamide + goserelin PD 0 [59]
37 SDC m 68 Bicalutamide + goserelin PD 0 [59]
38 SDC f 64 Bicalutamide PD 0 [59]
39 SDC m 39 Bicalutamide PD 0 [59]
40 SDC m 73 Bicalutamide PD 0 [59]
1 Patients are sorted by tumor histology and then best response; 2 At start of ADT; 3 This patient received external
beam radiotherapy together with ADT. ADT, androgen deprivation therapy; PFS, progression-free survival; Ref.,
reference; AC NOS, adenocarcinoma not otherwise specified; Cyst AC, cystadenocarcinoma; Poor diff., poorly
differentiated; SDC, salivary duct carcinoma; m, male; f, female; N.K., not known; CR, complete response; PR,
partial response; SD, stable disease; PD, progressive disease.
Of note, several dramatic responses to ADT in SGC patients were published only as case reports
of extraordinary responders. A recent preliminary study including all SDC patients treated with
ADT in the Netherlands showed somewhat more modest results, with partial response in four (13%)
cases, stable disease in 10 (32%) cases, and progressive disease in 17 (55%) cases, and a median PFS
of 3.8 months [45]. On the other hand, since the majority of SGCs are chemotherapy-resistant, the
treatment options for patients with generalized disease are limited and AR is the most promising target
for these patients with otherwise incurable disease. Several clinical trials are currently ongoing,
investigating the efficacy of ADT in patients with recurrent/metastatic AR-positive SGC, using
abiraterone, bicalutamide or enzalutamide in male and female patients (NCT02749903, NCT01969578,
NCT02867852). In addition to providing valuable clinical response information, these trials will
also collect tumor tissue for correlative research, facilitating further understanding of molecular
determinants of response to ADT in AR-positive SGC.
6. Conclusions
AR is expressed in a majority of SDCs and in a minority of other SGCs such as AC NOS, and ADT
has emerged as a promising therapy in patients with AR-positive SGC. Several potential mechanisms
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of resistance to ADT have been described, including the expression of AR splice variants and mutations
in FOXA1 and FASN. Ongoing and future clinical trials will likely shed light on the clinical benefit and
limitations of ADT in AR-positive SGC.
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Abstract: Hepatocellular carcinoma (HCC) is a male-dominant disease with poor prognosis.
Sorafenib is the only approved systemic chemotherapeutic drug for patients with advanced HCC.
Previous studies have shown that androgen and androgen receptor (AR) are involved in human
hepatocarcinogenesis and the development of HCC. Here, we discuss the recent data on AR
and HCC, and the combination of sorafenib and inhibitors of AR for advanced-HCC patients.
Androgen-dependent and androgen-independent AR activation exist in human hepatocarcinogenesis.
AR could directly control hepatocarcinogenesis and regulate the innate immune system to influence
HCC progression. Combination of sorafenib with AR inhibitors might represent a potential treatment
for patients with advanced HCC.
Keywords: androgen receptor; hepatocellular carcinoma; sorafenib
1. Introduction
Hepatocellular carcinoma (HCC) is one of the poor-prognosis cancers [1,2]. In Japan, HCC is the
major cancer among primary liver cancers, which have 5- and 10-year survival rates of 34% and 16%,
respectively [3]. HCC mostly occurs in patients with cirrhosis. It is not easy to cure HCC by surgical
resection other than liver transplantation [4]. In patients with advanced HCC, sorafenib is the only
approved systemic chemotherapeutic drug, and new treatment options are eagerly awaited [1].
To surpass the treatment with sorafenib alone for advanced HCC, new treatments have been
developed in recent years [2,5,6]. Histone deacetylase inhibitor resminostat plus sorafenib was safe and
showed early signs of efficacy for advanced HCC patients progressing on sorafenib-only treatment [5].
Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin achieved favorable overall survival
when compared with sorafenib alone for advanced HCC patients [6]. Regorafenib was also shown to
provide survival benefit in advanced HCC patients progressing on sorafenib treatment [2].
HCC is one of the male-dominant cancers [7]. We and others have reported that male sex
hormone androgen and androgen receptor (AR) are involved in human hepatocarcinogenesis and the
development of HCC [8–12]. AR antagonists such as flutamide and bicalutamide have been used for
prostate cancer for many decades, and new AR antagonists are also under development [13]. Herein,
AR and HCC will be discussed. We also describe the combination treatment of sorafenib and inhibitors
of AR for patients with advanced HCC.
Cancers 2017, 9, 43 229 www.mdpi.com/journal/cancers
Cancers 2017, 9, 43
2. AR and AR Signaling
Androgens act through AR, a 110-kDa ligand-inducible nuclear receptor (Figure 1A) [14].
The classical steroid receptors such as AR, estrogen receptor, progesterone receptor, glucocorticoid
receptor and mineral corticoid receptor are grouped as type 1 nuclear receptors. AR has four functional
domains: NH2-terminal transactivation domain, DNA-binding domain (DBD), hinge region and
ligand-binding domain (LBD).
AR regulates the expression of target genes that have androgen response elements (AREs)
(Figure 1A) [14,15]. AREs exist in the promoter region of vascular endothelial growth factor (VEGF) [8]
and glucose-regulated protein 78 kDa (GRP78) [9], and they play a role in the growth of human
hepatocytes. Transforming growth factor, beta 1 (TGF-β1) transcription is also activated by androgen
and AR complex in hepatocytes [16,17]. This transcriptional activation function of AR is important in
the normal sexual development of the male gender as well as the progression of cancer [8,14,18].
AR co-regulators also influence a number of functional properties of AR, including ligand
selectivity and DNA binding capacity [14]. Oncogenes such as erb-b2 receptor tyrosine kinase 2 (ERBB2)
and HRas proto-oncogene, GTPase (HRAS) increase mitogen-activated protein kinase signaling, which
can cause ligand-independent activation of AR (Figure 1B) [19,20]. There is a cross-talk mechanism
between growth factor signaling and androgen in prostate development, physiology, and cancer [20].
Ligand-independent activation of AR pathways also plays a role in human HCC and pancreatic cancer
progression [8,21].
The activation of Src kinase is involved in the ligand-independent activation of AR [22]. Two
UDP-glucuronosyltransferases (2B15 and 2B7) are also involved in inactivation of androgens, and
may have a major role in persons that is null genotype of UGT2B17 [23]. Hepatitis B X (HBx) also
augmented AR activity by enhancing the phosphorylation of AR through HBx-mediated activation of
the c-Src kinase signaling pathway in human hepatocarcinogenesis [11,24].
(A) (B)
Figure 1. Androgen-dependent and androgen-independent androgen receptor (AR) activation in
human hepatocarcinogenesis. (A) Androgen-dependent signaling. (B) Androgen-independent
signaling. Phosphorylation of mitogen-activated protein kinase (MAPK), signal transducer and
activator of transcription 3 (Stat3), AKT serine/threonine kinase 1 (Akt) and Proto-oncogene
tyrosine-protein kinase (Src) activates AR. VEGF, vascular endothelial growth factor; GRP78,
glucose-regulated protein 78 kDa; TGF-β, transforming growth factor, beta 1; PI3K,
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha.
3. AR and HCC
Human HCC and normal liver express AR [7,10,25]. Hepatitis B virus (HBV) and hepatitis
C virus (HCV) are two major causes of HCC. AR signaling is involved in human HCC associated
with HBV and HCV [26]. AR signaling should be involved in hepatocarcinogenesis to some extent,
irrespective of the cause of human and mouse HCC [27]. As androgen and AR-signaling are
230
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associated with the development of steatosis [28], AR may be associated with HCC that is related to
non-alcoholic steatohepatitis.
Increased expression of variant transcripts from the AR gene (ARVs) has been shown to be
involved in the development of castration-resistant prostate cancer [29]. The expression of ARVs was
observed in the liver and may be involved in hepatocarcinogenesis [30]. AR variants may also lead to
resistance to HCC antiandrogen therapy in the liver.
4. AR and Sorafenib in the Treatment of HCC (Table 1)
At present, sorafenib is the only approved drug for systemic chemotherapy of HCC. We observed
that sorafenib-induced apoptosis was enhanced by the inhibition of AR and GRP78 in human hepatoma
cell lines [9]. Sorafenib also inhibits AR activation induced by HBx in vitro and in vivo [31]. Of
interest, this AR-targeting ability of sorafenib was not mediated by its well-known kinase inhibitory
activity; however, this ability of sorafenib was achieved by enhancing the activity of K-box region and
MADS-box transcription factor family protein (SHP-1) tyrosine phosphatase [31]. There are contrary
opinions concerning hepatic AR and the effect of sorafenib, namely that hepatic AR suppresses HCC
metastasis through modulation of cell migration and anoikis [30,32,33]. Natural killer (NK) cells
suppress HCC; and interleukin 12 (IL12A), one of the NK cell stimulatory factors, plays a role in
the activation of NK cell function [34,35]. In NK cells, AR could suppress IL12A expression at the
transcriptional level, resulting in repressing the efficacy of NK cell cytotoxicity against HCC [34].
Sorafenib treatment interacts with AR and enhances IL12A signals [34]. AR could regulate the innate
immune system to influence HCC progression [34,36,37]. Although AR suppresses HCC metastasis at
late stage [28,32,33,37], androgen and the AR axis maintain and promote cancer cell stemness through
activation of Nanog in HCC [38].
Table 1. Molecular targets during anti-cancer drug treatment for hepatocellular carcinoma (HCC)
through androgen receptor (AR).
References Targets Effects of Anti-Cancer Drugs
Jiang et al. [9] GRP78 Knockdown of GRP78 and AR enhances apoptosis induced bysorafenib in human hepatoma cells.
Wang et al. [31] SHP-1 Sorafenib inhibited HBx-enhanced AR activity by activatingSHP-1 phosphatase in HBx-transgenic mice.
Shi et al. [34] IL12A Sorafenib interacts with AR and enhances IL12A signals.
Shi et al. [36] ULBP2 By suppressing AR, cisplatin could up-regulate cytotoxicity ofNK cells to target HCC.
Ma et al. [28] p-p38, NFκB, MMP9 Addition of sorafenib improved HCC survival of L-AR−/y mice.
Xu et al. [33] miR-367
Combining miR-367-3p with Sorafenib showed better efficacy of
suppressing HCC cell invasion by altering AR signals in vitro
and in vivo.
GRP78, glucose-regulated protein 78 kDa; SHP-1, K-box region and MADS-box transcription factor family protein;
HBx, hepatitis B x; IL12A, interleukin 12A; ULBP2, UL16-binding protein 2; p-p38, phosphorylation of p38 kinase;
NF-κB, nuclear factor kappa B; MMP9, matrix metalloproteinase 9.
5. Conclusions
We have already reviewed clinical trials targeting androgen in HCC [25]. However, the previous
reports demonstrated that anti-androgen therapies did not show any survival benefits in advanced
HCC patients [39,40]. That might be considered to be attributed by the lower expression of AR
and androgen-independent AR activation mechanism in the advanced HCC. A recent review [13]
described phase I/II clinical trials of the androgen antagonist enzalutamide with or without sorafenib
for advanced HCC that are currently underway. Enzalutamide binds to the AR with greater relative
affinity than the clinically used antiandrogen bicalutamide, reduces the efficiency of its nuclear
translocation, and impairs both DNA binding to androgen response elements and recruitment of
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coactivators [41]. The combination of sorafenib and enzalutamide is a potentially new approach for
the treatment of castration-resistant prostate cancer [42]. This combination may present a potential
treatment for patients with advanced HCC. In prostatic cancer cells with downregulated AR expression
by short interfering RNA, treatment with sorafenib increased apoptosis in an additive manner [43],
suggesting that there might be a potential to use inhibitors of AR in HCC as an adjuvant therapy option
for sorafenib-resistant HCC patients. Moreover, immune checkpoint inhibitors such as programmed
cell death 1 (PD-1), programmed cell death ligand 1 (PD-L1), or cytotoxic T-lymphocyte-associated
protein 4 (CTLA-4) are now undergoing clinical trials, and they may open new doors for the treatment
of HCC [44]. In this new era, AR could control NK cell function and may be a more attractive target.
In conclusion, recent advances regarding AR in HCC have been described. AR is an attractive target
with or without anti-cancer drugs in HCC, one of the male dominant diseases.
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